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Abstract 
Primary Sjögren’s syndrome (pSS) is an autoimmune disease of the exocrine glands. The 
syndrome is characterized by many systemic features, including a markedly increased risk 
of lymphoma development. PSS-associated lymphoma was first reported in 1963, however, 
the mechanisms and the risk factors of lymphoma development in pSS patients remain 
incompletely understood. The aim of my project is to identify a whole-blood gene 
expression signature in pSS-associated lymphoma. To achieve this goal, I first evaluated 
the effect of the depletion of the abundant globin mRNA in whole-blood samples on 
microarray analyses of pSS. Then I prepared samples (globin mRNA depleted samples) 
from a “Discovery cohort” which consisted of five subject groups (“pSS (non-lymphoma)”, 
“pSS-associated lymphoma”, “pSS-paraproteinemia”, “pSS-other cancers” and “healthy 
controls”) to identify a list of differentially expressed genes (DEGs) between the “pSS 
(non-lymphoma)” and the “pSS-associated lymphoma” groups.  The next step was to 
confirm the differential expression of these genes using qRT-PCR. This has led to the 
identification of a potential gene expression signature for pSS-associated lymphoma. To 
further explore the role of these genes in the pathogenesis of pSS-associated lymphoma, I 
performed pathway analysis using various algorithms provided by Ingenuity Pathway 
Analysis (IPA). I also compared the microarray data of different subject groups to 
investigate whether the potential gene signature was “specific” for pSS-associated 
lymphoma.  I then validated the potential transcriptomic signature “biologically” using an 
independent cohort (the “Validation cohort”) consisting of two subject groups – “pSS 
(without lymphoma) and “pSS-associated lymphoma”. Moreover, the potential biosignature 
was tested in a group of pSS patients with untreated lymphoma. Prediction modelling was 
used to identify the important genes within the potential biosignature that best predict the 
development of pSS-associated lymphoma.  
I showed that globin mRNA depletion of whole-blood samples provided potentially more 
sensitive microarray data compared with paired non–globin RNA depleted samples. From 
the microarray analysis of the “Discovery cohort”, 68 DEGs were identified between the 
lymphoma and non-lymphoma groups (68-DEGs-Mi). qRT-PCR confirmed the differential 
expression of 26 genes (26-DEGs-MiPCR). Biological validation with an independent 
xv 
 
cohort verified 3 genes (3-gene biosignature), 2 of which were up-regulated (NUDT14, 
MGST3) and 1 gene was down-regulated (BMS1) in pSS-associated lymphoma. Moreover, 
2 genes in addition to NUDT14 (DRAP1, DYNLL1) were also differentially expressed in a 
cohort of pSS patients with untreated lymphoma. Prediction modelling suggested that 
NUDT14 was the most important gene in predicting membership in the pSS-associated 
lymphoma group. Pathway analysis of the differentially expressed genes in pSS-associated 
lymphoma revealed several canonical pathways such as “Aryl Hydrocarbon Receptor 
Signalling,” “Histamine Degradation,” “Unfolded protein response,” “Neuregulin 
Signalling,” and “T Cell Receptor Signalling.” In addition, the Downstream Effects 
analysis revealed the biological functions in pSS-associated lymphoma and the Upstream 
Regulators analysis investigates possible gene regulators. Moreover, comparisons of 
microarray gene-expression data between other pSS subgroups suggest the DEGs were 
unique to pSS-associated lymphoma. IPA showed that “Interferon Signalling pathway” was 
the top canonical pathway in all pSS subgroups.  Furthermore, similar patterns were seen in 
the IPA Downstream Effects analyses for the “pSS (non-lymphoma)”, “pSS-
paraproteinemia” and “pSS-other cancers” groups, while the “pSS-associated lymphoma” 
group showed a unique pattern, further indicate that a unique gene expression signature 
exist in pSS-associated lymphoma.           
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Chapter 1 
Introduction and literature review 
1.1 Overview of primary Sjögren’s Syndrome (pSS): 
Sjögren's Syndrome (SS) is an autoimmune disease of the exocrine glands, particularly the 
salivary and lacrimal glands. The hallmark features of SS are a dry mouth and dry eyes. In 
addition, a variety of systemic manifestations can be observed. Occurring alone without any 
other associated autoimmune conditions, it is referred to as primary Sjögren's Syndrome 
(pSS); when Sjögren's syndrome occurs with other autoimmune disease, it is referred to as 
secondary Sjögren's Syndrome (sSS) (Kassan and Moutsopoulos, 2004).  
Historically, the first case of a dry mouth and dry eyes (sicca syndrome) was reported by 
W.B. Hadden and J. W. Hutchinson in 1871. Afterward the term ‘Mikulicz disease’, which 
describes the association of parotid, submandibular and lacrimal glands enlargement with 
sicca syndrome, was introduced by Johann von Mikulicz-Radecki  in 1888. In 1925, 
Gougerot’s syndrome was described; this syndrome had the three main symptoms of 
Sjögren’s syndrome - a dry mouth, dry eyes and polyarthritis (Ghafoor, 2012). In 1933, the 
Swedish ophthalmologist Henrik Sjögren demonstrated the clinical symptoms of a dry 
mouth and dry eyes in association with rheumatoid arthritis in 13 of 19 women, and coined 
the term ‘keratoconjunctivitis sicca’ that discriminates the syndrome from xerophthalmia 
that results from vitamin A deficiency. Since then, the term ‘Sjögren's Syndrome’ has been 
widely accepted (Bloch et al., 1992). Henrik Sjögren’s work was published in English in 
1943 and given recognition for his contributions to the field of medicine (Ghafoor, 2012).  
Primary Sjögren's syndrome (pSS) has a population prevalence of about 0.5% with a 9:1 
female to male ratio (Bowman et al., 2004). Recently, a meta-analysis study including 21 
epidemiological studies of pSS which reported data on incidence rates (IRs), prevalence 
rates (PRs) and the female to male ratio was conducted by Qin and colleagues (Qin et al., 
2015). The pooled IRs of pSS was 6.92 (95% CI: 4.98 to 8.86)/100,000 person-years and 
the overall PRs was 60.82 (95% CI: 43.69 to 77.94) cases/100,000 inhabitants. 
Furthermore, within the incidence data the female to male ratio was 9.15 (95% CI: 3.35 to 
13.18), while the female to male ratio in the prevalence data was 10.72 (95% CI: 7.35 to 
15.62) (Qin et al., 2015).  
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pSS is characterized by lymphocytic infiltration in the affected glands. T-cells particularly 
the CD4
+
 subsets represent the majority of the infiltrating cells and seem to be the dominant 
cells in mild lesions, while the proportion of B-cells increased in the more severely affected 
glands (Mavragani and Moutsopoulos, 2010). The production of autoantibodies derived 
from autoreactive B-cells in both the affected glands and peripheral blood is another 
characteristic feature of pSS. Indeed, autoantibodies targeting the ribonucleoproteins Ro 
(SSA) and La (SSB) are included in the classification criteria of pSS by the American-
European Consensus Group (Vitali et al., 2002). In addition to the glandular manifestations, 
extraglandular manifestations also occur including fatigue, musculoskeletal involvement, 
dermatological involvement, pulmonary involvement, gastroenterological involvement, 
renal involvement, neurological involvement, Raynaud's phenomenon, liver involvement 
and lymphoproliferative disease particularly non-Hodgkin lymphoma (NHL) (Kassan and 
Moutsopoulos, 2004). 
Secondary Sjögren’s Syndrome (sSS) is defined as the presence of SS with other 
autoimmune diseases such rheumatoid arthritis (RA), systemic lupus erythromatosus (SLE) 
and others. The prevalence of sSS in RA has been estimated to be as high as 62% (Coll et 
al., 1987). Another study reported that 28% of a group of 307 RA patients has at least one 
positive feature of sicca complex but only 3.6% had sSS (Haga et al., 2012). The 
prevalence of sSS with SLE varies from 6.5–19% (Pan et al., 2008, Patel and Shahane, 
2014). SS may also occur with systemic sclerosis (SSc) and with other systemic and organ-
specific autoimmune diseases (Ramos-Casals et al., 2012). The occurrence of SS with other 
autoimmune disorders increases the number of symptoms and also complicates diagnosis, 
depending on the type of concurrent autoimmune disease. For instance, sSS patients with 
rheumatoid arthritis (RA) often differ clinically, pathologically, serologically and 
genetically from pSS, whereas patients with sSS in association with systemic lupus 
erythromatosus (SLE) are more similar to pSS patients (Peters and Isenberg, 2012).   
1.2 Characteristic features of primary Sjögren’s Syndrome: 
1.2.1 Histological features of primary Sjögren’s Syndrome: 
The characteristic histopathological feature of pSS is lymphocytic infiltration in the 
affected organs (salivary and lacrimal glands). At the initial stages of the disease the 
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infiltrates consist of CD4
+
 T-cells, B-cells, macrophages and dendritic cells (DCs), with 
CD4
+
 T-cells being the dominant cell type (Mavragani and Moutsopoulos, 2010). B-cell 
infiltrates in the glands contribute to the secretion of autoantibodies such as anti-Ro/SSA 
and anti-La/SSB, accompanied by the formation of germinal centre-like structure (GC-like 
structure (Routsias and Tzioufas, 2010). The germinal centre-like structure can be defined 
as the aggregation of immune cells (mostly T- and B-cells) to form a microenvironment or 
structure resembling germinal centres within the affected organs. These GC-like structures 
were identified in 17% of pSS patients and contributed to the production of autoantibodies, 
as patients with GC-like structure had increased levels of autoantibodies (Salomonsson et 
al., 2003). The proportion of different cell types within the cellular infiltrates changes with 
the degree of lesion severity. Although CD4
+
 T-cells are the dominant cells in the 
lymphocytic infiltrates in pSS salivary glands, the proportion of CD4
+
 T-cells proportion 
declines with increased lesion severity. In contrast, the proportion of CD20
+
 B-cells 
increases with increased severity of the lesion. Furthermore, the proportion of FOXP3
+ 
regulatory T-cells (Treg) increases in lesions with intermediate severity, while the 
percentages of CD8
+
 T-cells, follicular dendritic cell  (fDC) and natural killer (NK) cells in 
the inflammatory infiltrate had no correlation with the degree of lesion severity 
(Christodoulou et al., 2010). 
1.2.2 Immunological features of primary Sjögren's syndrome: 
Immune cells in pSS  
Various immune cells are involved in pSS, although much of the research has focused on 
T- and B-cells. Many researchers have studied CD4
+
 T-cells, which consist of T helper 
cells (Th) such as Th1, Th2, Th17, as well as other subtypes such as regulatory cells (Treg). 
It has been reported that Th1/Th2 imbalance is associated with pSS severity locally 
(salivary glands) and systematically (peripheral blood). However, pSS patients cannot be 
distinguished from those with non-pSS sicca syndrome according to this feature (van 
Woerkom et al., 2005, Alunno et al., 2013). Th17 cells rely on TGF-β, IL-6 and IL-1β for 
differentiation. Th17 cells and their products (IL-17, IL-6, IL-23 and IL-12) have also been 
implicated in pSS, as expansion of Th17 cells in pSS patients and animal models of SS as 
well as their role in the immunopathology in pSS has been documented (Katsifis et al., 
2009, Lin et al., 2014). Moreover, it has been suggested that Th17 cells play a critical role 
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in the pathology of pSS in animal models and might be a possible target for pSS treatment 
(Lin et al., 2015). With regard to regulatory T cells, it has been shown that FOXP3
+ 
Tregs 
were increased in severe lesions in the minor salivary gland of pSS patients. Furthermore, a 
reduced number of FOXP3
+ 
Treg
 
cells correlated with adverse predictors of lymphoma 
development such as low C4 levels and salivary gland enlargement (Christodoulou et al., 
2008). Another study recently described a subset of CD4
+
 T-cells, called the follicular T 
helper cells (Tfh), in the labial salivary gland in pSS patients. Tfh contributes to the 
progression of pSS, as these cells play an important role in the development of B-cells, and 
they are associated with the lymphocytic infiltration in pSS and the formation of GC-like 
structure (Maehara et al., 2012, Gong et al., 2014). 
B-cells are among the infiltrating cells in the salivary gland and are also the source of 
autoantibody production. The main types of infiltrative B-cells are type II transitional B-
cells (IgD
high
, CD38
low
) and the marginal zone-like B-cells (Youinou et al., 2010). Other B-
cell types that are found in pSS salivary glands include memory B-cells, naïve B-cells, 
plasmablast and long-lived plasma cells. The frequency of memory B-cells was less than 
other types of B-cells while the long-lived plasma cells seemed to have the highest 
frequency in the salivary gland (Aqrawi et al., 2012). In pSS patients, CD27
+
 memory B-
cells were found to be accumulating in the parotid glands, which might explain the finding 
of the reduction of these cells in peripheral blood (Hansen et al., 2002).  
The interaction between T-cells, B-cells and chemokines is known but not fully understood. 
Recently, Jin and colleagues have reported that B-cell maturation is promoted by 
CD4
+
CXCR5
+
Tfh cells, which are CD4
+
 T-cells that highly express the chemokine receptor 
CXCR5 which control Tfh migration to the salivary gland. In their study, the number of 
CD4
+
CXCR5
+
Tfh cells was increased in both the salivary glands and peripheral blood of 
pSS patients and was associated with increased number of abnormal CD19
+
CD27
+
 memory 
B cells and CD19
+
CD27
high
 plasma cells in the salivary glands, suggesting that these 
CD4
+
CXCR5
+
Tfh cells might contribute to pSS pathogenesis by promoting B-cells 
maturation (Jin et al., 2014a). The newly described regulatory B-cells (Bregs), which 
include CD19
+
CD24
hi
CD38
hi
 IL-10 producing cells, has been implicated in pSS 
(Furuzawa-Carballeda et al., 2013), but their role in pSS is still not clear. 
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Other immune cells that may be associated with the pathology of pSS include dendritic 
cells, monocytes and macrophages. It is likely that all these cells work together with 
various autoantibodies, cytokines and chemokines leading to the development of this 
complex inflammatory disease.              
Autoantibodies in pSS 
The presence of autoantibodies has been well described in autoimmune diseases. In pSS, 
the most commonly associated autoantibodies are antibodies against Ro/SSA and La/SSA 
autoantigens. Ro/SSA has two non-homologous proteins, Ro52/TRIM21 and 
Ro60/TROVE2. The tripartite motif Ro52/TRIM21 participates in many functions such as 
acting as an intracellular Fc-receptor or E3-ubiquitin ligase. When Ro52/TRIM21 serves as 
an E3-ubiquitin ligase, it regulates cell proliferation, as well as the activation and induction 
of cell death. Additionally, it regulates TLR-signaling leading to the production of 
interferon (IFN) through polyubiquitin-mediated degradation of interferon regulatory 
factors (IRFs); (reviewed (Oke and Wahren-Herlenius, 2012, Yang et al., 2009, Kyriakidis 
et al., 2014). The ring-shaped RNA binding protein (Ro60/TROVE2) is involved in RNA 
degradation, promoting cell survival after UV irradiation (Bollain-y-Goytia et al., 2000).  
Researchers have also showed that other type of autoantibodies are linked to pSS. For 
example, antinuclear antibodies (ANA) are found in 83% of pSS patients (Nardi et al., 
2006). Rheumatoid factor (RF) and cryoglobulins are also associated with pSS, present in 
36–74% and 9–15% of pSS sera respectively (Fauchais et al., 2010, Martel et al., 2011). 
The presence of cryoglobulins predicts a poor disease outcome and an increased risk of 
lymphoma development. Anti-centromere antibodies (ACA) are found in 3.7–27.4 % of 
pSS patients (Caramaschi et al., 1997, Hsu et al., 2006). Another autoantibody, anti-
mitochondrial antibody (AMA), has also been implicated in pSS (Zurgil et al., 1992). 
Antibodies against muscarinic receptor (anti-M3R), smooth muscle (anti-SMA)), carbonic 
anhydrase II (anti-CA-II) and cyclic citrullinated peptides (anti-CCP) have also been 
reported in pSS (Manthorpe et al., 1979, Bacman et al., 1996, Takemoto et al., 2005, 
Barcelos et al., 2009).           
Cytokines and chemokines in pSS 
Cytokines are produced by a variety of cells and their role is to regulate both innate and 
adaptive immunity. pSS is a chronic inflammatory disease and the chronic inflammatory 
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responses indicate cytokine imbalance in the affected organs and peripheral blood. The 
predominance of Th2 cytokines occurs in the initial stages of pSS, with disease 
progression, Th1 cytokines become more prevalent (Mitsias et al., 2002). Cytokines can act 
as pro-inflammatory or anti-inflammatory agents. Since the association of IFN in pSS has 
been widely investigated. Type I IFN includes IFN-α and IFN-β, and its upregulation in the 
salivary gland and peripheral blood of pSS patients has been well documented. It is thought 
that plasmacytoid dendritic cells (pDCs) found in pSS salivary glands are responsible for 
the production of IFN-α (Emamian et al., 2009, Oxholm et al., 1992, Gottenberg et al., 
2006, Szodoray et al., 2005). In addition to type I IFN, high levels of type II IFN 
(represented by IFN-γ) have also been documented in both the sera and salivary glands of 
pSS patients and may play a pathological role in pSS (Willeke et al., 2009).  
Another cytokine named Tumour Necrosis Factor alpha (TNF-α), which is produced by 
epithelial cells and CD4
+
 T-cells, correlates with the degree of systemic features of pSS 
(Garcic-Carrasco et al., 2001). Interestingly, both TNF-α and interleukin (IL)-1β are found 
in high levels in pSS patients and may contribute to the chronic inflammatory features of 
pSS within the affected glands (Ek et al., 2006). IL-12 and IL-18, both produced by 
monocytes and macrophages, are elevated in pSS and promote the secretion of IFN-γ 
(Dinarello, 2007, Manoussakis et al., 2007). IL-6 contributes in many functions, it plays a 
role in the differentiation and growth of B-cells and is present at high levels in the sera of 
pSS patients. IL-6 also stimulates T-cells and their transition to cytotoxic T-cells. Finally, 
IL-6 works with TNF-α in contributing to the inflammatory features in the pSS salivary 
gland (Ishihara and Hirano, 2002, Vucicevic Boras et al., 2006). The levels of B-cell 
activating factor (BAFF), known also as the tumour necrosis factor ligand superfamily 
member 13 B (TNFSF13B), are elevated in the serum and salivary glands of pSS patients 
(Szodoray et al., 2004). Moreover, it has also been suggested that A proliferation-inducing 
ligand (APRIL), which is another ligand of the BAFF receptor, may be important in pSS 
pathogenesis (Vosters et al., 2012). Other pro-inflammatory cytokines such as IL-17, IL-21 
and IL-22 and anti-inflammatory cytokines such as IL-4, IL-10 and TGF-β, may also be 
involved in pSS pathogenesis. More recently, over-expression of IL-22 receptor in pSS and 
pSS-associated lymphoma and the regulation of IL-22 by IL-18 have been reported (Ciccia 
et al., 2015).  
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Chemokines are important in the activation and chemotaxis of leucocytes and maintaining 
the Th1/Th2 balance in diseases and conditions such as autoimmune diabetes, atopic 
keratoconjunctivitis and cutaneous lupus erythematosus (Kim et al., 2002, Yamagami et al., 
2005, Wenzel et al., 2005). In pSS, they are involved in the process of recruiting 
inflammatory cells (T-cells) into the salivary gland. For instance, interferon-γ–inducible 10-
kd protein (IP-10) also known as (CXCL10) and monokine induced by IFN-γ (MIG) also 
known as (CXCL9) have been implicated in pSS pathogenesis (Ogawa et al., 2002). 
Another chemokine reported to be associated with pSS is chemokine (C-X-C Motif) Ligand 
13 (CXCL13), which regulates B-cell chemotaxis and serves as a biomarker for pSS 
(Kramer et al., 2013). More recently, it has been reported that high levels of serum 
CXCL13 was associated with lymphoma development and disease activity in pSS patients 
(Nocturne et al., 2015a) 
1.3 The pathogenesis of primary Sjögren's Syndrome: 
The exact aetiology of pSS is unknown. It is believed that one of the potential disease 
triggers is viral infection. Various viruses have been implicated, including Epstein–Barr 
virus (EBV), Human T-Lymphotropic virus 1 (HTLV-1) and retroviruses (Ramos-Casals et 
al., 2002, James et al., 2001, Terada et al., 1994, Lee et al., 2012).  Another aetiological 
factor is genetic predisposition, in particularly the major histocompatibility complex 
(MHC) class II molecules (Nakken et al., 2001). There is strong evidence for a relationship 
between the development of pSS and polymorphisms of MHC class II molecules. In 
European pSS patients, the production of anti-SSB/La autoantibodies correlates with the 
presence of human leukocyte antigen (HLA)-DQ heterodimer and is highly associated with 
HLA-DQB1*02 and HLA-DQA1*0501 allele (Tzioufas et al., 2002). HLA-DR2, DR3, and 
DQ8 are correlated with T-cell and B-cell responses to the human Ro60 molecules in mice 
(Paisansinsup et al., 2002). Meta-analyses of STAT4 rs7574856 single nucleotide 
polymorphism (SNP) showed a significant effect of the T allele on pSS development, 
implicating the gene in pSS pathogenesis (Palomino-Morales et al., 2010). Furthermore, it 
has been suggested that IRF-5, in particular the IRF5 rs2004640 T allele, may represent a 
genetic susceptibility allele but this finding requires confirmation using a bigger population 
(Miceli-Richard et al., 2007). Lessard and colleagues (2013) conducted a genome–wide 
association study (GWAS) to identify new risk loci that are important in the development 
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of pSS. In this study, the association of HLA region at 6p21 was revealed. In addition, new 
association were established as all of the associations identified surpassed the genome-wide 
significant (GWS) threshold (p= 5 × 10
-8
) including the interferon regulatory factor 5 
(IRF5), Signal transducer and activator of transcription 4 (STAT4), IL-12A, Family with 
sequence similarity 167, member A- B lymphoid kinase (FAM167A-BLK), chemokine (C-
X-C motif) receptor 5 (DDX6-CXCR5) and TNFAIP3 interactive protein 1 (TNIP1). 
Moreover, 8 associations were identified (statistically significant in the meta-analysis) but 
they did not exceed the GWS threshold, these associations were TNFAIP3, PTTG1, 
PRDM1, DGKQ, FCGR2A, IRAK1BP1, ITSN2, and PHIP (Lessard et al., 2013). In another 
study, GWAS experiment was performed in three stages (discovery and 2 replication 
stages), using samples from pSS patients and controls in Han Chineses. The previously 
identified associations of STAT4, TNFAIP3 and the MHC regions with pSS in Europeans 
were also confirmed in the Han Chinese samples. In addition, a new susceptibility locus 
represented by GTF2I at 7q11.23 was identified. Moreover, the rs117026326 in GTF2I 
showed the most significant  association with pSS (Li et al., 2013). Furthermore, in another 
study, 2 SNPs in TNIP1 (NF-κB repressor) were identified to be associated with 
seropositive pSS patients. The 2 identified SNPs are rs3792783 and rs7708392 (Nordmark 
et al., 2013).  
The first stage of pSS pathology is lymphocytic infiltration into the salivary and lacrimal 
glands. The cellular infiltrate is composed of T cells (CD4
+
) which form about 50–70% of 
the total population, other immune cells may also be involved and their proportion vary 
according to severity of the disease (Christodoulou et al., 2010). However, some patients 
suffer from glandular dysfunction without having severe inflammatory infiltration. In such 
cases, glandular dysfunction might be the result of an imbalance between pro-inflammatory 
(IFNs, IL-12, IL-18, TNF-α, IL-1β, IL-6, BAFF, IL-17 and IL-23) and anti-inflammatory 
cytokines (Transforming growth factor β (TGFβ), IL-4 and IL-10). The overall 
inflammatory milieu may decrease fluid secretion as well as cause systemic manifestations 
and lymphomagenesis (Roescher et al., 2009). 
Interestingly, vitamin D, which is known for its immune-modulatory function, may also be 
important in pSS. In this regard, the association between decreased levels of vitamin D and 
the presence of neuropathy or lymphoma has been described in pSS as well as in other 
conditions (Agmon-Levin et al., 2012).    
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Overall, exposure to the possible etiological factors leads to an imbalance of the 
immunological and autoimmune responses. Furthermore, glandular epithelial cells 
activation leads to the production of exosomes and apoptotic blebs that contain intracellular 
antigens. These self-antigens are then captured by antigen-presenting cells, which in turn 
may further promote the autoimmune responses. These biological processes eventually lead 
to glandular inflammation (Tzioufas et al., 2012). Figure 1.1 illustrates a possible model of 
pSS pathogenesis.       
 
 
Figure 1.1 A hypothetical model for pSS pathogenesis (Ramos-Casals et al., 2012) 
1.4 Biomarkers in pSS: 
A biomarker can be defined as a substance or a chemical that indicates a certain biological 
state. Biomarkers are useful for the assessment of normal vs. pathological states. 
Definitions of biomarkers in the literature share the same concepts. In 1998, the National 
Institute of Health Biomarkers Definition Working Group, defined a biomarker as ‘a 
characteristic that can be objectively measured and evaluated as an indicator of normal 
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biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention’. The World Health Organization (WHO), the United Nations and the 
International Labour Organization define biomarkers as ‘any substance, structure, or 
process that can be measured in the body or its products and influence or predict the 
incidence of outcome or disease’ (reviewed in (Strimbu and Tavel, 2010). 
The detection of biomarkers in pSS is useful for several reasons. First, the diagnosis of pSS 
involves an invasive procedure (biopsy) that may lead to diagnosis delay. Since pSS affects 
the salivary glands, identification of pSS biomarkers in the saliva is a promising approach. 
Accordingly, Hu and colleagues (Hu et al., 2007) identified protein and genomic 
biomarkers in the saliva of pSS patients. In their study, they have discovered 16 protein 
biomarkers in the whole saliva of pSS patients: 10 were upregulated and 6 were 
downregulated in pSS in comparison to healthy controls. In addition, they investigated the 
presence of genomic biomarkers in saliva. They reported the detection of the expression of 
27 genes including GIP2, which is an IFN-α inducible gene, could differentiate pSS cases 
and controls.  
Recently, a study reported profilins and carbonic anhydrase I (CA-I) as biomarkers in oral 
fluids in pSS, after removing high-abundance proteins in the samples (Deutsch et al., 2015, 
Krief et al., 2011). Profilins, which are actin–binding proteins, play a role in organizing 
microfilaments and cell motility, and regulate the dynamics of the actin polymerization as 
well as the development of embryos. Profilins contribute to many biological processes such 
as membrane trafficking and nuclear activity, as well as tumour formation (Witke, 2004, 
Rawe et al., 2006). Additionally, profilins have also been reported as a biomarker for oral 
cancer (Hu et al., 2008). CA-I is a metalloenzyme that is involved in many biological 
processes; its main role is to catalyse the hydration of carbon dioxide (Supuran, 2008). In 
addition, CA-I was also reported to predict the presence of oral squamous cell carcinoma 
(Liu et al., 2012). Another recent proteomic study revealed that salivary IL-4, IL-5 and 
clusterin were biomarkers of pSS (Delaleu et al., 2015).  
Along with the salivary glands, pSS also affects the lacrimal glands. Therefore, it has been 
proposed that tear fluid may be another source for pSS biomarkers. Tear cathepsin S was 
recently found to be increased significantly in pSS patients. Although cathepsin S activity 
was elevated in tear samples, it did not correlate with anti-Ro/SSA or anti-La/SSB levels in 
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pSS patients (Hamm-Alvarez et al., 2014). Furthermore, PAX6, a corneal lineage 
commitment regulator, is down-regulated in pSS which is associated with ocular surface 
damage in pSS patients depending on the levels of inflammation. Thus, PAX6 has been 
suggested to be a biomarker for ocular damage in pSS (McNamara et al., 2014). Several 
other biomarkers have also been reported in pSS. Many studies have shown that IFN type I 
activation is a common feature in pSS (Bave et al., 2005, Brkic et al., 2013, Brkic and 
Versnel, 2014). Moreover, myxovirus resistance protein A (MxA), which is a marker of 
type I IFN activity, correlates with disease activity and is reduced by IFN inhibitors such as 
hydroxychloroquine (Maria et al., 2014).  
Regarding genomic biomarkers, the contribution of epigenetics was investigated in pSS 
including DNA methylation, histone modification and microRNA (miRNA) (Konsta et al., 
2014). Several studies have been performed in order to identify miRNA biomarkers in pSS. 
For instance, miRNA-768-3p and miRNA-574 were found to be associated with salivary 
gland dysfunction (Alevizos et al., 2011). In addition, miRNA-146a was significantly 
elevated in pSS patients peripheral blood mononuclear cells (PBMCs) as well as in 
PBMCs, the salivary and lacrimal glands of SS-prone mice and WT C57BL/6J mice 
(Pauley et al., 2011). Another miRNA, miR-5100, was reported to be a biomarker for 
salivary gland function in pSS (Tandon et al., 2012).  
 
1.5 The diagnosis of primary Sjögren’s Syndrome: 
In 1993, the preliminary criteria for the classification of Sjögren's Syndrome were proposed 
(Vitali et al., 1993). Later on in 2002, the American-European Consensus Group (AECG) 
revised these to produce a more reliable set of criteria that enable a more accurate diagnosis 
for the syndrome. The AECG classification criteria include 6 criteria—ocular symptoms, 
oral symptoms, ocular signs, histopathology of minor salivary gland biopsies, salivary 
gland involvement and autoantibodies (Table 1.1) (Vitali et al., 2002). To fulfil the AECG 
criteria, a subject has to fulfil a minimum of 4 out of 6 criteria, of which must include either 
positive histopathology or autoantibodies or both. A subject fulfilling 3 out of the 4 
objective criteria can also be classified as having pSS.        
A new set of classification criteria were proposed recently by the American College of 
Rheumatology (ACR), led by investigators of the Sjögren’s International Collaborative 
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Clinical Alliance (SICCA) (Shiboski et al., 2012). The classification criteria proposed by 
SICCA are illustrated in Table 1.2. The ACR classification requires the fulfilment of at 
least 2 out of 3 criteria.  
The ACR classification criteria include the addition of IgG4-related disease as an exclusion 
criterion, as IgG4-related disease mimics pSS in some features (Masaki et al., 2009). The 
exclusion criteria of the ACR classification criteria include: History of head and neck 
radiation treatment, Hepatitis C infection, AIDS, Sarcoidosis, Amyloidosis, Graft versus 
host disease and IgG4-related disease (reviewed in (Fazaa et al., 2014). An ACR-EULAR 
working group is currently developing a revised set of ACR-EULAR criteria, with the aim 
of unifying the AECG and ACR criteria. 
Table 1.1 AECG classification criteria for primary Sjögren’s Syndrome(Vitali et al., 
2002) 
AECG classification criteria for Sjögren’s syndrome  
I. Ocular symptoms: a positive response to at least one of the following questions: 
1. Have you had daily, persistent, troublesome dry eyes for more than 3 months? 
2. Do you have a recurrent sensation of sand or gravel in the eyes? 
3. Do you use tear substitutes more than 3 times a day? 
II. Oral symptoms: a positive response to at least one of the following questions: 
1. Have you had a daily feeling of dry mouth for more than 3 months? 
2. Have you had recurrently or persistently swollen salivary glands as an adult? 
3. Do you frequently drink liquids to aid in swallowing dry food? 
III. Ocular signs—that is, objective evidence of ocular involvement defined as a positive result for at 
least one of the following two tests: 
1. Schirmer’s I test, performed without anaesthesia (<5 mm in 5 minutes) 
2. Rose bengal score or other ocular dye score (>4 according to van Bijsterveld’s scoring system) 
IV. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal 
lymphocytic sialoadenitis, evaluated by an expert 
histopathologist, with a focus score >1, defined as a number of lymphocytic foci (which are adjacent to 
normal-appearing mucous acini and contain more than 50 lymphocytes) per 4 mm
2
 of glandular tissue 
V. Salivary gland involvement: objective evidence of salivary gland involvement defined by a positive 
result for at least one of the following diagnostic tests: 
1. Unstimulated whole salivary flow (<1.5 ml in 15 minutes) 
2. Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary or destructive   pattern), 
without evidence of obstruction in the major ducts 
3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer 
VI. Autoantibodies: presence in the serum of the following autoantibodies: 
1. Antibodies to Ro(SSA) or La(SSB) antigens, or both 
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Table 1.2 Classification criteria proposed by the Sjögren International Collaborative 
Clinical Alliance Group (SICCA). A patient can be classified as having pSS when there 
are at least 2 out of the 3 of the following criteria (Shiboski et al., 2012) 
Classification criteria  
 Positive serum anti-SSA/Ro and/or anti-SSB/La or (positive rheumatoid factor and 
antinuclear antibodies with titre ≥1:320) 
 Labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus 
score ≥1 focus/4 mm2 
 Keratoconjunctivitis sicca with ocular staining score ≥ 3 (assuming that individual is 
not currently using daily eye drops for glaucoma and has not had corneal surgery or 
cosmetic eyelid surgery in the last 5 years) 
 
1.5.1 The UK primary Sjögren's Syndrome Registry (UKPSSR): 
The UK primary Sjögren's Syndrome Registry (UKPSSR) was established in 2009. To 
date, it consists of a cohort of over 800 pSS patients recruited from 35 centres from the UK. 
All patients fulfil the AECG classification criteria and the clinical data that have been 
collected in the registry are provided in Table 1.3. All information is stored in a secured 
database in an anonymised manner. The samples that have been collected include 
peripheral blood mononuclear cells, whole blood RNA, DNA and serum samples. In 
addition, age- and sex-matched healthy controls are also being recruited, with over 350 
recruited to date (Ng et al., 2011). 
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Table 1.3 The clinical and outcome measure data collected for the UKPSSR (Ng et al., 
2011) 
Clinician’s assessment Patient-reported outcome 
AECG classification criteria 
Demographics 
Treatment (pharmacological and non-
pharmacological) 
Comorbidity 
Disease activity 
  ESSDAI 
  SCAI 
  SSDAI 
Disease damage 
  SDI 
  SSDDI 
Optional 
  Cardiovascular risk assessment 
Symptom assessment 
  PROFAD-SSI 
  ESSPRI 
  Epworth Sleepiness Scale 
  Orthostatic symptoms scale 
Quality of life 
  EQ-5D 
  SF-36 
Anxiety and depressive symptoms 
  HADS 
Optional 
  Autonomic symptoms (COMPASS) 
  Cardiovascular risk 
  Lifestyle (smoking, physical activity) 
Clinician’s assessment Patient-reported outcome 
1.6 The treatment of primary Sjögren’s Syndrome: 
Currently there is no effective treatment for the syndrome and that in part is because the 
exact aetiology that triggers the disease is unknown. It is important for patients to be aware 
of the symptoms and the consequences so that general measures can be taken by the 
patients, such as strict maintenance of dental hygiene, avoidance of smoking and dry 
environments and the application of eye ointments and petroleum jelly on the lips 
(Venables, 2004). In addition, fluid replacement is often used for alleviating the sicca 
symptoms (Talal, 1991). Oral pilocarpine may be helpful in improving symptoms but not in 
objective measures such as Schirmer’s test (Tsifetaki et al., 2003). Pilocarpine as well as 
cevimeline are being used for xerostomia symptoms in pSS. Both medications stimulate the 
M1 and M3 receptors in the salivary glands and therefore enhance the secretary function 
(Fox et al., 2001, Fife et al., 2002). Other medications may be used for both glandular and 
extra-glandular manifestations. These medications include corticosteroids and other 
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immunomodulatory drugs such as: hydroxychloroquine, which may be effective in 
reducing salivary gland inflammation (Tishler et al., 1999); methotrexate (Winzer and 
Aringer, 2010); and cyclophosphamide (Mavragani and Kassan, 2012). Other 
immunomodulatory drugs such as leflunomide, interferon-α, mizoribine, mycophenolic 
acid, rebamipide, cladribine and fingolimod have also been tried in pSS treatment (Carsons, 
2012) but none of these medications are commonly used in clinic. Finally, the use of 
biological therapies in pSS is gaining interest among clinicians, researchers and the 
pharmaceutical industry. For instance, rituximab (RTX), an antibody against CD20 
expressed on most B-cell surface and B-cell lymphoma cells, is being investigated as a 
treatment for pSS with or without lymphoproliferative disorders (Somer et al., 2003, 
Quartuccio et al., 2009). Seror and colleagues reported that RTX treatment showed a good 
efficacy in 4 out of 5 pSS-associated lymphoma patients and 9 out 11 pSS patients with 
systemic features. Moreover, RTX treatment increased the level of BAFF along with B cell 
biomarkers level’s decline (Seror et al., 2007). The efficacy of RTX treatment in pSS 
patients was evaluated in a placebo-controlled randomised controlled trial (RCT), which 
consist of 120 patients with recent disease onset. In addition, all patients had visual 
analogue scales (VAS) > 50 mm in at least 2 out of 4 of global disease, pain, fatigue and 
dryness. Primary endpoint was measured at 24 weeks. Although RTX treatment did not 
show significant improvement in disease activity or symptoms over placebo at 24 week, 
significant improvement of some symptoms were noted in the RTX group at earlier time 
points (6 weeks) of the trial especially with the fatigue VAS score which was decreased by 
30 mm (Devauchelle-Pensec et al., 2014).     
1.7 Gene expression and primary Sjögren's Syndrome: 
Gene expression studies have been investigated in pSS using different kinds of samples 
including: exocrine gland biopsies, PBMCs and whole blood. Each of these studies will be 
described in more detail below.   
1.7.1 Gene expression studies in the salivary glands: 
The use of microarray profiling to investigate global gene expression in the minor salivary 
glands has been documented in several studies, implicating several chemokines, cytokines, 
the MHC molecules, the Bcl-like gene and the type I interferon (IFN) pathways in pSS. 
These data suggest that both innate and acquired immune system contribute to the pSS 
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pathology. In one study, CXCL13 and CD3D were overexpressed in more than 90% of pSS 
patients. Furthermore, lymphotoxin β, several MHC genes, cytokines and lymphocyte 
activation factors were also overexpressed. Type I IFNs, which play an important role in 
the protection against viral infections, were among the top 200 genes that were 
overexpressed in the minor salivary glands of pSS patients (Hjelmervik et al., 2005). In 
another study, 23 genes of the IFN pathway, including  Toll like receptor 8 and 9 (TLR8 
and TLR9), were found to be differentially expressed in salivary gland epithelial cells of 
pSS patients. Moreover, stimulation of salivary gland epithelial cells (SGECs) in vitro with 
IFN induced the expression of these genes (Gottenberg et al., 2006). Conversely, some 
genes were reported to be down-regulated such as carbonic anhydrase II and bcl-2 genes 
(Hjelmervik et al., 2005).  
1.7.2 Gene expression studies in lacrimal glands: 
The lacrimal gland is another organ affected in pSS. The main clinical manifestation is the 
reduction of tear secretion, which in turn results in chronic irritation of the eyes and 
keratoconjuctivitis sicca (KCS) (Rose and Mackay, 1998). Studying lacrimal glands faces 
many challenges. First, it is difficult to obtain a biopsy sample from the glands. Second, the 
lacrimal gland biopsy itself might result in more complications for the patient. As a result, 
few studies have investigated gene expression in human lacrimal glands. One study has 
shown that Fas, FasL and BAX genes, involved in promoting lacrimal glands epithelial 
cells apoptosis (pro-apoptotic genes), were up-regulated in pSS lacrimal glands; at the same 
time, the anti-apoptotic gene bcl-2 were down-regulated in the same patients (Wu et al., 
2000). Furthermore, in another study increased expression levels of IFITM1 and BAFF 
(2.5-fold and 3-fold, respectively) were reported in the conjunctival cells of pSS patients 
(Gottenberg et al., 2006). 
The majority of lacrimal gland studies were carried out on animal models, with easier 
access to lacrimal gland sampling. Data from these gene expression studies implicated 
abnormality in inflammatory responses, secretory function of the glands and the gland’s 
structure organization in the disease process. In an animal model using C57BL/6.NOD-
Aec1Aec2 mice, Nguyen and colleagues performed lacrimal glands gene expression 
profiling in the early phase of the disease.  Their experiment collected data at intervals 
ranging from 4–20 weeks and showed that 552 genes were differentially expressed. These 
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included ApoE, Baff, Clu, Ctla4, Fas/Fasl, Irf5, Lyzs, Nfkb, Socs3, Stat4, Tap2, Tgfb1, 
Tnfa, and Vcam1. Most of the differentially expressed genes were related to apoptosis and 
fatty acid homeostasis (Nguyen et al., 2009). Additionally, changes in gene expression were 
observed in the genes encoding the inter-epithelial junction proteins and the focal adhesion 
maturation; these changes led to an increase of infiltration of leukocytes into the lacrimal 
glands in the early stages of dacryoadenitis in C57BL/6.NOD-Aec1Aec2 mice (Peck et al., 
2011). 
1.7.3 Gene expression studies in peripheral blood: 
Peripheral blood consists of various types of cells which might provide a source of 
information about the ongoing biological events in pSS. Few studies have investigated 
peripheral blood gene expression profiling in pSS and pSS-associated lymphoma. Similar 
to the findings from gene expression in the salivary glands, activated IFN pathways were 
documented in these studies (Wildenberg et al., 2008, Emamian et al., 2009, Ogawa, 2010). 
Furthermore, a marked overexpression of the IFN-inducible gene, IFN-α–inducible protein 
27 (IFI27), was reported in one study (Kimoto et al., 2011). In another study, the 
overexpression of the genes that control IFN-α was demonstrated in the blood samples from 
pSS patients, in parallel with the overexpression of these genes in the labial salivary glands 
of these patients (Zheng et al., 2009). A very recent study has shown that miR-155 and the 
suppressor gene of cytokine signalling 1 (SOCS1) were overexpressed in the PBMCs of 
pSS patients (Chen et al., 2015a). The published peripheral blood gene expression data is 
summarised in more details in the introductions of Chapters 3 and 4.  
1.8 Primary Sjögren’s syndrome -associated lymphoma: 
The lymphomas associated with pSS not only develop in the affected organs such as the 
salivary glands, but might also develop in other extra-nodal sites such as the stomach, lungs 
and skin. The commonest type of lymphoma was the extranodal marginal-zone B-cell 
lymphoma of the mucosa-associated lymphoid tissue (MALT) (Voulgarelis et al., 1999). 
Furthermore, different types of non-Hodgkin’s lymphoma have been reported in pSS 
patients in addition to MALT lymphoma including low-grade marginal-zone lymphoma 
(MZL), and high-grade B cell-lymphomas such as diffuse large B cell lymphoma (DLBCL) 
(Royer et al., 1997, Kim et al., 2012). Although the first association of lymphoma with pSS 
was described in 1963, the increased risk of lymphoma development in pSS was not 
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reported until 1978. Lymphoma was found in 4.3% of pSS patients in a study carried out in 
1999 (Voulgarelis et al, 1999). The relative risk (RR) of lymphoma in pSS, especially non-
Hodgkin’s lymphoma (NHL) has been investigated in several studies and in different pSS 
cohorts. The first published study estimated up to a 44 times higher risk in pSS patients 
(Kassan et al., 1978). In two other studies, the RR was 15–20 while another study reported 
an odds ratio of 6.1 (95% CI: 1.4 to 27) (Zintzaras et al., 2005, Theander et al., 2006, 
Smedby et al., 2006). Recently, another study evaluated the risk of lymphoma development 
in pSS in a Norwegian cohort, reporting a 9-time increase in lymphoma development in 
pSS patients than the general population (Johnsen et al., 2013). Recently, a meta-analysis of 
the association of NHL with autoimmune diseases showed a smaller standardized incidence 
ratio (SIR) of 4.9 in pSS patients (Fallah et al., 2014). The SIR of lymphoma was estimated 
in different cohorts since 1978 and a summary of these studies is demonstrated in Table 1.4 
as reviewed in (Nishishinya et al., 2015).  
 
Table 1.4 Standardized incidence ratio of lymphoma in different pSS cohorts 
(Nishishinya et al., 2015) 
Study Name of the study cohorts Number of 
lymphomas 
SIR (95% CI) 
(Kassan et al., 1978)  Connecticut cancer register 4 44.40 (16.70–118.40) 
(Kauppi et al., 1997) Finnish cancer registry 11 8.70 (4.30–15.50) 
(Valesini et al., 1997) Local cancer registers 9 33.30 (17.30–64.00) 
(Davidson et al., 1999)  Cancer registry statistic 3 14.40 (4.70–44.70) 
(Pertovaara et al., 2001) Finnish cancer registry 3 13.00 (2.70–38.00) 
(Theander et al., 2006) National and local registers 11 15.57 (7.80–27.90) 
(Lazarus et al., 2006) Thames cancer registry 11 37.50 (20.70–67.60) 
(Zhang et al., 2010) Local cancer registers 8 48.10 (20.70–94.80) 
(Solans-Laque et al., 2011) GLOBOCAN database 11 15.60 (8.70–28.20) 
(Weng et al., 2012) Nationwide population 
cohort 
23 7.10 (4.25–10.30) 
(Johnsen et al., 2013) Cancer registry of Norway 7 9.00 (7.10–26.30) 
(Fallah et al., 2014) Nationwide cohort (meta-
analysis) 
143 4.90 (4.20–5.80) 
SIR—standardized incidence ratio, CI—confidence interval 
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1.8.1 Risk factors in pSS-associated lymphoma  
Several studies have examined risk factors for NHL development in pSS. These risk factors 
include: recurrent or constant swelling of salivary glands, lymphadenopathy, 
cryoglobulinaemia, splenomegaly, and lymphopenia; other factors include low complement 
factor C4 and C3, skin vasculitis or palpable purpura, monoclonal components in serum or 
urine, peripheral neuropathy, glomerulonephritis, elevated β2-microglobulin, CD4
+
 T-
lymphocytopenia, germinal center-like structures in minor salivary gland biopsies, genetic 
factors, and down-regulation of A20 (Jonsson et al., 2012, Ioannidis et al., 2002).  
Lymphadenopathy, which is an abnormal enlargement of the lymph node, is reported to be 
associated with pSS (Chen et al., 2013). Cryoglobulins, are serum immunoglobulins that 
precipitate at low temperatures. Three types of cryoglobulins have been described: type I 
(simple cryoglobulins) are monoclonal immunoglobulins which are mostly IgM. Type I 
cryoglobulins often accompany haematological disorders and monoclonal gammopathy. 
Type II and III are “mixed” cryoglobulins. Type II cryoglobulins consist of monoclonal 
IgM with rheumatoid factor (RF) activity and polyclonal IgG. Type III cryoglobulins also 
consist of polyclonal IgG, IgM and/or IgA, with one of them having RF activity. Type II 
and III cryoglobulins are associated mostly with systematic and infectious diseases. Mixed 
monoclonal cryoglobulinaemia as well as the monoclonal rheumatoid factor (mRF)–
associated cross-reactive idiotype (CRI) have been reported as predictive factors in pSS-
associated lymphoma (Tzioufas et al., 1996). Consistently, cryoglobulinaemia is associated 
with pSS-associated lymphoma (in particularly low-grade lymphoma) (Charitaki et al., 
2011, Anand et al., 2015). Recently, Quartuccio and colleagues reported the association of 
lymphoma with cryoglobulinaemic vasculitis (CV), but not with cutaneous vasculitis or 
hypergammaglobulinaemic vasculitis (HGV) in pSS patients (Quartuccio et al., 2015). 
Splenomegaly has been reported as a risk factor for lymphoid malignancies (Hall and Kahl, 
2015). The association of splenomegaly, cryoglobulinaemia and lymphopenia as lymphoma 
predictors in pSS has been noted in (Baimpa et al., 2009). Recently, RF was reported along 
with disease activity to be predictors of lymphoma development in pSS patients. These data 
was estimated in 101 pSS-associated lymphoma patients (Nocturne et al., 2015c).  
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1.8.2 Gene expression, biomarkers and predictors in pSS-associated lymphoma: 
Several studies have examined gene expression in pSS-associated lymphoma. The main 
limitation with these studies is their small sample sizes. For instance, Hu and colleagues, 
comparing the gene expression in the parotid glands with pSS-associated lymphoma and 
those without, reported eight candidate genes that discriminated pSS from pSS-associated 
lymphoma (Hu et al., 2009). These genes, listed in order of the highest level of statistical 
significant (lowest p-value), include GRB2, ARHGDIB, CD40, PSMB9, ALDOA, PRDXS, 
PARC and PPIA. The key limitation of this study was the small sample size, with only 8 
pSS and 9 pSS-associated lymphoma samples.  
Several clinical and serological parameters have been proposed as predictors for lymphoma 
development in pSS patients. One of the interesting biomarkers in pSS-associated 
lymphoma is Fms-like tyrosine kinase 3 ligand (Flt-3L). The serum level of Flt-3L was 
elevated in treated pSS-associated lymphoma (history of lymphoma) as well as at time of 
lymphoma diagnosis. Moreover, high levels of Flt-3L were associated with the presence of 
risk factors of lymphoma including low levels of C4 and IgM, high levels of β2-
microglobulin and pSS disease activity, lymphopenia and the presence of purpura (Seror et 
al., 2010, Tobon et al., 2013). Another biomarker that has been reported in pSS-associated 
lymphoma is the B-cell homeostatic chemokine CXCL13. This chemokine was reported to 
be elevated in both the serum and the salivary gland of pSS patients (Kramer et al., 2013, 
Chen et al., 2015b). Furthermore, CXCL13 is known for its association with ectopic 
reactive lymphoid tissue in the salivary gland of MALT lymphoma in pSS (Barone et al., 
2008). In addition, the serum level of CXCL13 was reported to be significantly high in 
pSS-associated lymphoma patients in compare with pSS patients without lymphoma 
(Nocturne et al., 2015a)   
The germinal center (GC)–like structure in the labial salivary glands is described as a 
potential predictive biomarker of lymphoma in pSS: in one study the GC-like structure 
occurred in 25% of pSS patients (43 patients out of 175); within this subgroup 6 patients 
who subsequently developed lymphoma were GC+ at the time of diagnosis. In contrast, 
among those without GC on biopsy at the time of diagnosis (n = 132), only one pSS patient 
subsequently developed lymphoma (Theander et al., 2011). Recently, the International 
Prognostic Index (IPI) score, which is a model to predict the outcome of patients with 
aggressive NHL based on their clinical characteristics prior to treatment, as well as the 
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EULAR SS disease activity index (ESSDAI) were identified as predictive indicators of 
pSS-associated lymphoma development (Papageorgiou et al., 2015b). 
More recently, the role of TNF alpha induced protein 3 (TNFAIP3) in pSS-associated 
lymphoma development was reported in a French cohort. Germline and somatic genetic 
variations of TNFAIP3 were more common in pSS-associated lymphoma compared with 
pSS patients without lymphoma (Nocturne et al., 2013). The TNFAIP3 gene, also known as 
A20, is found on chromosome 6, and encodes an ubiquitin-editing enzyme that regulates 
the activation of the nuclear factor κB (NF-κB), tumour necrosis factor receptor 1, CD40, 
toll-like receptors and IL-1 receptor (reviewed in (Ma and Malynn, 2012)). Furthermore, 
TNFAIP3 polymorphism (TT>A dinucleotide) is associated with other autoimmune 
diseases such as SLE and SSc (Adrianto et al., 2011, Koumakis et al., 2012). Data from 
animal models indicate that A20 deficiency in mice causes a severe inflammatory reaction 
leading to death, which was thought to be a consequence of failure in A20-mediated 
termination of TNF-induced NF-κB responses (Lee et al., 2000). Very recently, the 
germline polymorphism rs2230926 of TNFAIP3 was assessed in an UK cohort and a 
French cohort, which showed that the rs2230926G variant was correlated to pSS-associated 
lymphoma in the UK cohort. Additional confirmation was also obtained by performing 
meta-analysis of the data from both cohorts (Nocturne et al., 2015b). 
There is data suggesting that BAFF might play a role in the formation of ectopic germinal 
center leading to lymphomagenesis. Gottenberg and colleagues reported that high levels of 
BAFF and β2-microglobulin in patients who currently have lymphoma or have a history of 
lymphoma compared with patients without lymphoma (Gottenberg et al., 2013). Moreover, 
the serum level of BAFF was associated with high systemic disease activity, 
lymphoproliferative disorders and B-cell clonal expansion in pSS (Seror et al., 2010, 
Quartuccio et al., 2013). Another mutation in the BAFF receptor (BAFF-R His159Tyr 
mutation) was recently linked to pSS-associated lymphoma. In the literature, the correlation 
of BAFF, lymphoproliferative disorders and autoimmune diseases has been documented. In 
addition, the BAFF-R His159Tyr mutation is also documented in NHL (Ferrer et al., 2009, 
Hildebrand et al., 2010). Therefore, the assessment of BAFF-R His159Tyr mutation in 
pSS-associated lymphoma was compelling. Accordingly, this mutation occurs in 8.6% of 
pSS-associated lymphoma patients compared to 6.2% in pSS patients without lymphoma, 
and 1.7% in healthy controls. These differences between groups were statistically 
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significant. Moreover, the prevalence of this mutation was increased in a group of pSS-
associated lymphoma patients with disease onset below the age of 40 years (Papageorgiou 
et al., 2015a). Recently, polymorphisms of BAFF were reported to play a role in the 
development of lymphoma in pSS, as distinct BAFF gene haplotypes related to the 
increased risk and development of lymphoma in pSS (Nezos et al., 2014).  
Another mutation—the somatic MYD88 Leu265Pro mutation, recently described in 
Waldenström's macroglobulinemia (WM)—was tested in the peripheral blood of pSS 
patients and minor salivary glands biopsies of pSS and pSS-associated lymphoma patients. 
This mutation activates the IRAK-mediated NF-κB signaling. However, pSS and pSS-
associated lymphoma patients did not harbor this mutation, suggesting other mechanisms 
that might be implicated in pSS-associated lymphoma (Voulgarelis et al., 2014).   
1.8.3 Mechanisms of lymphoma development in pSS 
The mechanism underlying lymphoma development in pSS is still not fully understood. 
Nonetheless, studies of lymphomagenesis in pSS have provided several key observations 
and highlighted areas that need further investigation. To date, it is generally believed that 
the degree of disease severity along with B-cell activation and inflammation leads to pSS-
associated lymphoma development (Theander et al., 2006).  
Oncogenes may also play a role in lymphomagenesis in pSS. For instance, anti-p53 
antibodies were found in pSS-associated lymphoma patients, raising the possibility that the 
appearance of anti-p53 antibody may be an indicator of malignant transformation. 
Interestingly, while total inactivation of p53 leads to the progression of high-grade 
lymphoma, partial inactivation of p53 leads to low-grade lymphoma (Mariette et al., 1999, 
Du et al., 1995). 
The generation of immunoglobulins (Ig) starts at the early stages of B-cell development. 
The production and maturation of Ig involve breaking and reconnecting DNA 
(recombination, somatic mutation and isotype switching). These DNA ‘editing’ processes 
during Ig production increase the risk of translocation of oncogenes. One such sample is the 
translocation of the Bcl-2 and c-myc oncogenes into the Ig loci in chromosome 14q32 
(Sugai et al., 1994). This translocation event leads to the formation of mutagenic B-cells 
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with a V(H) mutation, which was found to occur in high frequency in the parotid glands in 
pSS (Zuckerman et al., 2010).  
B-cell activation factor (BAFF), which is thought to play an important role in the 
pathogenesis of pSS, may play an important role in the development of lymphoma in pSS 
patients. Thus, it has been reported that lymphoma develops more commonly in pSS 
patients with high levels of BAFF (Groom et al., 2002). Data suggest that germinal centres 
in the salivary glands of pSS patients can lead to the expansion of oligoclonal B-cell 
population, which in turn may lead to the development of MALT lymphoma (Voulgarelis 
and Moutsopoulos, 2001).  
Taken together, the existing body of evidence suggests that the interactions between 
epithelial cells, T cells and B cells in the salivary glands may provide a platform for 
lymphoma development. Lymphomagenesis is likely to be a multi-step process which 
evolves from polyclonal lymphoproliferation to monoclonal lymphoproliferation to MALT 
lymphoma and eventually to high-grade malignant lymphoma. Lymphoma development in 
pSS may also involve antigen-driven B-cell activation and oncogenic events such as p53 
inactivation and bcl-2 activation (Masaki and Sugai, 2004). Figure 1.2 illustrates a 
hypothetical model of lymphoma development in pSS. 
More recently, a new proposed mechanism for the pathophysiology of pSS-associated 
lymphoma was published by Nocturne and Mariette (Nocturne and Mariette, 2015). This 
new mechanism suggests that the chronic stimulation of polyclonal RF
+
 B-cells 
(autoreactive B-cells that express a B-cell antigen receptor (BCR) with CDR3 that is 
strongly homologous to RF) in the salivary gland by auto-antigens (potentially Ro and La 
or other auto-antigens) might be essential in lymphomagenesis. RF
+
 B-cell survival is 
promoted by BAFF and other cytokines production during pSS. Furthermore, the 
involvement of TNFAIP3 in pSS-associated lymphoma might play a role, as mutation and 
deletion in this gene, which controls NF-κB activation, support RF+ B-cell survival. 
Interestingly, genetic mutations of TNFAIP3 or other NF-κB–controlling genes might affect 
these B-cells, resulting in their escape as lymphoma B cells. In addition, the formation of 
GC-like structures might increase the stimulation of autoreactive B-cells that might have an 
oncogenic mutation featured by NF-κB signalling dysregulation. The failure of elimination 
of these auto-reactive B-cells within the GC-like structure may also leads to prolonged 
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activation-induced cytidine deaminase (AICDA or AID) activity (which has a role in RNA-
editing and it is the enzyme that mediates somatic hypermutations of the immunoglobulin 
variable region heavy chain (IgVH)), increasing the risk of oncogenic somatic mutations 
that give these B-cells a feature akin to low-grade B-cell lymphoma. 
 
Figure 1.2 Hypothetical model of pSS-associated lymphoma Chronic stimulation of 
antigen-specific B cells proliferation by external antigens or autoantigens plays a 
significant role in the multi-step process of developing lymphoma in pSS. Step 1—
Inflammation: CD4
+
 T cells, memory B cells and dendritic cells infiltration in the minor 
salivary glands perpetuate chronic inflammation. Step 2—Polyclonal B cell proliferation: 
Increased production of BAFF and IFNs in pSS patients cause the proliferation of 
polyclonal B cell and thereby contribute to the characteristic feature of myoepithelial 
sialadenitis (MESA) or the benign lymphoepithelial lesion. Step 3—Oligoclonal B cell 
proliferation: BAFF specifically play a role in the regulation and survival of B lymphocyte 
proliferation, altered the differentiation of B cells. Chronic stimulation by external antigens 
or autoantigens may drive the proliferation of antigen-specific B cells through the 
immunoglobulin heavy chain (IgVH-CDR3) restricted usage and increase their 
transformation frequency. Step 4—Monoclonal B cell proliferation: During the 
development of B cell, immunoglobulins undergo multiple processes including 
recombination, somatic mutation and isotype switching. Such events may increase the risk 
of the translocation of oncogenes (e.g. Bcl-2 and c-Myc) to the immunoglobulin loci 
(chromosome 14q32). Step 5—Transformation to high grade malignancy: the progression 
from low-grade MALT lymphoma to high-grade lymphoma may be facilitated by the P53 
tumour-suppressor activity defect, amplification of bcl-2 and/or c-Myc, high frequency of 
t(14,18) translocation and trisomy 3 (Dong et al., 2013). 
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1.8.4 Treatment of pSS-associated lymphoma: 
There are various therapeutic agents available for the treatment of pSS-associated 
lymphoma. Ideally, the treatment should target the autoimmunity and the malignancy at the 
same time. Anti-CD20 monoclonal antibody (e.g., rituximab (RTX)) has been used for the 
treatment of pSS-associated lymphoma. Rituximab depletes B cells and inhibits B-cell 
activation but its precise mechanism of action is still unclear (Abdulahad et al., 2012). 
Another treatment is belimumab, a monoclonal antibody targeting BAFF. Recently, it has 
been shown that belimumab results in the normalisation of the frequency of peripheral 
blood B-cells in pSS (Pontarini et al., 2015). Moreover, treatment of pSS with belimumab 
led to improvement in ESSDAI and ESSPRI scores as well as reduction of B-cell 
biomarkers after 28 weeks (De Vita et al., 2015). Despite these promising agents, more 
research is needed to identify the most effective therapeutic strategies for the management 
of pSS-associated lymphoma.  
1.9 Overall design of the project:  
Most studies have focused on serum protein biomarkers. However, genetic biomarkers for 
pSS-associated lymphoma have not been reported. The primary aim of the project is to 
identify a whole blood gene expression signature in pSS-associated lymphoma that would 
be useful for diagnosis. In order to accomplish this aim, I have used the following 
approach.  
First, because of the predominance of globin RNA in peripheral blood, I needed to 
investigate and optimise the effects of globin mRNA depletion on gene expression profiling 
in pSS. The reason behind performing the optimisation experiment in pSS but not in pSS-
associated lymphoma is the availability of gene expression data in pSS in the literature that 
I can use as a reference. Second, I identified a whole-blood gene expression signature of 
pSS-associated lymphoma using a whole genome microarray on a set of samples that I refer 
to as the ‘Discovery cohort.’ The Discovery cohort consisted of five subject groups—four 
pSS subgroups and a healthy controls group. The four pSS groups were: pSS (without 
lymphoma), pSS-associated lymphoma, pSS with paraproteinemia and pSS with other 
cancers. In this experiment, the microarray data were analysed to identify candidate genes 
in pSS-associated lymphoma by comparing the pSS (without lymphoma) and the pSS-
associated lymphoma groups. The differentially expressed genes were then technically 
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validated using qRT-PCR. A machine learning modelling was performed to predict which 
genes can serve as candidates to predict lymphoma in pSS. Third, an independent set of 
samples (the ‘Validation cohort’) was used to test whether the potential gene expression 
signature (i.e., the differentially expressed genes that were detected in the microarray and 
the qRT-PCR data), was also present in the Validation cohort. In this experiment, I also 
included a set of untreated pSS-associated lymphoma samples to test whether the potential 
gene expression signature identified in the Discovery cohort was also present in untreated 
lymphoma samples. Gene-expression levels were measured in the Validation cohort and the 
untreated pSS-associated lymphoma group using qRT-PCR. In addition, I performed 
biological pathway analysis in the Discovery cohort to explore the most important 
biological pathways in pSS-associated lymphoma using the Ingenuity Pathway Analysis 
(IPA) platform. Finally, I analysed gene expression microarray data and pathway analysis 
for the other pSS subgroups to ensure that the gene expression signatures and the pathway 
analysis data were unique to the pSS-associated lymphoma group. Diagram 1.3 illustrates 
the overall design of the project. 
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Figure 1.3 Overall design of the project. Boxes with the same colour are reported in the same chapter.  
28 
 
Chapter 2 
Materials and methods 
2.1 UK primary Sjögren’s syndrome registry (UKPSSR) and sample collection 
The majority of the samples used in this study were taken from the UK Primary Sjögren’s 
Syndrome Registry (UKPSSR) biobank (Ng et al., 2011). All pSS patients fulfil the 
American European Consensus Group (AECG) classification criteria. Each patient and/or 
healthy control has various biological samples to be collected including peripheral blood 
mononuclear cells, serum, RNA and DNA. Throughout my study I have used the RNA 
samples where the whole blood samples were collected into PAXgene blood RNA tubes 
(catalogue number 762165, BD, U.S.A.). The tubes contain reagents that stabilise 
intracellular RNA. The stabilisation of the RNA happens by preventing in vitro RNA 
degradation and gene induction from occurring after blood draw thereby enabling more 
accurate intracellular RNA analysis of the samples. All samples were kept in the PAXgene 
blood RNA tubes at –80 ºC until extraction. The following clinical data were extracted 
from the UKPSSR database for each sample: age, gender, unstimulated oral salivary flow, 
schirmer’s test, presence or absence of anti-Ro/SAA and anti-La/SSB, white cells count, 
Neutrophils count, lymphocytes count, erythrocyte sedimentation rate (ESR), 
immunoglobulin G (IgG), complement component 3 (C3), complement component 4 (C4), 
C-reactive protein (CRP), presence or absence of rheumatoid factor (RF), Sjögren’s 
Syndrome Damage Index (total SSDDI), EULAR Sjögren’s Syndrome Patient Reported 
Index (ESSPRI) and EULAR Sjögren’s Syndrome Disease Activity Index score  (ESSDAI 
score). For the samples in the Discovery and the validation cohorts, a Mann-Whitney U test 
was performed to evaluate any statistical differences on the above clinical data between the 
subject groups. The clinical data are presented in the relevant result sections of chapter 3 
and chapter 4. 
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2.2 Whole blood RNA extraction 
Materials: 
1. PAXgene Blood miRNA kit (catalogue number 763134, PreAnalytiX, Switzerland). The 
kit provides the following materials (some of the buffers were provided as concentrated 
solutions and they were diluted as instructed in the manufacturer’s protocol): 
 PAXgene RNA Spin Columns (red) 
 PAXgene Shredder Spin Columns (lilac) 
 Buffer BM1 (resuspension buffer) 
 Buffer BM2 (binding buffer) 
 Buffer BM3 (washing buffer) 
 Buffer BM4 (washing buffer) 
 Buffer BR5 (elution buffer) 
 Proteinase K 
 RNase-Free DNase set, which includes lyophilized RNase-Free DNase, Buffer RDD 
and RNase-Free water 
 Secondary Hemogard closures 
 RNase-Free water 
 Microcentrifuge and processing tubes  
2. Isopropanol (Catalogue number P/7490/17, Fisher Chemical, UK) 
Equipment: 
1. Pipettes (Labnet International, U.S.A.) 
2. SIGMA 6K15 swing-out rotor centrifuge (Sigma, Germany) 
3. Vortex Genie2 (Scientific Industries, U.S.A.) 
4. Thermomixer Compact, shaker- incubator (Eppendorf, Germany) 
5. AccuspinTM Micro microcentrifuge (Fisher Scientific, Germany) 
6.  Nano-drop ND-1000 spectrophotometer (Nanodrop Technologies,  U.S.A.) 
Method: 
Whole blood total RNA was extracted using the PAXgene blood miRNA kit according to 
the manufacturer’s protocol. Briefly, frozen samples were thawed at room temperature (15–
30 
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ºC) for 4 hours to ensure complete lysis of blood cells; the subsequent procedures of 
RNA extraction were as follows:  
1. Samples were pelleted using a swing-out rotor centrifuge for 10 min at 3000–5000 x g, 
the supernatant was then gently decanted into a container with Virkon solution and the 
rim of the tube dried with a clean paper towel.   
2. The pellets were washed by adding 4 ml RNase-free water, the tubes sealed using a 
new secondary Hemogard closure, and then the pellets were dissolved by vortex 
mixing followed by centrifugation for 10 min at 3000–5000 x g, after which the 
supernatant was discarded by decanting. 
3. The pellets were resuspended with buffer BM1 (350 μl) and vortexed until they were 
visibly dissolved. 
4. Samples were transferred into 1.5 ml microcentrifuge tubes and digested by adding 
buffer BM2 (300 μl) and proteinase K (40 μl) separately, samples then vortexed for 5 s,  
then an incubation for 10 min at 55 ºC in a shaker-incubator at 1400 rpm. 
5. The homogenisation step was then performed by pipetting the samples into PAXgene 
Shredder Spin Columns (lilac) placed in a 2 ml processing tube, which were spun in a 
microcentrifuge for 3 min at 13,000 x g. The supernatant of the flow-through was 
gently transferred into a new microcentrifuge tube to avoid disturbing the pellets. 
6. In order to optimise the binding conditions, Isopropanol (700 μl, 100%, purity grade 
puriss grade (p.a. = 98.5%)) was added and mixed by vortexing. 
7. A PAXgene RNA Spin Column (red) placed into a 2 ml processing tube was used at 
this stage. A portion of the sample (700 μl) was pipetted into the column and 
centrifuged for 1 min at 13,000 x g; this step was repeated with the remaining sample 
after replacing the processing tube with a new one. The RNA and miRNA in the 
sample were bound to the PAXgene silica-membrane in the RNA Spin Column.  
8. Buffer BM3 (350 μl) was then added, centrifuged for 15 s at 13,000 x g followed by 
replacing and discarding the used processing tube.    
9. DNase I was prepared by mixing 10 μl of DNase I stock solution (previously prepared 
by adding 550 μl RNase-free water to 1500 Kunitz units of solid DNase that was 
provided with the kit), with 70 μl of Buffer RDD for each sample, which was then 
flicked gently followed by brief centrifugation.  
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10. Genomic DNA was removed by adding the DNase mixture prepared in step 9 directly 
onto the PAXgene RNA Spin Column membrane and incubating the tube at room 
temperature for 15 min. 
11. Further washing steps were carried out by adding Buffer BM3 (350 μl) and Buffer 
BM4 (500 μl), respectively; each buffer addition was followed by centrifugation for 15 
s at 13,000 x g. The final washing step was carried out by adding Buffer BM4 (500 μl), 
followed by centrifugation for 2 min at 13,000 x g. The processing tubes were replaced 
with a new one after each washing step.  
12. To ensure all buffer solution was removed from the RNA Spin Column membrane, the 
columns were centrifuged for an additional 1 min at 13,000 x g. 
13. The RNA was eluted by placing the RNA Spin Columns in a new 1.5 μl 
microcentrifuge tube and adding 40 μl of Buffer BR5 directly onto the column’s 
membrane. The lid was closed gently and the tube centrifuged for 1 min at 13,000 x g 
and was repeated using another 40 μl Buffer BR5 in the same microcentrifuge tube, 
resulting in 80 μl of extracted RNA. 
14. The A26/A280 and A260/A230 ratios of the eluent (RNA) were assessed using the 
Nano-drop ND-1000 spectrophotometer and the RNA samples were then stored at -80 
ºC.  
2.3 Optimisation of whole blood gene expression signatures in pSS by globin mRNA 
depletion 
2.3.1 RNA clean up and concentration 
Materials: 
1. RNeasy ® MinElute ® Cleanup Kit (catalogue number 74204, QIAGEN, Netherlands). 
The kit provides the following materials (some of the buffers were provided as  
concentrated solutions and they were diluted as instructed in the manufacturer’s 
protocol): 
 RNeasy MinElute Spin Columns 
 Collection tubes with two capacities, 1.5 ml and 2 ml 
 Buffer RLT 
 Buffer RPE 
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2. RNase-Free water  
3. Ethanol 100% (catalogue number E/0650DF/17, Fisher Chemical) 
Equipment: 
1. Pipettes (Labnet International) 
2. Vortex Genie2 (Scientific Industries) 
3. AccuspinTM Micro microcentrifuge (Fisher Scientific) 
4. Nano-drop ND-1000 spectrophotometer (Nanodrop Technologies) 
Method: 
The RNeasy 
® 
MinElute 
® Cleanup Kit was used in this experiment. Briefly, 1 μg of RNA 
from each sample was taken and its volume adjusted to 100 μl with RNase-free water. 
Buffer RLT (350 μl) was added and mixed well, followed by 250 μl of 96–100% ethanol 
and mixed by pipetting. Each sample was then transferred to an RNeasy MinElute Spin 
Column that was placed in a 2 ml collection tube and centrifuged for 15 s at 13,000 x g. 
Each Spin Column was placed in a new collection tube, 500 μl of Buffer RPE added and 
centrifuged for 15 s at 13,000 x g. This was followed by a washing step with 80% ethanol 
(500 μl), centrifuged for 2 min at 13,000 x g, and the columns were dried by placing them 
in new collection tubes and centrifuging them for 5 min at full speed with an opened lid. At 
this point, the columns were placed in new 1.5 μl microcentrifuge tubes and 14 μl of elution 
Buffer BR5 was added and centrifuged for 1 min at full speed to elute the concentrated 
RNA. The purity and concentration of the samples (A260/A280 and A260/A230 ratio) were 
measured using a Nano-drop ND-1000 spectrophotometer.  
2.3.2 Globin mRNA depletion 
Materials:  
1. Human GLOBINclear kit (catalogue number AM1980, Ambion Inc., U.S.A.) The kit 
provides the following materials (some of the buffers were provided as concentrated 
solutions and they were diluted as instructed in the manufacturer’s protocol): 
 Globin mRNA depletion reagents, which include Capture Oligo Mix, Streptavidin 
Magnetic Beads, 2X Hybridization Buffer, Streptavidin Bead buffer and Nuclease-
free water. 
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 RNA purification reagents, which include RNA Binding Beads, RNA wash solution 
(concentrated), Elution Buffer, RNA Bead Buffer, RNA Binding Buffer 
(concentrated). 
Equipment: 
1. Pipettes (Labnet International) 
2. Tube Magnetic stand 
3. Vortex Genie2 (Scientific Industries) 
4. Dry bath system (Star Lab, Taiwan) 
5. AccuspinTM Micro microcentrifuge (Fisher Scientific) 
6. Nano-drop ND-1000 spectrophotometer (Nanodrop Technologies) 
 
Pre procedure preparations: 
1. Streptavidin Magnetic Beads preparation: For each sample, 30 μl of beads were added to 
a 1.5 ml microcentrifuge tube and washed by subjecting the beads to a magnet to remove 
the supernatant followed by resuspension with 30 μl of Streptavidin Beads Buffer.  
2. Bead Resuspension Mix: For each sample, a total volume of 20 μl was prepared by 
combining 10 μl of RNA binding beads, 4 μl of RNA Beads Buffer and 6 μl of 
Isopropanol followed by mixing thoroughly by a vortex mixer. 
 
Method: 
The globin RNA was depleted using the Human GLOBINclear kit, which was used 
according to the manufacturer’s protocol, except that a dry bath system instead of an 
incubator was used to warm up the 2X hybridization buffer and the Streptavidin Bead 
Buffer as well as other procedures requiring incubations. The kit uses a hybridization 
capture technology to remove globin mRNA as demonstrated in Figure 2.1. First, the 
globin mRNA was hybridized with the Globin Capture Oligonucleotides; to each 14 μl of 
the sample, 1μl of the Capture Oligo mix and 15 μl of pre-warmed 2X hybridization Buffer 
were added and the mixture allowed to hybridize by incubation for 15 min at 50 ºC. During 
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this stage the biotinylated oligonucleotides in the Capture Oligo mix bind to the globin 
mRNA in the sample. Second, the globin mRNA was removed by adding the pre-prepared 
Streptavidin Magnetic Beads (30 μl). The globin mRNA/biotinylated oligonucleotides were 
bound to the beads via a 30 min hybridization period at 50 ºC. Third, the bound globin 
mRNA/biotinylated oligonucleotides were removed by pulling the Streptavidin Magnetic 
Beads out of suspension using a magnet; the enriched  RNA (Globin mRNA–depleted) that 
was retained in the supernatant was transferred into a new 1.5 ml microcentrifuge tube. 
Fourth, the RNA samples were washed by adding 100 μl RNA Binding Buffer and 20 μl 
pre-prepared Bead Resuspension Mix. The enriched RNA bound to the resuspension beads, 
which were pulled out using a magnet, and the RNA eluted with the Elution Buffer (30 μl) . 
Finally, the purity and concentration of the RNA was measured using a Nano-drop ND-
1000 spectrophotometer and stored at -20 ºC until use. 
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Figure 2.1 Globin mRNA depletion procedure using the Human GLOBINclear kit 
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2.3.2 Evaluation of β-globin RNA expression levels in total RNA samples with or 
without Globin mRNA depletion 
Materials: 
1. M-MLV Reverse Transcriptase kit (Invitrogen, Life Technologies, U.S.A.) 
2. DNase-RNase-free water (catalogue number W 4502, SIGMA) 
3. TaqMan® Gene Expression Master Mix (catalogue number 4369016, Applied 
Biosystems, U.S.A.)  
Equipment:  
1. Pipettes (Labnet International) 
2. Vortex Genie2 (Scientific Industries) 
3. AccuspinTM Micro microcentrifuge (Fisher Scientific) 
4. PTC-200 Peltier Thermal Cycler (MJ Research Inc., U.S.A.) 
5. MicroAmp® Fast Optical 96-well (catalogue number 4346906, Applied Biosystems, 
U.S.A.) 
6. MicroAmp® Optical Adhesive Film (catalogue number 4311971, Applied Biosystems, 
U.S.A.) 
7. Heraeus Megafuge 40 (Thermo Scientific, Germany) 
8. Applied Biosystems 7900HT Real-Time PCR System, U.S.A. 
Method: 
The efficacy of globin mRNA depletion was evaluated using TaqMan qRT-PCR. As the 
amount of total RNA was limited in some samples, we assessed the level of β-globin 
mRNA in 11 paired samples with or without globin mRNA depletion (2 pSS patients, 9 
healthy controls). The forward and reverse primers for the β-globin gene were designed 
using the Universal probe library assay design and their sequences were 5’-
GCACGTGGATCCTGAGAACT-3’ and 5’-CACTGGTGGGGTGAATTCTT-3’ 
respectively. The primers were manufactured by SIGMA-Aldrich. The no. 61 Universal 
probe was used in the RT-PCR reaction. The 18S subunit mRNA sequence was used as a 
housekeeping gene. The step-by-step protocol is described below: 
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Step 1:  Reverse Transcription PCR. A total of 200 ng of RNA (in 8 μl) from each sample 
was used to generate cDNA as described in Table 2.1, based on the number of replicates 
needed for each assay, including an extra amount to allow for pipetting error.  
Step 2:  A 5 μl aliquot of the resultant cDNA solution from each sample was used for qRT-
PCR. The sample’s dilutions used were 1:5 for β-globin, and 1:10000 for 18S. To each 
cDNA sample, 15 μl of RT-PCR master mix were added. The reference volumes of Master 
mix reagents for a single reaction (20 μl) in the RT-PCR shown in Table 2.2. 
Step 3: qRT-PCR data were analysed by normalising the values obtained to the 
housekeeping gene 18S, and the relative expression level of the β-globin gene in the 
samples with or without globin mRNA depletion was calculated.  
 
Table 2.1 The M-MLV Reverse Transcriptase PCR reference volumes and their 
corresponding programs in the thermal cycler  
Component Volume (μl)/reaction 
Step 1: Master Mix 1 
dNTP 3 μl 
Hexamers 1 μl 
 Add 4 μl of Master Mix 1 to each sample 
 Heat to 70 ºC for 5 min. using the thermal cycler  
Step 2: Master Mix 2 
1
st
 strand 5X buffer 4  μl 
DTT 2  μl 
MMLV (M-MLV RT) 0.5 μl 
H2O 1.5 μl 
 Add 8 μl of Master Mix 2 to each sample (total 20 μl) 
 Heat to 37 ºC for 50 min. then 75 ºC for 15 min using the 
thermal cycler  
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Table 2.2 Master mix reagents reference volumes of a single reaction in the RT-PCR .
Component Volume (20 μl)/ reaction 
Forward primer 0.4 μl 
Reverse primer 0.4 μl 
Probe 0.2 μl 
TaqMan Gene Expression Master Mix 10 μl 
H2O 4 μl 
Total volume 15 μl 
 
2.3.4 Illumina Human HT12-v4 Expression BeadChip (Cambridge Genome 
Science/University of Cambridge, UK) 
A total of 48 samples, 24 globin mRNA-depleted samples (G-depleted group) and 24 non-
globin mRNA depleted samples (G non-depleted group) were used in this experiment. Two 
aliquots from each sample were sent for whole genome microarray analysis at the 
Cambridge Genomic Services (CGS), University of Cambridge. The first aliquot contained 
a total of 250 ng of RNA and a second aliquot contained 3 μl from the original sample for 
quality control (QC). RNA quality was assessed by the Aglient 2100 bioanalyzer using a 
special Aglient RNA Nano kit. The Bioanalyzer has software (Agilent 2100 Expert 
Software) for the analysis of the overall integrity of the RNA sample. An RNA Integrity 
Number (RIN score) was generated for each sample on a scale of 1–10 (1=lowest; 
10=highest) as an indication of RNA quality. The 18s/28s ratio and an estimation of RNA 
concentration were also produced. The Total Prep 96-RNA amplification kit (Ambion, Inc., 
U.S.A.) was used to amplify the sample by in vitro transcription of cDNA generated from 
the total RNA and the generation of biotin-labelled cRNA. The biotin-labelled cRNA was 
then used in the direct hybridization assay, which included sequential steps of array 
hybridization, washing, blocking and streptavidin-Cy3 staining as shown in Figure 2.2. The 
Illumina iScan was used to detect Cy3 fluorescence emission and the GenomeStudio 
(version 1.6) was used for the extraction of the raw data. 
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Figure 2.2 Direct Hybridization Assay used in illumina microarray. The left panel is an 
overview of the method and on the right panel is an illustration of the workflow 
(www.illumina.com)  
 
 
Microarray data analysis: 
Microarray data analysis was carried out with the assistance of the Bioinformatics Support 
Unit (BSU) at Newcastle University. The raw gene expression data was received from CGS 
in the form of IDAT files, which are binary data files directly from the microarray scanner. 
The IDAT files were background-corrected in Illumina’s Genome Studio, and exported as a 
sample probe profile that contained data fields specific to bead-level information such as 
bead standard error. The subsequent analysis was performed in R, utilising Bioconductor 
libraries (www.bioconductor.org) (Gentleman et al., 2004). The sample probe profile was 
read into R and pre-processed using the Lumi package (Du et al., 2008). Pre-processing 
steps consisted of a dataset transformation using the variance stabilising transformation 
(VST), and robust spline normalisation (RSN). VST is a log2-like transformation optimised 
for microarray data, and RSN is a normalisation method to help make samples comparable 
to one another. After pre-processing, a QC step was carried out to identify problematic or 
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outlier samples; common metrics were used including: detection p-values, principle 
component analysis (PCA), and unsupervised hierarchical clustering. If samples were 
deemed to be outliers or problematic then they were removed from the analysis and the pre-
processing stages ran again. Annotation of the array probes was mapped using the 
lumiHumanAll.db package, specifically nuID, Illumina ID, gene symbol, and description. 
Differential expression was achieved by fitting linear models using the Limma package 
(Smyth, 2004). Filters for significance were defined as a greater than absolute log2(1.2)-
fold change, and a Benjamini-Hochberg false discovery rate (FDR) corrected p-value of 
<0.05. The results of this analysis were visualised using volcano plots. Pathway analysis 
utilised the KEGG REST API as this is still currently maintained, unlike the Bioconductor 
package. Significant pathways were identified using a hypergeometric test, with an FDR 
adjusted p-value < 0.05. Additionally, Gene Ontology (GO) terms were identified in the 
same manner as pathways, for molecular function (MF), cellular components (CC), and 
biological process (BP). The R scripts for this microarray analysis can be found in 
supplementary table S1. 
2.4 Identification of whole blood gene expression signature of pSS-associated 
lymphoma 
2.4.1 Illumina Human HT12-v4 Expression BeadChip (Cambridge Genome 
Science/University of Cambridge, UK) 
The set of samples used to identify the whole blood gene expression signature of pSS-
associated lymphoma is the Discovery cohort, which consisted of 144 globin mRNA–
depleted subjects. To reduce the potential influence of gender on the transcriptomic 
signature of pSS-associated lymphoma, and since pSS predominantly affects females, I 
chose to use only female subjects. The cohort consists of the following 5 subject groups:   
1. 61 pSS patients without history of lymphoma (primary comparator group) 
2. 16 pSS-associated lymphoma patients  
3. 21 pSS-other cancers patients  
4. 23 pSS-paraproteinemia patients  
5. 23 healthy controls 
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All patients in the pSS-associated lymphoma group had a diagnosis of lymphoma in the 
past and had received treatment for the lymphoma. RNA extraction, depletion of globin 
mRNA, and a whole genome expression microarray analysis were carried out as described 
in section 2.3 with some additional steps, which are explained below.  
Microarray data analysis: 
The analysis of the Discovery cohort microarray data was similar to the protocol used for 
the Globin study, with some additional steps. An additional QC step was performed to 
identify outlier samples, using the arrayQualityMetrics package (Kauffmann et al., 2009). 
Outlier samples were removed from the raw data object and VST, and RSN pre-processing 
steps as previously described were reapplied. Samples with a RNA integrity number (RIN) 
of < 7 were removed, except for pSS-associated Lymphoma samples, since the pSS-
associated lymphoma group size in this experiment was already relatively small. Following 
pre-processing, batch effect was identified and this was corrected for using the ComBat 
function from the SVA package (Johnson et al., 2007). The ComBat function uses an 
empirical Bayes approach to remove a known batch effect. The resulting matrix from 
ComBat is used in the linear model to explore differential expression. The primary 
comparison that I used to identify the whole blood transcriptome of pSS-associated 
lymphoma was between the pSS and the pSS-associated lymphoma group. In the primary 
analysis, all samples with RIN < 7 were excluded in the pSS group. On the other hand, as 
the pSS-associated lymphoma samples were limited, only the technical outliers were 
excluded as the microarray data of these outliers are markedly different from the remaining  
samples and therefore might skew the analysis. In order to reduce the risk of overlooking 
genes that might be important in developing lymphoma in pSS, I performed several sub-
analyses in which different criteria were used for inclusion or exclusion of samples within 
the pSS-associated lymphoma groups based on the quality of the RNA samples and the 
detection as outliers during PCA analysis. More details about these analyses are described 
in Chapter 4. The final list of differentially expressed genes in pSS-associated lymphoma 
was compiled by combining the genes from all sub-analyses and ranking them according to 
their fold change and p-value.  
Finally, additional group comparisons were also performed in order to determine the 
specificity of the gene expression signature identified, these include: 
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1. pSS-associated lymphoma vs pSS-other cancers 
2. pSS-associated lymphoma vs pSS-paraproteinemia 
3. pSS vs pSS-other cancers 
4. pSS vs pSS-paraproteinemia 
5. pSS-other cancers vs pSS-paraproteinemia 
6. pSS vs HC 
7. pSS-associated lymphoma vs HC  
8. pSS-other cancers vs HC 
9. pSS-paraproteinemia vs HC 
In addition to identifying a list of differentially expressed genes, I have also conducted 
pathway analysis using the differentially expressed genes using Ingenuity Pathway 
Analysis (IPA) for all the comparisons. The methods of these additional analyses are 
described in the respective result chapters. The R scripts for this microarray analysis can be 
found in supplementary table S2. 
  
2.4.2 Technical validation of the differentially expressed genes from the microarray 
data by qRT-PCR 
The qRT-PCR was performed using TaqMan
®
 Custom gene expression array plates (Fast 
plates) from Applied Biosystems (Life Technologies, U.S.A.) for the technical validation of 
the potential signature identified from the microarray. Because of the limitations on the 
total amount of RNA available following globin mRNA removal, a total of 61 differentially 
expressed genes (out of 68) were chosen according to the fold change and p-value (higher 
fold changes and lower p-values). In addition, the selection of genes in common among the 
all the analyses (i.e. including the sub-analyses) was considered. Only samples from the 
pSS without lymphoma and pSS-associated lymphoma groups were used in the technical 
validation in all the array plates batches, while, samples from all pSS subgroups were used 
in the first 2 plate batches to evaluate the expression stability of the housekeeping genes.  
The TaqMan
®
 Custom gene expression array plates is a technology in which a fast TaqMan 
gene expression assay (probe and primers sets) is dried-down in a 96-well format plate. 
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Two formats (32-format and 16-format) of the plates were used. The TaqMan array plate 
assay involved two steps: 
1. Converting the RNA into cDNA by RT-PCR. 
2. TaqMan® Custom gene expression array.  
1. Converting the total RNA into cDNA by Reverse Transcription PCR 
Materials: 
1. High-Capacity cDNA Reverse Transcription Kit (catalogue number 4368814, Thermo 
Fisher Scientific, U.S.A.), which includes 10X RT Buffer, 10X RT Random Primers, 
25X dNTP Mix and MultiScribe
TM
 Reverse Transcriptase. 
2. DNase-RNase-free water (catalogue number W 4502, SIGMA) 
Equipment: 
1. Pipettes (Labnet International) 
2. Vortex Genie2 (Scientific Industries) 
3. AccuspinTM Micro microcentrifuge (Fisher Scientific) 
4. Heraeus Megafuge 40 (Thermo Scientific) 
5. PTC-200 Peltier Thermal Cycler (MJ Research Inc.) 
Method: 
1. The kit’s components were thawed on ice. 
2. As a result of limited RNA entities, both globin mRNA-depleted and non-depleted 
samples were used to validate the candidate genes. A total of 44 pSS and 15 pSS-
associated lymphoma globin mRNA-depleted samples with 250 ng of total RNA were 
used to validate 49 deferentially expressed genes. A total of 37 pSS and 8 pSS-
associated lymphoma non-depleted samples with 200 ng of total RNA were used to 
validate another 14 deferentially expressed genes.  For the protocol, 10 μl of each 
sample is required. Therefore, for samples with high RNA concentrations, DNase-
RNase-free water was added to make up the required volume, while for samples with 
low RNA concentrations, the RNA samples were concentrated by precipitation to 
achieve the required volume.  
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3. The RT master mix was prepared by calculating the component volumes as listed in 
Table 2.3, taking into account the total number of reactions and margins of error in 
pipetting. 
4. A volume of 10 μl of the 2X RT master mix was added to each 10 μl sample in a PCR 
micro tube, and mixed well by pipetting. The samples were then centrifuged briefly and 
placed on ice until RT-PCR was performed. 
5. The thermal cycler was programmed according to the conditions listed in Table 2.4. 
 
Table 2.3 The High-Capacity cDNA Reverse Transcription reference volumes of a single 
reaction  
 Component  Volume (μl)/reaction 
10X RT buffer 2 
25X dNTP Mix (100mM) 0.8 
10X RT Random Primers 2 
MultiScribe
TM
 Reverse Transcriptase 1 
Nuclease Free water 4.2 
Total volume per reaction 10 
 
Table 2.4 The High-Capacity cDNA Reverse Transcription thermal cycler conditions  
 Step 1 Step 2 Step 3 Step 4 
Temperature 25 ºC 37 ºC 85 ºC 4 ºC 
Time  10 min 120 min 5 min Continually 
 
 
2. TaqMan
®
 Custom gene expression array 
Materials: 
1. TaqMan® Gene Expression Master Mix (Applied Biosystems)  
2. DNase-RNase-free water (catalogue number W 4502, SIGMA) 
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Equipment: 
1. Pipettes (Labnet International) 
2. Vortex Genie2 (Scientific Industries) 
3. AccuspinTM Micro microcentrifuge (Fisher Scientific) 
4. Heraeus Megafuge 40 (Thermo Scientific) 
5. TaqMan® Custom gene expression array plates (Fast plates) (Applied Biosystems, 
U.S.A.) 
6. MicroAmp® Optical Adhesive Film (Applied Biosystems) 
7. Applied Biosystems 7900HT Real-Time PCR System  
Method: 
a. Housekeeping genes selection: 
The selection of the housekeeping genes (endogenous controls) for the experiment was 
performed using NormFinder (http://moma.dk/normfinder-software), an algorithm that 
ranks a set of candidate normalisation genes according to their expression stability in a 
given sample set and given experimental design (Andersen et al., 2004). The functionality 
of NormFinder can be added directly into Microsoft Excel. In my Discovery cohort dataset, 
32 housekeeping genes (representing 21 unique genes as each gene has several 
corresponding probes in the microarray) from the microarray data were selected by 
NormFinder as candidates. Two genes (YWHAZ and UBC) were identified as the best 
candidate genes for normalisation. In addition, in the first and second batches of the qRT-
PCR array, I included two other housekeeping genes: the first one was ACTB, which had 
the most stable expression value after the YWHAZ and UBC. The second one was the 18S 
subunit, because it is a commonly used housekeeping genes in RT-PCR analysis. After 
performing the first and the second batches of qRT-PCR, the expression levels of the four 
housekeeping genes were compared among the five subject groups using the Mann-
Whitney U Test. The third and fourth plate batched contain only YWHAZ and ACTB (the 
most stable housekeeping genes according to the results of the first two batches). 
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b. Sample preparations: 
The TaqMan
®
 Custom gene expression array plates require a total cDNA amount between 
1 and 100 ng. Given the limited amount of RNA samples, I chose to use 5 ng cDNA (in 10 
μl) per reaction for the analysis. Equal volumes of cDNA and the TaqMan® Gene 
Expression Master Mix, as shown in Table 2.5, were mixed together by vortex followed by 
a brief centrifugation. The total volumes of cDNA and Master Mix needed for the entire 
experiment was calculated from the total number of TaqMan assays. The preparations were 
placed on ice until the plates were ready. To each well of the array plate, 20 μl of the 
mixture was added before loading the plate into a qRT-PCR instrument using the suitable 
thermal cycling conditions. The genes that I have technically validated for the discovery 
cohort are listed in Table 2.6. 
 
Table 2.5 TaqMan gene expression Master mix reference volumes of a single reaction 
 Component  Volume (20 μl)/ 
reaction 
5 ng cDNA + DNase-free water 10 μl 
2X TaqMan
®
 Gene Expression Master Mix 10 μl 
Total volume 20 μl 
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Table 2.6 TaqMan gene expression assays of the technical validation of the Discovery 
cohort  
Gene 
symbol 
TaqMan assay ID type of gene Gene 
symbol 
TaqMan assay ID Type of gene 
18S Hs99999901_s1 housekeeping gene LGALS1 Hs00355202_m1 DEG 
ACTB Hs99999903_m1 housekeeping gene LRFN3 Hs00225874_m1 DEG 
UBC Hs00824723_m1 housekeeping gene LRIG1 Hs00394267_m1 DEG 
YWHAZ Hs00237047_m1 housekeeping gene MAGED1 Hs00986269_m1 DEG 
ALDH9A1 Hs00997881_m1 DEG MGST3 Hs01058946_m1 DEG 
ATG12 Hs01047860_g1 DEG MYC Hs00153408_m1 DEG 
ATP1A1 Hs00167556_m1 DEG NAT10 Hs01120371_m1 DEG 
BCL11B Hs01102259_m1 DEG NCSTN Hs00950933_m1 DEG 
BMS1 Hs01036249_m1 DEG NUDT14 Hs00418228_m1 DEG 
BTBD11 Hs00537023_m1 DEG OAF Hs00420156_m1 DEG 
C10orf32 Hs00376014_m1 DEG PAF1 Hs00219496_m1 DEG 
CBLL1 Hs01128720_m1 DEG POM121C Hs03406359_mH DEG 
Cd96 Hs00175524_m1 DEG PRKCQ Hs00989970_m1 DEG 
CDR2 Hs00386212_m1 DEG PRPF8 Hs01556852_m1 DEG 
CDV3 Hs00250190_m1 DEG RAB37 Hs03988369_g1 DEG 
CNPY3 Hs00198139_m1 DEG RASGRP1 Hs00996727_m1 DEG 
CYFIP2 Hs00910722_m1 DEG RBL2 Hs00180562_m1 DEG 
DDB1 Hs01096550_m1 DEG RBP7 Hs00364812_m1 DEG 
DRAP1 Hs01012815_g1 DEG RNA28S5 Hs03654441_s1 DEG 
DYNLL1 Hs00853309_g1 DEG RPA2 Hs00358315_m1 DEG 
EHBP1L1 Hs00411094_m1 DEG RRN3 Hs01592557_m1 DEG 
ESYT1 Hs00248693_m1 DEG SEC61G Hs00414142_m1 DEG 
ETS1 Hs00428293_m1 DEG SF3A1 Hs01066327_m1 DEG 
HCFC1R1 Hs01002754_m1 DEG SGK223 Hs00410725_m1 DEG 
HLA-DRB1 Hs99999917_m1  DEG SLC7A1 Hs00931450_m1 DEG 
HNMT Hs02759756_s1 DEG SMARCA2 Hs01030846_m1 DEG 
HNRNPUL1 Hs00199870_m1 DEG SPOCK2 Hs00360339_m1 DEG 
HSP90B1 Hs00427665_g1 DEG SRP14 Hs03055045_g1 DEG 
HSPA9 Hs00269818_m1 DEG SUN2 Hs00391446_m1 DEG 
ITK Hs00950637_m1 DEG UBXN11 Hs00377277_m1 DEG 
KCTD12 Hs00540818_s1 DEG VCP Hs00997642_m1 DEG 
KHDRBS1 Hs00173141_m1 DEG WAC Hs00249774_m1 DEG 
LEF1 Hs01547250_m1 DEG  
* DEGs= differentially expressed genes 
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c. Plate preparations: 
The first step of TaqMan
®
 Custom gene expression array plate preparation was to 
centrifuge the plate shortly, to prevent the loss of the lyophilized primers that are provided 
within each well when the plate is opened. After removing the plate cover, 20 μl of the 
cDNA-master mix mixture was dispensed into the appropriate wells, finally the plate was 
covered with MicroAmp
®
 Optical Adhesive Film and centrifuged shortly. 
d. Running the plate in an RT-PCR instrument: 
The plate was run using the Applied Biosystems 7900HT Real-Time PCR System. The 
software that used was the SDS v2.4.  The details of the PCR program used for the reaction 
are shown in Table 2.7.  
 
Table 2.7 TaqMan gene expression experimental parameters. The reactions were carried 
out using the Applied Biosystems 7900HT Real-Time PCR System 
Experiment parameters Thermal cycling conditions 
Stage Temp. (ºC) Time (min:sec) 
Reaction volume 20μl 
Ramp rate: Standard 
Stage 1 50 2:00 
Stage 2 95 10:00 
Stage 3 
(40 cycles) 
95 0:15 
60 1:00 
 
e. RT-PCR data analysis: 
The data were analysed using SDS RQ Manager 1.2.1. The analysis consisted of several 
steps: 
i. The AQ file was converted to an RQ file. 
ii. In analysing the levels of expression of each gene, the same baseline and threshold were 
used across all the samples. 
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iii. The data was normalised using the most stable “housekeeping” gene (YWHAZ) in the 
dataset as determined by the levels of expression across all subject groups. The relative 
expression level for individual gene to YWHAZ was then estimated. 
iv. Comparisons of the expression level of each candidate gene in the pSS versus pSS-
associated lymphoma groups were made using a non-parametric test (Mann-Whitney U 
Test) and p-values < 0.05 were considered statistically significant. 
2.5 Biological validation of the whole blood gene expression signature in pSS-
associated lymphoma 
A second set of independent samples (the Validation cohort) was used to provide biological 
validation of the potential whole blood gene expression signature in pSS-associated 
lymphoma that were identified in the Discovery cohort. This cohort consisted of 119 pSS 
and 17 pSS-associated lymphoma samples. Moreover, an additional set of 7 pSS-associated 
lymphoma samples was included from patients with pSS-associated lymphoma before 
treatment. Regarding the pSS-associated lymphoma samples, 8 were obtained from 
collaborators at the University of Uppsala, Sweden (2 pSS-associated lymphoma and 4 
untreated pSS-associated lymphoma), and 7 pSS-associated lymphoma samples were 
obtained from collaborators at Stavanger University, Norway. 
2.5.1 RNA clean up and concentration 
Materials: 
1. glycogen solution (catalogue number G 1767, SIGMA) 
2. 3 M sodium acetate (catalogue number S 7899, SIGMA) 
3. Ethanol 100% (catalogue number E/0650DF/17, Fisher Chemical) 
4. Ethanol 70% 
5. Free-DNase-RNase-water (catalogue number W 4502, SIGMA) 
Equipment: 
1. AccuspinTM Micro microcentrifuge (Fisher Scientific) 
2. Nano-drop ND-1000 spectrophotometer (Nanodrop Technologies) 
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Method: 
RNA precipitation was used to concentrate RNA samples. Briefly, 1 μl of glycogen 
solution was added to each sample. Next, 0.1 volume of 3 M sodium acetate were added 
followed by 2 volumes of cold Ethanol 100%. After an overnight incubation at -80 ºC the 
samples were centrifuged (13,000 x g at 4 ºC for 20 min), the supernatant was carefully 
removed and the pellets were washed with 250 μl of 70% ethanol, followed by another 
centrifugation (13,000 x g at 4 ºC for 5 min). The supernatant was removed without 
disturbing the pellets, then the pellets were air-dried for 30 min. The RNA pellets were 
resuspended with 12 μl of free-DNase-RNase-water. The purity and concentration of the 
samples (A260/A280 and A260/A230 ratio) were measured by the Nano-drop ND-1000 
spectrophotometer. 
2.5.2 Biological validation of the microarray data by qRT-PCR 
The TaqMan
®
 custom gene expression plates were used as described previously in section 
2.4.2. Samples from all the groups including 119 from the pSS and 17 from the pSS-
associated lymphoma groups (treated lymphoma) and 7 from the untreated pSS-associated 
lymphoma (untreated lymphoma) were used to validate 24 genes out of the 26 genes that 
were differentially expressed in both microarray and qRT-PCR in the Discovery cohort.  
The genes and their assay IDs are listed in Table 2.8. 
The qRT-PCR data were normalised to the most stable housekeeping gene (YWHAZ), and 
the relative expression levels were calculated. A non-parametric test (Mann-Whitney U 
test) was used  to compared the expression levels of the genes tested between the 
lymphoma groups and the non-lymphoma group. 
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Table 2.8 TaqMan gene expression assays of the biological validation  
Gene symbol TaqMan assay ID Type of gene 
ACTB Hs99999903_m1 Housekeeping gene 
YWHAZ Hs00237047_m1 Housekeeping gene 
BMS1 Hs01036249_m1 DEG 
C10orf32 Hs00376014_m1 DEG 
CBLL1 Hs01128720_m1 DEG 
CNPY3 Hs00198139_m1 DEG 
CYFIP2 Hs00910722_m1 DEG 
DRAP1 Hs01012815_g1 DEG 
DYNLL1 Hs00853309_g1 DEG 
ESYT1 Hs00248693_m1 DEG 
HNRNPUL1 Hs00199870_m1 DEG 
LEF1 Hs01547250_m1 DEG 
LGALS1 Hs00355202_m1 DEG 
MAGED1 Hs00986269_m1 DEG 
MGST3 Hs01058946_m1 DEG 
NUDT14 Hs00418228_m1 DEG 
OAF Hs00420156_m1 DEG 
POM121C Hs03406359_mH DEG 
PRPF8 Hs01556852_m1 DEG 
RBP7 Hs00364812_m1 DEG 
SEC61G Hs00414142_m1 DEG 
SF3A1 Hs01066327_m1 DEG 
SGK223 Hs00410725_m1 DEG 
SRP14 Hs03055045_g1 DEG 
UBXN11 Hs00377277_m1 DEG 
VCP Hs00997642_m1 DEG 
                      * DEG= differentially expressed genes from the discovery cohort 
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2.6 Prediction models in pSS-associated lymphoma 
To identify the most important genes that can predict the group membership of pSS-
associated lymphoma, I have used modelling techniques. The gene expression data from 
qRT-PCR of the Discovery cohort was used to build these models, using multiple logistic 
regression techniques.  A training sets were based on a random two-thirds training set, with 
the remaining one-third of the cases was retained for testing of the models.  A stepwise 
regression analysis was performed with SAS JMP software.  A number of tools were used 
to minimise over-fitting including cross-validation, evaluation of Akaike and Bayesian 
Information Criteria and inspection of the residual deviance.  Robustness of the models was 
evaluated by inclusion and exclusion of alternative gene candidates.  Models based on the 
training set were then evaluated on the testing set comparing predicted group membership 
with observed group membership.  For the dataset from the independent validation cohort 
the models were tested by comparison of observed and predicted group membership and 
misclassification analysis and the results were represented by mosaic plots. 
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Chapter 3 
Optimisation of the identification of a whole blood gene expression 
signature in primary Sjögren’s Syndrome by globin mRNA depletion 
3.1. Introduction  
Gene expression profiling in Primary Sjögren’s Syndrome (pSS) using samples from a large 
patient cohort is very challenging for several reasons. Firstly, given the relatively low 
prevalence of pSS, samples from pSS patients and healthy controls have to be recruited 
from different centres across the UK. Moreover, because of the involvement of a variety of 
centres we needed a robust sample collection method that reduced variability between the 
samples. This led to our decision of using whole blood samples, an approach that is 
frequently employed in such multi-centre studies. Using whole blood sample has many 
advantages. Whole blood samples can reduce the variability in sample processing during 
the isolation of different cell subsets, as it involves additional steps. There are additional 
challenges in ensuring the same equipment and reagents are used in each tissue collection 
centre. Furthermore, the time from sample collection to processing may have a greater 
impact on the quality and quantity of RNA extracted from the samples. In addition, RNA 
extraction from whole blood is less time-consuming and less expensive, and provides an 
opportunity to study all the white blood cells subsets together (Vartanian et al., 2009). On 
the other hand, there are also disadvantages. For instance, whole blood samples contain 
numerous cellular and non-cellular components that contain RNA materials which may 
affect gene expression studies. 
A major concern regarding whole blood gene expression studies is the abundance of globin 
mRNA within the samples. It is known that the whole blood consists of red blood cells 
(RBCs; ~95%), platelets (~5%) and white blood cells (WBCs). WBCs typically constitute 
less than 1% of the cellular content (Mastrokolias et al., 2012). Therefore, globin transcripts 
represent about 70% of the total amount of mRNA isolated from whole blood samples 
(Field et al., 2007). The abundance of globin mRNA in whole blood samples may therefore 
affect the sensitivity of the microarray by reducing fluorescent label availability for other 
less-abundant transcripts and hence preventing them from detection by the microarray 
assay (Liu et al., 2006, Mastrokolias et al., 2012). Therefore, one approach to overcome this 
54 
 
problem is to perform blood fractionation, which removes RBCs from the samples for gene 
expression study, leaving a more homogenous cell population. However, the blood 
fractionation procedure may affect gene expression by WBCs as well as introduce 
additional sample variability due to the additional experimental procedures (Fan and 
Hegde, 2005). 
Globin mRNAs are stable mRNAs in RBCs that is important for the synthesis of globin 
proteins after RBC enucleation. There are 3 members of the globin gene family: α-globin 
genes, which are located in chromosome 16 (Goh et al., 2005); β-globin genes, which are 
located in chromosome 11 and are highly expressed in erythrocytes; and γ-globin genes, 
which are normally expressed only in foetal liver (Levings and Bungert, 2002).  Being the 
dominant mRNA species in whole blood samples, α-globin and β-globin transcripts may 
interfere with gene expression profiling using these samples, reducing the sensitivity of 
microarray signals. Several studies have been carried out to investigate globin reduction for 
blood-based gene expression studies, with the majority of these studies concluding that 
globin reduction is preferable (Winn et al., 2011). This preference results from that the 
reduction of globin mRNA from whole blood samples produced microarray data similar to 
those obtained from PBMC samples (Raghavachari et al., 2009, Wright et al., 2008). 
Furthermore, some investigators suggest that the interference of globin mRNA with whole 
genome gene expression studies is more prominent if the genes of interest are not highly 
expressed. However, globin mRNA depletion involves additional procedures that may 
introduce sample variability and damage to mRNAs.  
Various methods have been developed to eliminate globin mRNA from blood samples. One 
of these methods is the GLOBINclear
TM
 Kit. This kit uses a method that benefits from the 
strong binding between biotin and streptavidin molecules, nucleic acid hybridisation 
specificity and the use of magnetic beads to separate globin mRNAs from the remaining 
RNA species. This kit removes both α- and β-globin mRNA (Ambion, 2007). Another 
method of globin reduction involves blocking of the α- and β-globin mRNA by peptide 
nucleic acids  (PNAs) during the cDNA synthesis. The globin-reduction PNA oligomers are 
a set of four oligomers complimentary to globin mRNA (Affymetrix, 2004). This method 
works as an immobiliser that masks globin mRNA during reverse transcription, making 
non-globin mRNA more available for detection in microarray analysis.  
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Up to date, a few gene expression studies using pSS peripheral blood samples have also 
been carried out. One of these studies revealed that genes of the IFN pathways are among 
the most overexpressed genes involved in pSS pathogenesis, with ten of the top 20 up-
regulated genes in pSS being IFN-α inducible genes (Kimoto et al., 2011). The up-
regulation of IFN-α inducible genes was also detected in PBMCs from pSS (Emamian et 
al., 2009). This activated IFN signature in pSS was present regardless of the different 
versions of gene chips used. Interestingly, the IFN signature correlated with high levels of 
anti-Ro/SSA and anti-La/SSB autoantibodies. Peripheral blood gene expression profiling 
also revealed differentially expressed genes that are related to the inflammatory and other 
immune-related pathways. These pathways include B and T cell receptors, IGF-1, GM-
CSF, PPARα/RXRα, and PI3/AKT signalling. Moreover, the authors observed that the 
abundance of globin mRNA in peripheral blood may have reduced the sensitivity of 
detection of differentially expressed genes (DEGs) because the number of DEGs identified 
was greater when PBMC samples were used  (Emamian et al., 2009). To my knowledge, no 
study has been reported regarding the impacts of globin mRNA on whole blood gene 
expression profiling in pSS. 
In my first experiment, globin mRNA depletion was carried out using the GLOBINclear
TM
 
Kit. The kit separates out globin mRNA, permitting use of non-3'-bias techniques including 
the chemical labelling of RNA. Although this method affects RNA quality due to the 
additional preparation steps, it results in an improved gene expression profile outcome 
compared with other methods (Liu et al., 2006). Different downstream steps were evaluated 
and compared with paired samples without globin depletion.   
3.2 Aim and Design of the Experiment 
The aim of this experiment is to evaluate the effect of globin mRNA depletion on the whole 
blood gene expression signature in pSS. The data will also be used to optimize the gene 
expression profiling protocol to identify the transcriptomic signature of pSS-associated 
lymphoma. 
A total of 24 whole blood samples, collected in PAXgene RNA tubes, were selected from 
the UKPSSR biobank (pSS patients=12, healthy controls=12). The RNA was extracted, 
cleaned and concentrated (if required). Each sample was split into 2 aliquots, one aliquot 
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was subjected to the globin mRNA depletion protocol (G-depleted group), the other aliquot 
was kept without further processing (G non-depleted group). All forty-eight samples (G-
depleted=24 and G non-depleted=24) were sent to Cambridge Genomic Services (CGS) at 
the University of Cambridge for whole genome microarray analysis. The design of the 
experiment is shown in Figure 3.1. 
 
Figure 3.1 Globin mRNA depletion experimental design.  pSS= primary Sjögren’s syndrome, 
HC= Healthy Controls  
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3.4 Results: 
3.4.1 Demography of study subjects 
The pSS patients and healthy controls were selected from the UKPSSR (pSS patients=12, 
healthy controls=12). All the patients fulfilled the AECG classification criteria and were 
females with an average age of 52 yrs. (25–76 yrs). The presence of paraproteinemia, 
lymphoma or other types of cancer was not reported in the chosen pSS patients. The aged-
matched healthy controls included two males (females=10, male=2) with an average of 49 
yrs. (25–72 yrs). The clinical characteristics and demographics of the patients and healthy 
controls are shown in Table 3.1 
Table 3.1 Clinical data of pSS patients selected for the globin mRNA depletion 
experiment  
Clinical criteria pSS patients  
(mean ± S.E.M) 
Healthy control 
Age (years) 52 ± 4.49 49 ± 3.00  
Unstimulated oral salivary flow (ml/15 mins) 1.34 ± 0.54 N/A 
Schirmer’s test (mm/5 mins) 7.70 ± 3.34 N/A 
Anti-Ro/SSA positive (%) 75% N/A 
Anti-La/SSB positive (%) 66.6% N/A 
WCC (x 10^9/l) 5.41 ± 0.88 N/A 
Neutrophil (x 10^9/l) 3.13 ± 0.40 N/A 
Lymphocytes (x 10^9/l) 1.87 ± 0.36 N/A 
ESR (mm/hr) 25.60 ± 6.08 N/A 
IgG (g/L) 16.14 ± 1.99 N/A 
C3 (mg/dl) 1.18 ± 0.16 N/A 
C4 (mg/dl) 0.40 ± 0.20 N/A 
CRP (mg/L) 4.5 ± 1.53 N/A 
RF (IU) 62.5 ± 35.83 N/A 
Total SSDDI 3.5 ± 0.33 N/A 
ESSPRI (0-10) 6.47 ± 0.56 N/A 
ESSDAI (0-123) 4.45 ± 1.00 N/A 
 WCC= White Cell Count, ESR= Erythrocyte Sedimentation Rate, C3= Complement Component 3, 
C4= Complement Component 4, CRP=C-reactive Protein, RF=Rheumatoid Factor, 
IU=International units, ESSDAI score=(0-4 no activity, 5-12 moderate activity and ≥ 13 high 
activity) 
 
58 
 
3.4.2 Assessment of globin mRNA depletion from RNA samples: 
Before sending the RNA samples for microarray, the efficacy of globin mRNA depletion 
was assessed using qRT-PCR. Since the β-globin gene is the main globin gene expressed in 
adult erythrocytes (Antoniou et al., 1988, Johnstone et al., 2013), I chose to measure the 
amount of β-globin mRNAs in the samples to assess the efficacy of globin mRNA 
depletion. As the amount of RNA available from the biobanked samples was limited, the 
levels of β-globin transcripts from 11 paired samples (HC=9 and pSS patients=2) with or 
without globin mRNA depletion were measured.  The level of expression was normalised 
to the housekeeping gene 18S. The results showed a significant reduction (average of 64-
fold) in the amount of the β-globin mRNA in the G-depleted samples in comparison with 
their corresponding G non-depleted samples (p < 0.0001, Mann-Whitney U test) (Figure 
3.2).  
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Figure 3.2 Relative gene expression levels of β-globin with and without globin mRNA 
depletion. The amount of β-globin mRNA in paired samples, G-depleted and G non-
depleted samples (n=11), measured using qRT-PCR. There was a significant reduction 
(average of 64-fold, p<0.0001) in the expression levels of β-globin mRNA in the G-depleted 
samples compared to the G non-depleted samples, the error bars show the standard error 
of the means. 
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3.4.3 RNA quality for microarray analysis with or without globin mRNA depletion. 
The Bioanalyzer measured the RNA quality, and the data were analysed using the RIN 
algorithm, which ranks different RNA features, including the 28S to 18S ratio and other 
factors to give a robust evaluation of RNA quality. The higher the RIN score, the better the 
RNA quality. Depletion of globin mRNA led to a slight reduction in the RNA quality as 
shown by a reduction of the RIN score. Nevertheless, the RNA quality of the G-depleted 
samples remained good (with RIN values being greater than 7), which is considered 
suitable for microarray experiments.  As shown in Table 3.2, the RIN score for some 
samples could not be determined by the Bioanalyzer (shown in Table 3.2 as N/A). This 
does not necessarily mean that the RNA quality of the samples was low. An “N/A” result 
may be returned due to different factors, for instance, unusual ribosomal ratio and 
background noise. The quality of such samples was therefore judged by visual inspection of 
the electropherograms and the gel-like images of them. The electropherograms of the 
amplified cRNA from both pSS and healthy controls from the G-depleted group 
demonstrate the lack of a sharp peak of about 700 bp, which represents the Globin mRNA 
in the G-depleted group and which give the curve a bell shape similar to that obtained from 
PBMCs as demonstrated in Figure 3.3. All samples were judged by CGS staff to be of good 
quality for the microarray experiment. The electropherograms of the amplified cRNA found 
in supplementary figures SF1, SF2, SF3 and SF4. 
Table 3.2 The RIN scores of RNA samples with or without globin mRNA depletion. RIN 
scores were calculated by the algorithms provided by the Agilent Bioanalyzer 2100. 
Samples IDs with a suffix of “0” represented the healthy controls; whereas a suffix of “1” 
represented pSS patients   
Sample ID G-depleted G-non depleted Sample ID G-depleted G-non depleted 
BAS-017-0 7.4 8 NCL-011-1 8 N/A 
LEE-059-0 7.5 8.3 DER-006-1 8.1 10 
GAT-027-0 8.5 9.6 BIR-051-1 7.9 N/A 
BAT-023-0 8.4 9.6 NCL-055-1 7.6 N/A 
NCL-136-0 7.7 8.9 BIR-029-1 7.8 10 
NCL-091-0 7.8 9.8 NCL-052-1 8 9.9 
NCL-123-0 7 N/A NCI-083-1 7.6 9.6 
CAM-006-0 7.5 9.4 NCL-084-1 7.5 N/A 
NCL-113-0 7.3 9.2 NCL-024-1 7.5 9.8 
NCL-117-0 8.1 N/A NCL-060-1 7.7 9.8 
NCL-130-0 7.9 9.2 BIR-005-1 8.3 N/A 
LEE-049-0 7.5 N/A SUN-009-1 8.2 9.2 
*N/A-  RIN score not calculable by the Bioanalyzer software 
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Figure 3.3 Representative electropherograms of amplified cRNA of a paired sample with 
or without globin mRNA depletion. A) “G non-depleted” sample showing a sharp peak of 
about 700 base pair representing the globin mRNA, B) “G-depleted” sample shows a bell-
shaped curve and the absence of the globin mRNA’s sharp peak.  
 
3.3.4 The effect of globin mRNA depletion on microarray signal intensity and samples 
variability 
The single signal intensity for each probe in the microarray was calculated by 
GenomeStudio software, after the Illumina BeadChips was scanned (Johnstone et al., 
2013). The boxplots in Figure 3.4 illustrate how the probe signal intensity was distributed 
in the G-depleted and G non-depleted datasets. With regard to the raw data, the boxplots in 
the G non-depleted groups showed a more disproportionate spread and the mean of each 
array had a greater intra-group variability in comparison to the G-depleted groups. The 
normalised data (RSN method) showed a similar trend, with the G non-depleted samples 
showing a higher variability between individual arrays while the G-depleted group had a 
more homogeneous signal intensity across individual arrays. Furthermore, principle 
component analysis (PCA) of the normalised data of both groups revealed that the G-
depleted samples clustered closer together comparing to the G-non depleted samples 
(Figure 3.5). When the samples were further sub-classified  according to their disease status 
(i.e., pSS patients or healthy controls), again, G-depleted samples clustered closer together 
than the G non-depleted samples (Figure 3.6). Taken together, these observations suggest 
that the microarray data generated using G-depleted samples were of a better quality. 
 
     -                 -                
 ~700 bp  
globin mRNA 
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Figure 3.4 Boxplots of the microarray signal intensity of the paired samples with or without globin mRNA depletion. Left: raw data, 
showing a great spread of the boxplots medians among the G-non depleted group for both pSS patients and HC in comparison to the G-
depleted group. Right: normalised data (RSN method), the G-non depleted samples showed a slight variability unlike the G-depleted group, 
which revealed a more even signal intensity across individual microarrays.  
Raw data Normalizes data 
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Figure 3.5 PCA of normalised microarray data with or without globin mRNA depletion. 
The triangles represent the G depleted group whereas the G non-depleted group is 
represented by circles. Each paired samples have the same corresponding number showing 
its clustering location in their respective groups   
 
 
G-depleted group 
G-non depleted group 
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Figure 3.6 PCA of normalised microarray data of pSS patients and healthy controls with 
or without globin mRNA depletion . Each paired sample has the same corresponding 
number showing its clustering location in their respective groups. 
 
 
 
G-non depleted HC 
G-non depleted pSS 
G-depleted HC 
G-depleted pSS 
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3.3.5 Differentially expressed genes in pSS with or without globin mRNA depletion: 
The gene expression profile in pSS patients was investigated. Analysis of the microarray 
data (Illumina HT-12v4) revealed a total of 24642 detected probes. Moreover, when the 
analysis was performed separately for the G-depleted and G non-depleted groups, there 
were 21929 and 17851 detected transcripts/entities respectively. These numbers represented 
the number of probes that had passed the basic filter step with a detection p-value threshold 
<0.01. A total of 17211 transcripts/entities overlapped between the two groups. There were 
640 distinctive transcripts/entities in the G non-depleted group and 4718 distinctive 
transcripts/entities in the G-depleted group (Figure 3.7(A)).  
There were also differences in the number of differentially-expressed genes (DEGs) (fold-
change ≥ 1.2, adjusted p < 0.05) detected for pSS using G-depleted or G-non depleted 
samples. When using the G-depleted samples, a total of 1070 DEGs (733 up-regulated and 
337 down-regulated DEGs) between pSS and HC were identified. When using the G non-
depleted samples, 942 DEGs (670 up-regulated and 272 down-regulated DEGs) between 
pSS and HC were identified. Among the identified DEGs using these two groups of 
samples, 559 DEGs were in common (Figure 3.7(B)). The volcano plot in Figure 3.8 shows 
the DEGs using the G-depleted and G non-depleted samples. Among the up-regulated 
DEGs identified using the two groups of samples,  80% of the DEGs in the top 20 and top 
50 of up-regulated genes for pSS were identical. However only 64% of the DEGs were the 
same in the top 100 up-regulated genes for the G-depleted and G-non-depleted groups. The 
IFN-inducible genes dominated the top 20 up-regulated DEGs regardless of whether G-
depleted and G non-depleted samples were used, consistent with the published literature 
(Emamian et al., 2009). For the down-regulated genes between pSS and HC, however, there 
were more differences in the DEGs identified using the two groups of samples. Only 30%, 
28%, 32% of the DEGs were the same in the top 20, top 50, and top 100 down-regulated 
genes respectively , The top 20 up-regulated genes are shown in Table 3.3 and the top 20 
down-regulated genes are shown in Table 3.4.  
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Figure 3.7 Venn diagram of the number of detectable transcripts/entities and DEGs 
identified using samples with or without globin mRNA depletion. A) Venn diagram of the 
number of detectable transcripts/entities that had passed the detection threshold in the 
microarray analysis in the G-depleted and G non-depleted groups.  B) Venn diagram of the 
number of differentially expressed genes in pSS identified using in G-depleted and G non-
depleted groups samples  
 
Figure 3.8 Volcano plots of the differentially expressed genes in pSS using samples with 
or without globin mRNA depletion.The G-depleted (right) and G non-depleted (left) 
groups. The x axis represents the log2 of the fold change (FC) and the y axis represents 
the–log10 of the p-value; the dots in black represent the differentially expressed genes using 
the threshold values of FC ≥ 1.2, and adjusted p value < 0.05. 
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Table 3.3 Top 20 up-regulated DEGs in pSS in the G-depleted and G non-depleted 
groups, p<0.05, FC≥1.2 
G- depleted group G non-depleted group 
  Gene symbol adjusted 
P Value 
Fold change Gene symbol adjusted 
P Value 
Fold change 
IFI27 0.0319 7.170 IFI27 0.0233 6.802 
IFIT1 0.0219 4.418 IFIT1 0.0134 4.192 
IFI44 0.0156 4.317 IFI44L 0.0284 3.859 
IFI44L 0.0437 4.224 IFI44 0.0110 3.496 
RSAD2 0.0234 3.669 EPSTI1 0.0099 3.353 
EPSTI1 0.0168 3.274 ISG15 0.0300 3.137 
ISG15 0.0416 3.199 RSAD2 0.0172 2.932 
OAS3 0.0378 2.936 IFIT3 0.0214 2.894 
IFIT3 0.0382 2.757 HERC5 0.0373 2.610 
IFIT3 0.0226 2.563 IFITM3 0.0486 2.567 
IFIT2 0.0192 2.554 IFIT2 0.0194 2.525 
OAS1 0.0355 2.389 OAS3 0.0225 2.459 
IFIT3 0.0283 2.384 IFI6 0.0288 2.373 
RPL26 0.0163 2.265 S100A8 0.0132 2.342 
CHMP5 0.0021 2.243 OAS1 0.0127 2.214 
OAS1 0.0428 2.242 IFIT3 0.0082 2.208 
XAF1 0.0213 2.232 XAF1 0.0254 2.175 
S100A8 0.0210 2.109 RPL26 0.0115 2.170 
GBP1 0.0125 2.054 OAS1 0.0171 2.132 
RPL31 0.0461 2.040 TRIM22 0.0023 2.101 
 
Table 3.4 Top 20 down-regulated DEGs on pSS in the G-depleted and G non-depleted 
groups, p<0.05, FC≥1.2 
G- depleted group G non-depleted group 
  Gene symbol adjusted 
P Value 
Fold change Gene symbol adjusted 
P Value 
Fold change 
GPR162 0.0123 1.710 HLA-H 0.0207 2.413 
CLIC3 0.0403 1.671 PABPC1 0.0030 1.647 
PTGDS 0.0332 1.638 IMPA2 0.0096 1.629 
IMPA2 0.0110 1.612 RPS28 0.0055 1.615 
NINJ2 0.0261 1.597 RNA18S5 0.0414 1.601 
MATK 0.0207 1.571 NINJ2 0.0266 1.584 
MPZL1 0.0122 1.495 MARCH2 0.0390 1.581 
RYBP 0.0153 1.489 RPL14 0.0057 1.553 
ZBTB16 0.0140 1.488 GPR162 0.0115 1.540 
CABIN1 0.0002 1.487 HLA-G 0.0452 1.522 
ZNF467 0.0309 1.484 SIPA1L3 0.0380 1.513 
NCR3 0.0039 1.466 MATK 0.0437 1.492 
CCNY 0.0002 1.449 TUBA4A 0.0056 1.455 
DDIT4 0.0120 1.444 SH3GLB2 0.0082 1.444 
VPS37C 0.0055 1.442 CD7 0.0356 1.443 
MAPK8IP1 0.0490 1.442 RPL23AP64 0.0173 1.438 
CD7 0.0399 1.427 AMY1C 0.0055 1.432 
MARCH6 0.0390 1.423 ABTB1 0.0278 1.409 
ARRB1 0.0058 1.411 RPLP1 0.0087 1.406 
TBL1X 0.0264 1.408 FTH1P2 0.0361 1.405 
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3.3.6 Pathway analysis 
 I then examined whether the biological pathways identified using G-depleted and G non-
depleted samples were similar. Using the KEGG pathway analysis, two pathways 
“Spliceosome” and “Oxidative phosphorylation” were identified to be differentially 
activated in pSS patients in both the G-depleted and G non-depleted datasets. Using the 
gene ontology analysis, 319 and 493 Gene Ontology (GO) terms from the G-depleted and 
G non-depleted datasets were identified to be associated with pSS. A total of 230 of these 
GO terms were identical between the two datasets. For the top 10 GO terms, 6 (60%) were 
in common between the G-depleted and G non-depleted datasets (Table 3.5). The top three 
GO terms for both datasets were “Antigen processing and presentation of exogenous 
peptide antigen via MHC class Ib,” “Antigen processing and presentation of exogenous 
protein antigen via MHC class Ib, TAP-dependent” and “Detection of virus” 
Table 3.5 Top 10 GO terms in pSS using samples from the G-depleted and G-non 
depleted groups 
G- depleted group G- non depleted group 
GO ID P value Term GO ID P value Term 
GO:0002477 0.00498 antigen processing and 
presentation of 
exogenous peptide 
antigen via MHC class Ib 
GO:0002477 0.0046242 antigen processing and 
presentation of 
exogenous 
peptide antigen via MHC 
class Ib 
GO:0002481 0.00498 antigen processing and 
presentation of 
exogenous protein 
antigen via MHC class 
Ib, TAP-dependent 
GO:0002481 0.0046242 antigen processing and 
presentation of 
exogenous protein 
antigen via MHC class 
Ib, TAP-dependent 
GO:0009597 0.00498 detection of virus GO:0009597 0.0046242 detection of virus 
GO:0033364 0.00498 mast cell secretory 
granule organization 
GO:0032439 0.0046242 endosome localization 
GO:0034343 0.00498 type III interferon 
production 
GO:0033364 0.0046242 mast cell secretory 
granule organization 
GO:0034344 0.00498 regulation of type III 
interferon production 
GO:0034343 0.0046242 type III interferon 
production 
GO:0036337 0.00498 Fas signaling pathway GO:0034344 0.0046242 regulation of type III 
interferon production 
GO:0044565 0.00498 dendritic cell 
proliferation 
GO:0035616 0.0046242 histone H2B conserved 
C-terminal lysine 
deubiquitination 
GO:1902044 0.00498 regulation of Fas 
signaling pathway 
GO:0035726 0.0046242 common myeloid 
progenitor cell 
proliferation 
GO:0002428 
 
0.01423 
 
antigen processing and 
presentation of peptide 
antigen via MHC class Ib 
 
GO:0036257 
 
0.004624 
 
multivesicular body 
organization 
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3.4 Discussion  
The aim of this experiment was to evaluate the effect of globin mRNA depletion on whole 
blood gene expression profiling in pSS. The data generated helped me to determine the 
approach that I should use to identify the whole blood gene expression signature in pSS-
associated lymphoma. The reasons for choosing pSS gene expression profiling instead of 
pSS-associated lymphoma gene expression profiling was two-fold. First, whole blood gene 
expression data on pSS are available in the literature as reference data for my experiment, 
while there is no such data available for pSS-associated lymphoma. Second, only a limited 
amount of whole blood RNA was available from the pSS-associated lymphoma group.  
Whole blood RNA samples 
The use of whole blood samples might increase noise and decrease the responsiveness in 
microarray experiments (Feezor et al., 2004). The use of PAXgene blood RNA tubes and 
their stabilising reagents helps to stabilise the transcriptome once the specimen has been 
taken, and minimises RNA degradation for a long period of time (Rainen et al., 2002). 
Therefore, this blood collecting system is suitable for gene expression studies using RT-
PCR or microarrays (Stordeur et al., 2003, Thach et al., 2003). In this study, most of the 
RNA samples extracted from PAXgene tubes required additional “clean up” and 
“concentration” steps before globin mRNA depletion with the GLOBINclear kit. The need 
for these extra preparatory steps has also been reported (Liu et al., 2006) and was thought to 
be related to the different incubation times of the PAXgene tubes resulting in different  
RNA yields (Wang et al., 2004). 
RNA quality 
The RIN scores (thus the RNA quality) of my samples decreased after globin mRNA 
depletion. This observation is not unexpected and is in agreement with previous reports 
(Mastrokolias et al., 2012, Choi et al., 2014). The electropherogram of the cRNAs 
demonstrating the lack of a globin mRNA peak in my globin-depleted samples is also 
consistent with previous studies (Liu et al., 2006, Vartanian et al., 2009). The efficiency of 
the novel hybridisation capture technology used in the GLOBINclear kit as a globin 
reduction protocol has previously been evaluated for next generation sequencing 
(Mastrokolias et al., 2012). It is believed that the design of these oligonucleotides is a 
69 
 
crucial factor for the effectiveness in globin removal (Affymetrix, 2003). Regardless, the 
efficient depletion of β-globin mRNA in my G-depleted samples was satisfying. 
Microarray data 
The improvement of the microarray signal intensity and the reduction of signal intensity 
variability among the samples following globin mRNA depletion is consistent with 
previous reports using samples from humans, mice and rats (Liu et al., 2006, Whitley P, 
2007, Whitley P, 2005, Winn et al., 2010). In addition, the principle component analysis 
(PCA) illustrated a reduction in the overall variability within the respective subject groups 
(pSS patients and healthy controls) in the ‘G-depleted’ dataset. This observation suggests 
that globin mRNA reduction improved sample homogeneity. Furthermore, the number of 
detectable transcripts/entities (present call) were higher in the G-depleted dataset, which 
also has been reported previously (Affymetrix, 2003).    
With regard to the ability to detect DEGs in pSS, more DEGs were identified using the G-
depleted samples than using G non-depleted samples. However, it may not be a simple case 
of more DEGs being detected in the G-depleted datasets, since only approximately half of 
the DEGs identified were in common using both G-depleted and G non-depleted samples. 
The difference was more apparent for down-regulated genes. One possible explanation is 
that globin depletion may be more efficient in unmasking less-abundant transcripts (Liu et 
al., 2006). Nevertheless, for both G-depleted and G non-depleted datasets, the up-regulated 
genes showed a dominant pattern of IFN-inducible genes in the top 20 up-regulated genes, 
consistent with the hypothesis that an activated IFN signature is a hallmark of pSS (Brkic 
and Versnel, 2014).  
Pathway analysis  
Pathway analysis showed that similar pathways were enriched in both G-depleted and G 
non-depleted datasets and 60% of the top 10 GO terms was in common. Interestingly, the 
top three GO terms were related to immune response to viruses; this finding is consistent 
with the hypothesis that viruses (such as EBV, CMV, retroviruses) may play a role in the 
pathogenesis of pSS (Venables and Rigby, 1997, Willoughby et al., 2002). 
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In summary, globin mRNA depletion improved microarray signal intensity, and reduced 
sample variability. Regarding its impact on gene expression profiling, globin mRNA 
depletion resulted in the detection of more DEGs, but had relatively little impact on the 
DEGs with the highest fold changes. Globin mRNA depletion also appears to have a small 
impact on the outcome of pathway analysis of the microarray data.  Based on the data from 
this study, I believe that globin mRNA depletion may offer a slight advantage in my 
subsequent whole blood gene expression study of pSS-associated lymphoma.  
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Chapter 4 
Identification of Whole Blood Gene Expression Signature in 
primary Sjögren’s Syndrome -associated lymphoma 
4.1 Introduction 
I. Primary Sjögren's Syndrome (pSS)-associated lymphoma 
Lymphoma is one of the most serious extraglandular manifestations of pSS. It was first 
reported in pSS patients in 1963 (Talal and Bunim, 1964). The prevalence of lymphoma in 
pSS patients is approximately 5%. It has been reported that pSS patients have a 44-fold 
increased risk of developing non-Hodgkin lymphoma (NHL) (Kassan et al., 1978), 
although another study has reported a 16-fold increased risk to develop NHL (Theander et 
al., 2006). A meta-analysis investigating the association of NHL with autoimmune diseases 
showed a smaller SIR of 4.9 in pSS patients (Fallah et al., 2014). A summary of the studies 
regarding lymphoma prevalence in pSS has also been provided in the introduction chapter 
(Table 1.4). It has been documented that the most common type of pSS-associated 
lymphoma is the mucosa-associated lymphoid tissue (MALT) lymphoma followed by the 
nodal marginal zone lymphomas (NMZLs), and then the diffuse large B-cell lymphomas 
(DLBCLs), based on a study of 53 pSS patients with lymphoma from a cohort of 584 pSS 
patients (Voulgarelis et al., 2012). As lymphoma is a potentially fatal manifestation of pSS, 
the determination of lymphoma’s risk factors provides a useful background to understand 
its evolution. Several risk factors have been linked to the increased risk of lymphoma 
development among pSS patients. These risk factors include: low C4 levels in the blood, 
cryoglobulinaemia (De Vita et al., 2012), paraproteinemia, persistent salivary gland 
swelling, and palpable purpura (Skopouli et al., 2000). Reduced ratio of CD4
+
/CD8
+
 T cells 
and a low count of CD4
+
 T cells in peripheral blood are also associated with an increased 
risk; in this case, it has been speculated that the infiltration of CD4
+
 into the glandular 
tissue results in reduced CD4
+
 T cell number and reduced CD4
+
/CD8
+
 ratio in the blood 
(Pillemer, 2006). A recent paper from France reports that rheumatoid factor is also a risk 
factor (Nocturne et al., 2015c). 
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Few studies have been carried out investigating gene expression in pSS-associated 
lymphoma. These studies were limited by small sample size. As mentioned in the 
introduction chapter, one of the studies focused on the gene expression of MALT 
lymphoma in the parotid gland of pSS patients has identified eight candidate genes (GRB2, 
ARHGDIB, CD40, PSMB9, ALDOA, PRDXS, PARC and PPIA) that can differentiate pSS-
associated MALT lymphoma from pSS (Hu et al., 2009). Another study analysed the 
differentially expressed genes in the whole blood of pSS-associated lymphoma (marginal 
zone B cell lymphoma) patients using cDNA microarray; it showed that the ribosomal 
protein genes S29 and S27 are upregulated in pSS patients with lymphoma, while the IFN-
inducible genes, which are extensively overexpressed in pSS, were not. Interestingly, 
subsequently to chemotherapy and rituximab, the ribosomal protein genes S29 and S27 
were downregulated; this observation suggests that S29 and S27 may serve as biomarkers 
of pSS-related lymphoma (Kimoto et al., 2011, Ogawa, 2010). However, the molecular 
mechanisms that are important in the development of lymphoma remain poorly understood. 
 
II. Gene expression signature by microarray     
Recently, microarray technology has become a common tool to investigate gene 
expression. A microarray measures the expression of thousands of genes, giving the 
opportunity to use this huge source of information in different fields. This technology 
contributes widely in cancer research (Branca, 2003, Jeruss et al., 2008), disease treatments, 
and the identification of new biomarkers. The bead chip technology used in the Illumina 
Human HT-12 v4 Expression BeadChip utilises 3-micron silica beads that aggregate on 
either a planar silica slides or a fiber optic bundle, as illustrated in Figure 4.1. The 
BeadChip array is a more desirable technique as it requires less sample input and it is 
cheaper than other available platforms (Consortium, 2006). These beads are characterised 
by their ability of random self-assembly into microwells. This assemblage happens via van 
der Waals forces as well as the hydrostatic interaction of the beads and the well’s wall. The 
beads are covered with hundreds of thousands of specific copies of oligonucleotides, or 
probes, that capture particular sequences in the assay (www.illumina.com). Because of the 
random aggregation of the beads, the probes will be randomly distributed in different 
numbers and locations in the array. The analysis process includes the identification of the 
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bead locations, bead types, and the microarray intensity. Subsequently, images were 
obtained from the scanner, and a pre-processing procedure was followed. The pre-
processing method consists of three steps: registration of beads, insertion of the lasting 
beads, and pinpointing the grid above the array (Gunderson et al., 2004, Arteaga-Salas et 
al., 2008).  Eventually, the probes on each bead were identified. The microarray data was 
corrected for background noise, which was produced by the hybridisation of nonspecific 
transcripts in the samples. As a result, the foreground, which is the mean of sharpened 
intensities from a 4 × 4 pixel square on the bead-centre, is separated from the background 
(Tarca et al., 2006, Wu, 2009, Smith et al., 2010).         
 
 
Figure 4.1 Illumina BeadChip technology. This is the technology conducted by Illumina 
whole genome microarray. (www.illumina.com)    
 
The next step in microarray data analysis is transformation of the data into a log scale. This 
step is important as the data might be skewed and the transformation might bring it closer 
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to a normal distribution. The data is transformed either using Log2 scale or variance- 
stabilising transformation (VST). This latter has been reported to be more efficient than the 
Log2 transformation when using the Illumina platform (Lin et al., 2008). The selected 
normalisation method for the microarray data is crucial for further downstream analysis 
(Schmid et al., 2010). There are several normalisation methods that can be used to 
minimise the data variability that originates from noise and artifacts. The method that I 
used to analyse my data is the robust spline normalisation (RSN). This algorithm has the 
features of both the quantile and LOESS (Local regression) normalisation. In addition, this 
function, which is included in the “Lumi” package, will run the lumiT function if the data is 
not variance-stabilised, as it is designed to normalise VST-transformed data (Lin et al., 
2008).  
Conducting a large gene expression experiment involves many challenges. One such 
challenge is batch effects. Batch effects are derived from miniature differences in non-
biological factors, such as the use of different batches of reagents in sample preparation or 
minor differences in sample handling by different researchers and many others. It has even 
been reported that ozone levels have an impact on the microarray data (Fare et al., 2003, 
Chen et al., 2011, Luo et al., 2010). Many methods were introduced in order to minimise 
batch effects in order to obtain an accurate gene expression dataset for downstream 
analysis. One of these methods is ComBat function. ComBat is an empirical Bayes 
framework that effectively eliminates batch effects. The method works by "borrowing 
information” from across the probes and experimental conditions in hope that the 
“borrowed information” will lead to better estimates or more stable inferences. (Johnson et 
al., 2007, Stein et al., 2015). In comparison with other batch effect removal tools, ComBat 
is more effective in eliminating batch effects and producing more accurate microarray data 
(Chen et al., 2011). The final step in microarray analysis was to identify a list of 
differentially expressed genes and/or biological pathways between the comparative groups. 
Such differentially expressed genes might be valuable in biomarker discovery and the 
identification of key genes or biological pathways in the pathogenesis of the disease being 
studied.  
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III. Validation of microarray data by Real-Time RT-PCR 
High-throughput experiments, such as microarray, might be affected by the complexity of 
the assay. This complexity is reflected in the manufacturing of the array and the preparation 
procedures of the samples (Eisen and Brown, 1999). For this reason, it is important to use 
another method to confirm the findings of differentially expressed genes identified in 
microarray experiments. Real-Time RT-PCR is a standard technique in quantitative 
measurements of mRNA. RT-PCR has many advantages: it is inexpensive, not time-
consuming, and requires only a small amount of mRNA (Rajeevan et al., 2001). In this 
project, TaqMan® real-time PCR primers and probes were used in the validation of my 
potential gene expression signature in pSS-associated lymphoma identified from 
microarray. The TaqMan® Gene Expression Assays kit includes: one pair of unlabeled 
PCR primers, TaqMan® probe that is labeled with FAM
TM
 or VIC
®
 dye, and the third 
component is the minor groove binder (MGB) and non-fluorescent quencher (NFQ) on the 
3’ end. The MGB presence in the assay is very significant as it increases the probe’s 
melting temperature (Tm), leading to the stabilisation of the probe-target complex. This 
advantage enables the probes to be shorter than the outdated probes, and it also allows more 
specific detection targets by using probe sequences that are more specific to the target 
mRNA (www.lifetechnologies.com, 2012). Figure 4.2 illustrates the TaqMan® gene 
expression assay technology.   
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Figure 4.2 The TaqMan gene expression assay reaction steps.(taken from 
www.lifetechnologies.com) 
 
TaqMan® Array 96-Well Fast plates were used to perform the validation experiment. The 
advantages of this method are speed and the requirement of only small amounts of mRNA. 
Therefore, this method is well suited for a large experiment with many samples and genes 
to validate, such as mine. Within each of the plates, the predesigned TaqMan® Gene 
Expression Assays were dried down into the wells of the plates. The assays work with the 
pre-prepared cDNA of the sample, and the expression data for a given gene is measured 
(www.lifetechnologies.com, 2011). 
IV. Prediction models in pSS-associated lymphoma 
After the identification and technical validation of the whole blood potential gene 
expression signature in pSS-associated lymphoma, it was useful to find out which genes are 
the most important in predicting the membership in pSS-associated lymphoma. A 
prediction model is a collection of mathematical techniques that aims to identify a 
mathematical relationship between the genes of interest and the phenotype. When using 
prediction models, it is important to keep in mind that they are usually imperfect; and 
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therefore it is important to include with the prediction a measurement of the percentage of 
uncertainty (Dickey, 2012).        
4.2 Aim and experimental design 
The ultimate aim of the project is to identify a whole blood gene expression signature in 
pSS-associated lymphoma. In order to achieve this goal, 144 samples were selected from 
the UKPSSR (Discovery cohort), and categorised into five groups. The group of interest is 
the pSS-associated lymphoma group (n=16) that will be used for comparison with the non-
lymphoma pSS group (n=61), which represents the disease controls. Additional 
controls/comparison groups were also included. The pSS-paraproteinemia group (n=23) 
was included to represent an “at risk” group, as paraproteins play an important role in many 
malignant diseases (Cook and Macdonald, 2007) and are a risk factor for lymphoma 
development in pSS. The pSS-other cancers group (n=21) was included to explore whether 
any of the altered gene expression detected in the pSS-lymphoma group is associated with 
malignancies ‘in general’ or is specific to lymphoma. Finally, a healthy control group 
(n=23) was also included. 
My first experiment is to perform a whole genome gene expression microarray. The 
microarray was performed by CGS after I extracted the RNA samples and depleted the 
globin mRNA. Data from the microarray were used to identify the differentially expressed 
genes between the lymphoma and the non-lymphoma groups. These differentially 
expressed genes were technically validated using qRT-PCR. Differentially expressed genes 
that have been confirmed using qRT-PCR were further validated using an independent set 
of samples (Validation cohort). In the independent cohort, I have also included a group of 
patients with pSS-associated lymphoma but have not yet received any treatment for their 
lymphoma (untreated pSS-associated lymphoma). Using the data from the RT-PCR of the 
Discovery cohort, I have tested the biological ‘signature’ based on these differentially 
expressed genes using a prediction modeling fit. Figure 4.3 summarises the experimental 
design. 
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Figure 4.3 The identification of whole blood gene expression signature in pSS-associated 
lymphoma experimental design 
 
4.4 Results 
4.4.1 Demography of study subjects 
All selected pSS patients used for identifying the gene expression signature in pSS-
associated lymphoma fulfil the AECG classification criteria. The clinical parameters of the 
subjects in the Discovery cohort, Validation cohort, and untreated lymphoma are illustrated 
in Tables 4.1 and 4.2, respectively. In the Discovery cohort, after applying the Mann-
Whitney test on the data, the results showed that the white cell count was significantly 
lower in the “pSS-associated lymphoma” group in comparison with the “pSS” group (p 
value = 0.040). In addition, a significantly lower level of C4 in the “pSS-associated 
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lymphoma” group was observed in comparison with the “pSS” and “pSS-other cancers” 
groups (p value = 0.0029 and 0.0027, respectively). The titre of IgG was significantly 
higher in the “pSS-associated lymphoma’ group in comparison with the “pSS-other cancer” 
group (p value = 0.038). SSDDI scores were statistically different among all of the groups 
(p value = 0.000).  
In the Validation cohort, after applying the Mann-Whitney test on the data (only from the 
samples from the UKPSSR biobank), the results showed a significantly lower C4 level in 
the “pSS-associated lymphoma” group in comparison with “pSS” (p = 0.0199). Significant 
differences were also showed in the  SSDDI and ESSDAI between the “pSS-associated 
lymphoma” and the “pSS” groups with p values of 0.0026 and 0.0266 respectively.      
The “pSS-associated lymphoma” group consists of patients who had different histological 
types of lymphomas. The type of lymphoma for each patient is listed in Table 4.3. In 
addition, all patients in the lymphoma group from the Discovery cohort had received 
treatment for their lymphoma at the time of blood sampling. 
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Table 4.1 Clinical data of pSS subgroups subjects in the Discovery cohort 
Clinical criteria Mean ± S.E.M 
pSS pSS-paraproteinemia pSS-other cancers pSS-associated lymphoma Healthy control 
Age (years) 60 ± 1.43 64 ± 2.73  66 ± 1.5 62 ± 3.33  57 ± 2.9 
Unstimulated oral salivary flow 
(ml/15 mins) 0.38 ± 0.08 0.63 ± 0.25 0.45 ± 0.14 0.18 ± 0.08 N/A 
Schirmer’s test (mm/5 mins) 3.07 ± 0.85 4.39 ± 1.17 4.76 ± 1.31 3.53 ± 1.43 N/A 
Anti-Ro/SSA positive (%)  93.4%  86.9%  80.9%  93.7%  N/A 
Anti-La/SSB positive (%)  83.6%  73.9%  57.1%   81.2% N/A 
WCC (x10^9/l) 5.79 ± 0.29 5.27 ± 0.40 5.49 ± 0.39 4.37 ± 0.43 N/A 
Neutrophil (x10^9/l) 3.65 ± 0.22 3.21 ± 0.28 3.50 ± 0.29 3.07 ± 0.35 N/A 
Lymphocytes (x10^9/l) 1.55 ± 0.08 2.31 ± 0.80 1.38 ± 0.11 1.23 ± 0.16 N/A 
ESR (mm/hr) 32.11 ± 3.30 36.30 ± 6.20 23.81 ± 5.53 39.63 ± 7.08 N/A 
IgG (g/L) 17.65 ± 0.98 15.64 ± 1.59 13.88 ± 1.75 17.39 ± 1.96 N/A 
C3 (mg/dl) 1.17 ± 0.04 1.17 ± 0.04 1.22 ± 0.10 1.10 ± 0.09 N/A 
C4 (mg/dl) 0.23 ± 0.02 0.16 ± 0.02 0.22 ± 0.02 0.14 ± 0.02 N/A 
CRP (mg/L) 3.87 ± 0.56 3.60 ± 0.62 6.39 ± 2.22 3.78 ± 0.90 N/A 
RF (IU) 56.45 ± 7.64 63.17 ± 14.13 42.38 ± 9.67 133.87 ± 72.05 N/A 
Total SSDDI 4.21 ± 0.20 4.61 ± 0.42 4.24 ± 0.41 9.06 ± 0.41 N/A 
ESSPRI (0-10) 4.86 ± 0.28 5.41 ± 0.46 5.48 ± 0.52 5.92 ± 0.79 N/A 
ESSDAI (0-123) 6.16 ± 0.92 4.61 ± 0.95 5.43 ± 1.02 6.06 ± 1.89 N/A 
WCC= White Cell Count, ESR= Erythrocyte Sedimentation Rate, C3= Complement Component 3, C4= Complement Component 4, CRP=C-reactive 
Protein, RF=Rheumatoid Factor, IU= International Units, ESSDAI score=(0-4 low activity, 5-12 moderate activity and ≥ 13 high activity), parameters 
in bold depict those values that were statistically significantly different to other subject groups when tested using Mann-Whitney test.  
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Table 4.2 Clinical data of pSS and pSS-associated lymphoma subjects in the Validation cohort 
Clinical criteria Mean ± S.E.M 
pSS (n = 119) pSS-associated lymphoma (n = 14) 
Age (years) 57 ± 1.11 60 ± 4.65 
Unstimulated oral salivary flow (ml/15 mins) 0.78 ± 0.15 0.59 ± 0.25 
Schirmer’s test (mm/5 mins) 6.05 ± 0.69 7.14 ± 3.36 
Anti-Ro/SSA positive (%) 88.2% 86.6% 
Anti-La/SSB positive (%) 64.7% 64.2% 
WCC (x10^9/l) 5.33 ± 0.17 5.54 ± 0.35 
Neutrophil (x10^9/l) 3.73 ± 0.51 3.55 ± 0.35 
Lymphocytes (x10^9/l) 1.73 ± 0.28  1.43 ± 0.18 
ESR (mm/hr) 25.39 ± 1.99 23.50 ± 6.76 
IgG (g/L) 18.18 ± 1.85 13.96 ± 1.32 
C3 (mg/dl)* 19.33 ± 12.97 1.16 ± 0.13 
C4 (mg/dl) 0.29 ± 0.07 0.16 ± 0.02 
CRP (mg/L)* 3.15 ± 0.30 4.87 ± 1.43 
RF (IU)* 64.15 ± 11.95 68.71 ± 23.07 
Total SSDDI* 3.32 ± 0.17 6.43 ± 1.09 
ESSPRI (0-10)* 5.02 ± 0.25 6.57 ± 0.52 
ESSDAI (0-123) 4.10 ± 0.44 6.79 ± 1.32 
* number of pSS-associated lymphoma samples = 7, WCC= White Cell Count, ESR= Erythrocyte Sedimentation Rate, C3= Complement Component 3, 
C4= Complement Component 4, CRP=C-reactive Protein, RF=Rheumatoid Factor, IU= International Units, ESSDAI score=(0-4 low activity, 5-12 
moderate activity and ≥ 13 high activity), parameters in bold are those values that were statistically significantly different between groups when tested 
using the Mann-Whitney test.  
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Table 4.3 Histological types of the subjects in the two pSS-associated lymphoma cohorts 
Type of lymphoma 
Discovery 
cohort 
Validation cohort 
treated  
pSS-associated 
lymphoma 
Untreated  
pSS-associated 
lymphoma 
Non- Hodgkin’s lymphoma 
DLBCL -  1 - 
Low grade follicular lymphoma - - 1 
Low grade MALT lymphoma - 1 - 
MALT lymphoma   7 13 5 
MZL  2 - - 
Not specific 3 1 - 
Parotid lymphoma  1 - 1 
Periorbital lymphoma  1 - - 
T cell/ histiocyte rich b cell lymphoma - 1 - 
Hodgkin's lymphoma 
Hodgkin's lymphoma 2 - - 
Total number of samples 16 17 7 
DLBCL = Diffused Large B-cell Lymphoma, MALT =  mucosa-associated lymphoid tissue, 
MZL = Marginal Zone lymphoma  
 
4.4.2 RNA quality  
Total RNA from patients and healthy controls were extracted from the PAXgene tubes, and 
the concentration of each sample was measured initially by Nano-drop. The quality and the 
concentration of the samples were also checked using an Agilent 2100 Bioanalyzer at the 
CGS. Generally, samples with RIN above 7 are considered achieving the quality standards 
for microarray experiments. A total of 117 RNA samples out of 144 were of good quality, 
with an RIN score that ranged from 7 to 8.8. Three RNA samples from the pSS group have 
N/A RIN values, but the samples were subsequently inspected visually by the staff at CGS 
and were considered as being of good quality (by comparing them with the profiling of a 
good-quality sample). Twenty-four samples have an RIN score < 7, of which 18 were 
considered being of ‘medium’ quality, with RIN scores ranging between 5 and 7. These 18 
samples were from 2 healthy controls, 5 pSS, 3 pSS-paraproteinemia, 6 pSS-other cancers 
and 2 pSS-associated lymphoma. The remaining 6 samples were of low quality with RIN 
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score < 5; these 6 samples were from 1 healthy control, 1 pSS-other cancers, and 4 pSS 
patients. The distribution of the samples according to their RIN scores is shown in Figure 
4.4. The amplification cRNA for all the samples showed the lack of a sharp peak of ~700 
bp that represents the globin mRNA, indicating that globin mRNA had been effectively 
removed.  
 
Figure 4.4 RNA integrity number (RIN) of the Discovery cohort. The black squares 
represent each sample, and the horizontal red lines mark out RIN score =5 and RIN score 
=7 cutoffs. 
 
 
4.4.3 Whole genome gene expression Bead Chip of pSS-associated lymphoma 
1. Microarray data analysis 
The microarray data analysis was performed using R packages. The data were transformed 
and normalised using the RSN method, followed by quality control analysis. These include 
removal of technical outliers that were detected during the analysis by Principal Component 
Analysis (PCA). The reason behind removing the technical outliers is that they might affect 
the downstream analysis of the data because they have dissimilar behaviours from the other 
samples in the data. The RNA quality of the samples was also taken into consideration.  
Since the sample size of the pSS-associated lymphoma group is the smallest among the five 
subject groups, all samples from the four different pSS subgroups with RIN score < 7 were 
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removed, but the two pSS-associated lymphoma samples with RIN score < 7 were kept 
during the analysis. The reason for keeping these two lymphoma samples is that their RIN 
score were more than 5, which is still considered acceptable for microarray experiments. 
Furthermore, excluding those 2 samples would have substantially reduced the power of the 
study due to the resultant smaller sample size of the lymphoma group. All technical outliers 
were removed from the analysis (including a pSS-associated lymphoma sample). This 
analysis will be referred to as Analysis A later in the chapter, and all of the figures and 
tables presented are generated using this analysis unless stated otherwise. 
 
2. Batch effect  
A large experiment such as this one might be affected by what is known as batch effects. 
PCAs were used to investigate these potential batch effects. PCA prior to batch correction 
showed batch effects that separate the samples into 3 groups, where each group represents a 
number of samples that were processed and scanned at a specific time, which differs from 
the time that the other two groups were processed and scanned. These differences created a 
non-biological variation leading to the batch effects as shown in Figure 4.5. Following 
batch correction, which was achieved by applying the ComBat correction method, the PCA 
showed that all of the samples were distributed more evenly as one group, indicating 
effective elimination of batch effects (Figure 4.6).    
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Figure 4.5 Batch effects of the microarray data of the Discovery cohort. Principal 
component analysis (PCA) showed that batch effects were present in the normalised gene 
expression microarray data. Three color coded groups of samples (red (1), green (2) and 
blue(3)) were clustered separately due to non-biological variation caused by differences in 
the time of sample processing and scanning. Each group is represented by a unique color 
to distinguish the clustering.  
 
Figure 4.6 Batch correction of the microarray data of the Discovery cohort. Principal 
component analysis (PCA) after batch correction of the normalised gene expression 
microarray data. All samples from the three color coded groups of samples (red (1), green 
(2) and blue(3)) were now more evenly distributed as a single group. 
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3. Differentially expressed genes in pSS-associated lymphoma 
As mentioned earlier, the pSS-associated lymphoma group has the smallest sample size (n= 
16). In the main analysis (Analysis A), for the lymphoma group, I have removed the one 
technical outlier in the analysis but included the two pSS-associated lymphoma samples 
with RIN scores 5.6 and 5.2; thus, the sample size was reduced from 16 to 15 samples. For 
the pSS-non-lymphoma group, the sample size, after removing samples based on technical 
outliers and RIN score (< 7), was 52 samples. The list of differentially expressed genes was 
generated from the comparison between the “pSS” and “pSS-associated lymphoma” 
groups. A negative log fold change (Log (FC)) means a downregulation of that gene in the 
pSS (non-lymphoma) group (or upregulation in the pSS-associated lymphoma group). 
Similarly, a positive Log (FC) represents an upregulation of the gene in the pSS group (i.e. 
downregulated in pSS-associated lymphoma group). Throughout the chapter, I will use the 
pSS-associated lymphoma group as the reference point to describe the level of gene 
expression (i.e. the direction of regulation) of the differentially expressed genes (DEGs). In 
the main analysis (Analysis A), a total of 57 DEGs were identified: 11 genes were 
upregulated in the pSS-associated lymphoma group, and 40 genes were downregulated, 6 
probes were identified as not applicable (NA), theses NAs represent a potential gene which 
has not been officially identified or validated. The NAs were excluded from the presented 
data shown in Table 4.4. The DEGs were also shown using a volcano plot (Figure 4.7). The 
heat map and the hierarchical clustering of the samples according to the DEGs in Analysis 
A are shown in Figure 4.8. 
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Table 4.4 Differentially expressed genes in pSS-associated lymphoma from Analysis A of the microarray data of the Discovery cohort. 
Data analysis performed in R, Cutoff values: adjusted p < 0.05, and fold change ≥ 1.2  
Gene symbol Name of gene 
Adjusted 
P. value 
Regulation in pSS-
associated lymphoma 
Fold change 
LGALS1 lectin, galactoside-binding, soluble, 1 0.0199 upregulation 1.36 
KCTD12 potassium channel tetramerisation domain containing 12 0.0329 upregulation 1.28 
DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) 0.0280 upregulation 1.27 
RBP7 retinol binding protein 7, cellular 0.0272 upregulation 1.26 
MGST3 microsomal glutathione S-transferase 3 0.0423 upregulation 1.23 
NUDT14 nudix (nucleoside diphosphate linked moiety X)-type motif 14 0.0058 upregulation 1.22 
UBXN11 UBX domain protein 11 0.0081 upregulation 1.21 
ATG12 autophagy related 12 0.0199 upregulation 1.21 
C10orf32(BORCS7) chromosome 10 open reading frame 32 0.0224 upregulation 1.21 
DYNLL1 dynein, light chain, LC8-type 1 0.0195 upregulation 1.2 
RNF7 ring finger protein 7 0.0294 upregulation 1.2 
RNA28S5 RNA, 28S ribosomal 5 0.0030 downregulation 1.6 
LEF1 lymphoid enhancer-binding factor 1 0.0390 downregulation 1.42 
SPOCK2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 0.0195 downregulation 1.4 
ETS1 v-ets avian erythroblastosis virus E26 oncogene homolog 1 0.0292 downregulation 1.39 
POM121C POM121 transmembrane nucleoporin C 0.0062 downregulation 1.35 
MYC v-myc avian myelocytomatosis viral oncogene homolog 0.0199 downregulation 1.32 
SGK223 homolog of rat pragma of Rnd2 0.0442 downregulation 1.32 
HSP90B1 heat shock protein 90kDa beta (Grp94), member 1 0.0071 downregulation 1.31 
RPL23AP5 ribosomal protein L23a pseudogene 5 0.0224 downregulation 1.31 
BCL11B B-cell CLL/lymphoma 11B (zinc finger protein) 0.0353 downregulation 1.3 
DDB1 damage-specific DNA binding protein 1, 127kDa 0.0058 downregulation 1.28 
CYFIP2 cytoplasmic FMR1 interacting protein 2 0.0498 downregulation 1.27 
WAC WW domain containing adaptor with coiled-coil 0.0058 downregulation 1.27 
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ESYT1 extended synaptotagmin-like protein 1 0.0442 downregulation 1.26 
MAGED1 melanoma antigen family D, 1 0.0442 downregulation 1.26 
PRPF8 pre-mRNA processing factor 8 0.0390 downregulation 1.26 
SUN2 Sad1 and UNC84 domain containing 2 0.0417 downregulation 1.26 
HNRNPUL1 heterogeneous nuclear ribonucleoprotein U-like 1 0.0390 downregulation 1.25 
CD96 CD96 molecule 0.0498 downregulation 1.24 
CDR2 cerebellar degeneration-related protein 2, 62kDa 0.0206 downregulation 1.24 
NAT10 N-acetyltransferase 10 (GCN5-related) 0.0330 downregulation 1.24 
VCP valosin containing protein 0.0195 downregulation 1.24 
ALDH9A1 aldehyde dehydrogenase 9 family, member A1 0.0212 downregulation 1.23 
BAG3 BCL2-associated athanogene 3 0.0235 downregulation 1.23 
LRIG1 leucine-rich repeats and immunoglobulin-like domains 1 0.0159 downregulation 1.23 
NCSTN Nicastrin 0.0465 downregulation 1.23 
PAF1 Paf1, RNA polymerase II associated factor, homolog (S. cerevisiae) 0.0199 downregulation 1.23 
SF3A1 splicing factor 3a, subunit 1, 120kDa 0.0442 downregulation 1.23 
ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide 0.0058 downregulation 1.22 
KHDRBS1 KH domain containing, RNA binding, signal transduction associated 1 0.0405 downregulation 1.22 
LRFN3 leucine rich repeat and fibronectin type III domain containing 3 0.0452 downregulation 1.22 
RBL2 retinoblastoma-like 2 0.0224 downregulation 1.22 
RRN3 RRN3 RNA polymerase I transcription factor homolog (S. cerevisiae) 0.0153 downregulation 1.22 
SDHA succinate dehydrogenase complex, subunit A, flavoprotein (Fp) 0.0390 downregulation 1.22 
CBLL1 Cbl proto-oncogene-like 1, E3 ubiquitin protein ligase 0.0244 downregulation 1.21 
CDV3 CDV3 homolog (mouse) 0.0475 downregulation 1.21 
FOXJ3 forkhead box J3 0.0153 downregulation 1.21 
SMARCA2 
SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
0.0299 
downregulation 
1.21 
HNRNPDL heterogeneous nuclear ribonucleoprotein D-like 0.0350 downregulation 1.2 
HSPA9 heat shock 70kDa protein 9 (mortalin) 0.0202 downregulation 1.2 
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Figure 4.7 Volcano plot of the differentially expressed genes in pSS-associated 
lymphoma in the Discovery cohort. The x axis represents log2 of the fold change and the y 
axis represents the –log10 of the adjusted p value. The dots in red represent the 
differentially expressed genes, and the red horizontal and vertical lines indicate the cut-off 
values of the adjusted p value and the fold changes. 
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Figure 4.8 Heat map and hierarchical clustering of samples in the Discovery cohort 
based on the Analysis A of the microarray data. The empty places represent the probes 
that were identified as NAs in the analysis.  
 
Since the main objective of the Discovery cohort was to identify a list of candidate genes 
that distinguish the lymphoma and the non-lymphoma groups, I have performed additional 
analyses using different RIN cut-off values (Analysis B, C, and D).  Although these 
analyses have included lymphoma samples that did not meet the ‘standard’ quality 
requirements for microarrays, I considered this approach to be acceptable for the Discovery 
cohort for two reasons. Firstly, the candidate genes identified in the Discovery cohort will 
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be validated technically and with an independent cohort; therefore, it will reduce the risk of 
identifying any false DEGs revealed using these additional analyses. Secondly, the 
lymphoma group has the smallest sample size and was therefore the key factor limiting the 
power of the study. Increasing the sample size of the lymphoma group could enable the 
detection of DEGs that are important but did not reach the statistical significance values 
due to a small sample size. The description of these additional analyses is provided in Table 
4.5. Each of these different analyses has yielded a set of deferentially expressed genes. For 
Analysis B (14 pSS-associated lymphoma samples) has generated 20 DEGs including 4 
NAs, Analysis C (16 pSS-associated lymphoma samples) has generated 45 DEGs including 
9 NAs, while Analysis D (13 pSS-associated lymphoma samples), generates 19 DEGs 
including 3 NAs. Each set of DEGs from these four analyses contains genes that are in 
common with one or more analyses, but there are also DEGs that were unique to each 
analysis (see Venn diagram in Figure 4.9). The lists of DEGs with the exclusion of the NAs 
of Analyses B, C, and D are shown in Tables 4.6, 4.7, and 4.8, respectively. The final list of 
candidate DEGs in pSS-associated lymphoma was generated by combining the lists of 
DEGs from all 4 analyses. The combined genes list contains 68 DEGs from the microarray 
experiments is referred to as the  “68-DEGs-Mi”. The workflow of the Discovery cohort 
and the genes selection for validation is shown schematically in Figure 4.10.   
 
Table 4.5 The analytic criteria used in the four microarray data analyses of pSS-
associated lymphoma gene expression signature in the Discovery cohort.  
 pSS group pSS-associated lymphoma group 
RIN<7 
removed 
Technical 
outliers removed 
RIN < 7 
removed 
Technical 
outliers removed 
No. of pSS-associated 
lymphoma samples 
Analysis A Yes Yes No Yes 15 
Analysis B Yes Yes Yes No 14 
Analysis C Yes Yes No No 16 
Analysis D Yes Yes Yes Yes 13 
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Table 4.6 Differentially expressed genes in pSS-associated lymphoma from Analysis B of the microarray data of the Discovery cohort. 
Data analysis performed in R, cutoff values: adjusted p < 0.05, fold change ≥ 1.2  
Gene symbol Gene name Adjusted p 
value 
Regulation in pSS-
associated lymphoma 
Fold change 
DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) 0.0418 upregulated 1.29 
DYNLL1 dynein, light chain, LC8-type 1 0.0155 upregulated 1.23 
SRP14 signal recognition particle 14kDa (homologous Alu RNA binding protein) 0.0419 upregulated 1.23 
PSMC1 proteasome (prosome, macropain) 26S subunit, ATPase, 1 0.0408 upregulated 1.23 
UBXN11 UBX domain protein 11 0.0167 upregulated 1.22 
OAF OAF homolog (Drosophila) 0.0418 upregulated 1.22 
NUDT14 nudix (nucleoside diphosphate linked moiety X)-type motif 14 0.0167 upregulated 1.22 
SEC61G Sec61 gamma subunit 0.0363 upregulated 1.21 
CNPY3 canopy FGF signaling regulator 3 0.0226 upregulated 1.21 
C10orf32(BORCS7) chromosome 10 open reading frame 32 0.0418 upregulated 1.21 
RNA28S5 RNA, 28S ribosomal 5 0.0015 downregulated 1.67 
RPL23AP5 ribosomal protein L23a pseudogene 5 0.0398 downregulated 1.31 
WAC WW domain containing adaptor with coiled-coil 0.0145 downregulated 1.27 
HSP90B1 heat shock protein 90kDa beta (Grp94), member 1 0.0408 downregulated 1.26 
DDB1 damage-specific DNA binding protein 1, 127kDa 0.0392 downregulated 1.23 
RPA2 replication protein A2, 32kDa 0.0225 downregulated 1.20 
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Table 4.7 Differentially expressed genes in pSS-associated lymphoma from Analysis C of the microarray data of the Discovery cohort. 
Data analysis performed in R, cutoff values: adjusted p < 0.05, fold change ≥ 1.2  
Gene symbol Gene name Adjusted p 
value 
Regulation in pSS-
associated lymphoma 
Fold change 
LGALS1 lectin, galactoside-binding, soluble, 1 0.0166 upregulated 1.34 
DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) 0.0096 upregulated 1.32 
UBXN11 UBX domain protein 11 0.0019 upregulated 1.25 
NUDT14 nudix (nucleoside diphosphate linked moiety X)-type motif 14 0.0019 upregulated 1.24 
RBP7 retinol binding protein 7, cellular 0.0390 upregulated 1.23 
ATG12 autophagy related 12 0.0102 upregulated 1.22 
RAB37 RAB37, member RAS oncogene family 0.0127 upregulated 1.21 
HCFC1R1 host cell factor C1 regulator 1 (XPO1 dependent) 0.0096 upregulated 1.21 
EHBP1L1 EH domain binding protein 1-like 1 0.0397 upregulated 1.20 
HLA-DRB1 major histocompatibility complex, class II, DR beta 1 0.0486 downregulated 3.59 
RNA28S5 RNA, 28S ribosomal 5 0.0015 downregulated 1.63 
LEF1 lymphoid enhancer-binding factor 1 0.0399 downregulated 1.39 
ETS1 v-ets avian erythroblastosis virus E26 oncogene homolog 1 0.0245 downregulated 1.38 
SPOCK2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 0.0381 downregulated 1.34 
RPL23AP5 ribosomal protein L23a pseudogene 5 0.0116 downregulated 1.32 
POM121C POM121 transmembrane nucleoporin C 0.0161 downregulated 1.30 
HSP90B1 heat shock protein 90kDa beta (Grp94), member 1 0.0071 downregulated 1.30 
RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 0.0486 downregulated 1.30 
MYC v-myc avian myelocytomatosis viral oncogene homolog 0.0190 downregulated 1.30 
BCL11B B-cell CLL/lymphoma 11B (zinc finger protein) 0.0315 downregulated 1.29 
WAC WW domain containing adaptor with coiled-coil 0.0015 downregulated 1.29 
ITK IL2-inducible T-cell kinase 0.0346 downregulated 1.29 
DDB1 damage-specific DNA binding protein 1, 127kDa 0.0112 downregulated 1.25 
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CD96 CD96 molecule 0.0382 downregulated 1.24 
RBL2 retinoblastoma-like 2 0.0114 downregulated 1.23 
ALDH9A1 aldehyde dehydrogenase 9 family, member A1 0.0137 downregulated 1.23 
CDR2 cerebellar degeneration-related protein 2, 62kDa 0.0184 downregulated 1.23 
RRN3 RRN3 RNA polymerase I transcription factor homolog (S. cerevisiae) 0.0078 downregulated 1.23 
HNRNPA1P10 heterogeneous nuclear ribonucleoprotein A1 pseudogene 10 0.0441 downregulated 1.23 
LRIG1 leucine-rich repeats and immunoglobulin-like domains 1 0.0137 downregulated 1.22 
KHDRBS1 KH domain containing, RNA binding, signal transduction associated 1 0.0292 downregulated 1.22 
CDV3 CDV3 homolog (mouse) 0.0346 downregulated 1.22 
SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
0.0255 downregulated 1.20 
VCP valosin containing protein 0.0346 downregulated 1.20 
HSPA9 heat shock 70kDa protein 9 (mortalin) 0.0137 downregulated 1.20 
PRKCQ protein kinase C, theta 0.0479 downregulated 1.20 
 
 
 
 
 
 
 
95 
 
Table 4.8 Differentially expressed genes in pSS-associated lymphoma from Analysis D of the microarray data of the Discovery cohort. 
Data analysis performed in R, cutoff values: adjusted p < 0.05, fold change ≥ 1.2 
Gene symbol Gene name Adjusted p 
value 
Regulation in pSS-
associated lymphoma 
Fold change 
DYNLL1 dynein, light chain, LC8-type 1 0.0102 upregulated 1.25 
C10orf32(BORCS7) chromosome 10 open reading frame 32 0.0249 upregulated 1.23 
HNMT histamine N-methyltransferase 0.0470 upregulated 1.23 
OAF OAF homolog (Drosophila) 0.0470 upregulated 1.22 
SEC61G Sec61 gamma subunit 0.0470 upregulated 1.21 
RNA28S5 RNA, 28S ribosomal 5 0.0073 downregulated 1.64 
SPOCK2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 0.0450 downregulated 1.41 
POM121C POM121 transmembrane nucleoporin C 0.0249 downregulated 1.34 
CYFIP2 cytoplasmic FMR1 interacting protein 2 0.0470 downregulated 1.32 
DDB1 damage-specific DNA binding protein 1, 127kDa 0.0185 downregulated 1.27 
HSP90B1 heat shock protein 90kDa beta (Grp94), member 1 0.0481 downregulated 1.26 
WAC WW domain containing adaptor with coiled-coil 0.0327 downregulated 1.24 
ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide 0.0124 downregulated 1.23 
PAF1 Paf1, RNA polymerase II associated factor, homolog (S. cerevisiae) 0.0470 downregulated 1.23 
BMS1 BMS1 ribosome biogenesis factor 0.0260 downregulated 1.20 
BTBD11 BTB (POZ) domain containing 11 0.0278 downregulated 1.20 
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Figure 4.9 Venn diagram for the DEGs that are in common and unique among the four 
different microarray data analyses (A, B, C, and D) in the Discovery cohort 
 
Figure 4.10 Schematic representation of the microarray data analytic approach of the 
Discovery cohort. The NAs were excluded from the total number of the DEGs in each 
analysis. DEGs= Differentially expressed genes, IPA= Ingenuity Pathway analysis    
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4.4.4 Technical validation of the differentially expressed genes in pSS-associated 
lymphoma with qRT-PCR 
1. Housekeeping genes selection 
An important step in validating the DEGs associated with pSS-associated lymphoma is to 
select the most stable housekeeping genes for comparison. I used the NormFinder 
algorithm (Andersen et al., 2004) to calculate the stability of the housekeeping genes 
between the different subject groups. This algorithm revealed that UBC being the 
housekeeping gene with the most stable level of expression, with a stability value of 0.003 
(Figure 4.11). Moreover, taking into consideration of both the intra- and inter-group 
variations, the two genes with the most stable levels of expression are UBC and YWHAZ, 
with stability values of 0.003. In addition, I have included the ACTB gene, which came 
third in the stability value ranking based on NormFinder. Finally, I have also included the 
18S gene, as it has been frequently used in other studies and has been used in a previous 
study in our group to investigate the miRNA expression in pSS-associated lymphoma.       
 
Figure 4.11 The expression stability values for the housekeeping genes calculated by 
NormFinder. The bar chart shows the most stable housekeeping gene on the left and the 
most variable ones on the right. As the microarray contains more than one probe for some 
housekeeping genes, these probes were distinguished by adding a suffix of 1, 2, 3, etc. after 
the gene name.  
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Furthermore, the four selected housekeeping genes were also measured by qRT-PCR to 
check their levels of expression in the 5 subject groups. The qRT-PCR threshold cycle (Ct) 
value for each housekeeping gene was calculated and then compared among the 5 subject 
groups. The expression levels of YWHAZ and ACTB were stable across the subject groups. 
There was no statistically significant variation in the level of expression of these genes 
among the five groups (ANOVA p values of 0.819 and 0.892 for YWHAZ and ACTB, 
respectively). Furthermore, there were also no statistically significant differences when 
comparing the subject groups individually to each other. Finally, the standard deviations of 
expression levels for both genes across all samples were small (0.5532 and 0.7951, 
respectively). With regard to the UBC gene, there was no statistically significant variation 
between the five subject groups when analysed using ANOVA (p=0.123); however, there 
was a significant difference in the expression level when comparing the pSS-associated 
lymphoma versus pSS (p=0.009) groups. Interestingly, the 18S gene showed the highest 
variability of the 4 housekeeping genes that I have selected. Still, there was no significant 
variation between the 5 subject groups (ANOVA p=0.062). However, when comparing the 
pSS-associated lymphoma groups with all 4 other groups individually, there were 
statistically significant differences in the level of expression of 18S. I have therefore 
decided to exclude this housekeeping gene as well as UBC from my analysis. The details of 
these statistical analyses are provided in Table 4.9, and the comparisons of the Cts values 
are shown in Figure 4.12. Since the expression levels of YWHAZ are stable across all 
subject groups and have the lowest standard deviation, the data were normalised to this 
housekeeping gene in subsequent analysis. Due to limited RNA availability, the stability 
testing of the expression levels of the four housekeeping genes were performed in only the 
first two batches, while for the latter two batches I have used only YWHAZ and ACTB. The 
same strategy was employed with the second batch of qRT-PCR array plates, and the 
results were consistent with the results obtained from the first batch (Table 4.10).        
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Table 4.9 Statistical analysis of the expression levels stability of the 4 housekeeping 
genes across the 5 subject groups in the first batch of qRT-PCR plates. * = Statistically 
Significant (p < 0.05) 
 
 
Table 4.10 Statistical analysis of the expression level stability of the 4 housekeeping in 
the second batch of qRT-PCR plates. * = Statistically Significant (p < 0.05) 
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Figure 4.12 Bar charts of the Cts values of the 4 housekeeping genes measured with 
qRT-PCR for the 5 subject groups in the Discovery cohort. YWHAZ and ACTB had the 
most stable levels of expression. There was a significant difference in the expression level 
of UBC when comparing the pSS-associated lymphoma vs pSS groups. The expression level 
of 18S was the most variable among the samples. 
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2. Technical validation of the whole blood gene expression signature in pSS-associated 
lymphoma 
As the availability of RNA samples was limited, I was not able to technically validate 
differential expression of all of the candidate genes. In order to select the best candidates 
for technical validation, I used the following criteria. Firstly, the final list of DEGs (68-
DEGs-Mi) is ranked according to the fold change and the p value. Secondly, DEGs that 
were identified by all four analyses were selected.  A total of 61 out of the 68 DEGs were 
selected, the remaining 7 genes included 2 pseudogenes and 5 genes with small fold 
changes. The real-time RT-PCR experiment confirmed differential expression of 26 DEGs 
(Mann-Whitney test under P < 0.05) out of the 61 genes tested. These 26 DEGs included 
both upregulated and downregulated genes in pSS-associated lymphoma. The 
downregulated genes were BMS1, BTBD11, CBLL1, CYFIP2, ESYT1, HNRNPUL1, LEF1, 
MAGED1, POM121C, PRPF8, SF3A1, SGK223, and VCP, while the upregulated genes 
were C10orf32(BORCS7), CNPY3, DRAP1, DYNLL1, HNMT,  LGALS1, MGST3, 
NUDT14, OAF, RBP7, SEG61G, SRP14, and UBXN11. Twenty of these 26 genes were 
identified from the main analysis (Analysis A), and the remaining 6 genes were identified 
from the other analyses (Table 4.11). These 26 genes constituted the 26 differentially 
expressed genes from microarray and PCR (referred to as “26-DEGs-MiPCR”).  
Apart from these 26 DEGs, the expression level of RNA28S5 was also significantly 
different between the lymphoma and non-lymphoma groups, but the direction of regulation 
(i.e. up/down-regulation) was different in the qRT-PCR experiment and in the microarray. 
It is also important to mention that for HLA-DRB1, the expression levels could not be 
determined by the qRT-PCR experiment, as the amplification curves were jagged. A heat 
map representing the sample clustering according to the 26-DEGs-MiPCR is shown in 
Figure 4.13.      
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Table 4.11 The 26-DEGs-MiPCR of pSS-associated lymphoma from the Discovery cohort. For each DEG, the microarray analysis in 
which it was identified as candidate, the p value (measured by Mann-Whitney U test), the fold change and the regulation direction, Fc was 
calculated according to the housekeeping gene normalisation  
Gene symbol Gene name Analysis 
A 
Analysis 
B 
Analysis 
C 
Analysis 
D 
p value Fc & 
regulation 
NUDT14 Nudix (nucleoside diphosphate linked moiety X)-type motif 14 + + + - 0.0000 2.09 ↑ 
OAF OAF homolog (Drosophila) - + - + 0.0001 2.05 ↑ 
C10orf32(BORCS7) Chromosome 10 open reading frame 32 + + - + 0.0000 1.91 ↑ 
RBP7 Retinol binding protein 7, cellular + - + - 0.0005 1.88 ↑ 
LGALS1 Lectin, galactoside-binding, soluble, 1  + - + - 0.0001 1.74 ↑ 
DYNLL1 Dynein, light chain, LC8-type 1  + + - + 0.0000 1.65 ↑ 
HNMT histamine N-methyltransferase - - - + 0.0231 1.55 ↑ 
DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) + + + - 0.0000 1.50 ↑ 
SRP14 Signal recognition particle 14kDa (homologous Alu RNA 
binding protein) 
- + - - 0.0344 1.39 ↑ 
UBXN11 UBX domain protein 11 + + + - 0.0017 1.38 ↑ 
SEC61G Sec61 gamma subunit  - + - + 0.0005 1.37 ↑ 
CNPY3 Canopy FGF signaling regulator 3 - + - - 0.0004 1.32 ↑ 
MGST3 Microsomal glutathione S-transferase 3 + - - - 0.0079 1.07 ↑ 
VCP Valosin containing protein + - + - 0.0057 2.45 ↓ 
HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-like 1  + - - - 0.0238 2.35 ↓ 
ESYT1 Extended synaptotagmin-like protein 1 + - - - 0.0118 1.86 ↓ 
SGK223 Homolog of rat pragma of Rnd2 + - - - 0.0495 1.67 ↓ 
BTBD11 BTB (POZ) domain containing 11 - - - + 0.0338 1.66 ↓ 
BMS1 BMS1 ribosome biogenesis factor  - - - + 0.0012 1.50 ↓ 
PRPF8 Pre-mRNA processing factor 8 + - - - 0.0238 1.41 ↓ 
MAGED1 Melanoma antigen family D, 1 + - - - 0.0333 1.40 ↓ 
SF3A1 Splicing factor 3a, subunit 1, 120kDa + - - - 0.0106 1.32 ↓ 
LEF1 Lymphoid enhancer-binding factor 1 + - + - 0.0289 1.30 ↓ 
CYFIP2 Cytoplasmic FMR1 interacting protein 2  + - - + 0.0314 1.26 ↓ 
POM121C POM121 transmembrane nucleoporin C + - + + 0.0375 1.23 ↓ 
CBLL1 Cbl proto-oncogene-like 1, E3 ubiquitin protein ligase + - - - 0.0421 1.14 ↓ 
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Figure 4.13 Heat map and hierarchical clustering of samples of the Discovery cohort 
according to the 26-DEGs-MiPCR  
 
4.4.5 Biological validation of the potential whole blood gene expression signature of 
pSS-associated lymphoma 
A second independent set of samples (referred to as the Validation cohort) was used to 
validate the potential gene expression signature of pSS-associated lymphoma identified 
using the Discovery cohort. The Validation cohort consisted of only two groups, the pSS-
associated lymphoma group with 17 samples, and the pSS group with 119 samples. The 
clinical data for the samples are shown in Table 4.2. The reason for not including the 
additional pSS subgroups as in the Discovery cohort was that comparisons between the 
lymphoma group and the other pSS subgroups did not contribute to the identification of 
DEGs in the Discovery cohort (see chapter 6 for more details). Twenty-four genes were 
included in this biological validation experiment, of which only 3 genes were found to be 
differentially expressed between the lymphoma and the non-lymphoma groups. The qRT-
PCR data were normalised using YWHAZ as a housekeeping gene, the expression levels of 
which was also stable across the pSS-associated lymphoma and pSS groups in this cohort. 
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These 3 validated DEGs were BMS1 (downregulated gene in pSS-associated lymphoma), 
NUDT14 and MGST3 (upregulated). These genes were significantly differentially 
expressed with p values of <0.0000, 0.0137, and 0.0209 respectively, and fold changes of 2, 
1.40, and 1.28, respectively (Figure 4.14). Thus, these 3 genes (BMS1, NUDT14, and 
MGST3) were found to be the gene expression signature for pSS-associated lymphoma for 
this study (referred to as the “3-gene biosignature of pSS-associated lymphoma” in the 
thesis). For the remaining 21 genes, I have also examined in more detail those genes that 
satisfy the following criteria: (a) those with p values between 0.05 and 0.25 and (b) a 
consistent direction of regulation as observed in the Discovery cohort. Three genes satisfied 
these criteria: LEF1, OAF, and DRAP1. In addition, another five genes have a p value > 
0.25 but the same direction of regulation of the Discovery cohort; these genes were 
LGALS1, CBLL1, C10orf32 (BORCS7), DYNLL1, and SGK223 (Table 4.12). The p values, 
fold changes, and the direction of regulation of the remaining 13 non-validated genes are 
provided in supplementary table S3. 
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Figure 4.14 The relative gene expression levels of the 3-gene biosignature of pSS-
associated lymphoma. The expression levels of the genes were expressed as the ratio to the 
expression level of the housekeeping gene YWHAZ. The downregulated BMS1 gene is in 
red (p<0.0000, FC=2); the upregulated NUDT14 and MGST3 genes are in blue 
(p=0.0137, 0.0209 ;FC=1.40,1.28 respectively). The total number of samples used in the 
comparison were pSS = 119 and pSS-associated lymphoma = 17. 
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Table 4.12 The 3-gene biosignature of pSS-associated lymphoma and other potential 
candidate genes identified in the Validation cohort (i.e. those genes with expression levels 
that were not statistically significantly different between subject groups but have the same 
direction of regulation as the Discovery cohort). Fc was calculated according to the 
normalisation against the pSS group. 
Gene 
symbol 
Gene name p value Fold change 
and 
regulation  
3-gene biosignature of pSS-associated lymphoma (sig. p values & consistent regulation with 
the Discovery cohort) 
BMS1 BMS1 ribosome biogenesis factor  0.0000 2.00↓ 
NUDT14 Nudix (nucleoside diphosphate linked moiety X)-type 
motif 14 
0.0137 1.40 ↑ 
MGST3 Microsomal glutathione S-transferase 3 0.0209 1.28 ↑ 
Genes with 0.05 < p values >  0.25  consistent direction of regulation as the Discovery cohort 
LEF1 Lymphoid enhancer-binding factor 1 0.0607 1.25 ↓ 
OAF OAF homolog (Drosophila) 0.1370 1.33↑ 
DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) 0.1220 1.19 ↑ 
Genes with  p values >  0.25  consistent direction of regulation as the Discovery cohort 
LGALS1 Lectin, galactoside-binding, soluble, 1  0.3109 1.12 ↑ 
CBLL1 Cbl proto-oncogene-like 1, E3 ubiquitin protein ligase 0.5063 1.11 ↓ 
C10orf32 
(BORCS7) 
chromosome 10 open reading frame 32 0.4221 1.07 ↑ 
DYNLL1 Dynein, light chain, LC8-type 1  0.6263 1.07 ↑  
SGK223 homolog of rat pragma of Rnd2 0.6124 1.01 ↓ 
 
4.4.6 Testing the whole blood gene expression signature in untreated pSS-associated 
lymphoma patients  
A set of untreated pSS-associated lymphoma samples was also included within the 
Validation cohort. These samples were collected from 7 patients with untreated lymphoma 
at the time of sampling (4 samples were obtained from our collaborators in Sweden, while 
the remaining 3 were from the UKPSSR). Six genes (NUDT14, DRAP1, DYNLL1, RBP7, 
SF3A1, and VCP) were differentially expressed between “untreated lymphoma” and “non-
lymphoma” groups with p < 0.05 (Table 4.13). Among these 6 DEGs, NUDT14 was a DEG 
for both treated and untreated pSS-associated lymphoma groups. DRAP1 and DYNLL1 
were not validated in the Validation cohort, but they have the same direction of regulation 
in both treated lymphoma cohorts (i.e. Discovery and Validation cohorts). RBP7 was also 
not validated in the Validation cohort with p value > 0.05, and having an opposite direction 
of regulation between the Discovery and the Validation cohorts. Similarly, SF3A1 and VCP 
were downregulated in the “pSS-associated lymphoma” group in the Discovery cohort but 
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were ‘upregulated’ in the Validation cohort, albeit both with p < 0.05. Therefore, I 
considered that NUDT14, DRAP1, and DYNLL1 as genes that could be potential 
biomarkers for untreated pSS-associated lymphoma (Figure 4.15). The p values, fold 
changes, and the direction of regulation of the remaining genes are provided in 
supplementary table S4. 
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Figure 4.15 The relative gene expression levels of the 3 DEGs in untreated pSS-
associated lymphoma. All 3 genes (NUDT14, DRAP1 and, DYNLL1) were upregulated in 
the untreated lymphoma group with p=0.0097, 0.0323 and 0.0106; FC=1.68, 1.34 and 1.54 
respectively. The total number of samples used in the comparison were pSS = 119 and 
untreated pSS-associated lymphoma = 7 
Table 4.13 The significant DEGs in untreated pSS-associated lymphoma. Fc was 
calculated according to the normalisation against the control group. 
Gene symbol Gene name p value Fold change 
and 
regulation  
3-gene biosignature in pSS-associated lymphoma 
NUDT14 Nudix (nucleoside diphosphate linked moiety X)-type motif 14 0.0097 1.68 ↑ 
DEGs in untreated pSS-associated lymphoma (significant p values and consistent regulation direction 
with the treated lymphoma groups in both Discovery and Validation cohort) 
DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) 0.0323 1.34 ↑ 
DYNLL1 Dynein, light chain, LC8-type 1  0.0106 1.54 ↑ 
DEGs in untreated pSS-associated lymphoma (but not consistent regulation direction within treated 
lymphoma) 
SF3A1 splicing factor 3a, subunit 1, 120kDa 0.0123 1.79 ↑ 
RBP7 Retinol binding protein 7, cellular 0.043 1.29 ↑ 
VCP Valosin containing protein 0.0306 1.27 ↑ 
107 
 
4.4.7 Prediction models for transcriptomic biomarkers of pSS-associated lymphoma 
The gene expression data obtained from the qRT-PCR experiment of the Discovery cohort 
(60 DEGs) were used to build prediction models for pSS-associated lymphoma using 
logistic regression. Inspection of simple logistic regression plots for each of the individual 
candidates, followed by a stepwise logistic regression procedure, led to the identification of 
two candidate genes for subsequent modelling with one third of the data retained for model 
cross-validation, then the Two-Gene model.  
1. Two-Gene model 
In this model, a cross-validation method was used first to test the model within the data in 
the Discovery cohort, where the data is divided into thirds. Two thirds were used to build 
the model and the third part used to test it. Next, the Two-Gene model was applied to the 
whole dataset of the Discovery cohort.  
a. Cross-validation of the Two-Gene model 
The dataset set was randomly divided into thirds. Two-thirds of which were used as a 
“training set” to build the model and the remaining third was used for validation (named as 
the “test set”). NUDT14 and UBXN11 were identified as key candidates. Both genes were 
retained in the model. The correlation between the expression level of UBXN11 and the 
probability of having lymphoma in pSS patients was poor (p = 0.7743), while the 
correlation between NUDT14 expression levels and having lymphoma was statistically 
significant (p=0.0210) and robust to the inclusion of UBXN11, as in Table 4.14A. I also 
applied the “likelihood ratio test”, a statistical test used to compare the goodness of fit of 
the model to the null hypothesis. The test determines how many times more likely (i.e. the 
likelihood ratio) the data fit one model over the null model with the corresponding p value. 
In this model, the likelihood ratio test showed a significant p value for NUDT14 of 0.0027 
(Table 4.14 B), suggesting that NUDT14 may be a better predictor of pSS-associated 
lymphoma than UBXN11. 
The receiver operating characteristic (ROC) curve for the cross-validation of the Two-Gene 
model is shown in Figure 4.16 and the area under the curve (AUC) values for the training 
and testing sets were 0.875 and 0.944 respectively, indicating good overall performance.  In 
order to further evaluate the performance of the model, we performed a misclassification 
analysis comparing the observed and expected diagnoses according to the model in both the 
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training and test sets.  The off-diagonal values in the confusion matrix in Table 4.15 (A and 
B) highlight these misclassification errors.  Overall, the model correctly predicted 37 of the 
42 samples (88.09% accuracy) in the training set and correctly predicted 14 of the 18 
samples (77.7% accuracy) in the test set.  The model did not misclassify any of the 32 non-
lymphoma pSS controls, but 4 of the 9 pSS-associated lymphoma patients were 
misclassified in the training set. In the test set, the model did not misclassify any of the 12 
non-lymphoma pSS controls, but 4 of the 6 pSS-associated lymphoma patients were 
misclassified. Note that this model could be further refined by incorporating the prevalence 
of lymphoma in pSS patients as prior probabilities.  
  
 
Table 4.14 Statistical analysis of the Two-Gene model using cross-validation approach. 
A. Parameter Estimates. B. Effect Likelihood Ratio tests. The results were generated by 
JMP SAS. 
 
Parameter Estimates 
Term Estimate Std Error ChiSquare Prob>ChiSq 
intercept -5.3179632 2.5135689 4.48 0.0344* 
NUDT14 27.7794556 12.038592 5.32 0.0210* 
UBXN11 0.37521799 1.3085782 0.08 0.7743 
 
Effect Likelihood Ratio Tests 
Source Nparm DF ChiSquare Prob>ChiSq 
NUDT14 1 1 8.98441796 0.0027 
UBXN11 1 1 0.08133799 0.7755 
      * = Staistically signficant 
 
 
 
A 
B 
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Figure 4.16 Receiver operating characteristic (ROC) curves of the Two-Gene model 
using cross-validation approach. The specificity and sensitivity of the Two-Gene model to 
classify pSS patients with or without lymphoma using the cross-validation approach. The 
left figure is the ROC of the training set with AUC=0.875, and the right figure is the ROC 
of the test set with AUC=0.944. 
 
 
Table 4.15 Confusion matrix of the Two-Gene model using cross-validation approach. 
Showing actual and predicted classifications in training set (A) and test set (B). The results 
were generated by JMP SAS 
 
Actual classification  Predicted 
Training set pSS-associated lymphoma pSS 
pSS-associated lymphoma 5 4 
pSS 0 32 
 
Actual classification  Predicted 
Test set pSS-associated lymphoma pSS 
pSS-associated lymphoma 2 4 
pSS 0 12 
 
A 
B 
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b. Building the Two-Gene model 
In this model, a stepwise ordinal logistic regression method was used to identify the best 
classifier for pSS-associated lymphoma. For this model, I used the 60 DEGs (i.e. training 
and test sets were pooled together). NUDT14 and UBXN11 were again identified as key 
candidates. The correlation between UBXN11 expression and the probability of having 
lymphoma was not significant (p=0.0606), while that between NUDT14 expression levels 
and lymphoma development was statistically significant (p=0.0095) (Table 4.16A).  
I also applied the likelihood ratio test for this model, which showed a significant p value for 
NUDT14 of 0.0013 (Table 4.16B), suggesting that NUDT14 was a better predictor of pSS-
associated lymphoma than UBXN11. Similarly, the probability of the Lack of Fit test is not 
statistically significant, with a value of 0.927, suggesting that the goodness of fit of the 
model was good (Table 4.16 C). 
The ROC curve for this Two-Gene model has an area AUC value of 0.886, indicating good 
overall performance (Figure 4.17).  In order to further evaluate the performance of the 
model, I performed a misclassification analysis comparing the observed and expected 
diagnoses according to the model.  Overall, this model correctly predicted 50 of the 59 
samples (84.7% accuracy).  The model misclassified just 2 of the 44 non-lymphoma pSS 
patients, but 7 of the 15 pSS associated lymphoma patients were misclassified.  This model 
could be further refined by incorporating the prevalence of lymphoma in pSS patients as 
prior probabilities.  
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Table 4.16 Statistical analysis of the Two-Gene model. A. Parameter Estimates; B. Effect 
likelihood ratio tests; and C. the lack of fit. The results were generated by JMP SAS. 
 
Parameter Estimates 
Term Estimate Std Error ChiSquare Prob>ChiSq 
Intercept -7.0777384 2.0191171 12.29 0.0005* 
NUDT14 25.4739019 9.8198523 6.73 0.0095* 
UBXN11 1.50683684 0.80304 3.52 0.0606 
 
Effect Likelihood Ratio Tests 
Source Nparm DF ChiSquare Prob>ChiSq 
NUDT14 1 1 10.3598995 0.0013* 
UBXN11 1 1 3.60432543 0.0576 
 
Lack of Fit 
Source DF -LogLikelihood ChiSquare 
Lack of fit 56 20.714426 41.42885 
Saturated 58 0.000000 Prob>ChiSq 
Fitted 2 20.714426 0.927 
           * = Staistically signficant 
 
 
 
B 
C 
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Figure 4.17 Receiver operating characteristic (ROC) curve of the Two-Gene model. This 
represents the specificity and sensitivity of the Two Genes model to classify pSS patients 
with or without lymphoma; the AUC=0.8864. 
 
 
Table 4.17 Confusion Matrix of the Two-Gene model. Showing actual and predicted 
classifications in the Discovery cohort. The results were generated by JMP SAS 
Actual classification  Predicted 
Training pSS-associated lymphoma pSS 
pSS-associated lymphoma 8 7 
pSS 2 42 
 
 
2. The Single Gene model 
In the Two-Gene model, the UBXN11 gene achieves a small improvement on predictions, 
though it was only marginally significant. Since UBXN11 was not making a statistically 
significant contribution in the Two-Gene model, I have chosen to investigate whether a 
model that uses only the NUDT14 gene will also perform well in predicting membership of 
pSS-associated lymphoma. 
 
113 
 
a. Building the Single Gene model 
The logistic fit for NUDT14 is shown in Figure 4.18. It appears that NUDT14 plays an 
important role in distinguishing pSS patients with lymphoma from those without 
lymphoma. Thus, there was a statistically significant (p = 0.0011) correlation between the 
expression level of NUDT14 and the probability of having  lymphoma in pSS patients as in 
Table 4.18A. 
I then applied the likelihood ratio test, which showed a significant p value of 0.0001 (Table 
4.18 B). Similarly, the lack of fit test (p = 0.874) suggested that the goodness of fit of the 
model was good (Table 4.18 C). 
The ROC curve for the Single Gene model is shown in Figure 4.19 and the AUC was 
0.859, indicating good overall performance.  I then performed a misclassification analysis ( 
Table 4.19) Overall, the model correctly predicted 48 of the 59 samples (81.3% 
accuracy).  The model misclassified just 3 of the 44 non-lymphoma pSS patients, but 8 of 
the 15 pSS-associated lymphoma patients were misclassified.  This model could be further 
refined by incorporating the prevalence of lymphoma in pSS patients as prior probabilities.  
  
 
Figure 4.18 Logistic fit of NUDT14 in the Single Gene model. The red dots represent the 
pSS-associated lymphoma cases, and the blue dots represent the pSS without lymphoma 
cases. 
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Table 4.18 Statistical analysis of the Single Gene model. A. Parameter Estimates; B. 
Effect Likelihood ratio tests; and C. the Lack of Fit. The results were generated by JMP 
SAS. 
 
Parameter Estimates 
Term Estimate Std Error ChiSquare Prob>ChiSq 
Intercept -4.2933101 1.0582869 16.46 <0.0001* 
NUDT14 29.6484091 9.0728471 10.68 0.0011* 
 
Effect Likelihood Ratio Tests 
Source Nparm DF ChiSquare Prob>ChiSq 
NUDT14 1 1 21.8660478 <0.0001* 
 
Lack of fit 
Source DF -LogLikelihood ChiSquare 
Lack of fit 57 22.516588 45.03318 
Saturated 58 0.000000 Prob>ChiSq 
Fitted 1 22.516588 0.8743 
           * = Staistically signficant 
 
 
Figure 4.19 Receiver operating characteristic (ROC) curve of the Single Gene model. 
This represents the sensitivity and specificity of the Single Gene model to separate pSS 
patients with or without lymphoma; the AUC=0.859. 
B 
C 
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Table 4.19 Confusion matrix of the Single Gene model. Showing actual and predicted 
classifications in the Discovery cohort. The results were generated by JMP SAS 
Actual classification  Predicted 
Training pSS-associated lymphoma pSS 
pSS-associated lymphoma 7 8 
pSS 3 41 
 
3. Testing the Two-Gene and the Single Gene models using the Discovery and 
Validation cohorts  
Two-Gene model  
The Two-Gene model was applied to the Discovery and the Validation cohorts. The 
prediction was visualised with a mosaic plot that shows the predictions of non-lymphoma 
pSS and pSS-associated lymphoma groups. The x-axis represents the subject groups, while 
the y-axis represents the probability of patients belonging to the lymphoma group. The 
probability of predicting lymphoma membership for the lymphoma group was 80% in the 
Discovery cohort (Figure 4.20) but decreased to 38.5% in the Validation cohort (Figure 
4.21).  
 
Figure 4.20 Mosaic plot of the prediction probability of the Two-Gene model in the 
Discovery cohort. The red rectangles represent the proportion of patients predicted to have 
lymphoma. The blue rectangles represent the proportion of samples predicted not to have 
lymphoma. The actual diagnosis is shown on the horizontal axis. The vertical axis is the 
proportion of the prediction for a particular diagnosis. 
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Figure 4.21 Mosaic plot of the predictions probability of the Two-Gene model in the 
Validation cohort. The red rectangles represent the proportion of patients predicted to 
have lymphoma. The blue rectangles represent the proportion of samples predicted not to 
have lymphoma. The actual diagnosis is shown on the horizontal axis. The vertical axis is 
the proportion of the prediction for a particular diagnosis. 
 
The Single Gene model 
When the Single Gene model is applied to the datasets of the Discovery and Validation 
cohorts, the proportions of the prediction for each subject group are shown on the mosaic 
plots. The frequency of correctly predicting lymphoma cases in the lymphoma group was 
70% in the Discovery cohort (Figure 4.22), which reduced to 41.7% in the Validation 
cohort (Figure 4.23).  
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Figure 4.22 Mosaic plot of the prediction probability of the Single Gene model in the 
Discovery cohort. The red rectangles represent the proportion of patients predicted to have 
lymphoma. The blue rectangles represent the proportion of samples predicted not to have 
lymphoma. The actual diagnosis is shown on the horizontal axis. The vertical axis is the 
proportion of the prediction for a particular diagnosis. 
 
Figure 4.23 Mosaic plot of the predictions probability of the Single Gene model in the 
Validation cohort. The red rectangles represent the proportion of patients predicted to 
have lymphoma. The blue rectangles represent the proportion of samples predicted not to 
have lymphoma. The actual diagnosis is shown on the horizontal axis. The vertical axis is 
the proportion of the prediction for a particular diagnosis. 
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4.5 Discussion 
The goal of this project is to identify a whole blood gene expression signature in pSS-
associated lymphoma. For this goal, 144 whole blood globin-depleted samples represent the 
Discovery cohort. Then validate the potential gene expression signature identified in this 
cohort in an independent cohort. I also test the potential signature in a set of untreated pSS-
associated lymphoma and I attempted to use a machine learning approach to investigate 
which gene might be a candidate to predict lymphoma development in pSS patients.    
RNA quality  
The globin mRNA depletion is a multistep process, and adding more preparation steps 
might result in RNA degradation, as RNA is a molecule with thermodynamic stability. 
RNA degradation will have adverse impact on downstream analysis of RNA expression 
(Auer et al., 2003). In the Discovery cohort, the RIN score of 24 samples were below 7. 
The sub-optimal RIN scores might be caused by the globin depletion process, as it has been 
discussed in Chapter 3 and also in the literature (Shin et al., 2014, Choi et al., 2014, 
Mastrokolias et al., 2012). On the other hand, all of the amplified cRNA samples from the 
Discovery cohort lacked the ~700 bp peak that represents globin mRNA in the 
electropherograms (Vartanian et al., 2009), indicating  efficient globin mRNA depletion. 
Microarray data analysis 
The Illumina Human HT-12 v4 BeadChip microarray was used for the screening of the 
potential candidate gene expression signature of pSS-associated lymphoma. In general, 
avoiding bias is crucial in such experiments. For this reason, samples from the five subject 
groups were selected randomly to be run on the same microarray chip (each chip can 
measure up to 12 samples). This approach will avoid bias and systematic error being 
introduced (Pannucci and Wilkins, 2010). Because the sample size of the Discovery cohort 
is relatively large, it was therefore unavoidable to perform the microarray at different times 
and in different batches, which in turn will introduce batch effects. Batch effect detection 
and correction were therefore necessary when I analyse the microarray data. The correction 
of batch effects during microarray data analysis is important, and so is the choice of method 
to achieve that, in order to yield a robust data set (Larsen et al., 2014). Many methods have 
been developed for batch effect correction. The ComBat method has been suggested to 
have better performance than other batch effect correction methods (Chen et al., 2011). The 
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ComBat method collects information across genes and it minimises the parameter of the 
batch effects in the direction of the overall mean of the batch across the genes (Johnson et 
al., 2007, Larsen et al., 2014).  
In this project, I have identified many candidate genes from the Discovery cohort as a 
potential whole blood gene expression signature for pSS-associated lymphoma (68-DEGs-
Mi). The list of candidate genes is related to many different biological functions. For 
example, some of these genes have been linked to lymphoma development (such as 
BCL11B and MYC). Whether these genes are actually involved in lymphoma development 
in pSS is still under investigation.  
Technical validation of the microarray data 
I used real-time RT-PCR to technically validate the 68-DEGs-Mi. The results shown that 
DEGs were confirmed in 26 / 60 DEGs by qRT-PCR  (26-DEGs-MiPCR). The are several 
reasons why differential expression was not confirmed with RT-PCR for the remaining 34 
genes. It has been suggested that filtering of the microarray data by the fold change and p 
values is important to gain robust results (Morey et al., 2006). The fold changes of the 
DEGs from the microarray data ranged from 1.2-1.8, which  is relatively small. It is 
therefore unsurprising that not all of the DEGs were validated with qRT-PCR. A previous 
report has indicated that the correlation between microarray data and qRT-PCR decreases 
when the fold changes were less than 1.5 (Dallas et al., 2005). Furthermore, the biological 
and technical differences between the two techniques must be taken into consideration as a 
source of variation (Wurmbach et al., 2003, Chuaqui et al., 2002). One of the genes, HLA-
DRB1, failed to generate a normal amplification plot during the qRT-PCR. The failure in 
detecting this gene with RT-PCR might be due to the RNA concentration of the samples. 
Moreover, another reason of this failure is due to the polymorphism of HLA-DRB1. The 
polymorphism of HLA-DRB1 led to the use of alternative PCR techniques such as 
sequence-specific primers PCR to detect its expression (Song et al., 2012, Gersuk and 
Nepom, 2009). Certainly, the HLA-DRB1 gene plays an important role in the pathogenesis 
of pSS and other autoimmune diseases (Guggenbuhl et al., 1998, Doherty et al., 1998). 
Therefore, it warrants further investigation in the future.  
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Twenty of these 26 genes were identified from the main analysis (Analysis A), and the 
remaining 6 genes were identified from the other 3 sub-analyses. The validation of these 6 
additional genes justifies the inclusion of these analyses. 
 
Biological validation of whole blood gene expression signature in pSS-associated 
lymphoma  
Biological validation was carried out using an independent cohort. Differential expression 
of three genes (BMS1, NUDT14 and MGST3) was confirmed in this cohort.  These three 
genes are referred to as the 3-gene biosignature of pSS-associated lymphoma. The 
downregulated BMS1 or ribosome biogenesis factor, which is also known as ACC and 
BMS1L, is located in the nucleus of the cell. BMS1 encodes a protein called ribosome 
biogenesis factor,  which plays a role in ribosomal assembly and is critical for the 40S 
ribosome formation. Limited data are available concerning the role of BMS1. Nonetheless, 
it has been shown that the decrease in BMS1 level leads to late maturation of 18S rRNA. 
Furthermore, BMS1 mutation is linked to aplasia cutis congenital (ACC), which is caused 
by defects in cell cycle, reducing cell proliferation and affecting skin morphology 
(Marneros, 2013). No information linking this gene to any type of malignancy has been 
reported in the literature.  
NUDT14 or nudix (nucleoside diphosphate linked moiety X) – type motif 14, which was 
upregulated in pSS-associated lymphoma, is also known as NUDIX MOTIF 14, uridine 
diphosphate glucose pyrophosphatase (UGPP), UDPG pyrophosphatase, and UGPPase. 
The protein that this gene encodes is uridine diphosphate glucose pyrophosphatase, and it 
has a role in producing glucose 1-phosphate and UMP by hydrolysing UDPG (Yagi et al., 
2003). NUDT14 plays a role in the pyrophosphorylation of substrates that contain 
nucleosides (Yagi et al., 2003). In mice, the role of NUDT14 appears to be more related to 
ADP-ribose hydrolysis than UDP-glucose hydrolysis (Heyen et al., 2009). NUDT14 is 
located on chromosome 14q32.3. Deletion of NUDT14 has been described in the 14q32 
deletion syndrome, which causes mild facial dysmorphisms and intellectual disability 
(Holder et al., 2012).  
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Regarding the involvement of NUDT14 in malignancies,  Choi and co-workers (Choi et al., 
2011) reported an upregulation of NUDT14  in a rectal carcinoma cell line. However, the 
role of this gene in malignancy development is still unknown. Recently, modulation role of 
NUDT14 in viral infection, in particular, the human cytomegalovirus (HCMV), was 
reported. Wang and colleagues (Wang et al., 2016) found that the HCMV RL13 protein, 
which is encoded by the HCMV RL 13 gene, is co-localised with the NUDT14 protein in 
the cell membrane and the cytoplasm of human embryonic kidney HEK293 cells, and that 
they interact with each other. Furthermore, when the NUDT14 expression decreased, the 
number of the viral DNA copies in the infected cells increased. However, the 
overexpression of NUDT14 had no effect on the number of the viral DNA copies. NUDT14 
is differentially expressed in pSS-associated lymphoma cases regardless of their treatment 
status. Therefore, undertaking more studies is worthwhile to investigate the possible role of 
this gene in lymphoma development. 
MGST3 (microsomal glutathione S-transferase 3) is also known as GST III and GST-3. 
This gene encodes a protein named microsomal glutathione S-transferase 3. The protein is 
located mostly in the endoplasmic reticulum membrane, commonly expressed in skeletal 
muscles, adrenal cortex, and heart. The main function of this protein is to serve as a 
glutathione peroxidase (Jakobsson et al., 1997). The microsomal glutathione S-transferase 3 
(MGST3) is not evolutionarily related to the glutathione S-transferase (GST) gene family, 
but it encodes membrane-bound enzymes that possess GST-like activity (Nebert and 
Vasiliou, 2004). Young and Woodside (2001) have reported that the glutathione 
peroxidases contribute to the process of detoxification from both endogenous and 
exogenous toxins by eliminating lipid peroxidase (Young and Woodside, 2001). 
Furthermore, MGST3 is highly abundant in the liver as it is involved in drug metabolism 
(Morgenstern et al., 2011, Uno et al., 2013). Along with its main function in glutathione-
dependent peroxidase activity, MGST3 also contributes to the synthesis of the leukotriene 
C4, which leads to the production of inflammatory and hypersensitivity mediators (Ford-
Hutchinson, 1990). 
In the validation cohort, OAF, LEF1, and DRAP1 had adjusted p values  between 0.05 and 
0.25 with the same direction of regulation to the Discovery cohort. Five additional genes 
have a p value more than 0.25 but the same direction of regulation of the Discovery cohort. 
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these genes are CBLL1, C10orf32 (BORCS7), DYNLL1, LGALS1, and SGK223. I believe 
that these genes are also worthy of further investigation as potential gene expression 
signatures for pSS-associated lymphoma in the future. This is because the probability 
values report the likelihood of an effect being detected by chance but not the size of the 
effect. The p values are often affected by the sample size (Sullivan and Feinn, 2012).  
Identify possible whole blood gene expression signature for untreated pSS-associated 
lymphoma  
In this project, I had the opportunity to test whether the potential signature for pSS-
associated lymphoma was also present in untreated lymphoma samples. When compared to 
non-lymphoma pSS samples, 6 genes were found to be differentially expressed.  
Interestingly, NUDT14, which was upregulated in the treated lymphoma cases in both the 
Discovery and Validation cohorts, was also upregulated in untreated lymphoma cases.  
DRAP1 and DYNLL1 may also be of interest. Differential expression of these two genes 
was confirmed in the treated lymphoma samples from the Discovery cohort. These two 
genes also have the same direction of regulation in the treated lymphoma cases in the 
Validation cohort albeit with a p values of greater than 0.05. DRAP1 or DR1-associated 
protein 1 (also known as negative cofactor 2 alpha (NC2-alpha)) is a transcriptional 
repressor. In order to initiate a transcription, the assembly of RNA polymerase II is required 
as well as general transcriptional factors (GTFs) such as TFIIA, TFIIB, and TFIID. DRAP1 
interacting with TATA-binding protein (TBP) of TFIID precludeing TBP-DNA complex 
formation (Schluesche et al., 2007). Furthermore, evidence showed that in hypoxic 
conditions,  the activity of NC2 increases suggesting that a DRAP1 may play an important 
role in gene regulation in hypoxic conditions (Denko et al., 2003). In cancer settings,  
upregulation of DRAP1 has been reported to be an accurate predictor of radioresistance in 
prostate cancer patients undergoing radiotherapy, although the data were derived from a 
small dataset and therefore needs to be replicated (Valdagni et al., 2009).  
DYNLL1 or dynein light chain encodes the protein LC8-type 1, which is an enzyme 
complex that has a role in intracellular transport and motility. Evidence has revealed that 
the binding of the DYNLL1 encoded protein to pilin of the pathogen Pseudomonas 
aeruginosa stimulates an inflammatory response in the host, which might be harnessed for 
treatment purposes (Kausar et al., 2013). LC8 contributes to microtubule stability as 
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overexpression of LC8 increases microtubule acetylation and reduces microtubule 
susceptibility to cold- and nocodazole-induced depolymerisation, while decrease of LC8 
leads to disruption of bipolar spindle assembly, suggesting  a novel microtubule-associated 
protein-like function for LC8 (Asthana et al., 2012). LC8  also regulates the activity of the 
proapoptotic Bcl-2 family member BH3-only protein Bim,  through impounding Bim to the 
cellular microtubules in the state of healthy cells (Puthalakath et al., 1999). Therefore, the 
regulatory role of LC8 on Bim might have a role in malignancy development and resistance 
to cancer treatments (Izidoro-Toledo et al., 2013). Recently, DYNLL1 was reported to 
interact with human immunodeficiency virus type 1 integrase (HIV-1 integrase (IN)), 
leading to the reverse transcription and the multiplication of the virus (Jayappa et al., 2015). 
More experiments are needed to understand the possible role of DYNLL1 in pSS-associated 
lymphoma. 
Identifying the most important genes in predicting the group’s membership in pSS-
associated lymphoma  
To identify the key constituent genes of the pSS-associated lymphoma gene signature, I 
have examined two prediction models using the qRT-PCR data from the Discovery cohort 
based on the 60 DEGs. Both models indicated that NUDT14 is the best predictor or 
classifier of pSS-associated lymphoma membership. The data generated from these models 
were also consistent with my experimental findings, as NUDT14 has been shown to be 
differentially expressed in the two treated lymphoma cohorts and the untreated lymphoma 
cohort.  Although there is no data in the literature that implicate NUDT14 in lymphoma 
development, my data strongly suggest that further investigation into the role of NUDT14 
in the pathogenesis of lymphoma in pSS is worthwhile.    
In conclusion, the data from the microarray and qRT-PCR from the Discovery and 
Validation cohorts have identified several genes that warrant further investigations in larger 
cohorts of treated and untreated lymphoma as well as in longitudinal studies. Many of these 
candidate genes have not been linked directly to lymphoma development. Therefore, if the 
roles of these signature genes for pSS-associated lymphoma are confirmed, it will unravel 
novel mechanisms of lymphomagenesis in pSS. 
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Chapter 5 
Biological pathway analysis in primary Sjögren’s Syndrome -
associated lymphoma 
5.1 Introduction: 
Biological pathways in pSS, lymphoma and pSS-associated lymphoma 
A biological pathway refers to a series of molecular interactions within the cell that lead to 
the production of a certain molecule or a biological change within the cell. A valuable 
approach to the analysis of microarray gene expression data is to study whether there are 
indications of changes in biological pathways within the datasets. This linkage between the 
gene expression data and biological processes will help to gain a better understanding of a 
given disease.  
For instance, in pSS, analysis of microarray gene expression data have led to the discovery 
that the type I interferon pathway plays a major role in pSS pathology (Gottenberg et al., 
2006, Emamian et al., 2009). This observation is also consistent with the hypothesis that 
viruses being involved in the aetiology of pSS, as viral infections are potent inducers of 
IFN-alpha (Bave et al., 2005). The ‘Toll-like receptor (TLR) pathway’ is another pathway 
that has been shown to be activated in pSS. TLRs appear to be linked to salivary-gland 
epithelial cell pathology in pSS; epithelial cells from salivary glands of pSS patients have a 
higher level of TLR expression compared to those from healthy controls (Spachidou et al., 
2007).  
Many pathways have also been shown to be dysregulated in lymphoma. For example, it has 
been shown that the NF-κB signalling pathway is activated in lymphoma (Troppan et al., 
2015). Moreover, the NF-κB signalling pathway can be activated by the stimulation of B-
cells receptor in Diffused Large B Cells lymphoma (DLBCL). NF-κB signalling pathway 
also has an activating effect on the JAK2/STAT3 signalling pathway by stimulating TLR 
and interleukin receptors (IL-1 and IL-18), which leads to the progress of DLBCL 
lymphoma (Ngo et al., 2011, Turturro, 2015). Recently, the discovery of therapeutic drug 
that act as an inhibition of antigen receptor signalling pathway, including B-cell receptors, 
T-cells receptors, TLR and BAFF  might be a useful treatment for B cell lymphoma (Zhang 
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et al., 2015). Interestingly, the NF-κB signalling pathway has also been implicated in pSS 
pathogenesis (G'Sell et al., 2015). It is therefore possible that exploring the changes in 
biological pathways in pSS-associated lymphoma may improve our understanding of 
lymphomagenesis in pSS, reveal the biological meaning of the gene-expression signature 
for pSS-associated lymphoma and help to establish novel therapies.  
To date, there has been no published research on the use of microarray data to explore the 
biological processes that may be involved in pSS-associated lymphoma. Therefore, this 
study is the first attempt to investigate such relationships.       
Ingenuity Pathway Analysis (IPA):  
Many programs have been developed to analyse biological pathways for microarray data 
(Table 5.1). MetaCore by GeneGo, GenMapp and Ingenuity Pathway Analysis (IPA) 
(Bogner et al., 2011) are examples of such software. A key difference between these 
different tools is how up-to-date their databases are. In this regard, the knowledge database 
of Ingenuity Pathway Analysis is manually curated, literature supported, and frequently 
updated.  IPA is a web-based software program that enables researchers to discover the 
biological significance of their high-throughput biological data (Kramer et al., 2014). With 
IPA, specific pathways and networks that might be relevant to a certain disease (for 
example, pSS-associated lymphoma) can be identified. IPA uses a p-value calculated by the 
Fisher’s exact test, right-tailed and an activation z-score to present the outcome 
(Ingenuitysystems, IPA). A brief definition of some key terms used in the IPA is provided 
below:  
Focus genes: Probe identifiers of significantly differentially expressed genes (DEGs) 
uploaded from my experiment that are represented in the suggested network or a pathway.  
P-value: reflects the significance metric representative of the probability that the molecules 
or the genes are involved in a given pathway or network not by random chance. The lower 
the p-value below a given threshold (0.01 or 0.05) is the more significant.  
Z-score: reflects the statistical state of the direction of a relationship that is expected of the 
genes in a given experiment and the regulation direction that derived from the literature in 
IPA; normally, a z-score > 2 or z-score < -2 is considered significant.  
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Score: is the number of genes in the network, including the genes of the uploaded DEGs 
list from a given experiment and the genes that are added from the indirect interactions by 
IPA. 
Overlap p-value: is used in the upstream regulator analysis. It represents whether there is 
any statistically significant in common between the DEGs in a given experiment and their 
regulators.  
Ratio: the ratio is used in the canonical pathway analysis. It represents the ratio of the 
genes in the uploaded DEGs list from my experiment and the total number of genes that 
make up each pathway. Each indirect association is supported by literature. 
IPA maps a list of genes (commonly the list of DEGs) in a certain experiment to the 
Ingenuity Knowledge Base (IKB). The IKB is a database with detailed information on 
known biological interactions and functional annotations. The information was built from 
existing individual relationships between different molecules such as genes, proteins, cells, 
chemicals and diseases that can be found in the literature and is updated on a regular basis 
(http://www.ingenuity.com, 2015). Using IPA has many advantages: it provides biological 
function as well as sub-functions for each gene. Moreover, the bibliography in which the 
relationship is defined is provided through a direct link to the resource. Furthermore, the 
network analysis shows the interactions of the genes based on current knowledge (Jiménez-
Marín et al., 2009).  
Table 5.1 Software available for microarray data analyses(Jin et al., 2014b)   
Software  Feature Annotations URL 
PathMAPA A tool for displaying gene expression and performing 
statistical tests on metabolic pathways at multiple 
levels for Arabidopsis, based on expression data 
Local 
databases 
http://bioinformatics.
med.yale.edu/pathma
pa.htm 
MetaCore Based on a high-quality, manually curated database, 
MetaCore is an integrated software suite for functional 
analysis of microarray, metabolic, SAGE, proteomics, 
NGS, copy number variation, siRNA, microRNA and 
screening data 
MetaRodent, 
MetaLink, 
MetaSearch 
http://www.genego.co
m/  
Ingenuity 
Pathway 
Analysis 
(IPA) 
A comprehensive software/database search tool for 
finding functions and pathways for specific biological 
states. Manually curated in house 
GO, KEGG, 
BIND 
https://www.ingenuit
y.com/  
ePath3D An easy-to-use and powerful software for creating and 
managing illustrated 3D pathways for publications and 
presentations 
eProtein, 
ePathway 
http://www.proteinlou
nge.com/epath3d/  
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Pathway 
Builder 
An online pathway drawing tool which is the fastest 
and easiest method of creating signal transduction 
pathways, enabling the users to design their own 
project or use pre-made pathway templates to help get 
them started 
GenBank, 
Uniprot/Swiss-
Prot, TrEMBL, 
KEGG, 
ENZYME, etc 
http://www.pathwayb
uilder.com/  
Interactive 
Pathways 
Explorer 
(iPath) 
A web-based tool for the visualization, analysis and 
customization of various pathways maps from KEGG. 
The recently released version 2 could deal with 
metabolic pathway, regulatory pathway and 
biosynthesis of secondary metabolites 
KEGG https://pathwayexplor
er.genome.tugraz.at  
GSEA-P & R-
GSEA 
GSEA-P is a desktop application for Gene Set 
Enrichment Analysis, with a friendly graphic interface. 
R-GSEA is provided as a stand-alone R program. 
MSigDB, 
Gene Set 
Cards, GEO 
http://www.broadinsti
tute.org/gsea/  
DAVID A tool for augmenting and integrating functional 
annotations from other databases 
KEGG,GO http://david.abcc.ncifc
rf.gov/  
MetaCyc Applications include serving as an encyclopaedia of 
metabolism, providing a reference data set for the 
computational prediction of metabolic pathways in 
sequenced organisms, supporting metabolic 
engineering and helping to compare biochemical 
networks 
KEGG, 
BioCyc, 
EcoCyc 
http://metacyc.org/  
Reactome Intuitive bioinformatics tools for the visualization, 
interpretation and analysis of pathway knowledge to 
support basic research, genome analysis, modelling, 
systems biology and education 
KEGG http://www.reactome.
org/ 
GenMAPP Designed to visualize gene expression and other 
genomic data on maps representing biological 
pathways and groupings of genes 
GenMAPP, 
GO 
http://www.genmapp.
org 
FunCluster An integrative tool for analysing gene co-expression 
networks from microarray expression data; the analytic 
model implemented in the library involves two 
abstraction layers: transcriptional and functional 
(biological roles) 
GO, KEGG http://corneliu.henega
r.info/FunCluster.htm  
Graphite web A novel web tool for pathway analyses, consisting of 
topological-based analysis and network visualization 
for gene expression data of both microarray and RNA-
sequencing experiments 
KEGG, 
Reactome 
http://graphiteweb.bio
.unipd.it/  
 
5.2 Aim and experimental design: 
In this chapter, I will describe the biological pathway analysis in pSS-associated 
lymphoma, using the 68 DEGs from the microarray data generated in the Discovery cohort 
(68-DEGs-Mi) in order to gain a better understanding regarding the biology of pSS-
associated lymphoma. I used IPA for this analysis. In Chapter 4, I described the list of 
DEGs in pSS-associated lymphoma from the microarray experiment (68-DEGs-Mi), which 
is a combined list of DEGs that were generated from the four analyses of the microarray 
data using different criteria regarding sample inclusion.  
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The reason behind choosing the 68-DEGs-Mi is that the list contains the largest number of 
DEGs in comparison with the validated lists (26-DEGs-MiPCR and the 3-gene biosignature 
in pSS-associated lymphoma); the more genes the list contains the more associated 
pathways can be identified, the added power from 4 variations of the differential expression 
tests could yield more informative, disease relevant pathways. The uploaded DEGs list can 
be found in Table 5.2. 
Table 5.2 The 68-DEGs-Mi list used in Ingenuity pathway analysis  
Gene symbol adjusted P-value Fold change regulation in pSS-associated 
lymphoma 
LGALS1 0.019861522 1.36 upregulated 
DRAP1 0.009554204 1.32 upregulated 
KCTD12 0.032858824 1.28 upregulated 
RBP7 0.027203463 1.26 upregulated 
DYNLL1 0.010184961 1.25 upregulated 
UBXN11 0.001878176 1.25 upregulated 
NUDT14 0.001878176 1.24 upregulated 
C10orf32 0.024934079 1.23 upregulated 
HNMT 0.046978282 1.23 upregulated 
SRP14 0.041910977 1.23 upregulated 
PSMC1 0.040796915 1.23 upregulated 
MGST3 0.042260308 1.23 upregulated 
OAF 0.046978282 1.22 upregulated 
ATG12 0.010241707 1.22 upregulated 
SEC61G 0.046978282 1.21 upregulated 
RAB37 0.012720244 1.21 upregulated 
HCFC1R1 0.009554204 1.21 upregulated 
CNPY3 0.022617674 1.21 upregulated 
RNF7 0.029377902 1.20 upregulated 
EHBP1L1 0.039664006 1.20 upregulated 
HLA-DRB1 0.048625399 3.59 downregulated 
RNA28S5 0.001454575 1.67 downregulated 
LEF1 0.038999435 1.42 downregulated 
SPOCK2 0.045033431 1.41 downregulated 
ETS1 0.029209021 1.39 downregulated 
POM121C 0.00623275 1.35 downregulated 
RPL23AP5 0.011557085 1.32 downregulated 
MYC 0.019861522 1.32 downregulated 
CYFIP2 0.046978282 1.32 downregulated 
SGK223 0.044226587 1.32 downregulated 
HSP90B1 0.007110164 1.31 downregulated 
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BCL11B 0.03531743 1.30 downregulated 
RASGRP1 0.048625399 1.30 downregulated 
WAC 0.001538691 1.29 downregulated 
ITK 0.03462919 1.29 downregulated 
DDB1 0.00579247 1.28 downregulated 
MAGED1 0.044226587 1.26 downregulated 
ESYT1 0.044226587 1.26 downregulated 
PRPF8 0.039035069 1.26 downregulated 
SUN2 0.041735128 1.26 downregulated 
HNRNPUL1 0.038999435 1.25 downregulated 
CDR2 0.020642125 1.24 downregulated 
NAT10 0.033024722 1.24 downregulated 
CD96 0.038246765 1.24 downregulated 
VCP 0.019508447 1.24 downregulated 
RBL2 0.011367948 1.23 downregulated 
BAG3 0.023506309 1.23 downregulated 
ATP1A1 0.012439918 1.23 downregulated 
NCSTN 0.046450529 1.23 downregulated 
ALDH9A1 0.013677032 1.23 downregulated 
LRIG1 0.015856148 1.23 downregulated 
RRN3 0.007770882 1.23 downregulated 
HNRNPA1P10 0.044075354 1.23 downregulated 
PAF1 0.019861522 1.23 downregulated 
SF3A1 0.044226587 1.23 downregulated 
LRFN3 0.045230731 1.22 downregulated 
SDHA 0.038999435 1.22 downregulated 
KHDRBS1 0.040527676 1.22 downregulated 
CDV3 0.03462919 1.22 downregulated 
FOXJ3 0.015259771 1.21 downregulated 
SMARCA2 0.029889934 1.21 downregulated 
CBLL1 0.024405233 1.21 downregulated 
BMS1 0.026000737 1.20 downregulated 
HSPA9 0.020187775 1.20 downregulated 
RPA2 0.022508992 1.20 downregulated 
HNRNPDL 0.035037482 1.20 downregulated 
PRKCQ 0.047925118 1.20 downregulated 
BTBD11 0.027803403 1.20 downregulated 
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5.3 Results: 
5.3.1 The Canonical pathways of pSS-associated lymphoma  
A total of 188 canonical pathways have been identified as being over-representated in pSS-
associated lymphoma (p < 0.05, Fischer’s exact test, right-tailed). Moreover, the number of 
genes in common between 68-DEGs-Mi and the total number of the genes included in each 
pathway was calculated by IPA and were shown as “ratio”. The top 5 most significant (i.e., 
with the lowest p-values,) canonical pathways that were enriched in pSS-associated 
lymphoma are shown in Table 5.3. ‘Aryl Hydrocarbon Receptor (AHR) signalling’ was the 
statistically most significant pathway in pSS-associated lymphoma. The other top 4 
pathways were ‘histamine degradation,’ ‘unfolded protein response,’ ‘Neuregulin 
signaling’ and ‘T-cell receptor signalling.’ Supplementary table S5 shows the complete list 
of the 188 canonical pathways identified in this analysis. 
Of note, one of the five genes that was in common between the genes in the ‘AHR 
signalling’ pathway and the 68-DEGs-Mi is MGST3, which was also one of the three genes 
in the 3-gene biosignature of pSS-associated lymphoma. Indeed, when I focussed on the 
three genes in the 3-genes biosignature of pSS-associated lymphoma (NUDT14, MGST3 
and BMS1) and the canonical pathways that these genes might be involved in (Table 5.4), 
interesting observations emerged. NUDT14 was involved in six canonical pathways. 
MGST3 was involved in five other canonical pathways, in addition to the ‘AHR signalling’ 
pathway. Both genes appeared to be involved in metabolic pathways.  The third gene, the 
down-regulated BMS1, was not associated with any of the canonical pathways identified in 
pSS-associated lymphoma.  
Furthermore, DYNLL1, the gene that I found to be significantly differentiated in the 
untreated pSS-associated lymphoma was involved in one canonical pathway named 
‘Phagosome maturation’ with a –log (p-value) of 1.20E+00. While DRAP1 did not show 
any associated with any of the canonical pathways identified in pSS-associated lymphoma.  
The IPA, however, was unable to predict the directionality (i.e. whether the pathways were 
activated or suppressed) of these enriched canonical pathways (the z-score was 0 or near 0 
in all pathways). Figure 5.1 shows the directionality analysis of the top 10 canonical 
pathways.  
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Table 5.3 Top 5 canonical pathways in pSS-associated lymphoma identified by IPA  
Ingenuity Canonical 
Pathways 
-log (p-
value)** 
No. of genes 
in common 
between the 
canonical 
pathway and 
genes of 
interest 
Genes in common between 
the canonical pathway and 
genes of interest 
Aryl Hydrocarbon Receptor 
Signalling 
3.99E+00 5/135 (3.7 %) MYC, ALDH9A1, RBL2, 
HSP90B1, MGST3* 
Histamine Degradation 3.12E+00 2/12 (16.7 %) HNMT, ALDH9A1 
Unfolded Protein Response 3.09E+00 3/53 (5.7 %) HSPA9, HSP90B1, VCP 
Neuregulin Signalling 2.50E+00 3/85 (3.5 %) MYC, HSP90B1, PRKCQ 
T-Cell Receptor Signalling 2.38E+00 3/94 (3.2 %) PRKCQ, ITK, RASGRP1 
 * The gene in bold represents the gene from the three-gene biosignature of pSS-associated 
lymphoma 
** The p values are presented in a –log scale, therefore, the higher the value on –log scale, the 
higher is the statistical significance (i.e. lower p-value). 
 
Table 5.4 The canonical pathways involvement of the three genes in the 3-genes 
biosignature in pSS-associated lymphoma  
Ingenuity Canonical Pathways -log(p-value) Ratio    
68-DEGs-Mi / 
genes in  pathway 
NUDT14 
D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis 1.18E+00 1.64E-02 
D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis 1.18E+00 1.64E-02 
D-myo-inositol-5-phosphate Metabolism 1.08E+00 1.45E-02 
3-phosphoinositide Degradation 1.08E+00 1.44E-02 
3-phosphoinositide Biosynthesis 1.03E+00 1.34E-02 
Super-pathway of Inositol Phosphate Compounds 8.69E-01 1.08E-02 
MGST3 
Aryl Hydrocarbon Receptor Signalling 3.99E+00 3.70E-02 
Xenobiotic Metabolism Signalling 1.93E+00 1.56E-02 
NRF2-mediated Oxidative Stress Response 1.63E+00 1.69E-02 
Glutathione Redox Reactions I 1.22E+00 5.56E-02 
Glutathione-mediated Detoxification 1.10E+00 4.17E-02 
LPS/IL-1 Mediated Inhibition of RXR Function 7.92E-01 9.62E-03 
BMS1 
No significant pathway identified N/A N/A 
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Figure 5.1 Bar chart of the top 10 canonical pathways in pSS-associated lymphoma 
identified by IPA. Grey bars represent that no prediction of directionality can be made. 
White bars represent the canonical pathways with a z-score near 0. The vertical threshold 
line in yellow represents the p-value cutoff of statistical significance. The yellow dots 
represent the ratio of the genes in common between the 68-DEGs-Mi and the total number 
of genes that made up each pathway. 
 
 
5.3.2 The Downstream Effects Analysis of pSS-associated lymphoma: 
Another approach to biological pathway analysis is to study the downstream effects of the 
genes in pSS-associated lymphoma (68-DEGs-Mi) and their connection with known 
biological functions or pathological conditions. For example, gene A may be reported to be 
associated with cancer development or gene B with apoptosis. Such knowledge may 
provide additional insight apart from the biological pathways of the pSS-associated 
lymphoma. In this analysis ‘disease and function’ of the 68-DEGs-Mi were analysed by 
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IPA. The directionality of the prediction was made based on casual effects derived from the 
literature. Three possible predictions can be made according to the direction of change as 
follow: 
1. If the direction of change is the same as reported in the literature then the function 
is considered increased in pSS-associated lymphoma 
2. If the direction of change was opposite to that reported in the literature then the 
function is decreased in pSS-associated lymphoma 
3. If the direction of change does not have a clear relationship with that reported in 
the literature then IPA will not make a prediction. 
Ten “diseases and functions” were identified (Figure 5.2). The ten diseases and functions 
were analyzed using the z-score algorithm, which avoids creating random significant 
predictions in 68-DEGs-Mi (Ingenuitysystems, IPA). Nine of these functions were 
increased and one was decreased. Three of these diseases and functions were biased, which 
suggest that their regulations are skewed to particular direction (Table 5.5).  
Furthermore, 490 other “diseases and functions” were identified by IPA to be associated 
with the genes from the 68-DEGs-Mi list. These “diseases and function” were all 
statistically significant but IPA was unable to make prediction of the directionality of the 
expected relationship according to the z-score (i.e., -2 <  z-score < 2).  
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Figure 5.2 Heatmap of the downstream effects analysis of the pSS-associated lymphoma 68-DEGs-Mi by IPA. The square size 
corresponds to the statistical significance of the p value (i.e., larger square = more significant (lower p-value)). The colours of the squares 
reflect the direction of change (activated or inhibited). Orange: IPA predicts that the biological process or function is increased in pSS-
associated lymphoma with a positive z-score (z-score ≥ 2). Blue: IPA predicts that the biological process or function is decreased in pSS-
associated lymphoma with a negative z-score (z-score ≤ -2) Gray: represent that no prediction can be made with regard to directionality. 
White: represent the z-score is near 0. The strength of the prediction is represented by the intensity of the colour.   
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Table 5.5 The Downstream Effects analysis of pSS-associated lymphoma 68-DEG-Mi by IPA. The ten statistically significant biological 
processes and functions and the genes involved  
Categories Diseases or 
Functions 
Annotation 
p-Value Predicted 
Activation 
State 
Activation 
z-score 
Notes Genes No. of 
genes  
Infectious Diseases,  
Organismal Injury and 
Abnormalities 
infection of 
embryonic cell 
lines 
2.51E-02 Increased 2 bias HNRNPDL,KHDRBS1,PRPF8,SF3A1 4 
Haematological System 
Development and Function, 
Tissue Morphology 
quantity of T 
lymphocytes 
5.52E-04 Increased 2.211  ETS1,HLA-DRB1,HSP90B1,ITK,LGALS1, 
PRKCQ,RASGRP1 
7 
Cellular Function and 
Maintenance 
cellular 
homeostasis 
5.42E-04 Increased 2.228  ATG12,ATP1A1,BAG3,BCL11B,ETS1,HSP90B1, 
ITK,LEF1,LGALS1,MYC,NCSTN,PRKCQ, 
RASGRP1,VCP,WAC 
15 
Cell Death and Survival cell viability 2.04E-03 Increased 2.253 bias ATG12,BAG3,HNRNPUL1,HSP90B1,LEF1, 
LRIG1,MYC,NCSTN,PRKCQ,PRPF8,SF3A1, 
SMARCA2,VCP 
13 
Cell Death and Survival cell survival 1.05E-03 Increased 2.415  ATG12,BAG3,HNRNPUL1,HSP90B1,LEF1,LRIG
, MYC,NCSTN,PRKCQ,PRPF8,RRN3,SF3A1, 
SMARCA2,VCP 
14 
Cellular Movement cell movement 8.82E-03 Increased 2.539  ATG12,BCL11B,CBLL1,ETS1,ITK,KHDRBS1, 
LEF1,LGALS1,LRIG1,MYC,PAF1,PRKCQ,RASG
,RP1,RNF7,SUN2,VCP 
16 
Cell Death and Survival cell viability of 
tumour cell lines 
9.35E-05 Increased 2.557 bias BAG3,HNRNPUL1,HSP90B1,LEF1,LRIG1,MYC,
NCSTN,PRKCQ,PRPF8,SF3A1,SMARCA2,VCP 
12 
Tissue Morphology quantity of cells 1.40E-03 Increased 2.602  DYNLL1,ETS1,HLA-DRB1,HSP90B1,HSPA9, 
ITK,KHDRBS1,LEF1,LGALS1,MYC,NAT10, 
PRKCQ,RASGRP1,RBL2 
14 
Cellular Movement migration of cells 6.32E-03 Increased 2.893  ATG12,BCL11B,CBLL1,ETS1,ITK,KHDRBS1, 
LEF1,LGALS1,MYC,PAF1,PRKCQ,RASGRP1, 
RNF7,SUN2,VCP 
15 
Cell Death and Survival cell death of 
melanoma cell 
lines 
3.96E-04 Decreased -2.166  BAG3,CYFIP2,ETS1,MYC,PAF1,SF3A1 6 
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5.3.3 The Molecular Networks analysis of the 68-DEGs-Mi of pSS-associated 
lymphoma: 
Molecular Networks analysis provide information regarding the visualization of the 
relations of the genes of interest and the directionality of their regulation. Molecular 
networks analysis are related to the downstream effects analysis. In the Molecular Network 
analysis, two terms , ‘Focus Molecules’ and the ‘Score.’ are used in the report deserve 
further explanation. The ‘Focus molecules’ of a network represent the number of the genes 
in the uploaded DEGs list from my experiment that are represented in the network, while 
the ‘Score’ is the total number of genes in the network, including the genes of the 68-
DEGs-Mi and the genes that were added from the indirect interactions predicted by IPA. 
The networks analysis by IPA revealed nine potentially significant molecular networks in 
pSS-associated lymphoma. The top four networks showed the highest Scores (between 21 
and 32) while the other five showed much lower Scores (2). Therefore, only the top four 
networks are discussed in this chapter. 
The top network (Network 1) has a Score of 32 with Focus Molecules of 17. The top 
diseases and functions involved in this network, shown in Figure 5.3, include ‘Cell Death 
and Survival,’ ‘Cell-mediated Immune Response’ and ‘Cellular Development.’ Figure 5.4 
shows the second network (Network 2), involving ‘Cell Cycle,’ ‘DNA Replication,’ 
‘Recombination and Repair’ and ‘Gene Expression,’ and has a Score of 23 and Focus 
Molecules of 13. Network 3 (Figure 5.5) included the diseases and functions of ‘Cell-
mediated Immune Response,’ ‘Cellular Development’ and ‘Cellular Function and 
Maintenance’; this network has a Score and Focus Molecules of 21 and 12 respectively. 
Network 4 has the same Score and Focus Molecules as Network 3. The most important 
diseases and biological functions within the fourth network were ‘Cell Death and Survival,’ 
‘DNA Replication,’ ‘Recombination and Repair’ and ‘Cancer’ (Figure 5.6).  
Interestingly, two of these networks (Networks 2 and 4) included two genes in the three-
gene biosignature in pSS-associated lymphoma (NUDT14 and MGST3). The other two 
networks (Networks 1 and 3) included the two genes that were significantly associated with 
untreated pSS-associated lymphoma (DYNLL1 and DRAP1). The significant gene 
associated with untreated pSS-associated lymphoma, DYNLL1, was included in network 1 
and has an indirect interaction with complexes ERK and Jnk. In network 2, MGST3 was 
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included and was regulated by PPARA in a direct interaction. DRAP1, which was also 
significant in untreated pSS-associated lymphoma, has a direct interaction with myc in 
network 3. Network 4 contains NUDT14, the most consistently differentially expressed 
gene throughout all the cohorts. The interactions in Network 4  are most likely related to 
cancer biology, as it includes TP53, which binds to WT1, which in turn has a direct 
relationship with TCOF1.  TCOF1 has an indirect interaction with NUDT14.      
138 
 
 
Figure 5.3 Network 1 of pSS-associated lymphoma identified by IPA. A total of 17 genes from the pSS-associated lymphoma gene 
expression signature are involved in ‘Cell Death and Survival’ ,‘Cell-mediated Immune Response’ and ‘Cellular Development’. Genes in 
red represent up-regulated genes in pSS-associated lymphoma. Genes in blue represent down-regulated genes in pSS-associated lymphoma. 
Genes in white represent genes in the global network but not included in the putative pSS-associated lymphoma gene-expression signature. 
DYNLL1, which was differentially expressed in untreated pSS-associated lymphoma, was included in this network. 
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Figure 5.4 Network 2 of pSS-associated lymphoma identified by IPA. A total of 13 genes from the pSS-associated lymphoma gene 
expression signature are involved in ‘Cell Cycle’, ‘DNA Replication’, ‘Recombination and Repair’ and ‘Gene Expression’. Genes in red 
represent up-regulated genes in pSS-associated lymphoma. Genes in blue represent down-regulated genes in pSS-associated lymphoma. 
Genes in white represent genes in the global network not included in the putative pSS-associated lymphoma gene-expression signature. 
MGST3, which was differentially expressed in pSS-associated lymphoma (3-gene biosignature), was included in this network. 
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Figure 5.5 Network 3 of pSS-associated lymphoma identified by IPA. A total of 12 genes from the pSS-associated lymphoma gene 
expression signature are involved in ‘Cell-mediated Immune Response’, ‘Cellular Development’ and ‘Cellular Function and Maintenance’. 
Genes in red represent up-regulated genes in pSS-associated lymphoma. Genes in blue represents the down-regulated genes in pSS-
associated lymphoma. Genes in white represent genes in the global network not included in the pSS-associated lymphoma gene-expression 
signature. DRAP1, which was differentially expressed in untreated pSS-associated lymphoma, was included in this network. 
141 
 
 
Figure 5.6 Network 4 of pSS-associated lymphoma identified by IPA. A total of 12 genes from the pSS-associated lymphoma gene 
expression signature are involved in ‘Cell Death and Survival’, ‘DNA Replication’, ‘Recombination and Repair’, and ‘Cancer’. Genes in 
red represent up-regulated genes in pSS-associated lymphoma. Genes in blue represent down-regulated genes in pSS-associated lymphoma. 
Genes in white represent genes in the global network not included in the putative pSS-associated lymphoma gene-expression signature.  
NUDT14, which was differentially expressed in pSS-associated lymphoma (3-gene biosignature), is included in this network. 
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5.3.4 The Upstream Regulators Analysis of pSS-associated lymphoma:   
The Upstream Regulator Analysis by IPA allows researchers to identify the cascade of the 
upstream transcriptional factors that control the genes of interest. The interactions between 
certain genes and the upstream regulators may explain changes in the expression of these 
genes and the effects of these changes on a certain biological function. As in other analyses 
in IPA, it also predicts whether the regulators that are involved in genes of interest are 
activated or inhibited by calculating the z-score.  
Applying Upstream Regulator Analysis to my dataset (68-DEGs-Mi), I have identified 219 
regulators that were significantly linked to pSS-associated lymphoma (p < 0.05, Fisher’s 
Exact test). Focusing on my 3-gene biosignature of pSS-associated lymphoma, IPA 
predicted upstream regulators for NUDT14 and MGST3 but not BMS1. One regulator 
(TCOF1) was predicted to regulate NUDT14. Two regulators (NFE2L2 and PPARA) were 
predicted to be involved in the regulation of MGST3.  
Furthermore, I searched for upstream regulators that regulate the differentially expressed 
genes in untreated lymphoma. Five regulators (NFE2L2, PPARA, SLC6A2, BARX2 and 
SLC18A2) were predicted to regulate DYNLL1. However, SLC6A2, BARX2 and SLC18A2 
seem to be less important regulators as they only regulate one gene (DYNLL1). No 
upstream regulators were predicted for DRAP1. These six regulators identified included 
transcription regulators, transporters and ligand-dependent nuclear receptors (Table 5.6). 
Despite the statistically significant association, IPA was unable to make prediction to 
whether these regulators were activated or inhibited in pSS-associated lymphoma as the 
calculated absolute z-scores were not significant. 
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Table 5.6 The upstream regulators of pSS-associated lymphoma identified by IPA. Six 
regulators were predicted to be involved in the regulation of the genes in the 3-genes 
biosignature and the differentially expressed genes in untreated pSS-associated lymphoma. 
Z-score is not significant for all the upstream regulators. 
Upstream 
Regulator 
Molecule Type p-value  Target molecules  
NFE2L2 Transcription regulator 5.66E-04 ATP1A1, DYNLL1, HSP90B1, 
MGST3, PSMC1, VCP 
PPARA Ligand-dependent nuclear 
receptor 
2.52E-02 DYNLL1, MGST3, MYC, 
RBP7 
TCOF1 Transporter 2.36E-02 HNRNPDL, NUDT14 
BARX2 Transcription regulator 2.72E-02 DYNLL1 
SLC18A2 Transporter 3.06E-02 DYNLL1 
SLC6A2 Transporter 1.71E-02 DYNLL1 
 
5.4 Discussion:   
In this chapter I have focused on the biological processes/pathways that might be associated 
with pSS-associated lymphoma. The identified biological pathways will provide additional 
insight in particularly to understand the interactions of the genetic factors that are important 
in the pathogenesis of lymphoma in pSS.  
The Canonical pathways in pSS-associated lymphoma 
I applied different analytic methods provided by IPA to my dataset (68-DEGs-Mi). The 
first analysis in the IPA core analysis is the ‘Canonical Pathway Analysis’. The ‘Canonical 
Pathway Analysis’ identified a total of 188 pathways, most of these were related to cancer 
biology. It is important to keep on mind that many of these pathways were generated using 
cancer as research model, and therefore may introduce potential bias. The canonical 
pathway with the lowest p-value was the ‘AHR signalling’ pathway. Despite the highly 
significant p-value, no prediction of the direction of change (i.e., activation or inhibition) 
for the pathway could be made. One possible explanation is that the small number of genes 
in 68-DEGs-Mi may make it difficult to link the genes of interest with the pathway 
information in the Ingenuity Knowledge Base (IKB). AHR is a ligand-activation 
transcriptional factor in the Pern-Arnt-Sim (PAS) family (Burbach et al., 1992). This 
receptor is also considered to be a xenobiotic receptor. Originally, the role of AHR was 
believed to be limited to xenobiotic metabolism, until it was discovered that AHR has the 
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ability to mediate toxic responses. For this reason, AHR was heavily investigated in 
toxicology studies (Barouki et al., 2007). The link between AHR and immune responses 
and other endogenous functions was only recently discovered. For instance, AHR has a role 
in regulating cell shape, cell adhesion and cell migration (Carvajal-Gonzalez et al., 2009, 
Ikuta and Kawajiri, 2006). In addition, Aryl Hydrocarbon Receptor nuclear translocators 
(ARNT) are crucial for haematopoietic stem cell (HSC) viability. Furthermore, it has been 
found that the HSCs with ARNT deficiency experienced programmed death process 
(apoptosis) (Krock et al., 2015). Many studies have also been conducted to investigate the 
role of AHR in different types of lymphoma and cancer. Ding and co-workers recently 
reported that the AHR/ARNT complex regulates MEF2B, a transcription factor that 
regulates the expression of B-cell lymphoma 6 (BCL6). The regulation of BCL6 by both 
AHR/ARNT and MEF2B leads to the expression of the germinal centre markers in diffused 
B-cell lymphomas (Ding et al., 2015). Furthermore, AHR has been suggested to play a role 
in other malignancies such as pleomorphic adenoma, which is a benign mixed tumour of 
the parotid gland (Drozdzik et al., 2015).  
On the other hand, the linkage between the environmental and endogenous ligand by AHR 
can be harnessed as an adjunct to the treatment of cancers. For example, activation of AHR 
in the presence of chemo-preventive agents (Chrysin) in cancer cell lines, leads to the 
induction of Chrysin-induced apoptosis. This induction of apoptosis is due to the activation 
of TNF-α and TNF-β, which is dependent on AHR serving as a ligand to Chrysin 
(Ronnekleiv-Kelly et al., 2015). In another study, the presence of TNF-α plays a role in 
modulating the AHR function as an activator of apoptosis. These modulation effects were 
investigated by using 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), which acts as a ligand 
to AHR. In the presence of TNF-α and TCDD, lymphocyte apoptosis is reduced 
(Ghatrehsamani et al., 2015). Thus, it is noteworthy that TNF-α is over-expressed in pSS 
(Kang et al., 2011), which might suggest similar mechanisms lead to the development of 
lymphoma in pSS by reducing lymphocyte apoptosis.   
Emerging data indicate that AHR acts as a co-factor in autoimmune disease development. 
Veldhoen et al. (2008) have shown that AHR activation through a high-affinity ligand leads 
to the development of TH17 cells. Notably, this activation must occur during the 
development of this cell subset. Eventually, the increased percentage of TH17 cells leads to 
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an increase in TH17 cytokines, which include IL-22 (Veldhoen et al., 2008). Moreover, 
AHR also regulates the function of regulatory T cells (Treg), an important mechanism of 
self-tolerance (Quintana et al., 2008). It is known that IL-17 and IL-22 are elevated in pSS 
(Miletić et al., 2012, Lavoie et al., 2011). Therefore, it is plausible that similar mechanisms 
might be involved in the pathology of pSS and pSS-associated lymphoma. The role of AHR 
and the linkage between environmental and endogenous ligands is illustrated in Figure 5.7. 
 
Figure 5.7 The Aryl Hydrocarbon Receptor (AHR) integrates responses from 
environmental and endogenous ligands to mount appropriate immune responses at 
barrier organs (Cella and Colonna, 2015) 
 
It is of interest that one of the genes included within the AHR pathway is MGST3, one of 
the genes in the 3-gene biosignature in pSS-associated lymphoma. The genes connected to 
AHR pathways are summarized below:  
MGST3: Since AHR is involved in response to xenobiotics such as chemicals and drugs, 
many researchers have studied the role of AHR in drug metabolism. The microsomal GST3 
(MGST3) gene is known for its involvement in metabolic reactions. Given the close 
connection between the AHR pathway and the role of MGST3, it is not surprising that 
studies have confirmed the correlation (upregulation/activation) of MGST3 and AHR in 
drug metabolism in mice. Similar studies involving the gene ALDH9A1, which controls the 
metabolism of aldehydes, have demonstrated their correlation to AHR in drug metabolism 
in the liver of mice. Furthermore, MGST3 was reported to correlate with transcriptional 
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factors such as NFE2L2 and PPARA (Aleksunes and Klaassen, 2012, Fu and Klaassen, 
2014). Interestingly, the same transcriptional factors (NFE2L2 and PPARA) were 
discovered to regulate MGST3 in my dataset.   
MYC: Yang and colleagues in 2005 demonstrated that the activation of AHR in Hs578T 
cancer cells could inhibit the expression of the oncogene MYC. Down-regulation of MYC in 
our Discovery cohort microarray was consistent with this observation. Furthermore, AHR-
mediated regulation could affect apoptosis (increase or decrease) depending on the cell line 
used (Yang et al., 2005).   
HSP90: It is known that there is a link between AHR and heat shock proteins (HSP). Thus, 
HSP90 associates with AHR, leading to the activation of the receptor in response to 
xenobiotics (Tsuji et al., 2014).   
RBL2: It has been shown that the expression of AHR is associated with the retinoblastoma-
like 2 (RBL2) gene (also known as Rb2 and p130), and such association affected the AHR-
mediated cell cycle in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in 5L 
hepatoma cells (Ge and Elferink, 1998). Overexpression of the rbl2 gene acted as a tumour 
suppressor in nude mice. It has been suggested that RBL2 modulates angiogenetic balance, 
which is essential for tumour formation (Claudio et al., 2001). Consistently, RBL2 was 
down-regulated in my dataset.  
To summarise, ‘AHR signalling’ may play an important role in pSS pathogenesis and may 
provide a link between environmental factors and the progression of pSS (Inoue et al., 
2012). AHR signalling also has an important role in tumourigenesis, anti-cancer therapies, 
as well as pSS pathology. Further studies should be conducted to investigate the role of this 
pathway in pSS-associated lymphoma.  
The Histamine Degradation pathway is another canonical pathway in pSS-associated 
lymphoma. Moreover, histamine, in particular H4 histamine receptor (H4R), is important in 
the pathology of pSS. Studies have shown that dendritic cells and T-cells synthesize 
histamine (Oda et al., 2000). The role of H4R is important to sustain the health of the 
tubuloacinar epithelium (Stegaev et al., 2012). Furthermore, H4R activation inhibits TNF-
α/IMD-0354-induced apoptosis in salivary gland cells in pSS (Stegajev et al., 2014).  
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In my dataset, histamine N-methyltransferase (HNMT) was one of the genes that was 
involved in the histamine degradation pathway and was present in both the 68-DEGs-Mi 
and 26-DEGs-MiPCR signatures. Due to the fact that limited RNA samples were available, 
the expression of the HNMT gene was not tested during biological validation. HNMT has 
been linked to many malignancies. For example, HNMT has been identified as a key gene 
that predicted the prognosis of paediatric acute lymphoblastic leukaemia (ALL) (Gao et al., 
2015). Another study also reported that the HNMT gene was expressed in the bone marrow 
of breast cancer patients (Del Valle et al., 2014). Histamine degradation is also linked to the 
expression of ALDH9A1. Of note, ALDH9A1 gene was also differentially expressed in the 
microarray dataset in the Discovery cohort. Thus, the role of the ‘Histamine degradation 
pathway’ in pSS-associated lymphoma also warrants more investigation. 
Another canonical pathway associated with pSS-associated lymphoma is the ‘Unfolded 
protein response (UPR)’. This pathway is responsible for endoplasmic reticulum (ER) 
homeostasis. The key role of the ER is the organization of the biosynthesis and the 
secretion of proteins. The UPR consists of three ‘sensors’: first, the inositol-requiring 
transmembrane kinase/endoribonuclease 1 (IRE1), second, the double-stranded RNA 
(PKR)–activated protein kinase-like eukaryotic initiation factor 2α kinase (PERK), and 
third, the activating transcription factor-6 (ATF6). Figure 5.8 illustrates the relationships 
between the UPR pathway and infectious inflammatory diseases and cancer.  
The genes from my dataset that overlapped with genes that make up the UPR pathway were 
two heat-shock proteins (HSPA9, HSP90B1) and valosin-containing protein (VCP). Both 
heat shock protein genes were down-regulated in pSS-associated lymphoma. Data have 
shown that inhibition of the heat shock protein HSP90 will activate UPR in a myeloma cell 
line (Davenport et al., 2007). Furthermore, HSP90B1 inhibition has a role in the 
chaperoning of integrin and Toll-like receptor (TLR) in B cells, which is important in 
cancer and lymphoma pathogenesis (Liu and Li, 2008). VCP is associated with both heat 
shock protein and the activation of UPR (Abisambra et al., 2013). VCP has also been linked 
to the development of malignancies such as hepatocellular carcinoma (HCC) and has been 
considered a potential therapeutic target (Yi et al., 2012). 
 
148 
 
 
Figure 5.8 The Unfolded Protein Receptor (UPR) signalling in diseases. The three arms 
of the UPR pathway are IRE1α-XBP1s, PERK-eIF2α phosphorylation-ATF4 and ATF6, 
which are all important for tumour cell survival and growth under hypoxic conditions. 
IRE1α and PERK can trigger c-JUN N-terminal kinase (JNK) and NFκB to stimulate 
inflammation and apoptosis that can contribute to inflammation in the pancreatic β-cell 
death and obesity in diabetes. In addition, CHOP production in the PERK pathway 
exacerbates oxidative stress in diabetes and atherosclerosis, aggravating these diseases 
(Wang and Kaufman, 2012). 
 
The fourth pSS lymphoma-associated pathway is ‘Neuregulin Signalling.’ This pathway 
has been implicated in psychiatric disorders such as schizophrenia (Buonanno, 2010, 
Hatzimanolis et al., 2013). The neuregulins (NRGs) are members of the growth factor 
family, which has multiple functions regarding important organs such as the heart and the 
nervous system. It has also been linked to diseases such as cancer.  For instance, 
overexpression of NRG was found in many ovarian carcinoma cell lines (Gilmour et al., 
2002). The neuregulin family consists of four members: NRG1, NRG2, NRG3 and NRG4. 
NRG binds to the receptor tyrosine kinases (the human epidermal growth factor receptor 
HER) ErbB3 or ErbB4, leading to the formation of homo or heterodimer ErbB2, which is 
also known as HER2. Previous studies have demonstrated that NRG4 and HER4 are 
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predominantly expressed in MALT lymphoma clinical samples from patients with 
gastrointestinal lymphoma. The recombinant NRG4 stimulates HER4 tyrosine 
phosphorylation leading to proliferation in a lymphoma cell line (Ebi et al., 2011). 
Stimulation of heat-shock protein 70 inhibits the NRG1-induced demyelination through 
increased proteasomal degradation of c-Jun (Li et al., 2012). These biological mechanisms 
might provide an explanation to the association of ‘Neuregulin Signalling’ pathway in pSS-
associated lymphoma, as the heat-shock protein gene (HSP90B1) was down-regulated in 
the lymphoma group in my dataset. Investigating the role of NGRs and HER in pSS-
associated lymphoma may provide a better understanding of the pathogenesis of lymphoma 
in pSS.       
The fifth canonical pathway associated with pSS-lymphoma is the ‘T-cell receptor 
signalling’ pathway. T-cell receptor signalling, which involves many steps including the 
activation of NF-κB, has an important role in the development of lymphoma in 
haemophagocytosis (An et al., 2011).     
While the Canonical Pathway analysis has demonstrated that these pathways were enriched 
in pSS-associated lymphoma, IPA could not make a prediction of whether these canonical 
pathways were activated or inhibited in pSS-associated lymphoma. There are several 
reasons why no prediction on the directionality of these canonical pathways in pSS-
associated lymphoma could be made. First, there was insufficient information in the 
literature and/or the IPA knowledge base. Second, there were only 68 differentially 
expressed genes included in the analysis. Interestingly, among the three genes in the three-
gene biosignature in pSS-associated lymphoma, BMS1 does not appear to be associated 
with any of the 188 lymphoma-associated canonical pathways. In contrast, both NUDT14 
and MGST3 were associated with six different canonical pathways. The canonical pathways 
that were associated with NUDT14 were all metabolic pathways. Similarly, MGST3 is 
involved in metabolic pathways as well as the xenobiotic pathway (AHR signalling 
pathway).  
The Downstream Effects and Networks analysis in pSS-associated lymphoma 
With regard to the top ‘diseases and biological function’ that might be implicated in pSS-
associated lymphoma, IPA predicted that most of these functions were related to cell 
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function, cell viability, cell survival and cell movement. These functions are known to be 
associated with different types of malignancies and with lymphoma, in particularly, non-
Hodgkin lymphoma (Pon et al., 2015).  
The network analysis illustrated the involvement of the DEGs in pSS-associated lymphoma 
and their interactions through nine networks. Knowledge of such gene-gene interactions 
provides information of how my genes of interest may interact with each other and with 
other genes from the global molecular network at the molecular level. These data may 
improve the understanding of the pathogenesis of pSS-associated lymphoma. 
The Upstream Regulators analysis in pSS-associated lymphoma 
The Upstream Regulator analysis identified upstream regulators for the 2 genes of the 3-
gene biosignature of pSS-associated lymphoma and 1 gene of the significant genes in the 
untreated pSS-associated lymphoma (See Table 5.6). Nuclear factor (erythroid-derived 2)-
like 2 (NFE2L2) is known for its role in the regulation of the genes with antioxidant 
function MGST3. Both NFE2L2 and MGST3 were functioning within the same pathway in 
weakening the lung function in smokers. More interestingly, both genes were involved in 
the ‘AHR signalling’ pathway (Curjuric et al., 2012), reinforcing the association between 
pSS-associated lymphoma development and AHR signalling.  
Another upstream regulator of interest is peroxisome proliferator-activated receptor alpha 
(PPARA). PPARA regulates MGST3 and DYNLL1 and is a vital upstream regulator of genes 
that involve in cell metabolism (Blavy et al., 2014).   
The third identified upstream regulator is Treacher Collins-Franceschetti syndrome 1 
(TCOF1), which regulates NUDT14, involved in nucleotide sugar catabolism (Yagi et al., 
2003). TCOF1 encodes a protein called ‘treacle’ which is important for ribosomal RNA 
(rRNA) transcription. The gene was investigated in mouse Neuroblastoma cell line N1E-
115 in order to identify its role in the regulation of proliferation and differentiation of cells. 
In this study, genes with changes in expression level that were concordant with the TCOF1 
expression level were involved in promoting cell proliferation, whereas genes with changes 
in expression level discordant with TCOF1 were either involved in proliferation repression 
or cell-death stimulation. Interestingly, NUDT14 was one of the genes that correlated 
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negatively with TCOF1 (Mogass et al., 2004). Consistent with my dataset, NUDT14 is 
thought to have an indirect interaction with TCOF1.  
The upstream regulator analysis in pSS-associated lymphoma revealed the importance of 
metabolic genes in the development of lymphoma.  Regarding the upstream regulators 
analysis of the genes (DYNLL1) that were implicated in untreated pSS-associated 
lymphoma, BARX homobox 2 (BARX2) is a transcriptional factor that controls several 
genes through its homeodomain binding sites. A homeodomain is a 60 amino acid helix-
turn-helix DNA-binding domain. The DNA sequence that encodes the homeodomain is 
called the ‘homeobox’ and homeobox-containing genes are known as ‘hox genes’. BARX2 
abnormality has been linked to ovarian cancer cells through its role as a suppressor of cell 
adhesion, migration and invasion of these cells (Sellar et al., 2001). Another study has 
reported that inhibition of BARX2 affects the cell growth of a human breast cancer cell line 
(MCF7 breast cancer cell line) (Stevens et al., 2004).  
It would be of interest to investigate whether BARX2 may also affect pSS-associated 
lymphoma cell growth via its regulation of DYNLL1. The solute carrier family 18 (vesicular 
monoamine transporter), member 2 (SLC18A2) and the solute carrier family 6 
(neurotransmitter transporter) member 2 (SLC6A2) are upstream regulators of DYNLL1. 
SLC18A2 acts as a vesicular monoamine transporter; abnormalities in this gene have been 
associated with neuropsychiatric disorders through its role in regulating monoamine 
neurotransmitters. The only type of cancer that has been reported in the literature linked to 
SLC18A2 is prostate cancer. Thus, DNA hyper-methylation that causes silencing of 
SLC18A2 in prostate cancer, make this gene a novel predictor to the response to treatment 
(Sorensen et al., 2009). SLC6A2 is a norepinephrine transporter (NET). Studies have 
demonstrated that polymorphism of this gene contributes to Major Depression (MD) 
susceptibility (Wang et al., 2015). These associations might be of interest as depression and 
fatigue are common in pSS.  
In conclusion, the identification of the canonical pathways provides an improved 
understanding of the possible mechanisms that might be involved in pSS-associated 
lymphoma. Additionally, network analysis and upstream regulators analyses revealed 
molecules that interact with or regulate the genes of interest in pSS-associated lymphoma. 
As it is likely that many biological processes and mechanisms are involved in lymphoma 
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development in pSS, IPA has provided me with clues for further investigations into such 
mechanisms. 
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Chapter 6 
Gene expression profiling and pathway analysis of different pSS 
subgroups in the Discovery cohort 
6.1 Introduction 
The association between pSS and cancers, especially haematological tumours, is widely 
acknowledged. However, the associations with other types of cancer have also been 
reported, but without conclusive overall evidence. A meta-analysis of 14 cohort studies 
consisting of a total of over 14,523 patients reported a significant increase in the 
malignancy development including all forms of cancer. The authors also recommended the 
conduction of more studies to examine the role of NHL in increasing the risk of overall 
malignancy (Liang et al., 2014). The determination of the risk factors for other types of 
tumour in pSS has been poorly understood. However, in Sweden it has been reported that 
10 excess tumour cases were found in pSS patients in addition to the NHL cases (Theander 
et al., 2006). Lazarus and colleagues reported an increased risk of developing more than 
one type of cancer in pSS (Lazarus et al., 2006). One example is the lung adenocarcinoma 
association with pSS as pulmonary involvement is a known pSS systemic manifestation 
(Takabatake et al., 1999). Another example was a case report suggested hepatocellular 
carcinoma as a possible outcome of pSS (Yan et al., 2013). Breast cancer is another type of 
non-haematological tumours that might be linked to pSS, as evidence has suggested that 
systemic inflammation might affect neoplasia of the breast epithelia, especially in elderly 
women (Gadalla et al., 2009). The prevalence of different types of cancers other than 
lymphoma was also recorded in the UKPSSR cohort.  
Paraproteinemia or monoclonal gammopathy (MG) is a recognised extra-glandular 
manifestation of pSS. Paraproteinemia is defined as the presence of monoclonal 
immunoglobulins in the blood or immunoglobulin light chains (Bence Jones protein) in the 
urine. Paraproteinemia can be detected in two clinical conditions: monoclonal gammopathy 
of undetermined significance (MGUS), and multiple myeloma. Additionally, 
paraproteinemia is associated with many other disorders, including lymphoproliferative 
disorders such as chronic lymphocytic leukemia (CLL) and lymphoplasmacytic 
lymphoma/Waldenstrom macroglobulinaemia (LPL/WM) (reviewed in (Cook and 
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Macdonald, 2007). The association between paraproteinemia and autoimmune diseases has 
also been documented . Moreover, paraproteinemia indicates an increased risk of malignant 
progression in patients with these autoimmune disorders (Kelly et al., 1991). In pSS, the 
presence of MG was reported to be associated with a high risk for the development of 
multiple myeloma (MM), more so than for lymphoma development (Tomi et al., 2015). 
However, the presence of IgM and IgG paraproteinemia was observed in patients with low-
grade B-cell lymphoma (Iwatani et al., 2014). Recently, lymphoplasmacytic lymphoma, 
defined as a type of B-cell non-Hodgkin’s lymphoma, was linked to the presence of IgA 
paraproteinemia. More studies were needed to define more accurately the lymphoma type 
in this study (Guan et al., 2015). MG was correlated with high systemic disease activity in 
pSS (as measured using ESSDAI), which was in turn associated with a higher risk of death 
in those patients (Brito-Zeron et al., 2014). The UKPSSR database includes information on 
whether paraproteinemia was present in the pSS patients.  
Although identifying a gene expression signature in pSS-associated lymphoma is my main 
goal, given the documented association between paraproteinemia and the development of 
haematological malignancies, comparing the gene expression profiles of pSS patients with 
lymphoma and those with paraproteinemia is worthwhile. Similarly, comparing and 
contrasting the gene expression profiles of pSS-associated lymphoma and pSS patients with 
other cancers is also of interest. Because of the limited availability of biobanked RNA, I 
will focus my analysis on the DEGs from the microarray data and biological pathway 
analysis (using IPA).    
6.2 Aim and experimental design 
The aim of this chapter is to generate more evidence demonstrating that the whole blood 
gene expression signature of pSS-associated lymphoma that I identified in the Discovery 
cohort was “specific.” For this reason, nine different comparisons were made. The first two 
comparisons were made between pSS-associated lymphoma and pSS-other cancers and 
pSS-associated lymphoma and pSS-paraproteinemia. Additionally, the pSS-other cancers, 
pSS-paraproteinemia and pSS (without lymphoma) groups were compared with each other. 
These additional comparative analyses provide assurance that the identified signature is 
specific to pSS-associated lymphoma. The final four comparisons examined pSS,  pSS-
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associated lymphoma, pSS-other cancers and pSS-paraproteinemia versus healthy controls. 
To sum up, the new comparisons I have performed are as follows: 
1. pSS-associated lymphoma vs pSS-other cancers 
2. pSS-associated lymphoma vs pSS-paraproteinemia 
3. pSS vs pSS-other cancers 
4. pSS vs pSS-paraproteinemia 
5. pSS-other cancers vs pSS-paraproteinemia 
6. pSS vs HC 
7. pSS-associated lymphoma vs HC  
8. pSS-other cancers vs HC 
9. pSS-paraproteinemia vs HC 
As mentioned in Chapter 4, in the Discovery cohort, 144 globin mRNA-depleted samples 
were used, and the samples were categorized into five groups: pSS-associated lymphoma 
(n=16); pSS (n=61); pSS-paraproteinemia (n=23); pSS-other cancers (n=21) and healthy 
controls (n=23). Data from the whole genome gene expression microarray were analysed to 
generate lists of differentially expressed genes (DEGs) between groups (Analysis A) as 
described in Chapter 4. Each list of DEGs was then uploaded onto the IPA platform for 
pathway analysis, as described in Chapter 5.  
Patient demography can be found in Chapter 4, Table 4.1. The pSS-other cancer group 
includes a variety of different cancers, such as breast cancer, bowel cancer, cervical cancer, 
thyroid papillary carcinoma, benign meningioma, endometrial cancer, uterine cancer and 
renal cancer. 
6.3 Results 
6.3.1 RNA quality and RIN score 
The RNA quality of the samples has been described in detail in Section 4.4.2. 
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6.3.2 Whole genome gene expression Bead Chip of pSS subgroups 
1. Microarray data analysis 
The microarray data analysis was performed using R Packages, as previously described in 
chapter 4, section 4.4.3. All samples with RIN < 7 were excluded from the analysis for all 
the pSS subgroups. An exception was made for the pSS-associated lymphoma, where two 
samples with RIN < 7 were included. In addition, the technical outliers were removed. The 
data were transformed and normalised using the RSN method. Finally, the quality control 
was performed tested. Finally the DEGs were generated using a p-value cut-off of p < 0.05 
or the fold change cut-off of 1.2.  
2. Batch effects on the microarray data 
The ComBat function was applied to remove the batch effects from the microarray data, as 
described in Chapter 4 (Figures 4.5 and 4.6). 
3. Differentially expressed genes from the microarray data analysis 
The analyses to generate the list of differentially expressed genes (DEGs) for each of the 
nine comparisons. Not all the comparisons have generated a DEGs list, as the differences in 
gene expression levels between the comparison groups did not reach either the adjusted p-
value cut-off of p < 0.05 or the fold change cut-off of 1.2. The summary of the DEGs 
analysis is as follows: 
1. pSS vs HC                                                                           Generation of a DEGs list  
2. pSS vs pSS-other cancers                                                    No DEGs  
3. pSS vs pSS-paraproteinemia                                               No DEGs 
4. pSS-associated lymphoma vs HC                                       Generation of a DEGs list 
5. pSS-associated lymphoma vs pSS-other cancers                Only one DEG (RNA28S5) 
6. pSS-associated lymphoma vs pSS-paraproteinemia           No DEGs 
7. pSS-other cancers vs HC                                                     Generation of a DEGs list 
8. pSS-other cancers vs pSS-paraproteinemia                         No DEGs 
9. pSS-paraproteinemia vs HC                                                Generation of a DEGs list 
DEGs were identified only in the comparisons between pSS subgroups and healthy controls 
and the number of DEGs identified varied for each comparison. A total of 278 DEGs were 
identified in the comparison between pSS and healthy controls (221 upregulated genes, 57 
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downregulated genes). For pSS-paraproteinemia versus healthy controls, a list of 178 DEGs 
(148 upregulated genes, 30 downregulated genes) was generated, while pSS-other cancers 
versus healthy controls generated a list of 123 DEGs (113 upregulated genes, 10 
downregulated genes). The comparison of pSS-associated lymphoma against healthy 
controls generates the highest number of DEGs, with 557 (301 upregulated genes, 256 
downregulated genes). The comparison of pSS-other cancers and pSS-associated 
lymphoma identified only one DEG (RNA28S5). It is noticeable that the interferon-
inducible genes dominated the DEGs lists in these comparisons. The top 10 up- and down-
regulated genes in each comparison group are listed in Table 6.1. The DEGs from the four 
comparison groups are visualized using volcano plots in Figure 6.1. The complete DEGs 
lists (NAs excluded) for the four comparisons can be found in the supplementary tables S6, 
S7, S8 and S9. 
Focusing on comparing the 68-DEGs-Mi signature identified in the Discovery cohort to the 
DEGs list from the comparison of pSS-associated lymphoma versus healthy control, there 
were some DEGs that were in common between the two lists. Firstly, 54 (79.4%) of the 68-
DEGs-Mi signature were in common with the DEGs in the comparison of pSS-associated 
lymphoma versus healthy controls. Thus, 14 DEGs (20.6%) were specific for the 
comparison between pSS and pSS-associated lymphoma. The three genes of the 3-gene 
biosignature in pSS-associated lymphoma (NUDT14, MGST3 and BMS1) were found 
within the 54 DEGs that are in common. The rest of the 503 genes were differentially 
expressed only in pSS-associated lymphoma versus healthy controls. Furthermore, 
comparing the 26-DEGs-MiPCR signature identified in the Discovery cohort to the DEGs 
list from the comparison of pSS-associated lymphoma versus healthy controls, 20 DEGs 
(76.9%) were in common, with 6 DEGs (23.1%) unique to the 26-DEGs-MiPCR signature 
and 537 DEGs differentially expressed only in pSS-associated lymphoma versus healthy 
controls.  
Focusing on comparing the 68-DEGs-Mi signature identified in the Discovery cohort to the 
DEGs lists from the other comparisons of pSS subgroups versus healthy control. First, two 
genes, DRAP1 and SMARCA2, were in common with the 68-DEGs-Mi signature, in the 
differentially expressed genes of pSS-other cancers group versus healthy controls. Second, 
three DEGs (DRAP1, SMARCA2, BCL11B) were in common with the 68-DEGs-Mi 
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signature in the comparison between pSS-paraproteinemia and healthy controls. DRAP1 
was included in the 26-DEGs-MiPCR but DRAP1, SMARCA2 and BCL11B were not 
validated in the Validation cohort; DRAP1 was however differentially expressed in the 
untreated pSS-associated lymphoma group. Third, only DRAP1 was in common between 
the 68-DEGs-Mi signature and pSS versus healthy controls. There were no DEGs in 
common between the 3-gene biosignature and the DEGs lists for different pSS subgroups 
and healthy controls. Overall, these comparisons showed that DRAP1 was differentially 
expressed in all pSS subgroups as well as in pSS patients with untreated lymphoma. 
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Table 6.1 Top 10 up and down regulated DEGs in microarray analysis among different pSS subgroups versus healthy controls. A. 
Upregulated genes. B. Downregulated genes.  
pSS 
 
pSS-paraproteinemia 
 
pSS-other cancers 
 
pSS-associated lymphoma 
 
Gene 
symbol 
Adjusted 
P value 
Fold 
change 
Gene 
symbol 
Adjusted 
P value 
Fold 
change 
Gene 
symbol 
Adjusted 
P value 
Fold 
change 
Gene 
symbol 
Adjusted 
P value 
Fold 
change 
IFI27 6.12E-07 11.51 IFI27 0.00078165 9.26 IFI44L 8.9011E-05 7.13 IFI27 1.5037E-05 16.86 
IFI44L 9.852E-11 8.75 IFI44L 1.58534E-06 7.62 IFI27 0.03815265 6.60 IFI44L 7.4968E-09 12.44 
ISG15 2.151E-10 5.63 IFIT1 1.58534E-06 5.09 IFIT1 8.9011E-05 4.90 IFIT1 7.4968E-09 7.66 
IFIT1 9.852E-11 5.60 ISG15 4.80787E-06 4.88 ISG15 8.9011E-05 4.79 RSAD2 9.0914E-09 7.33 
RSAD2 1.618E-10 5.39 RSAD2 4.80787E-06 4.61 RSAD2 0.000102181 4.43 ISG15 2.5047E-08 7.23 
IFI44 1E-09 5.23 IFI44 6.83017E-05 4.05 IFIT3 5.16374E-05 4.00 IFI44 1.0884E-07 6.51 
OAS3 8.28E-10 4.35 IFIT3 1.58534E-06 3.82 IFI44 0.00085592 3.95 LY6E 1.2523E-07 5.43 
EPSTI1 9.852E-11 4.29 IFITM3 1.80416E-05 3.79 OAS3 0.000166919 3.77 EPSTI1 7.4968E-09 5.39 
IFIT3 9.852E-11 4.28 OAS3 1.50298E-05 3.76 EPSTI1 8.9011E-05 3.62 IFIT3 7.4968E-09 5.34 
IFITM3 6.055E-09 4.09 HERC5 4.44311E-06 3.66 LY6E 0.000653176 3.56 OAS3 1.2032E-07 5.19 
  
pSS 
 
pSS-paraproteinemia 
 
pSS-other cancers 
 
pSS-associated lymphoma 
 
Gene symbol Adjusted 
P value 
Fold 
change 
Gene 
symbol 
Adjusted 
P value 
Fold 
change 
Gene 
symbol 
Adjusted 
P value 
Fold 
change 
Gene 
symbol 
Adjusted 
P value 
Fold 
change 
HLA-DRB4 0.02191445 2.24 NELL2 0.0016615 1.51 NELL2 0.01363656 1.49 HLA-DRB1 0.01957886 4.75 
MYOM2 0.00632069 1.84 TXNDC12 0.04806856 1.45 ANXA7 0.00506038 1.25 MYH9 0.00154487 1.59 
TXNDC12 0.00356056 1.46 BCL11B 0.03711457 1.32 ESYT2 0.04281725 1.25 SPOCK2 0.00077385 1.55 
IMPA2 0.00518347 1.39 EIF3L 0.00087021 1.31 SMARCA2 0.04281725 1.24 SGK223 0.00041848 1.55 
GPR162 0.02652862 1.37 EIF4B 0.00364144 1.27 MID2 8.9011E-05 1.24 LEF1 0.00844086 1.52 
PYGL 0.03946276 1.35 TBC1D14 0.02947428 1.27 USP9X 0.00895127 1.24 TXNDC12 0.01253812 1.52 
FAM212B 0.00969497 1.32 EEF2 0.01107357 1.27 HNRNPA0 0.048907 1.22 NELL2 0.00229604 1.51 
PPM1F 0.0006649 1.31 SERTAD2 0.03359516 1.26 NR3C2 0.00206934 1.21 ABLIM1 0.00995283 1.49 
RPL3 0.00202947 1.30 FEZ1 0.03100429 1.26 DSC1 0.03419917 1.20 BCL11B 0.00050068 1.48 
MIR181A2HG 0.03875588 1.29 ALDOC 0.02060631 1.26  PIK3IP1 0.00202645 1.48 
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Figure 6.1 Volcano plots of the differentially expressed genes in the four pSS subgroups. A. pSS vs HC. B. pSS-paraproteinemia vs HC.  
C. pSS-other cancers vs HC. D. pSS-associated lymphoma vs HC. The x-axes represent log2 of the fold change and the y-axes represent the 
–log10 of the adjusted p value. The red dots represent the differentially expressed genes and the red lines indicate the cut-offs for the 
adjusted p value and fold change. 
A 
B 
C 
D 
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4. Validation of DRAP1 in pSS subgroups by qRT-PCR 
DRAP1 was the only gene from the 68-DEGs-Mi and 26-DEGs-MiPCR signatures of the 
Discovery cohort that was also differentially expressed in the pSS subgroups versus healthy 
control comparison. Furthermore, although DRAP1 was not included in the 3-gene 
biosignature in pSS-associated lymphoma, it was differentially expressed in the untreated 
pSS-associated lymphoma group. The gene was included in the qRT-PCR plates that I ran 
to detect the stability of the housekeeping genes. For this reason, qRT-PCR expression data 
from all the pSS groups was available for this gene. DRAP1 was significantly upregulated 
in all the pSS subgroups compared to healthy controls. The p values were < 0.0000, 0.0007, 
0.0005 and < 0.0000, with fold change values of 1.54, 1.54, 1.55 and 2.37 for pSS, pSS-
paraproteinemia, pSS-other cancers and pSS-associated lymphoma, respectively (Figure 
6.2). 
 
Figure 6.2 Relative expression levels of DRAP1 in pSS subgroups evaluated by qRT-
PCR. DRAP1 was differentially expressed in all pSS subgroups and the levels were 
significantly higher compared to healthy controls(n = 16). The p values were < 0.0000, 
0.0007, 0.0005 and < 0.0000  and fold change values of 1.54, 1.54, 1.55 and 2.37 for pSS 
(n = 44),  pSS-paraproteinemia (n = 15), pSS-other cancers (n = 14) and pSS-associated 
lymphoma (n = 15), respectively.  
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6.3.3 Pathways analysis of pSS subgroups 
1. Canonical pathways in different pSS subgroups 
For this canonical pathway analysis, the 4 lists of DEGs from comparing the 4 pSS 
subgroups with healthy controls (HC) were uploaded onto the IPA platform. Each 
comparison using different pSS subgroups revealed a different set of canonical pathways. 
In total, 178 pathways were identified in the pSS vs HC comparison: 216 pathways in the 
pSS-paraproteinemia vs. HC comparison and 74 pathways in the pSS-other cancers vs. HC 
comparison. The pSS-associated lymphoma vs HC comparison revealed the highest number 
of canonical pathways (351 pathways). The Venn diagram in Figure 6.3A showed that 
sixty-seven pathways were in common between all four comparisons. The p value was 
calculated using the Fischer’s exact right-tailed test. P < 0.05 was considered statistically 
significant. Moreover, the number of genes in the uploaded pSS subgroups’ DEGs lists 
from my experiment that were in common with the total number of the genes included in 
each pathway was calculated. The top 5 canonical pathways (based on levels of statistical 
significance) in each comparison are shown in Table 6.2 and Figures 6.4 and 6.5. The 
“Interferon Signalling pathway” was activated in all four pSS subgroups and was the most 
statistically significant pathway. Interestingly, 178 out of 188 canonical pathways (94.9%) 
identified from the pSS-associated lymphoma vs. pSS comparison were in common with 
the pathways identified in the pSS-associated lymphoma versus HC comparisons. The ten 
canonical pathways that are only identified in pSS versus pSS-associated lymphoma are: 
Retinoate Biosynthesis II, Mitochondrial Dysfunction, Amyloid Processing, Serotonin 
Degradation, GABA Receptor Signalling, Basal Cell Carcinoma Signalling, Role of 
Wnt/GSK-3β Signalling in the Pathogenesis of Influenza, Oxidative Phosphorylation, Role 
of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis and G-Protein 
Coupled Receptor Signalling. The canonical pathways identified in pSS-associated 
lymphoma versus healthy controls that have a significant z-score can be found in 
supplementary table S10. 
The number of pathways identified in the pSS versus pSS-associated lymphoma 
comparison from chapter 5 that were also identified in other group comparisons were as 
follows: 37 in the pSS-other cancers subgroup (all included in the list of the 178 canonical 
pathways that are in common when comparing pSS and/or healthy controls to pSS-
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associated lymphoma), 78 in the pSS group and 113 pSS-paraproteinemia group (for both 
groups 77 and 112 canonical pathways were included in the 178 canonical pathways that 
are in common when comparing pSS and/or healthy controls to pSS-associated lymphoma) 
Figure 6.3B.   
 
 
Figure 6.3 Venn diagram of the canonical pathways identified in the four pSS subgroup 
comparisons with healthy controls (HC). A. Sixty-seven canonical pathways were in 
common between the four pSS subgroups comparisons. B. The common canonical 
pathways between pSS subgroups and the common pathway identified between pSS-
associated lymphoma vs. pSS and pSS-associated lymphoma vs. healthy control. C.P.= 
Canonical Pathways. 
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Table 6.2 Top 5 canonical pathways analysis in the four pSS subgroups (compared to 
healthy controls) 
Ingenuity Canonical Pathways  -log 
(p-value) 
Ratio  Genes  
pSS 
Interferon Signaling 1.89E+01 3.89E-01 OAS1,IRF9,IFITM1,IFIT3,STAT2,IFI6,IFITM3,
TAP1,IFIT1,STAT1,ISG15,MX1,IFI35,SOCS1 
Activation of IRF by Cytosolic Pattern 
Recognition Receptors 
1.07E+01 1.75E-01 DHX58,IRF9,IRF7,STAT1,IFIH1,STAT2,ISG15,
ADAR,DDX58,ZBP1,IFIT2 
Role of Pattern Recognition Receptors 
in Recognition of Bacteria and Viruses 
7.40E+00 8.73E-02 EIF2AK2,OAS1,IRF7,MYD88,IFIH1,OAS3, 
C1QB,OAS2,CASP1,DDX58,C3AR1 
Antigen Presentation Pathway 7.25E+00 1.89E-01 HLA-A,TAP2,HLA-DRB4,TAP1,PSMB9, 
HLA-F,HLA-DRA 
Retinoic acid Mediated Apoptosis 
Signaling 
5.66E+00 1.13E-01 PARP10,PARP12,ZC3HAV1,TNFSF10,RXRA, 
PARP9,PARP14 
pSS-paraproteinemia 
Interferon Signaling 1.74E+01 3.33E-01 OAS1,IRF9,IFIT1,IFITM1,STAT1,IFIT3,STAT2,
ISG15,MX1,IFI35,IFI6,IFITM3 
Activation of IRF by Cytosolic Pattern 
Recognition Receptors 
1.26E+01 1.75E-01 DHX58,IRF9,IRF7,STAT1,IFIH1,STAT2,ISG15,
ADAR,DDX58,ZBP1,IFIT2 
Role of Pattern Recognition Receptors 
in Recognition of Bacteria and Viruses 
5.78E+00 6.35E-02 EIF2AK2,OAS1,IRF7,IFIH1,OAS3,OAS2, 
CASP1,DDX58 
UVA-Induced MAPK Signaling 5.77E+00 7.95E-02 PARP10,PARP12,ZC3HAV1,STAT1,PARP9, 
PARP14,RRAS 
Retinoic acid Mediated Apoptosis 
Signaling 
5.52E+00 9.68E-02 PARP10,PARP12,ZC3HAV1,TNFSF10,PARP9,
PARP14 
pSS-other cancers 
Interferon Signaling 1.94E+01 3.33E-01 OAS1,IRF9,IFIT1,IFITM1,STAT1,IFIT3,STAT2,
ISG15,MX1,IFI35,IFI6,IFITM3 
Activation of IRF by Cytosolic Pattern 
Recognition Receptors 
1.27E+01 1.59E-01 DHX58,IRF9,IRF7,STAT1,STAT2,ISG15,ADAR,
DDX58,ZBP1,IFIT2 
Retinoic acid Mediated Apoptosis 
Signaling 
5.06E+00 8.06E-02 PARP10,PARP12,TNFSF10,PARP9,PARP14 
Role of Pattern Recognition Receptors 
in Recognition of Bacteria and Viruses 
4.66E+00 4.76E-02 EIF2AK2,OAS1,IRF7,OAS3,OAS2,DDX58 
UVA-Induced MAPK Signaling 4.32E+00 5.68E-02 PARP10,PARP12,STAT1,PARP9,PARP14 
pSS-associated lymphoma 
Interferon Signaling 1.74E+01 4.44E-01 OAS1,IRF9,IFITM1,IFIT3,STAT2,JAK1,IFI6,IF
ITM3,TAP1,IFIT1,STAT1,ISG15,MX1,IFI35, 
SOCS1,PSMB8 
Activation of IRF by Cytosolic Pattern 
Recognition Receptors 
7.25E+00 1.75E-01 DHX58,IRF9,IRF7,STAT1,IFIH1,STAT2,ISG15,
ADAR,DDX58,ZBP1,IFIT2 
Role of Pattern Recognition Receptors 
in Recognition of Bacteria and Viruses 
5.70E+00 1.03E-01 EIF2AK2,OAS1,MYD88,CREB1,PRKCQ,OAS2,
CASP1,DDX58,C3AR1,IRF7,OAS3,IFIH1, 
PRKCH 
mTOR Signaling 5.11E+00 8.02E-02 PRKCQ,EIF4B,EIF3L,EIF3B,RPS3,ULK1, 
RPS6KA5,EIF3D,PDPK1,RPS4X,PRKCH, 
EIF4A3,VEGFB,RRAS,FNBP1 
Huntington's Disease Signaling 4.65E+00 6.99E-02 GNB4,CREB1,PRKCQ,NAPA,CASP1,PSME1, 
PSME2,HSPA6,TAF4,HSPA9,PDPK1,GNG5, 
SIN3A,PRKCH,HDAC1,GLS 
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Figure 6.4 Top 5 canonical pathways analysis in pSS and pSS-paraproteinemia.Grey bars indicate that no prediction of activation or 
inhibition can be made. Yellow bars represent pathways that are enriched and activated, with a significant positive z-score. Blue bars 
represent pathway that are enriched and inhibited, with a significant negative z-score. White bars represent the canonical pathways with a 
z-score near 0. The threshold line in yellow represents the statistically significant p value (0.05). The yellow dots represent the ratio of the 
number of genes that were present in my dataset to the total number of genes in each pathway. A. pSS, B. pSS-paraproteinemia.  
 
A B 
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Figure 6.5 Top 5 canonical pathways analysis in pSS-other cancers and pSS-associated lymphoma created by IPA Grey bars indicate that 
no prediction of activation or inhibition can be made. Yellow bars represent the pathways that are enriched and activated, with a significant 
positive z-score. Blue bars represent the pathways that are enriched and inhibited, with a significant negative z-score. White bars represent 
canonical pathways with a z-score near 0. The threshold line in yellow represents the statistically significant p value (0.05). The yellow dots 
represent the ratio of the number of genes present in my dataset to the total number of genes in each pathway. A. pSS-other cancers, B. pSS-
associated lymphoma. 
B 
A 
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2. The Downstream Effects analysis in pSS subgroups  
The downstream effects analysis including the identification of diseases and functions in 
the pSS subgroups revealed the top diseases and functions associated with each pSS 
subgroup. For the pSS, pSS-paraproteinemia and pSS-other cancers groups, the most 
significant “disease and function” was “infectious diseases,” as shown in Figures 6.6, 6.7 
and 6.8, respectively. The most significant function for the pSS-associated lymphoma was 
“cell death and survival,” as shown in Figure 6.9. Notably, the “infectious diseases” 
function was inhibited in all pSS subgroups. In contrast, the “cell death and survival” 
function was activated in all subgroups, and was the second most significant function in 
both the pSS-paraproteinemia and pSS-other cancers subgroups and the fourth most 
significant function in the pSS groups. “Inflammatory responses” was also increased in all 
4 subgroups. “Haematological system development” and “immune cell trafficking” were 
increased in pSS subgroup, but were much less prominent in the other 3 subgroups. The 
Downstream Effects analysis with the diseases and functions identified in pSS-associated 
lymphoma versus healthy controls that have a significant z-score can be found in 
supplementary table S11.  
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Figure 6.6 Heatmap of the Downstream Effects analysis in the pSS group.  The size of the squares is a graphic representation of the 
statistical significance of the p value (larger square = more significant). The colours of the squares reflect the direction of change. Orange: 
IPA predicts that the biological process or function is increased, with a positive z-score (z-score ≥ 2). Blue: IPA predicts that the biological 
process or function is decreased, with a negative z-score (z-score ≤ -2). Grey: no prediction can be made in the current situation. White: the 
canonical pathways with a z-score near 0. The strength of the prediction is indicated by the intensity of the colour.  
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Figure 6.7 Heatmap of the Downstream Effects analysis in the pSS-paraproteinemia group. The size of the squares is a graphic 
representation of the statistical significance of the p value (larger square = more significant). The colours of the squares reflect the 
direction of change. Orange: IPA predicts that the biological process or function is increased, with a positive z-score (z-score ≥ 2). Blue: 
IPA predicts that the biological process or function is decreased, with a negative z-score (z-score ≤ -2). Grey: no prediction can be made in 
the current situation. White: the canonical pathways with a z-score near 0. The strength of the prediction is indicated by the intensity of the 
colour.  
 
 
 
 
170 
 
 
Figure 6.8 Heatmap of the Downstream Effects analysis in the pSS-other cancers group. The size of the squares is a graphic 
representation of the statistical significance of the p value (larger square = more significant). The colours of the squares reflect the 
direction of change. Orange: IPA predicts that the biological process or function is increased, with a positive z-score (z-score ≥ 2). Blue: 
IPA predicts that the biological process or function is decreased with a negative z-score (z-score ≤ -2). Grey: no prediction can be made in 
the current situation. White: the canonical pathways with a z-score near 0. The strength of the prediction is indicated by the intensity of the 
colour.  
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Figure 6.9 Heatmap of the Downstream Effects analysis in the pSS-associated lymphoma group. The size of the squares is a graphic 
representation of the statistical significance of the p value (larger square = more significant). The colours of the squares reflect the 
direction of change. Orange: IPA predicts that the biological process or function is increased, with a positive z-score (z-score ≥ 2). Blue: 
IPA predicts that the biological process or function is decreased, with a negative z-score (z-score ≤ -2). Grey: no prediction can be made in 
the current situation. White: the canonical pathways with a z-score near 0. The strength of the prediction is indicated by the intensity of the 
colour.  
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3. Molecular Networks analysis in pSS subgroups: 
Many molecular networks were identified in each pSS subgroup. In the pSS group, IPA 
reported 13 networks. In the pSS-paraproteinemia and pSS-other cancers groups, IPA 
identified 10 and 8 networks respectively, whereas in the pSS-associated lymphoma group, 
25 different networks were identified. In the network analysis, the term “Focus molecules” 
refers to the number of genes in the uploaded DEG list that were also represented in the 
network, while the “Score” is the number of genes in the network (including genes from the 
uploaded DEG list and the genes that were added from the indirect interactions by IPA). I 
first focus on DRAP1, which was the only DEG in common for all pSS subgroups 
compared to HC. In the pSS subgroup, the network that involves DRAP1 includes 
biological functions such as “Antimicrobial Response, Inflammatory Response and Cell 
Signaling” (Score = 27, Focus molecules = 19) with DRAP1 interacted directly with HLA-
DRA in this network. Importantly, In the pSS-paraproteinemia and the pSS-other cancers 
groups, DRAP1 was involved in the network including biological functions of “Cellular 
Development, Cell Death and Survival and Tissue Morphology” (Score = 22, Focus 
molecules = 15) and “Cellular Development, Haematological System Development and 
Function and Haematopoiesis” (Score = 22, Focus molecules = 14) respectively. In both 
networks, DRAP1 interacted directly with MYC. The three networks are shown in Figures 
6.10, 6.11 and 6.12.    
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Figure 6.10 Network analysis of the pSS group. The networks show the interactions of DRAP1.  
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Figure 6.11 Network analysis of the pSS-paraproteinemia group. The networks show the interactions of DRAP1.  
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Figure 6.12 Network analysis of the pSS-other cancers group.  The networks show the interactions of DRAP1.  
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In the comparison of pSS-associated lymphoma versus healthy controls, 25 networks were 
identified. When investigating the networks that involves the genes from the 3-gene 
biosignature in pSS-associated lymphoma, only two of the genes (NUDT14 and MGST3) 
appeared in two networks. There were two other networks involving the two differentially 
expressed genes (DRAP1 and DYNLL1) in untreated pSS-associated lymphoma. NUDT14 
was involved in the “Molecular Transport, RNA Trafficking, RNA Post-Transcriptional 
Modification“ network (Score = 6, Focus molecules =  7). This gene interacted indirectly 
with TCOF1 in the network. TCOF1 had a direct interaction with WT1, which binds to 
TP53 (Figure 6.13). MGST3 was involved in the “Inflammatory Disease, Respiratory 
Disease, Antigen Presentation” network (Score = 15, Focus molecules = 15) and was 
regulated by PPARA (Figure 6.14). DRAP1 was included in the network “Lipid 
Metabolism, Molecular Transport, Nucleic Acid Metabolism” (Score = 43, Focus 
molecules = 30), in which DRAP1 directly interacted with MYC (Figure 6.15). 
Interestingly, the network containing DRAP1 was the most significant in the pSS-
associated lymphoma versus healthy control comparison. DYNLL1 was included in the 
“Infectious Diseases, Antimicrobial Response, Inflammatory Response” network (Score = 
32, Focus molecules = 25), with an indirect interaction with the NF-κB complex (Figure 
6.16). 
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Figure 6.13 The interactions of NUDT14 in the network analysis of pSS-associated lymphoma versus healthy controls. 
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Figure 6.14 The interactions of MGST3 in the network analysis of pSS-associated lymphoma versus healthy controls. 
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Figure 6.15 The interactions of DRAP1 in the network analysis of pSS-associated lymphoma versus healthy controls. 
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Figure 6.16 The interactions of DNYLL1 in the network analysis of pSS-associated lymphoma versus healthy controls. 
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4. Upstream regulators: 
Analysis of the upstream regulators revealed that a total of 401 upstream regulators were 
identified in pSS, 370 in pSS-paraproteinemia and 255 in pSS-other cancers. For pSS-
associated lymphoma 495 regulators were identified. Among these 495 regulators, 87 with 
absolute z-scores ≥ 2 or z-scores ≤ -2  (58 regulators were activated and 29 regulators were 
inhibited). The top 10 activated upstream regulators showed a predominance of IFN 
regulators, as shown in Table 6.3. When investigating the upstream regulators of the genes 
constituting the 3-gene biosignature of pSS-associated lymphoma and the 2 DEGs in 
untreated pSS-associated lymphoma, two of the three upstream regulators identified were 
the same as the upstream regulators identified previously in the “pSS versus pSS-associated 
lymphoma” comparison (chapter 5). These two regulators were NFE2L2 and TCOF1. The 
other upstream regulator was NR3C1. Two regulators involved in the regulation of 
NUDT14 and MGST3 and one upstream regulator controls both MGST3 and DYNLL1 
(Table 6.4). The Upstream regulators analysis identified in pSS-associated lymphoma 
versus healthy controls that have a significant z-score can be found in supplementary data 
S12.  
 
Table 6.3 Top 10 activated upstream regulators in pSS-associated lymphoma versus 
healthy control 
Upstream 
Regulator 
Molecule Type Predicted 
Activation 
State 
Activation 
z-score 
p-value  
IFNL1 cytokine Activated 6.664 9.18E-66 
IFNA2 cytokine Activated 6.539 6.77E-55 
PRL cytokine Activated 6.291 2.15E-54 
IRF7 transcription regulator Activated 5.798 4.99E-40 
IRF3 transcription regulator Activated 5.944 1.46E-38 
Ifnar group Activated 5.728 5.59E-37 
IFNG cytokine Activated 7.442 1.91E-35 
STAT1 transcription regulator Activated 5.378 4.25E-31 
MAVS other Activated 4.516 6.85E-26 
IFNB1 cytokine Activated 5.093 2.56E-25 
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Table 6.4 The upstream regulators of the genes constituting the 3-gene biosignature and 
DEGs in untreated pSS-associated lymphoma.  
Upstream 
regulator 
Molecule  p-value of 
overlap 
Target molecules in uploaded DEG list 
from my experiment 
NR3C1 Ligand-dependent 
nuclear receptor 
3.99E-03 ADCK3,AKTIP,ARRB1,BAG3,BTG1,CCL, 
CXCL10,DYNLL1,FOXO1,GADD45B, 
HSPA6,IFI6,IFIH1,IFIT2,IL15,ISG15, 
MYC,MYD88,OASL,SERTAD2,TNFAIP6 
NFE2L2 Transcription regulator 9.47E-03 ACTG1,ARF1,ATP1A1,CXCL10,DYNLL1, 
EPHB4,GSTO1,HSP90B1,IL1RN,LY6E, 
MGST3,PAFAH1B1,VCP 
TCOF1 Transporter 4.49E-02 AKR1B1,HNRNPDL,NUDT14,QRICH1 
* The genes from the 3-gene biosignature and those that were differentially expressed in 
untreated pSS-associated lymphoma are highlighted in bold  
 
6.4 Discussion 
Microarray gene expression data in pSS subgroups 
The aim of this chapter was to investigate whether the identified whole blood gene 
expression signature of pSS-associated lymphoma was also present in other pSS subgroups. 
The microarray gene expression data from the Discovery cohort revealed DEGs only in the 
comparisons between the pSS subgroups and healthy controls. In contrast, there were no 
DEGs identified in all other comparisons, with the exception of 1 gene (RNA28S5) that was 
differentially expressed between the pSS-associated lymphoma and pSS-other cancers 
groups but this gene was not validated. Importantly, the DEGs identified between the 3 
non-lymphoma pSS subgroups and healthy controls did not include the genes of the 3-gene 
biosignature of pSS-associated lymphoma. These observations indicate that the gene 
expression signature I have identified is unique to pSS-associated lymphoma. On the other 
hand, a dominant interferon signature was apparent in all 4 pSS subgroups. It should 
however be noted that IFN activation is not only well-documented in pSS, but also one of 
the key shared signatures with other inflammatory systematic diseases such as SLE and RA 
(Emamian et al., 2009, Toro-Dominguez et al., 2014). At an individual gene level, the gene 
DRAP1 may be of particular interest, as the differential expression of this gene was 
validated in all 4 pSS subgroups by qRT-PCR. DRAP1 is a transcriptional factor that has a 
role in either inhibition or activation of transcription (Cang and Prelich, 2002, Castaño et 
al., 2000, Creton et al., 2002, White et al., 1994).   
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The Canonical pathways in pSS subgroups 
Consistent with the microarray data, “Interferon signaling pathway” was a canonical 
pathway being identified in all 4 pSS subgroups. Type I interferon signaling activation in 
pSS has already been reported (Yao et al., 2013). Type I interferon signaling is crucial for 
pSS pathogenesis, as knockout mice (B6.Aec1Aec2Ifnar1
-/-
) that lack interferon alpha 
receptor 1 (Ifnar1) exhibit less salivary gland dysfunction (Szczerba et al., 2013). 
Moreover, it has been reported that type I interferon, together with other factors, are 
associated with both pSS and pSS-associated lymphoma (reviewed recently by (Nezos and 
Mavragani, 2015). Interestingly, in the canonical pathway analysis, almost all of the 
canonical pathways identified in pSS versus healthy controls were included in the list of 
canonical pathways identified in pSS-associated lymphoma versus healthy controls, with 
the exception of only 6 canonical pathways. Interestingly, when comparing the canonical 
pathways identified in the comparison between pSS-associated lymphoma and pSS 
(identified in Chapter 5), the top 5 canonical pathways were not included in the top 40 
canonical pathways identified from the comparison between pSS-associated lymphoma and 
healthy controls. These data suggest that the canonical pathways identified in Chapter 5 
comparing pSS and pSS-Lymphoma represent the important and unique pathways for pSS-
associated lymphoma.  
The Downstream Effects and Networks analyses of pSS subgroups  
Another interesting observation from the IPA was the Downstream Effects analysis. The 
pSS-associated lymphoma clearly displayed a different pattern from the other three pSS 
subgroups, which showed a more similar pattern with one other. Furthermore, the relative 
importance of the different “diseases and functions” also differed between the pSS-
associated lymphoma and the other pSS subgroups. Notably, “cell death and survival” was 
the most important downstream effects in the lymphoma group. This is perhaps 
unsurprising given the link between cell death and survival is well known in malignancies 
(Labi and Erlacher, 2015).  
The network analysis from different pSS subgroups revealed the interactions between the 
genes within the uploaded DEGs list from my experiment and with other genes in the 
pathways found in the literature. The networks analysis of pSS-associated lymphoma 
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versus healthy controls showed that two of the genes in the 3-gene biosignature in pSS-
associated lymphoma (with the exception of BMS1) were included in two networks (out of 
a total of 25 networks) identified by IPA. Furthermore, the two genes that were 
differentially expressed in untreated pSS-associated lymphoma were also included in two 
networks. All these genes had interactions with similar genes to those identified and 
discussed in Chapter 5.  
The Upstream regulators analysis in pSS subgroups 
Focusing on the upstream regulators of the genes in the 3-gene biosignature, IPA revealed 
two upstream regulators NFE2L2 and TCOF1. Both regulators have been also identified in 
when using the DEG list from the comparison between pSS and pSS-associated lymphoma 
(see chapter 5). The roles of NFE2L2 and TCOF1, have been discussed in chapter 5 with 
the former regulator linked to antioxidant functions and the latter related to cell 
proliferation. The analysis also identified NR3C1 as an upstream regulator of DYNLL1, 
which was differentially expressed in untreated the pSS-associated lymphoma. NR3C1 
(nuclear receptor subfamily 3 group C member 1), is a glucocorticoid receptor as well as a 
transcriptional factor. NR3C1 has recently been linked to tumorigenesis of adult acute 
lymphoblastic leukaemia (ALL) (Safavi et al., 2015) as well as being identified as a 
candidate gene related to the development of lung adenocarcinoma (Zhao et al., 2015). 
Therefore, further investigation of NR3C1 regulation of DYNLL1 might be important in 
understanding the pathogenesis of pSS-associated lymphoma.  
To summarise, no DEGs were identified in the comparison between the 3 non-lymphoma 
pSS subgroups. In the Downstream Effects analysis, all 3 non-lymphoma pSS subgroups 
exhibited a similar pattern with only minor differences, but were substantially different 
from the pSS-lymphoma group. This supports the notion that distinct biological 
mechanisms are involved in lymphoma development and pSS pathogenesis. Finally, further 
investigation of the role of the transcriptional factor DRAP1 in pSS pathogenesis and 
lymphoma development might be worthwhile.    
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Chapter 7 
Conclusion and future work 
7.1 Conclusion: 
During my PhD study, I have focused on the identification of a whole-blood gene 
expression signature in pSS-associated lymphoma. Several gene expression studies have 
been carried out regarding pSS, focusing on gene-expression profiling in the most affected 
organs (salivary and lacrimal glands). Only one study has used whole-blood samples from 
pSS patients (Emamian et al., 2009). No data was found in the literature, however, 
regarding whole-blood gene expression profiling in pSS-associated lymphoma.  
By identifying a whole-blood gene expression signature in pSS-associated lymphoma, it 
will help to understand the molecular mechanisms underlying the development of 
lymphoma in pSS patients and to discover genetic biomarkers that might help to predict, 
diagnose or monitor lymphoma development in pSS. Such biomarkers will have substantial 
translational potentials in the clinic. 
In contrast to salivary gland biopsy, which is an invasive procedure which can lead to 
permanent paraesthesia, obtaining peripheral blood samples is simple and widely 
acceptable to patients. In addition, collecting blood specimens can be easily repeated at 
regular intervals. One major problem with analysing gene expression using whole blood 
samples is the presence of globin mRNA. This abundance of globin mRNA can interfere 
with gene expression profiling studies. For this reason in my project, I first examined the 
impact of globin mRNA on gene expression study in pSS. This optimisation step is 
important as it has been recommended that globin mRNA depletion should be optimised for 
different experiments and microarray platforms (Dumeaux et al., 2008). In this experiment, 
I used pSS whole-blood samples and not pSS-associated lymphoma samples because 
peripheral blood gene expression data in pSS are available in the literature providing a 
robust set of data for comparison with my work. As described in chapter 3, I used paired 
samples with or without globin mRNA depletion from 12 pSS patients and 12 healthy 
controls. Globin mRNA depletion resulted in an increase in the microarray signal intensity, 
more  transcripts being detected and a higher number of differentially expressed genes 
being identified. The increased number of detectable transcripts indicated that the depletion 
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of globin mRNA may improve the detection of low-abundance genes (Kam et al., 2012). 
However, the overall gene expression profiles for pSS using samples with or without globin 
mRNA depletion were comparable. Important, these gene expression profiles were 
consistent with the published data in the literature. The concordance between the globin-
depleted and non-globin depleted datasets was more noticeable among the up-regulated 
genes, characterised by the presence of an activated type I IFN-inducible gene signature.  
Unlike the clear differences in gene expression profiles between pSS patients and healthy 
controls, I reasoned that the differences in gene expression between pSS and pSS-
associated lymphoma may be more subtle for two reasons.  Firstly, lymphoma development 
is likely to be a multi-step process from pre-lymphoma stage to lymphoma, therefore, gene 
expression changes relevant to lymphoma development may have occurred in some of the 
non-lymphoma pSS patients. Furthermore, the majority of the samples that I will be using 
for the experiment were from pSS patients who have already received treatment for their 
lymphoma, which may also blunted the differences in gene expression profiles between 
lymphoma and non-lymphoma cases. Therefore, I have decided to deplete globin mRNA 
from my samples for my microarray experiments as it may increase the sensitivity of 
detecting differentially expressed genes between the lymphoma and non-lymphoma groups. 
In the discovery experiment, 144 globin mRNA-depleted samples were used. There were 
five subject groups: first, the target group (pSS-associated lymphoma), and second, the 
disease control groups (pSS), in which the comparison will be made to identify the gene 
expression signature for pSS-associated lymphoma. The other three groups included two 
subgroups of pSS (pSS with paraproteinemia, pSS with other cancers) and a healthy control 
group. The inclusion of these groups was to test the “specificity” of the identified gene 
expression signature for pSS-associated lymphoma. Sixty-eight DEGs were identified in 
pSS-associated lymphoma from the microarray data of the Discovery cohort (68-DEGs-
Mi). Due to limited availability of RNA samples, the expression levels of only 61 genes 
were measured with qRT-PCR, which  validated the differential expression of 26 genes 
(26-DEGs-MiPCR). These 26-DEGs-MiPCR was selected as candidate whole-blood gene 
expression signature for pSS-associated lymphoma.   
Due to limited availability of RNA samples, the expression levels of 24 out of the 26 genes 
were measured in a second independent cohort (Validation cohort) using qRT-PCR. The 
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Validation cohort consisted of only pSS patients without lymphoma and pSS-associated 
lymphoma. This cohort has included patients from our collaborators in Sweden and 
Norway as well as the UKPSSR samples. Three genes (BMS1, NUDT14 and MGST3) were 
validated and they were referred to as the ‘3-gene biosignature of pSS-associated 
lymphoma’. 
During the study, I was able to obtain a few samples from the UKPSSR and our 
collaborators in Sweden of pSS patients with lymphoma before treatment was initiated. The 
expression levels of the same 24 genes were also tested for these samples. Six genes 
(NUDT14, DRAP1, DYNLL1, RBP7, SF3A1 and VCP) were differentially expressed 
between the untreated lymphoma and the non-lymphoma pSS groups. The differential 
expression for the latest 3 genes (RBP7, SF3A1 and VCP ) was not confirmed in the 
Validation cohort as the genes have opposite regulation direction, therefore, for my thesis I 
just considered the first 3 genes (NUDT14, DRAP1 and DYNLL1) for discussion. 
Interestingly NUDT14 is also one of the constituent genes of the 3-gene biosignature of 
treated pSS-associated lymphoma. Furthermore, DRAP1 and DYNLL1 were also candidate 
DEGs for treated pSS-associated lymphoma even though differential expression was not 
confirmed in the Validation cohort with p > 0.05 but they have the same regulation 
direction. The summary findings of the DEGs identified in each stage of the experiment are 
shown in Table 7.1. 
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Table 7.1 Summary of the DEGs in pSS-associated lymphoma at all the project’s stages  
Discovery cohort Validation cohort 
6 -DEGs in untreated pSS-
associated lymphoma   68-DEGs-Mi 26-DEGs-MiPCR 
3-gene biosignature of pSS-
associated lymphoma 
Gene symbol 
regulation in  
Gene symbol 
regulation in  
Gene 
symbol 
regulation in  
Gene symbol 
regulation in 
pSS-associated 
lymphoma 
pSS-associated 
lymphoma 
pSS-associated 
lymphoma 
 pSS-associated 
lymphoma 
ATG12 upregulated C10orf32(BORCS7) upregulated MGST3 upregulated DRAP1 upregulated 
C10orf32(BORCS7) upregulated CNPY3 upregulated NUDT14 upregulated DYNLL1 upregulated 
CNPY3 upregulated DRAP1 upregulated BMS1 downregulated NUDT14 upregulated 
DRAP1 upregulated DYNLL1 upregulated     RBP7 upregulated 
DYNLL1 upregulated HNMT upregulated     SF3A1 upregulated 
EHBP1L1 upregulated LGALS1 upregulated     VCP upregulated 
HCFC1R1 upregulated MGST3 upregulated         
HNMT upregulated NUDT14 upregulated         
KCTD12 upregulated OAF upregulated         
LGALS1 upregulated RBP7 upregulated         
MGST3 upregulated SEC61G upregulated         
NUDT14 upregulated SRP14 upregulated         
OAF upregulated UBXN11 upregulated         
PSMC1 upregulated BMS1 downregulated         
RAB37 upregulated BTBD11 downregulated         
RBP7 upregulated CBLL1 downregulated         
RNF7 upregulated CYFIP2 downregulated         
SEC61G upregulated ESYT1 downregulated         
SRP14 upregulated HNRNPUL1 downregulated         
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UBXN11 upregulated LEF1 downregulated         
ALDH9A1 downregulated MAGED1 downregulated         
ATP1A1 downregulated POM121C downregulated         
BAG3 downregulated PRPF8 downregulated         
BCL11B downregulated SF3A1 downregulated         
BMS1 downregulated SGK223 downregulated         
BTBD11 downregulated VCP downregulated         
CBLL1 downregulated             
CD96 downregulated             
CDR2 downregulated             
CDV3 downregulated             
CYFIP2 downregulated             
DDB1 downregulated             
ESYT1 downregulated             
ETS1 downregulated             
FOXJ3 downregulated             
HLA-DRB1 downregulated             
HNRNPA1P10 downregulated             
HNRNPDL downregulated             
HNRNPUL1 downregulated             
HSP90B1 downregulated             
HSPA9 downregulated             
ITK downregulated             
KHDRBS1 downregulated             
LEF1 downregulated             
LRFN3 downregulated             
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LRIG1 downregulated             
MAGED1 downregulated             
MYC downregulated             
NAT10 downregulated             
NCSTN downregulated             
PAF1 downregulated             
POM121C downregulated             
PRKCQ downregulated             
PRPF8 downregulated             
RASGRP1 downregulated             
RBL2 downregulated             
RNA28S5 downregulated             
RPA2 downregulated             
RPL23AP5 downregulated             
RRN3 downregulated             
SDHA downregulated             
SF3A1 downregulated             
SGK223 downregulated             
SMARCA2 downregulated             
SPOCK2 downregulated             
SUN2 downregulated             
VCP downregulated             
WAC downregulated             
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Another approach that I used to identify the gene expression signature for pSS-associated 
lymphoma was to use machine-learning method. This method enable me to predict which 
genes among the 60 DEGs from the qRT-PCR data in the Discovery cohort were most 
important in predicting the group membership of pSS-associated lymphoma. This method 
has yielded two prediction models. Both models identified NUDT14 being the best gene in 
distinguishing pSS patients with or without lymphoma. 
To further explore my microarray data, pathway analysis was performed using the IPA. 
Due to the small number of validated DEGs between the lymphoma and non-lymphoma 
groups (i.e. only 3 genes), I chose to use the 68 DEGs identified from the microarray 
experiment in the Discovery cohort (68-DEGs-Mi) for the pathway analysis. The top 5 
canonical pathways identified were “Aryl Hydrocarbon Receptor (AHR) signalling,” 
“Histamine Degradation,” “Unfolded protein response,” “Neuregulin Signalling,” and “T 
Cell Receptor Signalling.” AHR signalling appeared to have a special and important role in 
the pathology of pSS. Moreover, MGST3 is one of the genes in the AHR signalling 
pathway. Several other canonical pathways also included the genes of the 3-gene 
biosignature of pSS-associated lymphoma. Interestingly, all the pathways that contained 
these 3 genes related to metabolic functions. In addition to canonical pathway analysis, 
downstream effects and gene-gene interactions were explored through the molecular 
networks analysis. Additionally, important upstream regulators of the 3 biosignature genes 
include NFE2L2, PPARA and TOCF1. NFE2L2 and PPARA are regulators of MGST3 and 
also DYNLL1 (which was differentially expressed in untreated pSS-associated lymphoma) 
whereas  TOCF1 regulates NUDT14.  
In conjunction with the gene expression profiling and the pathway analysis of pSS-
associated lymphoma, I have also investigated the gene expression profiling and performed 
pathway analyses of the other comparison groups from the Discovery cohort. There were 
no DEGs among these additional pSS subgroups comparisons (with the exception of one 
DEG (RNA28S5) between the “pSS-associated lymphoma” and “pSS-other cancers” 
groups). DEGs were however identified between each of these pSS subgroups and healthy 
controls. The DEGs between these pSS subgroups and healthy controls were used for 
pathway analyses using IPA. The canonical pathways showed 67 common pathways among 
all the pSS groups. Focusing on pSS-associated lymphoma versus healthy controls, 351 
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canonical pathways were identified, 94.9% of the canonical pathways in this comparison 
were in common with the canonical pathways identified when comparing pSS-associated 
lymphoma with pSS. The “Interferon Signaling pathway” was the top pathway for all pSS 
subgroups comparing with healthy controls.  In addition, the non-lymphoma pSS subgroups 
(i.e. pSS, pSS-paraproteinemia and pSS-other cancers) showed similar patterns of “diseases 
and biological functions” in the downstream analysis, but were different from the “pSS-
associated lymphoma” group. These results further support the biosignature of pSS-
associated lymphoma identified was specific. Finally, DRAP1, a transcriptional factor, was 
found to be differentially expressed in all pSS subgroups compared to healthy controls. In 
addition, the molecular network analysis demonstrates DRAP1 in all pSS subgroups. These 
results might provide a key to a deeper understanding and a direction for future studies to 
investigate the development of lymphoma in pSS patients. 
7.2 Future work: 
In this project, I have identified a whole-blood gene expression signature in pSS-associated 
lymphoma. To explore the clinical and biological significance of my findings, several 
future experiments can be pursued. Below is a list of such experiments: 
 To investigate the presence or absence of the biosignature in different immune cell 
subsets. It will help to gain a better understanding of the role of theses genes in pSS-
associated lymphoma. The expression of these genes could be measured using single-
cell analysis technologies such as Mass Cytometry (CyTOF) or SmartFlare
TM
.  
 The determination of the type of cell responsible for the expression of each gene would 
facilitate knockout or knock-in studies in animal models of pSS. These kinds of studies 
help to understand the exact role of each gene in many biological functions, for instance, 
apoptosis and lymphoproliferation in pSS.    
 Evaluation of the expression of the signature genes in salivary and lacrimal glands of 
pSS patients with or without lymphoma as well as the lymphoma tissues from 
lymphoma patients without pSS.  
 Evaluation of the expression of the signature genes in the whole blood of lymphoma 
patients without pSS. 
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 A longitudinal study to determine the level of expression of the signature genes 
throughout different stages of pSS progression.  
 A microarray experiment using whole blood samples from untreated pSS-associated 
lymphoma and pSS patients without lymphoma may reveal a new set of genes that are 
important for lymphoma development in pSS.  
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Supplementary Tables 
S1 R scripts for microarray data analysis of the Globin mRNA depletion effects on pSS 
gene expression profiling  
source("http://bioconductor.org/biocLite.R") 
biocLite(c("lumi", "gplots", "ggplot2", "limma", "annotate", "lumiHumanAll.db", "limma", "sva", 
"lumiHumanIDMapping")) 
install.packages(c("scales", "reshape2")) 
library(stringr) 
library(sva) 
library(lumi) 
library(gplots) 
library(ggplot2) 
library(annotate) 
library(lumiHumanAll.db) 
library(limma) 
library(scales) 
library(reshape2) 
library(lumiHumanIDMapping) 
##'---------------------------------------------------------------------------------------------------------# 
filename              <- "raw_data_SA.txt" 
raw_data             <- lumiR(filename) 
pheno_table        <- read.table("pheno.txt", 
                                    header=T, 
                                    sep="\t", 
                                    row.names=1, 
                                    stringsAsFactors=F) 
pData(raw_data)  <- pheno_table 
##'---------------------------------------------------------------------------------------------------------# 
det <- melt(detection(raw_data)) 
dtp <- ggplot(data=det, aes(x=Var2, y=value)) + 
           geom_boxplot(outlier.size=0.5, 
          size=0.2) + 
          scale_x_discrete(name="") + 
          scale_y_continuous(name="Amplitude") + 
          theme_bw() + 
          theme(axis.text.x=element_text(angle=90, vjust=0.5, 
          size=6), 
          axis.text.y=element_text(size=6), 
          axis.title.y=element_text(size=6)) 
image_deploy(dtp, "DetectionPval_") 
##'---------------------------------------------------------------------------------------------------------# 
raw_data_det          <- raw_data 
raw_data_det          <- raw_data[, grep("Globin_Clear", pData(raw_data)$class)] 
# raw_data_det       <- raw_data[, grep("Full_RNA",     pData(raw_data)$class)] 
##'---------------------------------------------------------------------------------------------------------# 
vst_data               <- lumiT(raw_data_det, method='vst') 
rsn_data               <- lumiN(vst_data, method = "rsn") 
lumi.Q                 <- lumiQ(rsn_data) 
exprs_data           <- exprs(lumi.Q) 
present_count      <- detectionCall(lumi.Q) 
normalised_data  <- exprs_data[present_count > 0, ] 
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##'-----------------------------------------------------------------------------------------# 
probe_list      <- rownames(normalised_data) 
nuIDs            <- probeID2nuID(probe_list)[, "nuID"] 
symbol          <- getSYMBOL(nuIDs, "lumiHumanAll.db") 
name             <- unlist(lookUp(nuIDs, "lumiHumanAll.db", "GENENAME")) 
anno_df         <- data.frame(ID = nuIDs, probe_list, symbol, name) 
entrez_map   <- data.frame(nuID=as.vector(anno_df$ID), 
                           EntrezID=nuID2EntrezID(as.vector(anno_df$ID), 
                          "lumiHumanIDMapping")) 
##'-----------------------------------------------------------------------------------------# 
design                      <- model.matrix(~0 + factor(pData(raw_data_det)$treatment, 
                                     levels=c("SS", "control"))) 
colnames(design)    <- c("SS", "control") 
num_parameters      <- ncol(design) 
fit                             <- lmFit(normalised_data, design) 
cont_mat                 <- makeContrasts(SS-control, levels=c("SS", "control")) 
fit2                          <- contrasts.fit(fit, contrasts=cont_mat) 
fit2                          <- eBayes(fit2) 
fit2$genes               <- anno_df 
##'-----------------------------------------------------------------------------------------# 
comparisons <- c("SS - control") 
p_cut_off     <- 0.05 
fold_change <- 1.2 
i                    <- 1 
gene_list_unfiltered <- topTable(fit2, 
                                     coef="SS - control", 
                                     number=Inf, 
                                     adjust.method="BH") 
gene_list                  <- topTable(fit2, 
                                    coef="SS - control", 
                                    p.value=p_cut_off, 
                                    lfc=log2(fold_change), 
                                    number=Inf, 
                                    adjust.method="BH") 
##'-----------------------------------------------------------------------------------------# 
pca         <- prcomp(t(normalised_data)) 
d             <- as.data.frame(pca$x) 
d             <- cbind(d, pData(raw_data_det)) 
d$pairs   <- as.factor(d$pairs) 
 
gg1         <- ggplot(d, aes(x=PC1, y=PC2, shape=class)) + 
                   geom_point(size=3) + 
                   geom_text(label=d$pairs, size=4, vjust=1.2, hjust=-0.2) + 
               theme_bw() + 
               theme(axis.title.x = element_text(size=20), 
              axis.title.y = element_text(size=20)) 
 
gg2       <- ggplot(d, aes(x=PC1, y=PC2, shape=class)) + 
                 geom_point(aes(colour=treatment), size=3) + 
                 geom_text(label=d$pairs, size=4, vjust=1.2, hjust=-0.2) + 
                scale_colour_grey(start = 0, end = .9) + 
                theme_bw() + 
                theme(axis.title.x = element_text(size=20), 
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                axis.title.y = element_text(size=20)) 
##'-----------------------------------------------------------------------------------------# 
library(VennDiagram) 
unfiltered_fullrna    <- topTable(fit2, coef="SS - control", number=Inf, 
                                  adjust.method="BH") 
unfiltered_fullrna_in <- unfiltered_fullrna 
unfiltered_globin     <- topTable(fit2, coef="SS - control", number=Inf, 
                                  adjust.method="BH") 
unfiltered_globin_in  <- unfiltered_globin 
 
afc  <- 1.2 
pval <- 0.05 
 
unfiltered_fullrna_in$pass  <- unfiltered_fullrna_in$adj.P.Val < pval & 
abs(unfiltered_fullrna_in$logFC) > log2(afc) 
unfiltered_fullrna_in$class <- "Full_RNA" 
unfiltered_globin_in$pass   <- unfiltered_globin_in$adj.P.Val < pval & 
abs(unfiltered_globin_in$logFC) > log2(afc) 
unfiltered_globin_in$class  <- "Globin_Clear" 
df                          <- rbind(unfiltered_fullrna_in, unfiltered_globin_in) 
 
ggplot(df, aes(x=logFC, y=-log(adj.P.Val, 10))) + 
  geom_point(aes(colour=pass, shape=pass), show_guide=F) + 
  scale_colour_manual(values=c(alpha('grey', 0.5), 'black')) + 
  geom_hline(yintercept=-log(pval, 10), colour="black", linetype=2) + 
  geom_vline(xintercept=-log2(afc), colour="black", linetype=2) + 
  geom_vline(xintercept=log2(afc), colour="black", linetype=2) + 
  facet_grid(. ~ class) + 
  theme_bw() 
 
ggplot(unfiltered_fullrna_in, aes(x=logFC, y=-log(adj.P.Val, 10))) + 
  geom_point(aes(colour=pass, shape=pass), show_guide=F) + 
  scale_colour_manual(values=c(alpha('grey', 0.5), 'black')) + 
  geom_hline(yintercept=-log(pval, 10), colour="black", linetype=2) + 
  geom_vline(xintercept=-log2(afc), colour="black", linetype=2) + 
  geom_vline(xintercept=log2(afc), colour="black", linetype=2) + 
  ggtitle("Full RNA Differential Expression: PSS - Control") + 
  theme_bw() 
 
ggplot(unfiltered_globin_in, aes(x=logFC, y=-log(adj.P.Val, 10))) + 
  geom_point(aes(colour=pass, shape=pass), show_guide=F) + 
  scale_colour_manual(values=c(alpha('grey', 0.5), 'black')) + 
  geom_hline(yintercept=-log(pval, 10), colour="black", linetype=2) + 
  geom_vline(xintercept=-log2(afc), colour="black", linetype=2) + 
  geom_vline(xintercept=log2(afc), colour="black", linetype=2) + 
  ggtitle("Globin Clear Differential Expression: PSS - Control") + 
  theme_bw() 
##’---------------------------------------------------------------------------------------------------------# 
 
S2 R scripts for microarray data analysis of the whole blood gene expression signature in 
pSS-associated lymphoma 
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filename              <- "Fai_Sample_Probe_Profile.txt" 
raw_data              <- lumiR(filename) 
##'Gender Discrepancies 
raw_data              <- raw_data[, -c(2, 6)] 
pheno_table           <- read.table("sample_info.txt", 
                                    header=T, 
                                    sep="\t", 
                                    stringsAsFactors=F) 
rownames(pheno_table) <- pheno_table$Sentrix_ID 
pData(raw_data)       <- pheno_table 
##'---------------------------------------------------------------------------------------------------------# 
 
##'"IPS-004-1", - Detected Outlier 
removal     <- c("IPS-004-1", "IPS-002-1", "NCL-130-0", "SWI-084-0", "LEE-060-0", "NCL-113-
0", "TOR-006-1") 
removal_pos <- match(rownames(pData(raw_data)[pData(raw_data)$SampleID %in% removal,]), 
colnames(raw_data)) 
raw_data_in <- raw_data[,-removal_pos] 
 
##'RIN SCORE EXCLUSION 
##'Arrays Less than 7 
Seven <- c("LEE-060-0","BIR-033-1","NCL-097-0","NCL-007-1","TOR-006-1","BIR-039-
1","LEE-034-1", 
           "LEE-062-1","TOR-007-0","NOT-036-1","FIF-027-1","BIR-011-1","SWI-006-1","BIR-
030-1", 
           "IPS-002-1","DER-019-1","FIF-014-1","WIN-016-1","LEE-016-1","LEE-012-1","GLA-
019-1", 
           "BIR-041-1","SWI-031-1","NCL-053-1") 
removal_pos <- match(rownames(pData(raw_data_in)[pData(raw_data_in)$SampleID %in% 
Seven,]), colnames(raw_data_in)) 
raw_data_in <- raw_data_in[,-removal_pos] 
 
##'Arrays Less than 7 with lymphoma 
SevenL <- c("LEE-060-0", "BIR-033-1", "NCL-097-0", "NCL-007-1", "TOR-006-1", "BIR-039-1", 
"LEE-034-1", 
            "LEE-062-1", "TOR-007-0", "BIR-011-1", "SWI-006-1", "BIR-030-1", 
            "IPS-002-1", "DER-019-1", "FIF-014-1", "WIN-016-1", "LEE-016-1", "LEE-012-1", 
"GLA-019-1", 
            "BIR-041-1", "SWI-031-1", "NCL-053-1") 
removal_pos <- match(rownames(pData(raw_data_in)[pData(raw_data_in)$SampleID %in% 
SevenL,]), colnames(raw_data_in)) 
raw_data_in <- raw_data_in[,-removal_pos] 
 
 
##'Arrays Less than 5 
Five <- c("NCL-097-0", "BIR-011-1", "SWI-006-1", "BIR-041-1", "SWI-031-1", "NCL-053-1") 
removal_pos <- match(rownames(pData(raw_data_in)[pData(raw_data_in)$SampleID %in% 
Five,]), colnames(raw_data_in)) 
raw_data_in <- raw_data_in[,-removal_pos] 
 
##'BATCH EXCLUSION 
raw_data_in <- raw_data_in[,-grep(1, pData(raw_data_in)$Batch)] 
pData(raw_data_in)$Batch <- pData(raw_data_in)$Batch - 1 
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##'---------------------------------------------------------------------------------------------------------# 
 
det <- melt(detection(raw_data)) 
dtp <- ggplot(data=det, aes(x=Var2, y=value)) + 
  geom_boxplot(outlier.size=0.5, 
               size=0.2) + 
  scale_x_discrete(name="") + 
  scale_y_continuous(name="Amplitude") + 
  theme_bw() + 
  theme(axis.text.x=element_text(angle=90, 
                                 vjust=0.5, 
                                 size=6), 
        axis.text.y=element_text(size=6), 
        axis.title.y=element_text(size=6)) 
 
image_deploy(dtp, "DetectionPval_") 
##'---------------------------------------------------------------------------------------------------------# 
vst_data         <- lumiT(raw_data_in, method='vst') 
rsn_data         <- lumiN(vst_data, method = "rsn") 
lumi.Q           <- lumiQ(rsn_data) 
 
##'Detection Threshold Filtering 
exprs_data       <- exprs(lumi.Q) 
present_count    <- detectionCall(lumi.Q) 
normalised_data  <- exprs_data[present_count > 0, ] 
##'---------------------------------------------------------------------------------------------------------# 
batches             <- pData(raw_data_in)$Batch 
pheno               <- data.frame(sample=c(1:ncol(normalised_data)), 
                                  outcome=as.factor(pData(lumi.Q)$Group), 
                                  batch=batches) 
rownames(pheno)     <- colnames(normalised_data) 
batch               <- pheno$batch 
mod                 <- model.matrix(~as.factor(outcome), data = pheno) 
batchCorrected_data <- ComBat(dat=normalised_data, 
                              batch=batch, 
                              mod=mod, 
                              par.prior=T, 
                              prior.plots=F) 
##'---------------------------------------------------------------------------------------------------------# 
probe_list       <- rownames(batchCorrected_data) 
nuIDs            <- probeID2nuID(probe_list)[, "nuID"] 
symbol           <- getSYMBOL(nuIDs, "lumiHumanAll.db") 
name             <- unlist(lookUp(nuIDs, "lumiHumanAll.db", "GENENAME")) 
anno_df          <- data.frame(ID = nuIDs, probe_list, symbol, name) 
entrez_map       <- data.frame(nuID=as.vector(anno_df$ID), 
                               EntrezID=nuID2EntrezID(as.vector(anno_df$ID), 
                                                      "lumiHumanIDMapping")) 
##'---------------------------------------------------------------------------------------------------------# 
 
 
 
 
treatments          <- unique(pData(raw_data_in)$Group) 
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treatment_arrays    <- pData(raw_data_in)$Group 
batchCorrected_data <- data.matrix(batchCorrected_data) 
design              <- model.matrix(~0 + factor(treatment_arrays, levels = treatments)) 
colnames(design)    <- treatments 
num_parameters      <- ncol(design) 
fit                 <- lmFit(batchCorrected_data, design) 
 
cont_mat            <- makeContrasts(SS-Control, 
                                     Lymphoma-Control, 
                                     Cancer-Control, 
                                     PreMalignancy-Control, 
                                     SS-Lymphoma, 
                                     SS-Cancer, 
                                     SS-PreMalignancy, 
                                     Lymphoma-Cancer, 
                                     Lymphoma-PreMalignancy, 
                                     Cancer-PreMalignancy, 
                                     levels=treatments) 
fit2                <- contrasts.fit(fit, contrasts=cont_mat) 
fit2                <- eBayes(fit2) 
##'-----------------------------------------------------------------------------------------# 
comparisons <- c("SS - Control", "Lymphoma - Control", "Cancer - Control", 
                 "PreMalignancy - Control", "SS - Lymphoma", "SS - Cancer", 
                 "SS - PreMalignancy", "Lymphoma - Cancer", "Lymphoma - PreMalignancy", 
                 "Cancer - PreMalignancy") 
p_cut_off   <- 0.05 
fold_change <- 1.2 
i           <- 5 
 
gene_list_unfiltered <- topTable(fit2, 
                                 coef=comparisons[i], 
                                 number=Inf, 
                                 adjust.method="BH") 
 
gene_list            <- topTable(fit2, 
                                 coef=comparisons[i], 
                                 p.value=p_cut_off, 
                                 lfc=log2(fold_change), 
                                 number=Inf, 
                                 adjust.method="BH") 
##'-----------------------------------------------------------------------------------------# 
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S3 The qRT-PCR data for the remaining validated genes tested in the validation cohort. 
The table includes p values, fold changes and regulation in pSS-associated lymphoma. Fc 
was calculated according to the housekeeping gene normalisation   
Gene 
symbol 
Gene name p value 
Fold change 
and regulation  
CNPY3 Canopy FGF signaling regulator 3 0.163 1.09 ↓ 
CYFIP2 Cytoplasmic FMR1 interacting protein 2  0.1949 1.11 ↑ 
ESYT1 Extended synaptotagmin-like protein 1 0.1098 1.26 ↑ 
HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-like 1  0.3141 1.07 ↑ 
MAGED1 Melanoma antigen family D, 1 0.0617 1.30 ↑ 
POM121C POM121 transmembrane nucleoporin C 0.2661 1.00 ↑ 
PRPF8 Pre-mRNA processing factor 8 0.0515 1.19 ↑ 
RBP7 Retinol binding protein 7, cellular 0.6217 1.24 ↓ 
SEC61G Sec61 gamma subunit  0.0248 1.31 ↓ 
SF3A1 Splicing factor 3a, subunit 1, 120kDa 0.0005 1.39 ↑ 
SRP14 
Signal recognition particle 14kDa (homologous Alu RNA binding 
protein) 
0.0185 1.35 ↓ 
UBXN11 UBX domain protein 11 0.4145 1.10 ↓ 
VCP Valosin containing protein 0.037 1.20 ↑ 
 
S4 The qRT-PCR data for the remaining validated genes tested in the untreated pSS-
associated lymphoma. The table includes p values, fold changes and regulation in pSS-
associated lymphoma. Fc was calculated according to the housekeeping gene 
normalisation    
Gene 
symbol 
Gene name p value 
Fold change 
and regulation  
BMS1 BMS1 ribosome biogenesis factor  0.1695 1.17 ↓ 
C10orf32 Chromosome 10 open reading frame 32 0.8647 1.06 ↓ 
CBLL1 Cbl proto-oncogene-like 1, E3 ubiquitin protein ligase 0.0884 1.41 ↑ 
CNPY3 Canopy FGF signaling regulator 3 0.9406 1.10 ↓ 
CYFIP2 Cytoplasmic FMR1 interacting protein 2  0.5159 1.08 ↑ 
ESYT1 Extended synaptotagmin-like protein 1 0.5652 1.13 ↑ 
HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-like 1  0.2773 1.08 ↑ 
LEF1 Lymphoid enhancer-binding factor 1 0.1359 1.21 ↓ 
LGALS1 Lectin, galactoside-binding, soluble, 1  0.101 1.30 ↑ 
MAGED1 Melanoma antigen family D, 1 0.6701 1.03 ↑ 
MGST3 Microsomal glutathione S-transferase 3 0.0526 1.43 ↑ 
OAF OAF homolog (Drosophila) 0.0864 1.31 ↑ 
POM121C POM121 transmembrane nucleoporin C 0.2371 1.31 ↑ 
PRPF8 Pre-mRNA processing factor 8 0.9067 1.12 ↓ 
SEC61G Sec61 gamma subunit  0.628 1.05 ↑ 
SGK223 Homolog of rat pragma of Rnd2 0.5298 1.32 ↑ 
SRP14 
Signal recognition particle 14kDa (homologous Alu RNA binding 
protein) 
1.0000 1.22 ↑ 
UBXN11 UBX domain protein 11 0.8899 1.08 ↓ 
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S5 The canonical pathways in pSS-associated lymphoma. The table represents the canonical pathways in pSS vs pSS-associated lymphoma  
Ingenuity Canonical Pathways -log(p-value) Ratio z-score Overlapped 
downregulated 
genes 
Overlapped 
upregulated 
genes 
Molecules 
Aryl Hydrocarbon Receptor Signaling 3.99E+00 3.70E-02 NaN 1/135 (1%) 4/135 (3%) MYC,ALDH9A1,RBL2,HSP90B1,MGST3 
Histamine Degradation 3.12E+00 1.67E-01 NaN 1/12 (8%) 1/12 (8%) HNMT,ALDH9A1 
Unfolded protein response 3.09E+00 5.66E-02 NaN 0/53 (0%) 3/53 (6%) HSPA9,HSP90B1,VCP 
Neuregulin Signaling 2.50E+00 3.53E-02 NaN 0/85 (0%) 3/85 (4%) MYC,HSP90B1,PRKCQ 
T Cell Receptor Signaling 2.38E+00 3.19E-02 NaN 0/94 (0%) 3/94 (3%) PRKCQ,ITK,RASGRP1 
Telomerase Signaling 2.35E+00 3.12E-02 NaN 0/96 (0%) 3/96 (3%) MYC,HSP90B1,ETS1 
iCOS-iCOSL Signaling in T Helper Cells 2.33E+00 3.06E-02 NaN 0/98 (0%) 3/98 (3%) HLA-DRB1,PRKCQ,ITK 
CD28 Signaling in T Helper Cells 2.21E+00 2.78E-02 NaN 0/108 (0%) 3/108 (3%) HLA-DRB1,PRKCQ,ITK 
Molecular Mechanisms of Cancer 2.10E+00 1.39E-02 NaN 0/359 (0%) 5/359 (1%) NCSTN,MYC,PRKCQ,LEF1,RASGRP1 
Thyroid Cancer Signaling 2.10E+00 5.13E-02 NaN 0/39 (0%) 2/39 (5%) MYC,LEF1 
L-carnitine Biosynthesis 1.99E+00 3.33E-01 NaN 0/3 (0%) 1/3 (33%) ALDH9A1 
eNOS Signaling 1.94E+00 2.22E-02 NaN 0/135 (0%) 3/135 (2%) HSPA9,HSP90B1,PRKCQ 
Xenobiotic Metabolism Signaling 1.93E+00 1.56E-02 NaN 1/256 (0%) 3/256 (1%) ALDH9A1,HSP90B1,PRKCQ,MGST3 
Retinoate Biosynthesis II 1.86E+00 2.50E-01 NaN 1/4 (25%) 0/4 (0%) RBP7 
Endometrial Cancer Signaling 1.86E+00 3.85E-02 NaN 0/52 (0%) 2/52 (4%) MYC,LEF1 
Calcium-induced T Lymphocyte Apoptosis 1.84E+00 3.77E-02 NaN 0/53 (0%) 2/53 (4%) HLA-DRB1,PRKCQ 
Aldosterone Signaling in Epithelial Cells 1.81E+00 1.99E-02 NaN 0/151 (0%) 3/151 (2%) HSPA9,HSP90B1,PRKCQ 
Thrombopoietin Signaling 1.81E+00 3.64E-02 NaN 0/55 (0%) 2/55 (4%) MYC,PRKCQ 
ErbB4 Signaling 1.77E+00 3.45E-02 NaN 0/58 (0%) 2/58 (3%) NCSTN,PRKCQ 
Role of NFAT in Regulation of the Immune 
Response 
1.75E+00 1.87E-02 NaN 0/160 (0%) 3/160 (2%) HLA-DRB1,PRKCQ,ITK 
Cell Cycle: G1/S Checkpoint Regulation 1.70E+00 3.17E-02 NaN 0/63 (0%) 2/63 (3%) MYC,RBL2 
NRF2-mediated Oxidative Stress Response 1.63E+00 1.69E-02 NaN 1/177 (1%) 2/177 (1%) PRKCQ,VCP,MGST3 
Regulation of the Epithelial-Mesenchymal 
Transition Pathway 
1.61E+00 1.66E-02 NaN 0/181 (0%) 3/181 (2%) NCSTN,LEF1,ETS1 
Prolactin Signaling 1.58E+00 2.74E-02 NaN 0/73 (0%) 2/73 (3%) MYC,PRKCQ 
RAR Activation 1.57E+00 1.60E-02 NaN 1/187 (1%) 2/187 (1%) RBP7,PRKCQ,SMARCA2 
Acute Myeloid Leukemia Signaling 1.54E+00 2.60E-02 NaN 0/77 (0%) 2/77 (3%) MYC,LEF1 
Leukocyte Extravasation Signaling 1.54E+00 1.55E-02 NaN 0/193 (0%) 3/193 (2%) PRKCQ,ITK,RASGRP1 
Role of BRCA1 in DNA Damage Response 1.53E+00 2.56E-02 NaN 0/78 (0%) 2/78 (3%) RBL2,SMARCA2 
Prostate Cancer Signaling 1.51E+00 2.50E-02 NaN 0/80 (0%) 2/80 (3%) HSP90B1,LEF1 
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Factors Promoting Cardiogenesis in 
Vertebrates 
1.42E+00 2.25E-02 NaN 0/89 (0%) 2/89 (2%) PRKCQ,LEF1 
Chronic Myeloid Leukemia Signaling 1.39E+00 2.17E-02 NaN 0/92 (0%) 2/92 (2%) MYC,RBL2 
Assembly of RNA Polymerase III Complex 1.39E+00 8.33E-02 NaN 0/12 (0%) 1/12 (8%) SF3A1 
Glioma Signaling 1.38E+00 2.13E-02 NaN 0/94 (0%) 2/94 (2%) RBL2,PRKCQ 
Mouse Embryonic Stem Cell Pluripotency 1.38E+00 2.13E-02 NaN 0/94 (0%) 2/94 (2%) MYC,LEF1 
Nitric Oxide Signaling in the Cardiovascular 
System 
1.37E+00 2.11E-02 NaN 0/95 (0%) 2/95 (2%) HSP90B1,PRKCQ 
Huntington's Disease Signaling 1.36E+00 1.33E-02 NaN 0/226 (0%) 3/226 (1%) HSPA9,PRKCQ,SDHA 
HGF Signaling 1.30E+00 1.92E-02 NaN 0/104 (0%) 2/104 (2%) PRKCQ,ETS1 
The Visual Cycle 1.30E+00 6.67E-02 NaN 1/15 (7%) 0/15 (0%) RBP7 
Fatty Acid خ±-oxidation 1.30E+00 6.67E-02 NaN 0/15 (0%) 1/15 (7%) ALDH9A1 
Oxidative Ethanol Degradation III 1.30E+00 6.67E-02 NaN 0/15 (0%) 1/15 (7%) ALDH9A1 
PKCخ¸ Signaling in T Lymphocytes 1.27E+00 1.85E-02 NaN 0/108 (0%) 2/108 (2%) HLA-DRB1,PRKCQ 
Putrescine Degradation III 1.27E+00 6.25E-02 NaN 0/16 (0%) 1/16 (6%) ALDH9A1 
Tryptophan Degradation X (Mammalian, via 
Tryptamine) 
1.24E+00 5.88E-02 NaN 0/17 (0%) 1/17 (6%) ALDH9A1 
Protein Ubiquitination Pathway 1.24E+00 1.18E-02 NaN 1/254 (0%) 2/254 (1%) HSPA9,HSP90B1,PSMC1 
Glutathione Redox Reactions I 1.22E+00 5.56E-02 NaN 1/18 (6%) 0/18 (0%) MGST3 
P2Y Purigenic Receptor Signaling Pathway 1.20E+00 1.69E-02 NaN 0/118 (0%) 2/118 (2%) MYC,PRKCQ 
phagosome maturation 1.20E+00 1.69E-02 NaN 1/118 (1%) 1/118 (1%) HLA-DRB1,DYNLL1 
Ethanol Degradation IV 1.20E+00 5.26E-02 NaN 0/19 (0%) 1/19 (5%) ALDH9A1 
D-myo-inositol (1,4,5,6)-Tetrakisphosphate 
Biosynthesis 
1.18E+00 1.64E-02 NaN 1/122 (1%) 1/122 (1%) ATP1A1,NUDT14 
D-myo-inositol (3,4,5,6)-tetrakisphosphate 
Biosynthesis 
1.18E+00 1.64E-02 NaN 1/122 (1%) 1/122 (1%) ATP1A1,NUDT14 
Glucocorticoid Receptor Signaling 1.18E+00 1.11E-02 NaN 0/270 (0%) 3/270 (1%) HSPA9,HSP90B1,SMARCA2 
Cdc42 Signaling 1.17E+00 1.63E-02 NaN 0/123 (0%) 2/123 (2%) HLA-DRB1,ITK 
Dopamine Degradation 1.15E+00 4.76E-02 NaN 0/21 (0%) 1/21 (5%) ALDH9A1 
Endoplasmic Reticulum Stress Pathway 1.15E+00 4.76E-02 NaN 0/21 (0%) 1/21 (5%) HSP90B1 
Polyamine Regulation in Colon Cancer 1.13E+00 4.55E-02 NaN 0/22 (0%) 1/22 (5%) MYC 
Role of Macrophages, Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis 
1.12E+00 1.06E-02 NaN 0/284 (0%) 3/284 (1%) MYC,PRKCQ,LEF1 
B Cell Development 1.12E+00 4.35E-02 NaN 0/23 (0%) 1/23 (4%) HLA-DRB1 
TCA Cycle II (Eukaryotic) 1.12E+00 4.35E-02 NaN 0/23 (0%) 1/23 (4%) SDHA 
Estrogen-mediated S-phase Entry 1.10E+00 4.17E-02 NaN 0/24 (0%) 1/24 (4%) MYC 
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Glutathione-mediated Detoxification 1.10E+00 4.17E-02 NaN 1/24 (4%) 0/24 (0%) MGST3 
D-myo-inositol-5-phosphate Metabolism 1.08E+00 1.45E-02 NaN 1/138 (1%) 1/138 (1%) ATP1A1,NUDT14 
3-phosphoinositide Degradation 1.08E+00 1.44E-02 NaN 1/139 (1%) 1/139 (1%) ATP1A1,NUDT14 
Cell Cycle Control of Chromosomal 
Replication 
1.05E+00 3.70E-02 NaN 0/27 (0%) 1/27 (4%) RPA2 
Glioblastoma Multiforme Signaling 1.05E+00 1.38E-02 NaN 0/145 (0%) 2/145 (1%) MYC,LEF1 
3-phosphoinositide Biosynthesis 1.03E+00 1.34E-02 NaN 1/149 (1%) 1/149 (1%) ATP1A1,NUDT14 
Tec Kinase Signaling 1.02E+00 1.33E-02 NaN 0/150 (0%) 2/150 (1%) PRKCQ,ITK 
Role of p14/p19ARF in Tumor Suppression 1.02E+00 3.45E-02 NaN 0/29 (0%) 1/29 (3%) SF3A1 
Mitochondrial Dysfunction 1.01E+00 1.32E-02 NaN 0/152 (0%) 2/152 (1%) NCSTN,SDHA 
Retinoate Biosynthesis I 1.01E+00 3.33E-02 NaN 1/30 (3%) 0/30 (0%) RBP7 
Retinol Biosynthesis 1.01E+00 3.33E-02 NaN 1/30 (3%) 0/30 (0%) RBP7 
Ethanol Degradation II 1.01E+00 3.33E-02 NaN 0/30 (0%) 1/30 (3%) ALDH9A1 
Noradrenaline and Adrenaline Degradation 9.79E-01 3.12E-02 NaN 0/32 (0%) 1/32 (3%) ALDH9A1 
Autoimmune Thyroid Disease Signaling 9.54E-01 2.94E-02 NaN 0/34 (0%) 1/34 (3%) HLA-DRB1 
Wnt/ خ² -catenin Signaling 9.49E-01 1.20E-02 NaN 0/166 (0%) 2/166 (1%) MYC,LEF1 
Endothelin-1 Signaling 9.45E-01 1.20E-02 NaN 0/167 (0%) 2/167 (1%) MYC,PRKCQ 
B Cell Receptor Signaling 9.45E-01 1.20E-02 NaN 0/167 (0%) 2/167 (1%) PRKCQ,ETS1 
Nucleotide Excision Repair Pathway 9.42E-01 2.86E-02 NaN 0/35 (0%) 1/35 (3%) RPA2 
Antigen Presentation Pathway 9.31E-01 2.78E-02 NaN 0/36 (0%) 1/36 (3%) HLA-DRB1 
autophagy 9.31E-01 2.78E-02 NaN 1/36 (3%) 0/36 (0%) ATG12 
Notch Signaling 9.20E-01 2.70E-02 NaN 0/37 (0%) 1/37 (3%) NCSTN 
Allograft Rejection Signaling 8.98E-01 2.56E-02 NaN 0/39 (0%) 1/39 (3%) HLA-DRB1 
Graft-versus-Host Disease Signaling 8.98E-01 2.56E-02 NaN 0/39 (0%) 1/39 (3%) HLA-DRB1 
ILK Signaling 8.88E-01 1.10E-02 NaN 0/181 (0%) 2/181 (1%) MYC,LEF1 
Mechanisms of Viral Exit from Host Cells 8.78E-01 2.44E-02 NaN 0/41 (0%) 1/41 (2%) PRKCQ 
ERK/MAPK Signaling 8.73E-01 1.08E-02 NaN 0/185 (0%) 2/185 (1%) MYC,ETS1 
Superpathway of Inositol Phosphate 
Compounds 
8.69E-01 1.08E-02 NaN 1/186 (1%) 1/186 (1%) ATP1A1,NUDT14 
UVC-Induced MAPK Signaling 8.68E-01 2.38E-02 NaN 0/42 (0%) 1/42 (2%) PRKCQ 
Nur77 Signaling in T Lymphocytes 8.32E-01 2.17E-02 NaN 0/46 (0%) 1/46 (2%) HLA-DRB1 
nNOS Signaling in Neurons 8.32E-01 2.17E-02 NaN 0/46 (0%) 1/46 (2%) PRKCQ 
OX40 Signaling Pathway 8.15E-01 2.08E-02 NaN 0/48 (0%) 1/48 (2%) HLA-DRB1 
Amyloid Processing 7.98E-01 2.00E-02 NaN 0/50 (0%) 1/50 (2%) NCSTN 
LPS/IL-1 Mediated Inhibition of RXR 
Function 
7.92E-01 9.62E-03 NaN 1/208 (0%) 1/208 (0%) ALDH9A1,MGST3 
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UVB-Induced MAPK Signaling 7.75E-01 1.89E-02 NaN 0/53 (0%) 1/53 (2%) PRKCQ 
Serotonin Degradation 7.61E-01 1.82E-02 NaN 0/55 (0%) 1/55 (2%) ALDH9A1 
ErbB2-ErbB3 Signaling 7.54E-01 1.79E-02 NaN 0/56 (0%) 1/56 (2%) MYC 
Phospholipase C Signaling 7.51E-01 9.05E-03 NaN 0/221 (0%) 2/221 (1%) PRKCQ,ITK 
Myc Mediated Apoptosis Signaling 7.40E-01 1.72E-02 NaN 0/58 (0%) 1/58 (2%) MYC 
Colorectal Cancer Metastasis Signaling 7.22E-01 8.66E-03 NaN 0/231 (0%) 2/231 (1%) MYC,LEF1 
CCR5 Signaling in Macrophages 7.14E-01 1.61E-02 NaN 0/62 (0%) 1/62 (2%) PRKCQ 
T Helper Cell Differentiation 7.14E-01 1.61E-02 NaN 0/62 (0%) 1/62 (2%) HLA-DRB1 
ERK5 Signaling 7.14E-01 1.61E-02 NaN 0/62 (0%) 1/62 (2%) MYC 
GM-CSF Signaling 7.14E-01 1.61E-02 NaN 0/62 (0%) 1/62 (2%) ETS1 
Mitotic Roles of Polo-Like Kinase 7.07E-01 1.59E-02 NaN 0/63 (0%) 1/63 (2%) HSP90B1 
Pyridoxal 5'-phosphate Salvage Pathway 7.07E-01 1.59E-02 NaN 0/63 (0%) 1/63 (2%) PRKCQ 
Hypoxia Signaling in the Cardiovascular 
System 
7.07E-01 1.59E-02 NaN 0/63 (0%) 1/63 (2%) HSP90B1 
Remodeling of Epithelial Adherens Junctions 6.89E-01 1.52E-02 NaN 0/66 (0%) 1/66 (2%) CBLL1 
GABA Receptor Signaling 6.89E-01 1.52E-02 NaN 0/66 (0%) 1/66 (2%) ALDH9A1 
Erythropoietin Signaling 6.83E-01 1.49E-02 NaN 0/67 (0%) 1/67 (1%) PRKCQ 
Melatonin Signaling 6.78E-01 1.47E-02 NaN 0/68 (0%) 1/68 (1%) PRKCQ 
Macropinocytosis Signaling 6.78E-01 1.47E-02 NaN 0/68 (0%) 1/68 (1%) PRKCQ 
Growth Hormone Signaling 6.72E-01 1.45E-02 NaN 0/69 (0%) 1/69 (1%) PRKCQ 
Renal Cell Carcinoma Signaling 6.72E-01 1.45E-02 NaN 0/69 (0%) 1/69 (1%) ETS1 
Basal Cell Carcinoma Signaling 6.72E-01 1.45E-02 NaN 0/69 (0%) 1/69 (1%) LEF1 
IL-3 Signaling 6.61E-01 1.41E-02 NaN 0/71 (0%) 1/71 (1%) PRKCQ 
Small Cell Lung Cancer Signaling 6.61E-01 1.41E-02 NaN 0/71 (0%) 1/71 (1%) MYC 
IL-4 Signaling 6.61E-01 1.41E-02 NaN 0/71 (0%) 1/71 (1%) HLA-DRB1 
Role of Wnt/GSK-3 خ²  Signaling in the 
Pathogenesis of Influenza 
6.56E-01 1.39E-02 NaN 0/72 (0%) 1/72 (1%) LEF1 
LPS-stimulated MAPK Signaling 6.51E-01 1.37E-02 NaN 0/73 (0%) 1/73 (1%) PRKCQ 
NF-؛خB Activation by Viruses 6.51E-01 1.37E-02 NaN 0/73 (0%) 1/73 (1%) PRKCQ 
STAT3 Pathway 6.51E-01 1.37E-02 NaN 0/73 (0%) 1/73 (1%) MYC 
Communication between Innate and Adaptive 
Immune Cells 
6.45E-01 1.35E-02 NaN 0/74 (0%) 1/74 (1%) HLA-DRB1 
BMP signaling pathway 6.45E-01 1.35E-02 NaN 0/74 (0%) 1/74 (1%) MAGED1 
VEGF Family Ligand-Receptor Interactions 6.40E-01 1.33E-02 NaN 0/75 (0%) 1/75 (1%) PRKCQ 
HER-2 Signaling in Breast Cancer 6.35E-01 1.32E-02 NaN 0/76 (0%) 1/76 (1%) PRKCQ 
Altered T Cell and B Cell Signaling in 6.35E-01 1.32E-02 NaN 0/76 (0%) 1/76 (1%) HLA-DRB1 
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Rheumatoid Arthritis 
VDR/RXR Activation 6.30E-01 1.30E-02 NaN 0/77 (0%) 1/77 (1%) PRKCQ 
PDGF Signaling 6.30E-01 1.30E-02 NaN 0/77 (0%) 1/77 (1%) MYC 
GPCR-Mediated Nutrient Sensing in 
Enteroendocrine Cells 
6.02E-01 1.20E-02 NaN 0/83 (0%) 1/83 (1%) PRKCQ 
خ±-Adrenergic Signaling 5.93E-01 1.18E-02 NaN 0/85 (0%) 1/85 (1%) PRKCQ 
ErbB Signaling 5.93E-01 1.18E-02 NaN 0/85 (0%) 1/85 (1%) PRKCQ 
Bladder Cancer Signaling 5.89E-01 1.16E-02 NaN 0/86 (0%) 1/86 (1%) MYC 
G Beta Gamma Signaling 5.80E-01 1.14E-02 NaN 0/88 (0%) 1/88 (1%) PRKCQ 
Apoptosis Signaling 5.80E-01 1.14E-02 NaN 0/88 (0%) 1/88 (1%) PRKCQ 
Virus Entry via Endocytic Pathways 5.76E-01 1.12E-02 NaN 0/89 (0%) 1/89 (1%) PRKCQ 
Crosstalk between Dendritic Cells and 
Natural Killer Cells 
5.76E-01 1.12E-02 NaN 0/89 (0%) 1/89 (1%) HLA-DRB1 
PPAR Signaling 5.72E-01 1.11E-02 NaN 0/90 (0%) 1/90 (1%) HSP90B1 
Salvage Pathways of Pyrimidine 
Ribonucleotides 
5.68E-01 1.10E-02 NaN 0/91 (0%) 1/91 (1%) PRKCQ 
Fc خ³ Receptor-mediated Phagocytosis in 
Macrophages and Monocytes 
5.63E-01 1.09E-02 NaN 0/92 (0%) 1/92 (1%) PRKCQ 
Oxidative Phosphorylation 5.63E-01 1.09E-02 NaN 0/92 (0%) 1/92 (1%) SDHA 
Neuropathic Pain Signaling In Dorsal Horn 
Neurons 
5.37E-01 1.01E-02 NaN 0/99 (0%) 1/99 (1%) PRKCQ 
phagosome formation 5.37E-01 1.01E-02 NaN 0/99 (0%) 1/99 (1%) PRKCQ 
Cholecystokinin/Gastrin-mediated Signaling 5.33E-01 1.00E-02 NaN 0/100 (0%) 1/100 (1%) PRKCQ 
Type I Diabetes Mellitus Signaling 5.29E-01 9.90E-03 NaN 0/101 (0%) 1/101 (1%) HLA-DRB1 
Rac Signaling 5.22E-01 9.71E-03 NaN 0/103 (0%) 1/103 (1%) CYFIP2 
Corticotropin Releasing Hormone Signaling 5.12E-01 9.43E-03 NaN 0/106 (0%) 1/106 (1%) PRKCQ 
Fc Epsilon RI Signaling 5.08E-01 9.35E-03 NaN 0/107 (0%) 1/107 (1%) PRKCQ 
fMLP Signaling in Neutrophils 5.08E-01 9.35E-03 NaN 0/107 (0%) 1/107 (1%) PRKCQ 
Natural Killer Cell Signaling 5.05E-01 9.26E-03 NaN 0/108 (0%) 1/108 (1%) PRKCQ 
Renin-Angiotensin Signaling 5.05E-01 9.26E-03 NaN 0/108 (0%) 1/108 (1%) PRKCQ 
Androgen Signaling 4.98E-01 9.09E-03 NaN 0/110 (0%) 1/110 (1%) PRKCQ 
CCR3 Signaling in Eosinophils 4.92E-01 8.93E-03 NaN 0/112 (0%) 1/112 (1%) PRKCQ 
Sperm Motility 4.89E-01 8.85E-03 NaN 0/113 (0%) 1/113 (1%) PRKCQ 
Type II Diabetes Mellitus Signaling 4.86E-01 8.77E-03 NaN 0/114 (0%) 1/114 (1%) PRKCQ 
p38 MAPK Signaling 4.83E-01 8.70E-03 NaN 0/115 (0%) 1/115 (1%) MYC 
Synaptic Long Term Potentiation 4.80E-01 8.62E-03 NaN 0/116 (0%) 1/116 (1%) PRKCQ 
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14-3-3-mediated Signaling 4.80E-01 8.62E-03 NaN 0/116 (0%) 1/116 (1%) PRKCQ 
p70S6K Signaling 4.74E-01 8.47E-03 NaN 0/118 (0%) 1/118 (1%) PRKCQ 
Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses 
4.71E-01 8.40E-03 NaN 0/119 (0%) 1/119 (1%) PRKCQ 
PI3K/AKT Signaling 4.68E-01 8.33E-03 NaN 0/120 (0%) 1/120 (1%) HSP90B1 
Hereditary Breast Cancer Signaling 4.51E-01 7.94E-03 NaN 0/126 (0%) 1/126 (1%) SMARCA2 
GNRH Signaling 4.48E-01 7.87E-03 NaN 0/127 (0%) 1/127 (1%) PRKCQ 
Ovarian Cancer Signaling 4.42E-01 7.75E-03 NaN 0/129 (0%) 1/129 (1%) LEF1 
IL-12 Signaling and Production in 
Macrophages 
4.37E-01 7.63E-03 NaN 0/131 (0%) 1/131 (1%) PRKCQ 
Human Embryonic Stem Cell Pluripotency 4.37E-01 7.63E-03 NaN 0/131 (0%) 1/131 (1%) LEF1 
Protein Kinase A Signaling 4.36E-01 5.41E-03 NaN 0/370 (0%) 2/370 (1%) PRKCQ,LEF1 
Synaptic Long Term Depression 4.27E-01 7.41E-03 NaN 0/135 (0%) 1/135 (1%) PRKCQ 
Epithelial Adherens Junction Signaling 4.07E-01 6.99E-03 NaN 0/143 (0%) 1/143 (1%) LEF1 
Gخ±q Signaling 4.03E-01 6.90E-03 NaN 0/145 (0%) 1/145 (1%) PRKCQ 
CXCR4 Signaling 3.89E-01 6.62E-03 NaN 0/151 (0%) 1/151 (1%) PRKCQ 
Gap Junction Signaling 3.89E-01 6.62E-03 NaN 0/151 (0%) 1/151 (1%) PRKCQ 
Dopamine-DARPP32 Feedback in cAMP 
Signaling 
3.76E-01 6.37E-03 NaN 0/157 (0%) 1/157 (1%) PRKCQ 
Hepatic Cholestasis 3.74E-01 6.33E-03 NaN 0/158 (0%) 1/158 (1%) PRKCQ 
Dendritic Cell Maturation 3.68E-01 6.21E-03 NaN 0/161 (0%) 1/161 (1%) HLA-DRB1 
NF-؛خB Signaling 3.62E-01 6.10E-03 NaN 0/164 (0%) 1/164 (1%) PRKCQ 
PPARخ±/RXRخ± Activation 3.60E-01 6.06E-03 NaN 0/165 (0%) 1/165 (1%) HSP90B1 
Acute Phase Response Signaling 3.56E-01 5.99E-03 NaN 1/167 (1%) 0/167 (0%) RBP7 
CREB Signaling in Neurons 3.52E-01 5.92E-03 NaN 0/169 (0%) 1/169 (1%) PRKCQ 
Role of NFAT in Cardiac Hypertrophy 3.41E-01 5.71E-03 NaN 0/175 (0%) 1/175 (1%) PRKCQ 
AMPK Signaling 3.39E-01 5.68E-03 NaN 0/176 (0%) 1/176 (1%) SMARCA2 
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages 
3.34E-01 5.59E-03 NaN 0/179 (0%) 1/179 (1%) PRKCQ 
mTOR Signaling 3.29E-01 5.49E-03 NaN 0/182 (0%) 1/182 (1%) PRKCQ 
IL-8 Signaling 3.27E-01 5.46E-03 NaN 0/183 (0%) 1/183 (1%) PRKCQ 
Thrombin Signaling 3.20E-01 5.35E-03 NaN 0/187 (0%) 1/187 (1%) PRKCQ 
Systemic Lupus Erythematosus Signaling 3.19E-01 5.32E-03 NaN 0/188 (0%) 1/188 (1%) PRPF8 
Breast Cancer Regulation by Stathmin1 3.15E-01 5.26E-03 NaN 0/190 (0%) 1/190 (1%) PRKCQ 
Actin Cytoskeleton Signaling 2.85E-01 4.76E-03 NaN 0/210 (0%) 1/210 (0%) CYFIP2 
Role of Osteoblasts, Osteoclasts and 2.80E-01 4.67E-03 NaN 0/214 (0%) 1/214 (0%) LEF1 
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Chondrocytes in Rheumatoid Arthritis 
G-Protein Coupled Receptor Signaling 2.31E-01 3.94E-03 NaN 0/254 (0%) 1/254 (0%) RASGRP1 
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S6 DEGs list in pSS vs. healthy control. The (-) sign in FC column represents the 
downregulated genes in pSS-associated lymphoma (p<0.02, FC cut off=1.2). NAs excluded 
Gene symbol Adjusted p value FC Gene symbol Adjusted p 
value 
FC 
IFI27 6.1203E-07 11.51 IRF7 1.1052E-07 1.99 
IFI44L 9.8518E-11 8.75 OAS1 0.00286509 1.98 
ISG15 2.1509E-10 5.63 LAP3 1.5486E-06 1.96 
IFIT1 9.8518E-11 5.60 PARP9 2.3007E-08 1.96 
RSAD2 1.6184E-10 5.39 OAS2 2.485E-07 1.93 
IFI44 1.0004E-09 5.23 USP18 1.027E-05 1.92 
OAS3 8.2797E-10 4.35 PARP14 8.0137E-09 1.92 
EPSTI1 9.8518E-11 4.29 OAS2 1.2484E-07 1.91 
IFIT3 9.8518E-11 4.28 HERC6 2.1619E-06 1.89 
IFITM3 6.0553E-09 4.09 HELZ2 1.8633E-07 1.87 
HERC5 2.1509E-10 4.04 IFIH1 1.1189E-06 1.86 
LY6E 1.6081E-08 3.98 TIMM10 0.00141889 1.86 
IFI6 1.564E-10 3.64 PARP12 5.9388E-07 1.83 
OAS1 1.1626E-09 3.61 SPATS2L 3.8514E-06 1.80 
MX1 1.3295E-09 3.56 STAT1 4.7985E-08 1.79 
OASL 1.564E-10 3.45 SCO2 1.8633E-07 1.79 
OAS1 2.278E-09 3.33 MT1A 1.0666E-05 1.79 
XAF1 1.1351E-10 3.19 DDX60 1.8622E-06 1.78 
IFIT3 1.1052E-07 3.05 HLA-DRB4 0.00011162 1.78 
XAF1 8.9622E-09 3.01 STAT2 2.8561E-08 1.77 
OAS2 1.1833E-07 2.95 RTP4 7.1145E-07 1.77 
IFIT3 3.2097E-08 2.84 TNFAIP6 0.00337936 1.76 
IFIT2 1.1833E-07 2.70 PARP9 3.9313E-08 1.75 
OTOF 0.00182888 2.53 OASL 6.2852E-08 1.75 
EIF2AK2 6.4838E-09 2.43 BATF2 1.5139E-06 1.74 
SERPING1 6.3208E-08 2.37 CEACAM1 3.7958E-07 1.72 
SAMD9L 8.2597E-10 2.31 STAT1 1.0171E-08 1.71 
GBP1 1.7593E-07 2.28 STAT1 1.5486E-06 1.69 
HLA-DRB6 0.01348724 2.26 UBE2L6 3.2965E-07 1.68 
IRF7 6.2852E-08 2.19 DHX58 1.2289E-06 1.67 
ZBP1 4.7985E-08 2.12 GBP1P1 5.1765E-07 1.63 
IFI44L 2.2601E-06 2.11 FBXO6 3.3811E-07 1.63 
TRIM22 3.3867E-08 2.10 IFITM1 1.1052E-07 1.63 
HES4 2.7065E-05 2.09 IFI16 3.3811E-07 1.60 
IFI6 3.9313E-08 2.07 MX2 1.815E-05 1.60 
OAS1 7.1042E-07 2.06 BST2 8.0137E-09 1.60 
IFI35 9.3684E-09 2.04 CEACAM1 8.0804E-07 1.58 
GBP1 1.1189E-06 2.03 TNFSF10 4.2476E-05 1.56 
MT2A 1.9606E-06 2.03 FCGR1A 0.00599652 1.55 
GBP5 8.0916E-06 1.99 LAMP3 2.5802E-07 1.54 
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SHISA5 9.1194E-06 1.54 TOR1B 0.00017337 1.36 
DHRS9 0.00172583 1.54 APOBEC3A 0.02503283 1.36 
FCGR1B 0.01085872 1.53 HSH2D 0.00067639 1.36 
TNFSF13B 0.00019361 1.53 SP110 0.00056916 1.35 
OAS3 6.4975E-07 1.53 TYMP 0.00218665 1.35 
GBP4 0.00020481 1.53 CXCL10 0.02057559 1.35 
CHMP5 0.01816947 1.53 C3AR1 4.2476E-05 1.35 
TMEM140 0.00032783 1.52 TRIM69 9.3418E-06 1.34 
PARP10 2.9039E-06 1.52 CASP1 0.00590912 1.34 
SAMD9 0.00668398 1.52 LGALS9 9.1817E-05 1.34 
DDX60L 0.00016309 1.52 CMTR1 2.3946E-06 1.33 
PLSCR1 3.5562E-05 1.51 PIK3AP1 0.02021398 1.33 
REC8 1.5429E-08 1.50 C1QB 0.04448298 1.33 
DHRS9 0.01251414 1.50 GPR1 0.02591635 1.33 
DDX58 2.2505E-06 1.49 CASP1 0.01348724 1.33 
IFIT5 0.00056916 1.48 ISG20 0.00029951 1.32 
ANKRD22 0.03561342 1.47 DRAP1 0.00037743 1.32 
TAP1 0.00025813 1.47 GBP2 0.00681183 1.31 
CCR1 0.00062612 1.46 NT5C3A 0.03924027 1.31 
IRF9 4.1905E-08 1.46 GCH1 2.9457E-05 1.31 
TMEM123 0.03561342 1.46 NUB1 0.000285 1.31 
PSME2 8.4344E-07 1.45 RHBDF2 0.00110442 1.30 
TDRD7 6.1203E-07 1.45 FGD2 0.02977371 1.30 
TNFSF13B 0.00069558 1.45 IFI30 0.03504812 1.30 
FCGR1C 0.00484405 1.45 MAFB 0.02364289 1.30 
CMPK2 2.6863E-06 1.44 LGALS9 0.00011464 1.30 
UBE2L6 0.00019071 1.44 SMCO4 0.00608333 1.30 
PHF11 2.8262E-06 1.43 GPBAR1 0.04494512 1.30 
SP110 9.9778E-05 1.43 GALM 0.0086087 1.29 
LGALS3BP 0.00038232 1.42 SP140 0.00221738 1.29 
TAP2 0.00013868 1.42 SP110 0.01097291 1.29 
LAG3 0.01843014 1.42 CTSL 0.01365326 1.29 
BLVRA 3.1112E-05 1.41 TRIM38 0.00510626 1.28 
FAM46A 2.2154E-05 1.40 C19orf66 4.4689E-05 1.28 
PHF11 0.00015576 1.39 ADAR 0.00399478 1.28 
UNC93B1 8.7056E-05 1.39 SAT1 0.00892901 1.28 
SP110 0.00043463 1.39 IFIT1 0.00267798 1.28 
MOV10 8.5572E-06 1.38 PSMB9 0.02475062 1.28 
TRIM5 0.00013588 1.38 OAS2 0.00012809 1.27 
VAMP5 0.00127331 1.38 SCARB2 0.00056916 1.27 
CEACAM1 4.2476E-05 1.36 LOC100128274 0.00587583 1.27 
IL1RN 0.02859237 1.36 ANKFY1 0.00011731 1.27 
TYMP 0.00290922 1.36 SEPT4 0.01100047 1.27 
ADAR 3.3401E-05 1.36 RHBDF2 0.00243183 1.26 
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SP100 0.00011464 1.26 IMPA2 0.00518347 -1.39 
TRAFD1 0.00267487 1.26 GPR162 0.02652862 -1.37 
CTSL 0.00854154 1.26 PYGL 0.03946276 -1.35 
TRIM21 0.00217263 1.26 FAM212B 0.00969497 -1.32 
HLA-A 0.0165758 1.26 PPM1F 0.0006649 -1.31 
HLA-F 0.03282891 1.25 RPL3 0.00202947 -1.30 
PSMB9 0.00165278 1.25 MIR181A2HG 0.03875588 -1.29 
C1orf85 0.02995833 1.25 RPS5 0.01348724 -1.28 
TRIM25 0.01463022 1.25 TBL1X 0.01551496 -1.27 
MT1G 0.00087699 1.25 RXRA 0.02023698 -1.27 
TYMP 0.02107649 1.24 WLS 0.04310778 -1.27 
ETV7 0.00012809 1.24 EIF3L 0.00186693 -1.26 
TRIM6 0.00056916 1.24 EIF3L 0.00026111 -1.26 
BTN3A1 0.02976317 1.24 IMPDH1 0.011807 -1.26 
LYSMD2 0.02394556 1.24 FAM101B 0.00902316 -1.26 
LMO2 0.02672869 1.24 IRS2 0.04448298 -1.26 
TYMP 0.03490352 1.24 EEF1G 0.04786736 -1.25 
ZC3HAV1 0.00280296 1.24 TBC1D14 0.00376538 -1.25 
PCK2 0.00025813 1.23 RPS3 0.0101884 -1.25 
LHFPL2 0.04327692 1.23 ICAM3 0.00881026 -1.25 
REC8 1.0666E-05 1.23 CCNY 0.00027901 -1.25 
RNF213 0.04533332 1.23 RPS14 0.03669829 -1.25 
DUSP5 0.00235267 1.23 EEF2 0.00188502 -1.24 
ZC3HAV1 0.00787496 1.22 RPS6KA5 0.01089737 -1.24 
ACOT9 0.00620092 1.22 ZNF746 0.00280527 -1.24 
MT1IP 0.00362303 1.22 EIF4B 0.00071312 -1.23 
TRIM5 7.4935E-05 1.21 FEZ1 0.00890452 -1.23 
SOCS1 0.00255775 1.21 RASSF2 0.02995833 -1.23 
ANKFY1 0.00045049 1.21 RPS14 0.03715746 -1.23 
CD38 0.03927095 1.21 RPS8 0.04823418 -1.22 
MYD88 0.01463022 1.21 CCNJL 0.01884647 -1.22 
HLA-DRA 0.03421476 1.21 SCAP 0.02756616 -1.21 
TRIM56 0.00404656 1.21 ARRB1 0.03875588 -1.21 
GADD45B 0.00532618 1.21 RPL13A 0.02685321 -1.21 
CCL2 0.00349719 1.21 PTOV1 0.00205049 -1.21 
BTN3A3 0.00510626 1.21 TP53INP2 0.00344213 -1.21 
SP100 0.00100736 1.20 TPRG1L 0.00188502 -1.20 
MYOF 0.03504812 1.20 DSC1 0.00023024 -1.20 
ODF3B 0.00058825 1.20    
EPB41L3 0.01796162 1.20    
ATF3 0.00029951 1.20    
HLA-DRB4 0.02191445 -2.24    
MYOM2 0.00632069 -1.84    
TXNDC12 0.00356056 -1.46    
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S7 DEGs list in pSS-paraproteinemia vs. healthy control. The (-) sign in FC column 
represents the downregulated genes in pSS-associated lymphoma (p<0.02, FC cut off =1.2). 
NAs excluded 
Gene symbol Adjusted p value FC Gene symbol Adjusted p value FC 
IFI27 0.00078165 9.26 PARP14 0.0000452 1.82 
IFI44L 0.00000159 7.62 USP18 0.00393644 1.82 
IFIT1 0.00000159 5.09 MT1A 0.00082371 1.80 
ISG15 0.00000481 4.88 TNFAIP6 0.02834293 1.80 
RSAD2 0.00000481 4.61 OAS2 0.00069217 1.80 
IFI44 0.0000683 4.05 TIMM10 0.04089623 1.79 
IFIT3 0.00000159 3.82 LAP3 0.00450693 1.76 
IFITM3 0.000018 3.79 GBP1 0.02173078 1.76 
OAS3 0.000015 3.76 SCO2 0.00012054 1.76 
HERC5 0.00000444 3.66 OAS2 0.00092249 1.73 
IFI6 0.00000147 3.66 MX2 0.0000952 1.73 
EPSTI1 0.00000458 3.63 TRIM22 0.00502449 1.71 
LY6E 0.0000627 3.59 PARP9 0.00142196 1.69 
MX1 0.000005 3.39 OASL 0.00014469 1.67 
OAS1 0.00000938 3.29 STAT2 0.00017389 1.67 
OASL 0.00000159 3.27 SPATS2L 0.00469705 1.66 
OAS1 0.00000798 3.15 BATF2 0.00208978 1.63 
XAF1 0.00000798 3.00 DHX58 0.00062508 1.63 
XAF1 0.00000274 2.93 STAT1 0.00117505 1.61 
OAS2 0.00017389 2.76 GBP1 0.04749386 1.60 
IFIT3 0.00165209 2.48 DDX60 0.0086334 1.59 
EIF2AK2 0.00000444 2.48 BST2 0.00000798 1.59 
IFIT3 0.0007451 2.37 TNFSF10 0.00142196 1.59 
IFIT2 0.00196135 2.24 RTP4 0.00471405 1.59 
HES4 0.00070573 2.19 PARP10 0.0000795 1.58 
OAS1 0.01079063 2.15 TNFSF13B 0.00225167 1.58 
IRF7 0.0000931 2.10 IFITM1 0.00023134 1.56 
IRF7 0.00000938 2.09 STAT1 0.00047068 1.56 
SERPING1 0.00068254 2.09 PARP9 0.00215663 1.54 
SAMD9L 0.0000261 2.08 IFIH1 0.03874027 1.53 
IFI44L 0.0012519 2.00 CEACAM1 0.00803466 1.51 
OAS1 0.00057187 1.97 FBXO6 0.00185527 1.51 
ZBP1 0.00019114 1.97 UBE2L6 0.00502449 1.50 
IFI6 0.0000927 1.97 SHISA5 0.00293771 1.49 
MT2A 0.00076998 1.96 IFI16 0.00211597 1.48 
IFI35 0.0000348 1.95 OAS3 0.00069217 1.48 
HELZ2 0.0000703 1.87 DDX58 0.0005829 1.48 
HERC6 0.00066256 1.85 TNFSF13B 0.00890402 1.47 
PARP12 0.00012054 1.84 CEACAM1 0.00421342 1.46 
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REC8 0.0000823 1.44 ANKFY1 0.00443378 1.27 
IRF9 0.0000627 1.44 PSMB9 0.01873972 1.26 
FAM46A 0.00060689 1.43 KIAA0319L 0.01143196 1.26 
BLVRA 0.00097532 1.43 SP100 0.00125743 1.26 
GBP1P1 0.01832553 1.42 ODF3B 0.00068254 1.26 
ISG20 0.00024796 1.42 TRIM21 0.04027824 1.25 
UNC93B1 0.00153611 1.42 MS4A14 0.03229019 1.25 
TYMP 0.00661229 1.41 GSTO1 0.04427576 1.24 
TYMP 0.01229455 1.41 TRIM69 0.04802239 1.24 
VAMP5 0.01037169 1.41 ACOT9 0.03438561 1.23 
RNF213 0.04487247 1.41 ZC3HAV1 0.04241708 1.23 
FGD2 0.02784943 1.40 TTC21A 0.00048808 1.23 
SP110 0.01037169 1.39 TRIM56 0.02426733 1.23 
DRAP1 0.0007451 1.39 PCK2 0.01079063 1.23 
VCAN 0.04857966 1.39 TRIM14 0.0007451 1.21 
KLHDC8B 0.03177238 1.39 CD86 0.03479376 1.21 
PLSCR1 0.03471629 1.38 NELL2 0.0016615 -1.51 
LAMP3 0.00940818 1.38 TXNDC12 0.04806856 -1.45 
LGALS9 0.00091277 1.38 BCL11B 0.03711457 -1.32 
CASP1 0.03962541 1.37 EIF3L 0.00087021 -1.31 
MOV10 0.00171684 1.36 EIF4B 0.00364144 -1.27 
ADAR 0.00197242 1.36 TBC1D14 0.02947428 -1.27 
LGALS9 0.00044535 1.36 EEF2 0.01107357 -1.27 
PHF11 0.01650733 1.36 SERTAD2 0.03359516 -1.26 
TOR1B 0.00695755 1.36 FEZ1 0.03100429 -1.26 
SCARB2 0.00082371 1.34 ALDOC 0.02060631 -1.26 
CMPK2 0.01107357 1.34 GTF2IP1 0.00417508 -1.26 
SAT1 0.02060631 1.33 LRRC26 0.00242618 -1.26 
TYMP 0.01930483 1.33 EIF3L 0.03677415 -1.25 
TDRD7 0.00974749 1.33 CTDSP2 0.04539763 -1.25 
MT1G 0.00061761 1.33 ANXA7 0.00171491 -1.23 
PHF11 0.01722046 1.32 PAQR8 0.03493695 -1.22 
PSME2 0.01372558 1.32 SIAH1 0.01998406 -1.22 
TRIM38 0.02173078 1.32 ESYT2 0.03403468 -1.22 
CMTR1 0.00153534 1.30 NMT2 0.03644079 -1.22 
TYMP 0.03229019 1.30 SMARCA2 0.03358119 -1.22 
HK3 0.02598473 1.30 SIN3A 0.01180687 -1.22 
CEACAM1 0.02868831 1.29 CDKN1B 0.03711457 -1.22 
REC8 0.0000266 1.29 SESN1 0.01079063 -1.21 
RRAS 0.04052875 1.28 MBP 0.02598473 -1.21 
MS4A4A 0.00082371 1.28 MID2 0.0000795 -1.21 
SP100 0.00185527 1.28 LINC00623 0.03677967 -1.21 
MT1IP 0.0032513 1.28    
C19orf66 0.00400343 1.27    
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S8 DEGs list in pSS-other cancers vs. healthy control. The (-) sign in FC column represents 
the downregulated genes in pSS-associated lymphoma (p<0.02, FC cut off =1.2). NAs 
excluded 
Gene symbol Adjusted p value FC Gene symbol Adjusted p value FC 
IFI44L 8.90E-05 7.13 GBP1 0.045682442 1.81 
IFI27 0.03815265 6.60 PARP12 0.001679555 1.80 
IFIT1 8.90E-05 4.90 HERC6 0.007581113 1.80 
ISG15 8.90E-05 4.79 OAS2 0.003663257 1.77 
RSAD2 0.000102181 4.43 OAS2 0.006587646 1.77 
IFIT3 5.16E-05 4.00 USP18 0.034708812 1.77 
IFI44 0.00085592 3.95 STAT2 0.000233021 1.76 
OAS3 0.000166919 3.77 MT1A 0.01245208 1.74 
EPSTI1 8.90E-05 3.62 MX2 0.000929208 1.72 
LY6E 0.000653176 3.56 TRIM22 0.024572779 1.72 
HERC5 8.90E-05 3.55 STAT1 0.00167034 1.69 
MX1 8.90E-05 3.53 OASL 0.000880267 1.69 
OAS1 8.90E-05 3.42 STAT1 0.000233021 1.67 
IFI6 8.90E-05 3.28 PARP9 0.015134363 1.65 
OAS1 0.000102181 3.16 BATF2 0.010675641 1.64 
IFITM3 0.003696931 3.07 BST2 8.90E-05 1.61 
OASL 8.90E-05 3.06 DHX58 0.007337187 1.60 
XAF1 7.27E-05 3.01 UBE2L6 0.006303719 1.58 
XAF1 0.00017948 2.90 TNFSF13B 0.014490376 1.57 
IFIT3 0.003414857 2.68 CEACAM1 0.013311905 1.57 
OAS2 0.002156565 2.68 SP110 0.000880267 1.56 
IFIT3 0.000852243 2.63 RTP4 0.03815265 1.56 
EIF2AK2 8.90E-05 2.43 PARP10 0.001909718 1.54 
HES4 0.00121236 2.34 TNFSF10 0.03188489 1.52 
IFIT2 0.010804285 2.25 PARP9 0.022472172 1.51 
IRF7 0.000866371 2.10 FAM46A 0.000451667 1.50 
SAMD9L 0.000236626 2.09 TNFSF13B 0.024845865 1.50 
LAP3 0.000774552 2.06 REC8 0.00014025 1.50 
ZBP1 0.001019367 2.00 UNC93B1 0.00109746 1.49 
IFI35 0.00017948 1.99 IRF9 0.000102181 1.49 
SERPING1 0.012098879 1.97 FGD2 0.029604923 1.46 
MT2A 0.005060379 1.96 IFITM1 0.016946873 1.46 
IFI6 0.000880267 1.96 IFI16 0.026198366 1.45 
IRF7 0.000710192 1.96 SHISA5 0.03786659 1.45 
OAS1 0.005093636 1.94 OAS3 0.011555212 1.44 
PARP14 0.000102181 1.91 CEACAM1 0.042650839 1.43 
SCO2 0.000166919 1.87 LAMP3 0.018542689 1.42 
HELZ2 0.000880267 1.85 PSME2 0.005060379 1.41 
IFI44L 0.034708812 1.84 BLVRA 0.01109232 1.41 
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SP110 0.042650839 1.39    
DDX58 0.034037138 1.39    
PHF11 0.013636559 1.38    
MOV10 0.008061982 1.37    
ADAR 0.008240337 1.37    
LGALS9 0.006757455 1.37    
SP110 0.037659257 1.37    
ISG20 0.008951273 1.37    
CMPK2 0.023505453 1.37    
LGALS9 0.003663257 1.35    
FOXP1-IT1 0.042817254 1.34    
TDRD7 0.042650839 1.33    
CMTR1 0.003817828 1.32    
ANKFY1 0.003459426 1.32    
DRAP1 0.04332153 1.32    
NUB1 0.034037138 1.31    
SP100 0.005751943 1.30    
SYAP1 0.045683609 1.28    
DUSP5 0.016001267 1.28    
MT1G 0.028621277 1.27    
SP100 0.006759859 1.26    
TRIM56 0.039988487 1.25    
ATF3 0.003663257 1.25    
REC8 0.010675641 1.22    
ODF3B 0.03728581 1.21    
NEXN 0.042650839 1.21    
C9orf91 0.045680309 1.20    
NELL2 0.013636559 -1.49    
ANXA7 0.005060379 -1.25    
ESYT2 0.042817254 -1.25    
SMARCA2 0.042817254 -1.24    
MID2 8.90E-05 -1.24    
USP9X 0.008951273 -1.24    
HNRNPA0 0.048907002 -1.22    
NR3C2 0.002069335 -1.21    
DSC1 0.034199174 -1.20    
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S9 DEGs list of pSS-associated lymphoma vs. healthy control. The (-) sign in FC column 
represent the downregulated genes in pSS-associated lymphoma (p<0.02, FC=1.2) 
Gene symbol Adjusted p value FC Gene symbol Adjusted p value FC 
IFI27 1.5E-05 16.86 OAS2 1.41E-06 2.19 
IFI44L 7.5E-09 12.44 TNFAIP6 0.000917 2.18 
IFIT1 7.5E-09 7.66 PARP12 1.98E-06 2.15 
RSAD2 9.09E-09 7.33 GBP1 0.000172 2.10 
ISG15 2.5E-08 7.23 HERC6 6.21E-05 2.05 
IFI44 1.09E-07 6.51 RTP4 2.72E-06 2.05 
LY6E 1.25E-07 5.43 OAS1 0.018468 2.04 
EPSTI1 7.5E-09 5.39 OAS2 2.84E-05 2.04 
IFIT3 7.5E-09 5.34 MT1A 6.21E-05 2.01 
OAS3 1.2E-07 5.19 PARP9 1.94E-05 1.99 
HERC5 2.3E-08 5.03 USP18 0.000917 1.96 
IFITM3 7.27E-07 4.84 TNFSF10 2.05E-06 1.95 
IFI6 7.5E-09 4.78 HELZ2 4.17E-05 1.94 
OAS1 3.1E-08 4.61 PARP14 1.08E-05 1.93 
MX1 2.06E-07 4.14 GBP5 0.003049 1.90 
OAS1 6.55E-08 4.13 RNASE2 0.012504 1.90 
OASL 4.11E-08 3.94 IFIH1 0.000238 1.90 
IFIT3 4.79E-06 3.59 STAT2 4.38E-06 1.88 
XAF1 3.37E-08 3.59 SPATS2L 0.00029 1.88 
IFIT3 2.1E-06 3.28 DDX60 0.000119 1.88 
OAS2 3.93E-05 3.09 TNFSF13B 3.37E-05 1.82 
XAF1 1.1E-05 3.06 DHX58 2.18E-05 1.82 
EIF2AK2 7.35E-08 2.92 OASL 1.49E-05 1.81 
IFIT2 2.39E-05 2.89 STAT1 3.76E-05 1.81 
HES4 8.14E-06 2.76 BATF2 0.000172 1.80 
SAMD9L 2.5E-08 2.70 HLA-DRB4 0.003986 1.80 
OTOF 0.016387 2.61 IFITM1 1.43E-06 1.80 
IRF7 2.5E-08 2.59 PARP9 2.6E-05 1.77 
IFI44L 5.58E-06 2.59 STAT1 5.61E-06 1.76 
ZBP1 1E-06 2.45 SAMD9 0.002968 1.75 
IRF7 3.9E-06 2.44 FCGR1A 0.004621 1.75 
SERPING1 4.89E-05 2.39 MX2 0.000144 1.74 
OAS1 7.28E-06 2.38 UBE2L6 4.51E-05 1.74 
MT2A 1.96E-05 2.32 ANKRD22 0.009801 1.73 
IFI35 3.18E-07 2.30 IL1RN 0.000405 1.73 
SCO2 2.25E-08 2.30 FBXO6 1.94E-05 1.73 
LAP3 8.42E-06 2.29 CHMP5 0.012217 1.72 
GBP1 0.000202 2.23 SHISA5 2.6E-05 1.71 
IFI6 5.61E-06 2.23 TNFSF13B 8.86E-05 1.70 
TRIM22 8.54E-06 2.21 IFIT5 0.000218 1.70 
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BLVRA 5.31E-07 1.70 LGALS9 6.71E-06 1.47 
DRAP1 5.47E-08 1.68 TYMP 0.000474 1.47 
FCGR1B 0.01376 1.67 CASP1 0.003753 1.46 
GUSBP1 0.015554 1.65 PSMB9 8.42E-06 1.46 
CEACAM1 0.000714 1.65 NT5C3A 0.012504 1.46 
PARP10 2.72E-05 1.65 IFI30 0.008201 1.46 
IL1RN 0.001121 1.65 TOR1B 0.000429 1.46 
BST2 4.32E-06 1.64 CHMP5 0.018223 1.45 
DDX58 8.4E-06 1.64 CCR1 0.016069 1.45 
IRF9 5.93E-08 1.64 HSH2D 0.001736 1.44 
STAT1 0.001501 1.62 PHF11 0.002192 1.44 
VAMP5 0.000105 1.61 NT5C3A 0.044945 1.43 
GBP1P1 0.000404 1.61 TMEM140 0.045044 1.41 
TMEM123 0.031091 1.59 ADAR 0.000572 1.41 
CEACAM1 0.000405 1.57 TAP2 0.007716 1.40 
UNC93B1 2.84E-05 1.56 MS4A6A 0.036008 1.40 
OAS3 0.000122 1.56 DYNLT1 0.007837 1.40 
PSME2 9.01E-06 1.56 SEPT4 0.002296 1.40 
IFI16 0.00059 1.55 GBP4 0.047205 1.40 
FAM46A 1.94E-05 1.55 ISG20 0.000723 1.40 
ANKRD22 0.020882 1.55 TRIM5 0.003753 1.40 
LAMP3 0.00015 1.55 SAT1 0.003753 1.40 
DDX60L 0.00514 1.53 KLHDC8B 0.02115 1.40 
LGALS9 6.71E-06 1.53 MS4A7 0.006492 1.39 
CMPK2 4.34E-05 1.53 MS4A6A 0.017423 1.39 
PHF11 4.31E-05 1.52 HK3 0.001602 1.39 
TYMP 0.000563 1.52 CD36 0.031481 1.39 
GPBAR1 0.002153 1.52 SP110 0.010107 1.39 
CXCL10 0.00656 1.52 IFIT1 0.001648 1.38 
REC8 1.33E-05 1.51 PSMB9 0.012791 1.38 
TYMP 0.001319 1.51 TAP1 0.038526 1.38 
UBE2L6 0.001394 1.51 TRIM21 0.00059 1.38 
CASP1 0.0023 1.51 CST3 0.030373 1.38 
FFAR2 0.012071 1.49 LYSMD2 0.004199 1.37 
GLRX 0.044792 1.49 TRIM38 0.005591 1.37 
SMA4 0.03066 1.49 GSTO1 0.000651 1.36 
PLSCR1 0.003909 1.49 HSPA7 0.011826 1.36 
FCGR1C 0.020263 1.49 MT1G 0.00025 1.36 
GPBAR1 0.006059 1.49 ODF3B 3.43E-06 1.36 
FGD2 0.004199 1.49 LGALS3BP 0.036504 1.35 
TDRD7 7.65E-05 1.49 HSPA6 0.02616 1.35 
SP110 0.001172 1.49 CMTR1 0.00038 1.34 
MOV10 4.16E-05 1.49 SCARB2 0.001003 1.34 
LGALS1 0.001067 1.48 PLAC8 0.024225 1.34 
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LOC100128274 0.007811 1.34 TRAFD1 0.023378 1.27 
TYMP 0.010652 1.33 ADAR 0.046774 1.27 
RRAS 0.008912 1.33 SP140 0.043972 1.26 
NBN 0.003653 1.33 KIAA0319L 0.008183 1.26 
C19orf66 0.000457 1.33 RAB24 0.030636 1.26 
CREB1 0.001062 1.33 BRSK1 0.046237 1.26 
C1GALT1 0.010189 1.32 MS4A14 0.015701 1.26 
TRIM69 0.00282 1.32 FAM13A 0.009829 1.26 
WSB1 0.001292 1.32 POMP 0.000218 1.26 
LMO2 0.018223 1.32 CTSH 0.043277 1.26 
C3AR1 0.008294 1.31 NMI 0.042268 1.26 
AP5B1 0.046669 1.31 ANKFY1 0.008562 1.25 
GCH1 0.002263 1.31 OAF 0.008962 1.25 
GSTO1 0.006376 1.31 ACOT9 0.015421 1.25 
TRIM56 0.001003 1.31 RNF7 0.006271 1.25 
KYNU 0.049183 1.30 PRO0628 0.033767 1.25 
SOCS1 0.000954 1.30 ZDHHC19 0.049994 1.25 
ACER3 0.008612 1.30 NAPA 0.001067 1.25 
PRDX4 0.005904 1.30 LOC100128288 0.03597 1.24 
DUSP19 0.000463 1.30 GADD45B 0.012504 1.24 
LHFPL2 0.032922 1.30 REC8 0.000689 1.24 
SLIRP 0.018223 1.30 ATP5J2 0.005904 1.24 
LOC284837 0.006376 1.29 PSMA3 0.030059 1.24 
CAMK1 0.006759 1.29 DYNLL1 0.003715 1.24 
NEXN 0.000172 1.29 MGST3 0.036168 1.24 
MT1F 0.023286 1.29 NUDT14 0.002457 1.24 
SP110 0.046669 1.29 IL15 0.016102 1.24 
MYD88 0.007856 1.29 ZC3HAV1 0.028613 1.24 
SP100 0.002126 1.29 TRIM6 0.015483 1.24 
CARD16 0.013794 1.29 PSMB8 0.003134 1.24 
RAB24 0.013469 1.28 CYSLTR1 0.018349 1.23 
KLHL28 0.028917 1.28 GNG5 0.007716 1.23 
SP100 0.000318 1.28 ACOT9 0.011321 1.23 
MT1IP 0.003419 1.28 RBM43 0.007909 1.23 
ADAP2 0.016826 1.28 ZC3HAV1 0.03379 1.23 
HINT3 0.036666 1.28 PTTG1 0.006343 1.23 
NCOA7 0.036373 1.28 UNC93B1 0.003849 1.23 
CEACAM1 0.031829 1.27 TMOD2 0.014744 1.23 
MAD2L1BP 0.001509 1.27 GALNT4 0.021994 1.23 
CCL2 0.003057 1.27 HCFC1R1 0.004443 1.23 
OAS2 0.00667 1.27 TRIM14 0.000378 1.23 
KCTD12 0.040119 1.27 MS4A4A 0.011826 1.23 
CCDC53 0.000346 1.27 LRRFIP1 0.020685 1.23 
IGFBP7 0.019533 1.27 PCK2 0.010186 1.23 
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SP100 0.006946 1.23 FAM102A 0.000786 -1.42 
HNMT 0.025315 1.22 SEC14L1 0.017125 -1.41 
MED28 0.005891 1.22 ETS1 0.006399 -1.41 
THOC7 0.018952 1.22 SERTAD2 0.00029 -1.40 
ETV7 0.012464 1.22 ALDOC 0.000109 -1.40 
TRIM5 0.003057 1.22 CTDSP2 0.000346 -1.40 
SFT2D1 0.046894 1.22 MAGED1 0.002516 -1.39 
SCIMP 0.014539 1.22 POM121C 0.002162 -1.38 
C4orf3 0.028728 1.22 HIST1H1C 0.038916 -1.38 
PSMB8 0.013067 1.22 SCAP 0.000884 -1.38 
SEC61G 0.020633 1.22 SIRPA 0.019085 -1.38 
TMEM219 0.005891 1.21 HNRNPUL1 0.001521 -1.37 
RAB37 0.015716 1.21 IMPA2 0.049109 -1.37 
GNB4 0.002286 1.21 HNRNPA1P10 0.001159 -1.37 
TMSB10 0.007643 1.21 SF3A1 0.000713 -1.37 
DUSP5 0.035707 1.21 TBC1D14 0.001101 -1.36 
SRBD1 0.00656 1.21 EIF4B 6.21E-05 -1.36 
COMMD1 0.003134 1.21 JAK1 0.027337 -1.36 
RNF31 0.038024 1.21 ZNF746 0.000446 -1.36 
SSB 0.038673 1.20 TBL1X 0.012504 -1.36 
FAM13A 0.044387 1.20 SUN2 0.003786 -1.35 
PNPT1 0.00028 1.20 CYFIP2 0.008696 -1.35 
PSME1 0.03379 1.20 CD247 0.023958 -1.35 
FRMD3 0.006751 1.20 BAG3 0.000368 -1.35 
HLA-DRB1 0.019579 -4.75 RPL23AP5 0.008183 -1.35 
MYH9 0.001545 -1.59 ALDH9A1 0.00042 -1.34 
SPOCK2 0.000774 -1.55 ADCK3 0.002508 -1.34 
SGK223 0.000418 -1.55 FAM102A 0.002693 -1.34 
LEF1 0.008441 -1.52 SMARCA2 0.00026 -1.34 
TXNDC12 0.012538 -1.52 ESYT1 0.008661 -1.33 
NELL2 0.002296 -1.51 ATP6V1A 0.014592 -1.33 
ABLIM1 0.009953 -1.49 RPL10A 0.018349 -1.33 
BCL11B 0.000501 -1.48 ARRB1 0.007317 -1.33 
PIK3IP1 0.002026 -1.48 DDB1 0.000495 -1.33 
IL2RB 0.023723 -1.47 FNBP1 0.010107 -1.32 
ETS1 0.008164 -1.47 CD247 0.049653 -1.32 
IGF2R 0.004967 -1.47 APMAP 0.030463 -1.32 
SYTL2 0.009112 -1.45 HNRNPDL 0.000445 -1.32 
RNA28S5 0.021678 -1.45 SIN3A 8.86E-05 -1.32 
SORL1 0.019438 -1.44 LAMP1 0.007708 -1.32 
CACNA1I 0.001334 -1.43 PRKDC 0.000214 -1.32 
TKT 0.015824 -1.42 VCP 0.000704 -1.32 
PRPF8 0.0004 -1.42 VEGFB 0.020685 -1.31 
LEF1 0.042038 -1.42 PARP1 0.038153 -1.31 
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GTF2IP1 0.000448 -1.31 CIRBP 0.013827 -1.27 
UBE2H 0.004967 -1.31 WAC 0.004259 -1.26 
MEF2D 0.000956 -1.30 BACH2 0.010319 -1.26 
ITK 0.03597 -1.30 HNRNPUL1 0.01454 -1.26 
TPRG1L 0.000346 -1.30 VPS51 0.012045 -1.26 
SCYL1 0.004443 -1.30 ANKRD11 0.004535 -1.26 
CD96 0.011884 -1.30 AXIN2 0.012045 -1.26 
MYH9 0.045193 -1.30 EPHX2 0.041367 -1.26 
MBP 0.000619 -1.30 ULK1 0.023685 -1.26 
OSBPL10 0.012791 -1.30 RPS6KA5 0.039348 -1.26 
GLS 0.000451 -1.30 PAF1 0.006384 -1.26 
MAP7D1 0.02294 -1.30 NCL 0.02294 -1.26 
PRKCH 0.028917 -1.30 EEF2 0.014462 -1.25 
RGCC 0.048765 -1.30 LOC283070 0.047081 -1.25 
MSN 0.020569 -1.30 RPS4X 0.029797 -1.25 
RBL2 0.001591 -1.29 ABLIM1 0.04298 -1.25 
EIF3L 0.008456 -1.29 PEBP1 0.023532 -1.25 
ULK1 0.011854 -1.29 FOXJ2 0.002608 -1.25 
ID3 0.010653 -1.29 PHRF1 0.034796 -1.25 
KIAA1147 0.017676 -1.29 LRFN3 0.02487 -1.25 
KLF13 0.028613 -1.29 KHDRBS1 0.017423 -1.25 
NMT2 0.0029 -1.28 BTG1 0.012504 -1.25 
MED16 0.044467 -1.28 MID2 8.54E-06 -1.25 
RNF44 0.006524 -1.28 COBLL1 0.023532 -1.25 
CDR2 0.005421 -1.28 TP53INP2 0.007716 -1.25 
RPS4X 0.02473 -1.28 SLC12A9 0.018349 -1.25 
MYC 0.038922 -1.28 HDAC1 0.007716 -1.25 
ACOX1 0.038153 -1.28 PRKCQ 0.021994 -1.25 
FAM53C 0.03421 -1.28 GMEB2 0.00018 -1.24 
TGOLN2 0.010088 -1.28 SAFB 0.004935 -1.24 
SMAP2 0.041808 -1.28 BANP 0.005891 -1.24 
CRKL 0.001067 -1.27 FOXO1 0.004005 -1.24 
ARID1A 0.016338 -1.27 FRMD8 0.002608 -1.24 
ICAM3 0.028873 -1.27 CBLL1 0.006399 -1.24 
ARHGEF18 0.013838 -1.27 EPHA1 0.018349 -1.24 
ANXA7 0.000346 -1.27 HNRNPA0 0.005641 -1.24 
ZSCAN18 0.021678 -1.27 RPRD2 1.96E-05 -1.24 
PEX5 0.000122 -1.27 EIF3B 0.023886 -1.24 
RPA2 0.000321 -1.27 PI4KA 0.048768 -1.24 
RPS3 0.032879 -1.27 DOCK2 0.049261 -1.24 
HSP90B1 0.018107 -1.27 FOXJ3 0.003753 -1.24 
NOTCH1 0.030178 -1.27 DHRS3 0.018349 -1.24 
LRRC26 0.002057 -1.27 RAB22A 0.000364 -1.24 
EIF3L 0.006489 -1.27 TAF4 0.005587 -1.24 
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SLC7A1 0.000346 -1.24 ACTG1 0.008675 -1.21 
TUBB 0.008534 -1.23 NR3C2 0.000446 -1.21 
ST13P4 0.046641 -1.23 COCH 0.000349 -1.21 
GEMIN4 0.023723 -1.23 EIF3D 0.005577 -1.21 
KAT8 0.002078 -1.23 BMS1 0.005252 -1.21 
INTS1 0.007234 -1.23 RAPGEF6 0.031091 -1.21 
U2AF1 0.008294 -1.23 TNFRSF13B 0.023908 -1.21 
RPA1 0.002187 -1.23 THOC5 0.032389 -1.21 
QRICH1 0.002162 -1.23 PAFAH1B1 0.007971 -1.21 
RPN1 0.000218 -1.23 KLHL3 0.042037 -1.21 
ASNS 0.030636 -1.23 MAGED1 0.003599 -1.21 
PDPK1 0.03597 -1.23 STXBP5 0.014454 -1.21 
LRIG1 0.014497 -1.23 EIF4A3 0.043043 -1.21 
AP1M1 0.044312 -1.23 ENO2 0.024421 -1.21 
VPS35 0.021994 -1.23 PRPF19 0.012045 -1.21 
ALKBH5 0.009412 -1.23 FAM120B 0.016568 -1.21 
DSC1 0.002296 -1.23 LRRC47 0.006532 -1.21 
MAN1C1 0.040336 -1.23 RNF216 0.00652 -1.21 
DNAJA3 0.00667 -1.23 USP7 0.002126 -1.21 
ARCN1 0.03678 -1.23 FHL1 0.021284 -1.21 
CS 0.028841 -1.23 SRRM1 0.003582 -1.20 
RRN3 0.009783 -1.23 IMPDH2 0.048273 -1.20 
SYTL2 0.024498 -1.22 SNRPN 0.040929 -1.20 
SLC16A10 0.00038 -1.22 MDC1 0.036666 -1.20 
USP9X 0.003986 -1.22 HSPA9 0.019311 -1.20 
NDRG3 0.0023 -1.22 TBC1D9 0.048261 -1.20 
CALM3 0.03379 -1.22 ARF1 0.028643 -1.20 
DANCR 0.00042 -1.22 DEXI 0.021246 -1.20 
PRKCSH 0.028917 -1.22 ASF1B 0.046464 -1.20 
CDK19 0.008365 -1.22 NIPSNAP1 0.001486 -1.20 
SPECC1L 0.011998 -1.22 BCL2L13 0.010699 -1.20 
SMARCC1 0.001067 -1.22 FAM174A 0.029365 -1.20 
DSC1 0.002665 -1.22    
EPHB4 0.015716 -1.22    
XRN2 0.007856 -1.22    
GTF2IP1 0.02167 -1.22    
HSPBAP1 0.006979 -1.22    
CYB561D1 0.000767 -1.22    
BCAP31 0.01671 -1.22    
ATP1A1 0.006399 -1.22    
EXTL3 0.030463 -1.22    
AKR1B1 0.046774 -1.22    
AKTIP 0.039388 -1.22    
PTBP1 0.023723 -1.22    
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S10 The canonical pathways identified in pSS-associated lymphoma vs healthy controls  The table contains only the pathways that have a 
significant z-score (2 < z-score > -2) 
Ingenuity Canonical Pathways -log(p-value) Ratio z-score Molecules 
Interferon Signaling 1.74E+01 4.44E-01 2.84 
OAS1,IRF9,IFITM1,IFIT3,STAT2,JAK1,IFI6,IFITM3, 
TAP1,IFIT1,STAT1,ISG15,MX1,IFI35,SOCS1,PSMB8 
Dendritic Cell Maturation 2.95E+00 6.21E-02 2.333 
FCGR1B,IL15,HLA-DRB1,IL1RN,MYD88,CREB1, 
STAT1,FCGR1A,STAT2,HLA-DRB4,FCER1G 
RhoGDI Signaling 1.18E+00 4.05E-02 2.236 GNB4,GNG5,ACTG1,MSN,PI4KA,ARHGEF18,FNBP1 
Huntington's Disease Signaling 4.65E+00 6.99E-02 -2 
GNB4,CREB1,PRKCQ,NAPA,CASP1,PSME1,PSME2, 
HSPA6,TAF4,HSPA9,PDPK1,GNG5,SIN3A,PRKCH,HDAC1,GLS 
CD28 Signaling in T Helper Cells 1.96E+00 5.93E-02 -2 
HLA-DRB1,PDPK1,CALM1 (includes 
others),PRKCQ,ITK,FCER1G,CD247 
RhoA Signaling 9.71E-01 4.10E-02 -2 RAPGEF6,EPHA1,ACTG1,MSN,PI4KA 
Calcium-induced T Lymphocyte 
Apoptosis 
4.32E+00 1.25E-01 -2.236 
HLA-DRB1,CALM1 (includes 
others),PRKCQ,FCER1G,PRKCH,MEF2D,CD247,HDAC1 
iCOS-iCOSL Signaling in T Helper 
Cells 
2.76E+00 7.41E-02 -2.236 
HLA-DRB1,PDPK1,CALM1 (includes others),PRKCQ,ITK,IL2RB, 
FCER1G,CD247 
Aldosterone Signaling in Epithelial 
Cells 
1.87E+00 5.26E-02 -2.236 
HSPA9,PDPK1,HSP90B1,PRKCQ,NR3C2, 
PRKCH,HSPA6,PI4KA 
Nitric Oxide Signaling in the 
Cardiovascular System 
1.77E+00 6.00E-02 -2.236 
CALM1 (includes others),SLC7A1,HSP90B1,PRKCQ,PRKCH, 
VEGFB 
Signaling by Rho Family GTPases 6.84E-01 2.99E-02 -2.236 GNB4,GNG5,ACTG1,MSN,PI4KA,ARHGEF18,FNBP1 
Leukocyte Extravasation Signaling 9.41E-01 3.54E-02 -2.646 ACTG1,CRKL,PRKCQ,ICAM3,ITK,MSN,PRKCH 
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S11 The downstream analysis in pSS-associated lymphoma vs healthy controls  The table contains only the diseases and functions that 
have a significant z-score (2 < z-score > -2) 
Categories Diseases or 
Functions 
Annotation 
p-Value Predicted 
Activatio
n State 
Activatio
n z-score 
Molecules 
Cell-To-Cell Signaling and 
Interaction, Cellular Function 
and Maintenance, 
Inflammatory Response 
phagocytosis 
of blood 
cells 
1.25E-03 Increased 2.012 CD36,CXCL10,FCGR1A,GLRX,IL15,ISG15,MYD88,RGCC,SIRPA 
Cell Death and Survival cell death of 
leukocyte 
cell lines 
4.56E-08 Increased 2.026 CD247,CREB1,DNAJA3,EIF2AK2,EIF4B,GADD45B,GLS,HLADRB4,IFIH1,IL15, 
LGALS1,MYC,NBN,NOTCH1,PNPT1,PRKCQ,RRAS,SOCS1,TNFSF10,TUBB 
Cell Death and Survival apoptosis of 
hematopoieti
c cell lines 
7.96E-05 Increased 2.175 CREB1,DNAJA3,EIF2AK2,EIF4B,ICAM3,IFIH1,IL15,MYC,NBN,NOTCH1,PARP1, 
PNPT1,PRKCQ,SOCS1,TNFSF10 
Cell-To-Cell Signaling and 
Interaction, Inflammatory 
Response 
immune 
response of 
T 
lymphocytes 
3.88E-04 Increased 2.232 C3AR1,CASP1,ETS1,FOXO1,IL15,ITK,LGALS9,MYD88,PSME2 
Cell-To-Cell Signaling and 
Interaction, Hair and Skin 
Development and Function 
response of 
epithelial cell 
lines 
8.45E-07 Increased 2.377 DDX58,IFIH1,MID2,TRIM14,TRIM21,TRIM38,TRIM5,TRIM56,TRIM6 
Cell-To-Cell Signaling and 
Interaction, Embryonic 
Development 
response of 
embryonic 
cell lines 
1.00E-06 Increased 2.377 DDX58,IFIH1,MID2,TRIM14,TRIM21,TRIM38,TRIM5,TRIM56,TRIM6 
Cell-To-Cell Signaling and 
Interaction, Renal and 
Urological System 
Development and Function 
response of 
kidney cell 
lines 
1.19E-06 Increased 2.377 DDX58,IFIH1,MID2,TRIM14,TRIM21,TRIM38,TRIM5,TRIM56,TRIM6 
Neurological Disease, 
Skeletal and Muscular 
Disorders 
neuromuscul
ar disease 
1.16E-10 Increased 2.391 ANKRD11,ARRB1,ATP6V1A,BANP,BCL11B,CASP1,CCL2,CIRBP,COCH,CREB1, 
CST3,CYFIP2,DUSP5,DYNLT1,ENO2,EPHB4,EPHX2,EPSTI1,FCGR1A,FCGR1B, 
GBP1,GCH1,HNRNPDL,HSP90B1,ID3,IFIT1,IL1RN,IMPDH2,IRF7,ISG15,LAMP1
, 
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LY6E,MBP,MEF2D,MT1G,MT2A,MX1,NAPA,NDRG3,OAS1,OAS3,PARP1,PEBP1, 
PSMB8,PSMB9,PSME1,RPS4X,RPS6KA5,RSAD2,SAT1,SCARB2,SERPING1, 
SIN3A,SLIRP,SORL1,VCP 
Inflammatory Response immune 
response of 
cells 
3.56E-10 Increased 2.403 C3AR1,CASP1,CCL2,CD247,CD36,CEACAM1,CXCL10,DDX58,DOCK2,ETS1,FC
ER1G,FCGR1A,FOXO1,GLRX,IFIH1,IL15,IRF7,ISG15,ITK,JAK1,LGALS9,MID2,
MYC, 
MYD88,MYH9,PARP1,PSME2,RGCC,SF3A1,SIRPA,SOCS1,STAT1,TRIM14,TRIM2
1, 
TRIM38,TRIM5,TRIM56,TRIM6,UBE2L6 
Cell-To-Cell Signaling and 
Interaction, Inflammatory 
Response 
immune 
response of 
leukocytes 
6.21E-06 Increased 2.479 C3AR1,CASP1,CCL2,CD36,CXCL10,DDX58,ETS1,FCER1G,FOXO1,GLRX,IL15, 
ISG15,ITK,LGALS9,MYD88,PSME2,RGCC,SIRPA,UBE2L6 
Cell Death and Survival apoptosis of 
leukocyte 
cell lines 
6.71E-04 Increased 2.751 CREB1,DNAJA3,EIF2AK2,EIF4B,IFIH1,MYC,NBN,NOTCH1,PNPT1,PRKCQ,SOC
S1,TNFSF10 
Neurological Disease progressive 
motor 
neuropathy 
1.66E-06 Increased 2.891 ARRB1,CALM1(includesothers),CASP1,CCL2,CD36,CST3,ENO2,EPSTI1,FCGR1A, 
FCGR1B,FOXO1,GCH1,HNRNPDL,IFIT1,IMPDH2,IRF7,ISG15,LAMP1,LY6E, 
MAGED1,MBP,MEF2D,MX1,OAS1,OAS3,PEBP1,RPS4X,RSAD2,SCARB2,SERPIN
G1 
Cell Signaling I-kappaB 
kinase/NF-
kappaB 
cascade 
5.73E-07 Increased 3.067 BST2,CASP1,CD36,DNAJA3,HDAC1,LGALS1,LGALS9,MID2,MYD88,PDPK1,RNF
31,SHISA5,STAT1,TRIM22,TRIM38,TRIM5,ZC3HAV1 
Inflammatory Disease, 
Neurological Disease, 
Skeletal and Muscular 
Disorders 
Multiple 
Sclerosis 
8.20E-08 Increased 3.148 ARRB1,CASP1,CCL2,CST3,EPSTI1,FCGR1A,FCGR1B,IFIT1,IMPDH2,IRF7,ISG15
, 
LY6E,MBP,MX1,OAS1,OAS3,RSAD2,SERPING1 
Inflammatory Disease, 
Neurological Disease, 
Skeletal and Muscular 
Disorders 
relapsing-
remitting 
multiple 
sclerosis 
1.54E-07 Increased 3.148 EPSTI1,IFIT1,IRF7,ISG15,LY6E,MX1,OAS1,OAS3,RSAD2,SERPING1 
Cell Signaling protein 
kinase 
cascade 
1.74E-06 Increased 3.313 BST2,CASP1,CCL2,CD36,CEACAM1,CRKL,DNAJA3,DUSP19,EIF2AK2,GADD45
B, 
HDAC1,LGALS1,LGALS9,MID2,MYC,MYD88,NMI,PAFAH1B1,PDPK1,PEBP1,RN
F31,SHISA5,SOCS1,STAT1,STAT2,TRIM22,TRIM38,TRIM5,ZC3HAV1 
Infectious Diseases replication of 
virus 
1.41E-23 Decreased -4.852 ADAR,AKTIP,AP1M1,ARCN1,ATP6V1A,BST2,CBLL1,CCL2,CCR1,CEACAM1,CRE
B1,CST3,CXCL10,DDX58,EIF2AK2,EIF3L,EIF4A3,FCGR1A,GBP1,IFIH1,IFIT1,IF
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ITM1, 
IFITM3,IL15,IRF9,ISG15,ISG20,JAK1,LGALS9,LY6E,MED28,MX1,MX2,MYC,MY
D88,NCL,NMI,OAS1,OASL,PARP12,PI4KA,PRPF8,RSAD2,SAFB,SF3A1,SOCS1, 
SP110,STAT1,STAT2,TAP1,TNFSF10,TRIM14,TRIM21,TRIM38,TRIM5,TUBB,UBE
2L6,USP7,VCP,ZC3HAV1 
Infectious Diseases Viral 
Infection 
4.46E-27 Decreased -4.474 ADAR,AKTIP,AP1M1,ARCN1,ARF1,ARID1A,ARRB1,ATP6V1A,BST2,C3AR1,CAM
K1,CARD16,CBLL1,CCL2,CCR1,CD247,CD36,CEACAM1,CHMP5,CREB1,CST3,C
XCL10,DDX58,DDX60L,DNAJA3,EIF2AK2,EIF3L,EIF4A3,FCGR1A,FCGR1B,FO
XJ2,GBP1,GSTO1,HDAC1,HIST1H1C,HNRNPDL,HSPA6,HSPA9,IFI35,IFIH,IFIT
1,IFIT2,IFIT3, 
IFITM1,IFITM3,IGF2R,IL15,IL1RN,IL2RB,IMPA2,IMPDH2,IRF9,ISG15,ISG20,IT
K, 
JAK1,KHDRBS1,LEF1,LGALS1,LGALS9,LY6E,MED16,MED28,MOV10,MS4A4A, 
MT2A,MX1,MX2,MYC,MYD88,NCL,NMI,OAS1,OASL,PAF1,PARP1,PARP12,PARP
9, 
PI4KA,PRKCH,PRPF8,PSMA3,PSME2,PTTG1,RNASE2,RNF216,RPL10A,RSAD2, 
SAFB,SAMD9,SCARB2,SEC14L1,SEC61G,SF3A1,SFT2D1,SMARCA2,SOCS1,SP10
0, 
SP110,SPATS2L,SSB,STAT1,STAT2,TAP1,TKT,TNFSF10,TRAFD1,TRIM14,TRIM2
1, 
TRIM22,TRIM38,TRIM5,TRIM56,TUBB,UBE2H,UBE2L6,UNC93B1,USP7,VCP, 
ZC3HAV1 
Cell Signaling replication of 
viral replicon 
2.63E-18 Decreased -4.3 ADAR,BST2,EIF2AK2,IFI16,IFIT1,IFITM1,IFITM3,ISG15,ISG20,MX1,OAS1,OAS3,
OASL,PARP10,PI4KA,PLSCR1,RSAD2,TRIM6,ZC3HAV1 
Infectious Diseases replication of 
RNA virus 
1.21E-21 Decreased -4.225 ADAR,AKTIP,AP1M1,ARCN1,ATP6V1A,BST2,CBLL1,CCR1,CEACAM1,CREB1,CS
T3,CXCL10,DDX58,EIF2AK2,EIF3L,EIF4A3,FCGR1A,GBP1,IFIH1,IFIT1,IFITM1, 
IFITM3,IRF9,ISG15,ISG20,JAK1,LGALS9,LY6E,MED28,MX1,MYC,MYD88,NCL,N
MI,OAS1,OASL,PARP12,PI4KA,PRPF8,RSAD2,SAFB,SF3A1,SOCS1,SP110,STAT1,
STAT2,TAP1,TNFSF10,TRIM14,TRIM21,TRIM38,TRIM5,TUBB,UBE2L6,ZC3HAV1 
Protein Synthesis metabolism 
of protein 
1.49E-04 Decreased -3.372 ARRB1,BAG3,BANP,CASP1,CIRBP,CREB1,CST3,CTSH,CYFIP2,DNAJA3,EEF2,EI
F2AK2,EIF3B,EIF3D,EIF3L,EIF4A3,EIF4B,FBXO6,FOXO1,IFI30,IL1RN,LAMP1,
LAP3,MYC,MYD88,MYH9,NOTCH1,PARP12,PRKCQ,PTBP1,RPS4X,SAMD9L,SAT
1,SLC7A1,SORL1,SSB,TBL1X,TNFSF10,TNFSF13B,TP53INP2,UBE2H,USP18,US
P7,VCP 
Infectious Diseases replication of 
Herpesvirida
e 
1.58E-13 Decreased -3.189 ADAR,CST3,CXCL10,DDX58,IFIH1,IRF9,ISG20,MX2,MYD88,OAS1,OASL,PARP1
2, 
RSAD2,STAT1,STAT2 
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Infectious Diseases infection of 
kidney cell 
lines 
1.78E-06 Decreased -3.038 ADAR,ARID1A,EIF2AK2,FOXJ2,HDAC1,HNRNPDL,IFITM1,IFITM3,ISG20,KHD
RBS1,MT2A,PARP9,PRKCH,PRPF8,PSMA3,RNF216,RPL10A,RSAD2,SF3A1,TRIM
56, 
UBE2H,ZC3HAV1 
Infectious Diseases, 
Organismal Injury and 
Abnormalities 
infection of 
embryonic 
cell lines 
1.32E-06 Decreased -3.022 ADAR,ARID1A,EIF2AK2,FOXJ2,HDAC1,HNRNPDL,IFITM1,IFITM3,ISG20, 
KHDRBS1,MT2A,PARP9,PRKCH,PRPF8,PSMA3,RNF216,RPL10A,RSAD2,SF3A1, 
TRIM56,UBE2H,ZC3HAV1 
Infectious Diseases infection of 
epithelial cell 
lines 
1.32E-06 Decreased -3.022 ADAR,ARID1A,EIF2AK2,FOXJ2,HDAC1,HNRNPDL,IFITM1,IFITM3,ISG20, 
KHDRBS1,MT2A,PARP9,PRKCH,PRPF8,PSMA3,RNF216,RPL10A,RSAD2,SF3A1, 
TRIM56,UBE2H,ZC3HAV1 
Infectious Diseases replication of 
Flaviviridae 
4.97E-07 Decreased -2.931 CXCL10,EIF2AK2,IFIT1,IFITM1,IFITM3,ISG15,OASL,PI4KA,RSAD2,UBE2L6 
Infectious Diseases replication of 
Murine 
herpesvirus 4 
1.68E-10 Decreased -2.828 ADAR,CXCL10,DDX58,IFIH1,ISG20,MX2,OAS1,PARP12 
Infectious Diseases infection by 
DNA virus 
5.62E-08 Decreased -2.669 ADAR,EIF2AK2,FCGR1A,FCGR1B,IGF2R,IL15,IL1RN,LGALS1,MYD88,SAMD9, 
STAT1,TRIM21,UNC93B1 
Infectious Diseases infection of 
mammalia 
4.72E-06 Decreased -2.572 CASP1,CD36,DDX58,EIF2AK2,IFI30,IFIH1,IL15,ISG15,ITK,MYD88,STAT1,UNC9
3B1,USP18 
Cell Cycle interphase 6.05E-07 Decreased -2.476 ARRB1,BAG3,BRSK1,BTG1,CAMK1,CD247,EIF2AK2,ETS1,FOXO1,GADD45B, 
HDAC1,ID3,IGFBP7,IL15,LEF1,LGALS1,MT1A,MX2,MYC,NBN,NOTCH1,PAF1, 
PARP1,PLAC8,PLSCR1,PNPT1,PRKCH,PRKDC,PRPF19,PRPF8,PTTG1,RBL2, 
RGCC,RNF31,RPA1,SMARCA2,STAT1,SUN2,TRIM21 
Infectious Diseases infection by 
Herpesvirida
e 
8.89E-06 Decreased -2.463 FCGR1A,FCGR1B,IGF2R,IL15,IL1RN,LGALS1,MYD88,STAT1,UNC93B1 
Cell Cycle G1 phase 6.93E-06 Decreased -2.393 ARRB1,BAG3,CAMK1,CD247,EIF2AK2,ETS1,FOXO1,GADD45B,ID3,IGFBP7,LE
F1,LGALS1,MT1A,MX2,MYC,NOTCH1,PARP1,PLSCR1,PNPT1,PRKCH,PRKDC,P
RPF8, 
RBL2,RGCC,SMARCA2 
Infectious Diseases Bacterial 
Infections 
3.31E-07 Decreased -2.342 CASP1,CCL2,CCR1,CD36,CXCL10,CYSLTR1,FCER1G,FCGR1A,FCGR1B,IFI30,I
L15,IL1RN,IL2RB,MYD88,PARP1,RNASE2,RPS6KA5,SIRPA,SOCS1,STAT1,TRAF
D1, 
UNC93B1,USP18 
Infectious Diseases replication of 
vesicular 
stomatitis 
1.47E-12 Decreased -2.328 DDX58,FCGR1A,IFIH1,IFITM3,IRF9,ISG20,LY6E,OAS1,OASL,PARP12,SOCS1,SP
110,STAT2,TAP1,TRIM38 
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virus 
Infectious Diseases infection of 
cells 
1.18E-10 Decreased -2.265 ADAR,ARCN1,ARF1,ARID1A,ARRB1,CAMK1,CARD16,CASP1,CCR1,DDX58,DDX
60L,EIF2AK2,FOXJ2,HDAC1,HNRNPDL,HSPA9,IFI35,IFITM1,IFITM3,IGF2R,IL
15, 
ISG20,JAK1,KHDRBS1,LGALS9,MED28,MT2A,PAF1,PARP9,PI4KA,PRKCH,PRP
F8,PSMA3,PSME2,RNF216,RPL10A,RSAD2,SAMD9,SEC14L1,SEC61G,SF3A1,SF
T2D1, 
SP110,SPATS2L,SSB,STAT1,STAT2,TAP1,TRAFD1,TRIM21,TRIM5,TRIM56,UBE2
H, 
UNC93B1,ZC3HAV1 
Infectious Diseases replication of 
Influenza A 
virus 
8.05E-09 Decreased -2.257 ADAR,AKTIP,ARCN1,ATP6V1A,CBLL1,CREB1,DDX58,EIF2AK2,EIF3L,EIF4A3, 
GBP1,IFITM1,IFITM3,ISG15,JAK1,MX1,MYC,NMI,PRPF8,RSAD2,SAFB,SF3A1, 
STAT1,TRIM14,TRIM21,TUBB 
Inflammatory Response inflammation 
of eye 
3.81E-04 Decreased -2.236 CST3,IL1RN,IRF9,LGALS1,SOCS1,STAT1 
Infectious Diseases replication of 
Hepatitis C 
virus 
5.35E-04 Decreased -2.201 EIF2AK2,IFIT1,IFITM1,ISG15,PI4KA,UBE2L6 
Cancer, Organismal Injury 
and Abnormalities, 
Reproductive System Disease 
mammary 
tumor 
3.76E-04 Decreased -2.2 ACOT9,AKR1B1,ALDOC,ARID1A,ARRB1,ASF1B,ATP5J2,AXIN2,BLVRA, 
CALM(includesothers),CCL2,CMPK2,CXCL10,EIF2AK2,EIF3B,EIF4B,EPHX2,ETS
1, 
GADD45B,GSTO1,HDAC1,HIST1H1C,HNRNPUL1,HSP90B1,IFIT1,LGALS1,LMO
2, 
MT1F,MT1G,MT2A,MYC,MYH9,NBN,NCL,NOTCH1,PARP1,PDPK1,PRKCQ,PTB
P1,PTTG1,RNF7,RPS3,RPS4X,SIN3A,SLIRP,STAT1,TBC1D9,TNFSF10,TUBB,TYM
P,U2AF1/U2AF1L5,USP9X 
Infectious Diseases replication of 
Influenza 
virus 
2.08E-09 Decreased -2.135 ADAR,AKTIP,ARCN1,ATP6V1A,CBLL1,CREB1,DDX58,EIF2AK2,EIF3L,EIF4A3, 
GBP1,IFITM1,IFITM3,ISG15,JAK1,MX1,MYC,NMI,PRPF8,RSAD2,SAFB,SF3A1,S
TAT1,TNFSF10,TRIM14,TRIM21,TUBB 
Infectious Diseases infection by 
RNA virus 
7.27E-10 Decreased -2.077 ARCN1,ARF1,ARID1A,ARRB1,CAMK1,CARD16,CD36,CEACAM1,DDX58,DDX60
L, 
EIF2AK2,FCGR1A,FCGR1B,FOXJ2,HDAC1,HNRNPDL,HSPA9,IFI35,IFIH1,IFIT
M3, 
IL2RB,IMPDH2,ISG15,ISG20,JAK1,KHDRBS1,LGALS9,MED28,MT2A,MYD88,PA
F1,PARP9,PI4KA,PRKCH,PRPF8,PSMA3,PSME2,RNF216,RPL10A,RSAD2,SEC14
L1, 
SEC61G,SF3A1,SFT2D1,SP110,SPATS2L,SSB,STAT1,STAT2,TAP1,TNFSF10,TRAF
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D1,TRIM5,TRIM56,UBE2H,ZC3HAV1 
 
S12 The upstream regulators in pSS-associated lymphoma vs healthy controls  The table contains only the upstream regulators that have a 
significant z-score (2 < z-score > -2) 
Upstream 
Regulator 
Molecule 
Type 
Predicted 
Activation 
State 
Activation 
z-score 
p-value Target molecules in dataset 
IFNL1 cytokine Activated 6.664 9.18E-66 BST2,C19orf66,CXCL10,DDX58,DDX60,EIF2AK2,GBP1,HERC5,HERC6,IFI27,IFI35,IFI
44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IRF9,ISG15,ISG20,LGAL
S3BP,MX1,OAS1,OAS2,OAS3,OASL,PHF11,PLSCR1,PSMB9,RSAD2,SAMD9,SP100,SP1
10,STAT1,TDRD7,TMEM140,TRIM14,TRIM22,UBE2L6,USP18,ZC3HAV1 
IFNA2 cytokine Activated 6.539 6.77E-55 BST2,C19orf66,CXCL10,DDX58,DDX60,EIF2AK2,GBP1,HERC5,HERC6,HSH2D,IFI27,I
FI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IRF7,IRF9,ISG1
5,ISG20,LGALS3BP,LY6E,MX1,OAS1,OAS2,OAS3,PARP12,PLSCR1,RSAD2,SOCS1,SP10
0,SP110,STAT1,TDRD7,TNFSF10,TRIM14,UBE2L6,USP18,ZC3HAV1 
PRL cytokine Activated 6.291 2.15E-54 ADAR,BST2,C19orf66,CAMK1,CMPK2,CST3,CTSH,CXCL10,DDX58,DDX60L,DHX58,EI
F2AK2,EPSTI1,HELZ2,HERC5,HERC6,ID3,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT3,I
FIT5,IFITM1,IRF7,IRF9,ISG15,LAMP3,LY6E,MAGED1,MSN,MX2,MYC,OAS1,OAS2,OA
S3,PARP10,PARP12,PARP14,PLSCR1,PNPT1,PSME1,PSME2,REC8,RSAD2,SAMD9,SA
MD9L,SHISA5,SOCS1,SP100,SP110,STAT2,TDRD7,TMEM140,TRIM14,USP18,XAF1 
IRF7 transcription 
regulator 
Activated 5.798 4.99E-40 CMPK2,CXCL10,DDX58,DHX58,FCGR1A,GBP5,HELZ2,IFI16,IFIH1,IFIT2,IFIT3,IFIT
M3,IL15,IRF7,ISG15,ISG20,NT5C3A,OAS1,OAS2,OAS3,OASL,PARP12,PARP14,PHF11,
PLAC8,RSAD2,SAMD9L,STAT1,STAT2,TAP1,TDRD7,TNFSF10,UBE2L6,USP18,ZBP1 
IRF3 transcription 
regulator 
Activated 5.944 1.46E-38 CCL2,CMPK2,CXCL10,DDX58,DHX58,FCGR1A,GBP5,HELZ2,IFI16,IFI6,IFIH1,IFIT1,I
FIT2,IFIT3,IFITM3,IL15,IRF7,ISG15,ISG20,NT5C3A,OAS1,OAS2,OAS3,OASL,PARP12,P
ARP14,PHF11,PLAC8,RSAD2,SAMD9L,STAT1,STAT2,TAP1,TDRD7,UBE2L6,USP18,ZB
P1 
Ifnar group Activated 5.728 5.59E-37 CCL2,CXCL10,DDX58,EIF2AK2,FCER1G,IFI16,IFI35,IFIH1,IFIT2,IFIT3,IFITM3,IL15,I
RF7,IRF9,ISG20,MYD88,OAS1,OAS2,OASL,PNPT1,PSMB8,PSMB9,RSAD2,STAT1,STAT
2,TAP1,TAP2,TNFSF10,TRIM21,UBE2L6,UNC93B1,USP18,XAF1,ZBP1 
IFNG cytokine Activated 7.442 1.91E-35 ATP1A1,BATF2,BTG1,CASP1,CCL2,CEACAM1,CMPK2,CTSH,CXCL10,DDB1,DDX58,E
IF2AK2,FCER1G,FCGR1A,FCGR1B,GBP1,GBP4,GBP5,GCH1,GNB4,HERC6,IFI16,IFI2
7,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IL15,IL1RN,IRF7,IRF9,ISG15,ISG20,
KCTD12,LAMP3,LGALS3BP,LGALS9,LY6E,MX1,MX2,MYC,MYD88,NMI,NOTCH1,OAS
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1,OAS2,OAS3,OASL,PRKCQ,PRPF8,PSMB8,PSMB9,PSME1,PSME2,RNF31,RSAD2,RTP
4,SAMD9,SF3A1,SOCS1,SP100,SP110,STAT1,STAT2,TAP1,TAP2,TNFSF10,TNFSF13B,T
RIM22,TYMP,USP18 
STAT1 transcription 
regulator 
Activated 5.378 4.25E-31 BATF2,CASP1,CCL2,CEACAM1,CMPK2,CXCL10,EIF2AK2,FCER1G,GBP1,GBP5,HER
C6,IFI16,IFI27,IFI6,IFIT1,IFIT2,IFIT3,IFITM1,IL15,IRF7,IRF9,ISG15,KCTD12,MX1,MY
C,OAS2,OASL,PARP9,PSMB8,PSMB9,PSME1,PSME2,RSAD2,SOCS1,SP110,STAT1,STA
T2,TAP1,TNFSF10,TRAFD1 
MAVS other Activated 4.516 6.85E-26 CMPK2,CXCL10,DDX58,DHX58,IFIT1,IFIT2,IFIT3,IFITM3,IRF7,ISG15,ISG20,NT5C3A,
OAS1,OAS2,OASL,PARP12,RSAD2,SOCS1,STAT1,STAT2,UBE2L6 
IFNB1 cytokine Activated 5.093 2.56E-25 BST2,CASP1,CCL2,CMPK2,CXCL10,DDX58,EIF2AK2,GBP4,GBP5,GNB4,IFI16,IFI27,I
FIH1,IFIT1,IFIT2,IFIT3,IRF7,IRF9,ISG15,ISG20,MX1,MYC,NMI,NOTCH1,NT5C3A,OAS
1,OAS2,RSAD2,SOCS1,STAT1,STAT2,TNFSF10,TRIM21,USP18 
IRF5 transcription 
regulator 
Activated 4.383 1.95E-24 CMPK2,CXCL10,DDX58,DHX58,IFIH1,IFIT2,IFIT3,IFITM3,IRF7,ISG15,ISG20,NT5C3A
,OAS1,OAS2,OASL,PARP12,RSAD2,STAT1,STAT2,UBE2L6 
EIF2AK2 kinase Activated 4.856 1.52E-23 DDX58,EIF2AK2,IFI27,IFI35,IFI6,IFIT1,IFIT5,IFITM1,ISG15,ISG20,LGALS3BP,MYC,N
MI,OAS1,OAS3,PARP12,PARP9,PLSCR1,REC8,SP140,STAT1,UBE2L6,USP18,ZC3HAV1 
TGM2 enzyme Activated 4.906 2.13E-23 CCL2,CD36,CEACAM1,CXCL10,DDX60,DDX60L,FCER1G,FFAR2,HK3,ICAM3,IFI35,I
FI6,IFIT1,IFIT2,IFIT3,IFIT5,IRF9,LGALS9,LY6E,MT2A,MYC,OAS1,OAS2,OAS3,OASL,P
ARP14,PARP9,PLSCR1,SAMD9L,SIRPA,SP110,STAT1,TAP1,TOR1B,TRIM22,XAF1 
TLR3 transmembran
e receptor 
Activated 4.042 5.14E-22 CMPK2,CXCL10,DDX58,DHX58,EIF2AK2,GADD45B,GBP4,GCH1,HERC5,IFI16,IFI44,
IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IL15,IRF7,ISG15,ISG20,MX1,MX2,MYD88,OAS1,O
ASL,RSAD2,STAT1,TNFSF10,TNFSF13B,TRIM38,USP18,ZC3HAV1 
DDX58 enzyme Activated 3.615 1.07E-19 CXCL10,DDX58,EIF2AK2,IFI35,IFI44,IFIH1,IFIT1,IFIT2,IFIT3,IRF7,ISG15,ISG20,NMI,
OAS1,RSAD2,SOCS1,STAT1,STAT2 
IFNAR1 transmembran
e receptor 
Activated 3.665 1.53E-19 CMPK2,CXCL10,EIF2AK2,IFI16,IFI44,IFIH1,IFIT2,IFIT3,IL15,IRF7,ISG15,MYC,OAS1,
OAS2,OAS3,OASL,PARP12,RNASE2,RSAD2,RTP4,SOCS1,STAT1,TNFSF13B,USP18 
Interferon 
alpha 
group Activated 4.666 5.96E-17 BCL2L13,CASP1,CXCL10,DDX58,EIF2AK2,GBP1,IFI16,IFI27,IFIT1,IFIT2,IFIT3,IL15,I
RF7,ISG15,ISG20,MYD88,OAS1,OAS2,PHF11,RNF31,SF3A1,SOCS1,TNFSF10,TNFSF13
B,USP18 
TLR7 transmembran
e receptor 
Activated 4.534 6.61E-16 CCL2,CXCL10,IFI35,IFI44L,IFIT1,IFIT3,IFITM1,IRF7,IRF9,ISG15,ISG20,MX1,MX2,MY
D88,OAS2,OAS3,RSAD2,SOCS1,STAT1,STAT2,TRIM38 
TLR9 transmembran
e receptor 
Activated 4.357 2.27E-15 CXCL10,GADD45B,GCH1,IFI16,IFI35,IFI44L,IFIT1,IFIT2,IFIT3,IFITM1,IRF7,IRF9,ISG
15,ISG20,MX1,MX2,OAS2,OAS3,RSAD2,SOCS1,STAT1,STAT2,TNFRSF13B,USP18 
SASH1 other Activated 3.638 1.39E-14 CMPK2,CXCL10,HDAC1,HELZ2,IFIT2,IFIT3,IL15,IRF7,ISG15,ISG20,NMI,OASL,RSAD
2,SOCS1,STAT1,STAT2,TRIM21 
SAMSN1 other Activated 3.3 2.34E-14 CMPK2,CXCL10,HDAC1,HELZ2,IFIT2,IFIT3,IL15,IRF7,ISG15,ISG20,NMI,OASL,RGCC,
RSAD2,SOCS1,STAT1,STAT2,TRIM21 
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PAF1 other Activated 3.742 1.10E-13 DDX58,FAM46A,HELZ2,HERC5,IFI44,IFI44L,IFIT3,IFITM3,ISG15,ISG20,OAS2,OAS3,
OASL,ZC3HAV1 
DOCK8 other Activated 3.5 1.13E-13 CMPK2,CXCL10,HDAC1,HELZ2,IFIT2,IFIT3,IL15,IRF7,ISG15,ISG20,NMI,RSAD2,SOC
S1,STAT1,STAT2,TRIM21 
TLR4 transmembran
e receptor 
Activated 3.517 1.12E-12 CCL2,CMPK2,CXCL10,HDAC1,HELZ2,IFI16,IFIT2,IFIT3,IFITM3,IL15,IL2RB,IRF7,ISG
15,ISG20,MX1,NMI,OASL,RGCC,RSAD2,SOCS1,STAT1,STAT2,TNFRSF13B,TNFSF10,T
RIM21,TRIM38 
IFNA1/IFN
A13 
cytokine Activated 2.736 2.32E-12 EIF2AK2,IFI6,IFIT2,ISG15,MX1,OAS1,OAS2,RSAD2 
FADD other Activated 2.851 2.90E-12 CXCL10,DDX58,DHX58,EIF2AK2,GADD45B,IFIH1,IFIT2,IRF7,LY6E,MYC,PSMB8,SOC
S1,STAT1,STAT2,TRAFD1 
NFATC2 transcription 
regulator 
Activated 3.638 6.41E-12 CMPK2,CXCL10,HDAC1,HELZ2,IFIT2,IFIT3,IL15,IRF7,ISG15,ISG20,MYC,NMI,OASL,R
SAD2,SOCS1,STAT1,STAT2 
IRF1 transcription 
regulator 
Activated 2.569 7.88E-12 CASP1,CCL2,CEACAM1,CXCL10,IFI44L,IL15,MYC,PSMB8,PSMB9,PSME1,PSME2,SO
CS1,TAP1,TAP2,TNFSF10,TRIM22 
IFNAR2 transmembran
e receptor 
Activated 2.646 8.45E-11 HERC5,ISG15,OAS1,PSMB8,PSMB9,PSME2,UBE2L6,USP18 
TNF cytokine Activated 4.241 6.62E-10 ATP1A1,BST2,CASP1,CCL2,CCR1,CXCL10,DUSP5,ETS1,GBP1,GCH1,GNB4,HK3,HLA-
DRB4,IFI16,IFIT3,IL15,IL1RN,ISG15,JAK1,KYNU,LAMP3,MYC,OAS1,OAS2,OASL,PLSC
R1,PSMB8,PSMB9,PSME2,RNASE2,RNF31,RPS3,SAT1,SCO2,SLC7A1,SOCS1,STAT1,TA
P1,TDRD7,TNFSF10,TNFSF13B,TYMP,UBE2H 
TICAM1 other Activated 3.921 1.10E-09 CCL2,CMPK2,CXCL10,DDX58,IFI16,IFIT1,IFIT2,IFIT3,IL15,IRF7,ISG15,ISG20,OASL,R
SAD2,SOCS1,TNFSF10 
TNK1 kinase Activated 2.646 1.32E-08 IFI16,IFIH1,IFIT2,IRF7,ISG20,OAS2,TNFSF10 
IFN 
alpha/beta 
group Activated 3.132 1.17E-07 CCL2,IFI16,IFIT3,LY6E,RSAD2,SOCS1,STAT1,STAT2,TNFSF10,TRIM21 
FZD9 g-protein 
coupled 
receptor 
Activated 2.433 4.45E-07 CXCL10,IFI16,IFI44,IRF7,ISG15,STAT1 
IFN Beta group Activated 2 1.73E-06 IFI6,IFIT1,IRF9,MX1,OAS2,SOCS1,STAT1,USP18 
MAPKAP1 other Activated 2 8.15E-06 IFI16,IFIT2,OAS2,PHF11 
MYD88 other Activated 2.845 1.99E-05 CCL2,CMPK2,CXCL10,IFIT2,IL15,IL1RN,IRF7,ISG15,OASL,RSAD2,SOCS1,TNFRSF13B
,TNFSF13B,USP18 
MAP2K6 kinase Activated 2.224 2.83E-05 CXCL10,IRF9,ISG15,STAT1,TNFSF10 
Map3k7 kinase Activated 2.63 1.05E-04 CMPK2,CXCL10,IFIT2,IL15,ISG15,ISG20,RSAD2 
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ARHGAP2
1 
other Activated 2.449 1.45E-04 CXCL10,IFIT3,IL15,ISG20,NMI,TRIM21 
JAK1 kinase Activated 2.219 1.59E-04 CCL2,EIF2AK2,IFIT2,MX1,STAT1 
IFIH1 enzyme Activated 2.2 1.59E-04 CXCL10,IRF7,ISG15,OAS1,OAS2 
IL12B cytokine Activated 2.393 2.12E-04 CXCL10,DUSP5,IRF9,SOCS1,STAT1,STAT2 
SMARCB1 transcription 
regulator 
Activated 2.449 2.35E-04 BAG3,BTG1,CEACAM1,EIF2AK2,IFITM1,MX1,OAS1,OAS3 
MAP2K3 kinase Activated 2.213 3.05E-04 CXCL10,IRF9,ISG15,STAT1,TNFSF10 
JUN transcription 
regulator 
Activated 2.184 4.50E-04 ASNS,C3AR1,CCL2,CXCL10,IFI16,IGF2R,MBP,MT2A,MYC,RNF7,SNRPN,STAT1 
TMEM173 other Activated 2.236 4.70E-04 GBP5,IFI16,ISG15,OAS1,OASL 
IL12A cytokine Activated 2.183 6.94E-04 CXCL10,IRF9,SOCS1,STAT1,STAT2 
PLK4 kinase Activated 2 1.14E-03 CMPK2,CXCL10,IFIT2,IL15 
IKBKB kinase Activated 3.124 1.68E-03 CCL2,CCR1,CXCL10,ETS1,GCH1,IFI16,IL1RN,ISG15,MBP,MYC,SOCS1 
IL27 cytokine Activated 2.412 2.89E-03 CCL2,CXCL10,IL1RN,SOCS1,STAT1,TAP1 
CD14 transmembran
e receptor 
Activated 2 3.67E-03 CCL2,CXCL10,IFIT1,SOCS1 
P38 MAPK group Activated 2.071 3.99E-03 BATF2,CCL2,CXCL10,ETS1,GBP1,IRF7,MYC,STAT1,TNFSF10,ULK1 
NFkB 
(complex) 
complex Activated 2.775 4.49E-03 CCL2,CXCL10,DUSP5,IL15,IRF7,MYC,NOTCH1,PSMB9,RSAD2,SOCS1,TAP1,TAP2,TN
FSF10,TRIM38 
CD40LG cytokine Activated 2 1.27E-02 ANXA7,CCL2,GCH1,HLA-DRB4,LAMP3,STAT1 
IL1B cytokine Activated 2.629 1.96E-02 AKR1B1,ATP1A1,CCL2,CXCL10,FOXO1,GCH1,IL15,IL1RN,ISG15,MT2A,NMI,PLSCR1,
TNFAIP6 
IKBKG kinase Activated 2.417 2.17E-02 CCR1,GCH1,IFI16,IL1RN,IRF7,ISG15 
BTNL2 transmembran
e receptor 
Activated 2 5.30E-02 GBP4,IFITM3,NCOA7,TNFSF10 
MAPK1 kinase Inhibited -7.59 1.81E-46 ADAR,BST2,CDK19,DDX58,EIF2AK2,GBP1,GBP5,GLS,HERC5,IFI16,IFI27,IFI35,IFI44,
IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IGFBP7,IRF7,IRF9,ISG15,ISG20,L
AMP3,LAP3,LGALS1,LGALS3BP,MX2,NMI,OAS1,OAS2,OAS3,OASL,PARP12,PHF11,PL
SCR1,PSMB8,PSMB9,PSME2,SMARCC1,SP100,SP110,STAT1,STAT2,SUN2,TAP1,TDRD
7,TNFSF10,TRIM14,TRIM21,TRIM22,TRIM38,TRIM5,UBE2L6,USP18,ZC3HAV1 
TRIM24 transcription 
regulator 
Inhibited -5.874 2.04E-37 CMPK2,CXCL10,DDX58,DDX60,DHX58,EPSTI1,GBP4,HERC6,IFI35,IFI44,IFIH1,IFIT2
,IFIT3,IRF7,IRF9,ISG15,LGALS3BP,MOV10,NMI,OAS1,OASL,PARP12,PHF11,PLAC8,P
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RKCQ,PSMB8,PSMB9,RTP4,SAMD9L,SHISA5,SOCS1,STAT1,STAT2,TAP1,TRAFD1,USP
18 
CNOT7 transcription 
regulator 
Inhibited -2.621 1.11E-31 BST2,CMPK2,HERC6,IFI27,IFI35,IFI44L,IFI6,IFIT5,IFITM1,ISG15,LGALS3BP,OAS1,O
AS2,OAS3,PARP12,PLSCR1,PSMB8,SP110,STAT1,TAP1,TAP2,UBE2L6 
IL1RN cytokine Inhibited -5.385 6.14E-29 DDX58,GBP1,HERC6,IFI27,IFI44,IFI44L,IFI6,IFIH1,IFIT3,IFIT5,IRF7,IRF9,ISG20,LA
MP3,LGALS9,MX1,MX2,OAS1,OAS2,OAS3,OASL,RSAD2,RTP4,SAMD9,SP100,STAT2,T
NFSF10,TRIM22,USP18 
ACKR2 g-protein 
coupled 
receptor 
Inhibited -4.583 3.51E-27 ADAR,CXCL10,DDX58,DDX60,DHX58,EIF2AK2,IFI16,IFI44,IFIT2,IFIT3,IRF7,ISG15,IS
G20,OAS1,OAS2,OAS3,OASL,RSAD2,STAT1,STAT2,USP18 
SOCS1 other Inhibited -3.674 3.61E-14 CXCL10,DDX58,GBP5,IFI16,IFI44,IFIH1,IFIT1,IFIT2,IFIT3,IL2RB,IRF7,ISG15,ISG20,
MX1,OAS1,OAS2,SOCS1,STAT1 
USP18 peptidase Inhibited -3.104 1.92E-13 CXCL10,IFI6,IFITM3,IRF7,IRF9,ISG15,MX1,OAS1,SOCS1,TNFSF10 
PTGER4 g-protein 
coupled 
receptor 
Inhibited -4.013 9.02E-13 CCL2,CMPK2,CXCL10,DDX58,GBP4,HERC6,IFI16,IFI35,IFIH1,IFIT2,IRF7,ISG20,LHF
PL2,PARP14,RSAD2,RTP4,TNFSF10,TRIM21,USP18,XAF1 
DNASE2 enzyme Inhibited -2.606 3.66E-12 CXCL10,DHX58,IFIT3,IRF7,ISG15,OAS1,OAS3,RSAD2,RTP4,USP18,ZBP1 
BTK kinase Inhibited -3.101 5.55E-12 CXCL10,ETS1,IFI35,IFI44L,IFIT1,IFIT3,IFITM1,IRF9,ISG15,ISG20,MX1,MX2,OAS2,OA
S3,STAT1 
TAB1 enzyme Inhibited -2.985 1.76E-10 CXCL10,GBP1,GCH1,IFIH1,IFIT1,IRF7,TNFSF10,TNFSF13B,XAF1 
GAPDH enzyme Inhibited -2.534 2.24E-10 CCL2,FCER1G,IFI6,IFIT2,IFITM1,OAS1,OAS2,OAS3,STAT1,UBE2L6 
Irgm1 other Inhibited -2.53 4.31E-09 CXCL10,ID3,IFI16,IFIT2,IFIT3,IRF7,OAS2,OASL,RSAD2,USP18 
MAP3K7 kinase Inhibited -2.985 7.04E-09 CXCL10,GBP1,GCH1,IFIH1,IFIT1,IRF7,TNFSF10,TNFSF13B,XAF1 
ISG15 other Inhibited -2.219 1.36E-08 DDX58,IFI6,IFITM3,MX1,OAS1 
IRF4 transcription 
regulator 
Inhibited -2.377 1.52E-08 CXCL10,GBP1,IL1RN,IRF7,IRF9,PHF11,PLSCR1,PRKCQ,STAT1,STAT2,TNFSF10, 
TNFSF13B 
mir-21 microrna Inhibited -2.892 9.25E-07 CXCL10,DHX58,FCGR1A,GBP5,IFI16,ITK,MYD88,OAS2,OAS3,PSME2,STAT1,STAT2,T
AP1 
SOCS3 phosphatase Inhibited -2.804 1.73E-06 CXCL10,IFIT1,IFIT2,ISG20,MX1,OAS1,OAS2,SOCS1 
mir-146 microrna Inhibited -2.207 8.49E-06 CCL2,CXCL10,MBP,MYD88,SOCS1 
IL10RA transmembran
e receptor 
Inhibited -3 1.34E-04 BATF2,CD36,CYFIP2,FHL1,GBP5,HK3,IFI16,IL1RN,IRF7,PSMB8,PSMB9,RSAD2,STAT
1, 
TAP1,TAP2,ZBP1 
276 
 
CD3 complex Inhibited -2.411 1.75E-03 BTG1,CD247,ETS1,HSP90B1,IL2RB,IRF9,LAMP1,LEF1,STAT1,TNFSF10 
RPSA translation 
regulator 
Inhibited -2 2.02E-03 GBP4,ISG15,STAT1,TAP1 
SUMO3 other Inhibited -2 3.29E-03 CEACAM1,ISG15,LAMP3,LY6E 
SUMO2 enzyme Inhibited -2 5.00E-03 CEACAM1,ISG15,LAMP3,LY6E 
ERK1/2 group Inhibited -2.18 5.84E-03 ARRB1,CCL2,FOXO1,IFIT1,MYC,PSMB8,PSMB9,TAP1,TAP2 
MKNK1 kinase Inhibited -2.236 3.64E-02 BAG3,MYC,NELL2,PAFAH1B1,PTBP1 
ADORA2A g-protein 
coupled 
receptor 
Inhibited -2.236 6.64E-02 ALDOC,CXCL10,EEF2,IFITM3,NAPA 
CLDN7 other Inhibited -2 6.66E-02 GLS,LYSMD2,MT1A,MT2A 
IGF1 growth factor Inhibited -2.207 1.63E-01 MBP,PSMB8,PSMB9,TAP1,TAP2 
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Supplementary Figures 
SF1 Electropherograms of the amplified cRNA of the first 12 G-depleted samples. A01-
A12 represent the samples which distributed randomly on the Bioanalyzer chip   
 
SF2 Electropherograms of the amplified cRNA of the second 12 G-depleted samples. 
B01-B12 represent the samples which distributed randomly on the Bioanalyzer chip   
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SF3 Electropherograms of the amplified cRNA of the first 12 G-non depleted samples. 
C01-C12 represent the samples which distributed randomly on the Bioanalyzer chip. The 
sharp peaks represents the globin mRNA within the samples.    
 
SF4  Electropherograms of the amplified cRNA of the second 12 G-non depleted samples. 
D01-D12 represent the samples which distributed randomly on the Bioanalyzer chip. The 
sharp peaks represents the globin mRNA within the samples.    
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SF5 The molecular networks analysis in pSS-associated lymphoma vs healthy controls Only 18 networks from the analysis are shown as 3 
networks have only 2 genes 
    
Network 2 Network 3 
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